

19TH BIENNIAL CONFERENCE OF THE INTERNATIONAL SOCIETY
FOR SEXUALLY TRANSMITTED DISEASES RESEARCH

19th

ISSTD
QUÉBEC 2011

Québec City, CANADA
JULY 10 TO 13, 2011



From research to intervention: successes and challenges

www.isstdquebec2011.com



WELCOME

Dear friends and colleagues,

It is our great pleasure to welcome you in Quebec City at the 19th Meeting of the International Society for Sexually Transmitted Diseases Research (ISSTD). We hope that you will enjoy the conference as much as we had to plan it. We are convinced that the scientific program is of the highest quality and includes presentations on a wide range of innovative topics. Indeed, over 830 research abstracts were received of which approximately 170 were accepted for oral presentation and close to 600 as posters. The members of the Scientific Program Committee were impressed by the high quality of the research presented in the abstracts and would indeed have liked to be able to have more slots for oral presentations. The positive consequence is that the poster sessions will also be very exciting and present research results from high standards studies. The scientific program will be supplemented by state of the art plenary sessions that will take various forms depending on the topics. Finally, under the initiative of the Scientific Program Committee, and various partners, the program is completed by 15 non-abstract driven topical symposia. Consequently, during each parallel oral session, participants will have the opportunity to choose between a wide variety of presentations, with six to eight different simultaneous sessions during these time periods. Partly due to the large number of exciting sessions that will take place at the same time, the last day of the meeting will include rapporteur sessions to allow participants to hear about the main research results from presentations at the conference that they will not have been able to attend.

About 60 of you, including researchers from developing countries and graduate students, are attending with the support of travel grants, funded by generous contributions from the Bill & Melinda Gates Foundation, the Office of AIDS Research, National Institutes of Health, and the International Development Research Centre. We also thank the numerous companies, governmental agencies, and non-governmental organizations whose donations have contributed so much to a successful meeting. We encourage you to attend the sponsored symposia and visit the displays offered by many contributors. We also wish to thank the many individuals who donated their time and intellectual energy to make this meeting successful, in particular the members of the local organizing committees, of the scientific program committee and sub-committees, as well as all the abstract reviewers involved in the international scientific committee. We are also thankful to the members of the scholarship committee and of the early career development committee whose dedication allowed to select the best candidates for scholarships out of over 130 proposals and to organize training activities for our scholars and other young investigators attending the conference. Finally, we wish to thank all the members of the ISSTD Board whose support and experience with previous meetings has been highly helpful to us. The members of each of these groups are listed in the following pages and we encourage all meeting participants to express their personal thanks to each of them.

Finally, we hope that you will appreciate our wonderful city, that you will enjoy some of the activities of our social program and that you will have the opportunity to participate in our summer festival that is taking place during the whole period of the conference. We hope that you will enjoy your participation in the 19th ISSTD Meeting, both scientifically and personally, and we look forward to meeting you all.

Michel Alary and Marie-Claude Boily



Michel Alary, M.D., Ph.D.
President, ISSTD
Chair, 19th ISSTD Meeting
Co-Chair, Scientific
Program Committee

Président, ISSTD
Président, 19^{ème} Conférence
ISSTD
Co-président, Comité
du programme scientifique

MOT DE BIENVENUE



Marie-Claude Boily, Ph.D.
Co-Chair, Scientific
Program Committee

Co-présidente, Comité
du programme scientifique

Chers amis et collègues,

C'est avec grand plaisir que nous vous accueillons dans notre belle ville de Québec à l'occasion du 19^{ième} congrès de la « International Society for Sexually Transmitted Diseases Research (ISSTD) ». Nous espérons que la conférence vous plaira autant qu'il nous a plu la préparer pour vous. Nous sommes convaincus que le programme scientifique est de la plus haute qualité et inclut des présentations couvrant un grand nombre de sujets novateurs. En effet, plus de 830 résumés ont été reçus, desquels environ 170 ont été acceptés pour présentation orale et près de 600 comme affiches. Les membres du Comité du programme scientifique ont été impressionnés par la haute qualité des résumés présentés et auraient aimé avoir un plus grand nombre de périodes disponibles pour des présentations orales. Cela signifie donc que les sessions d'affiches seront très intéressantes et présenteront également des résultats de recherches de haut niveau. Le programme scientifique sera enrichi de sessions plénières de pointe et structurées différemment en fonction des thèmes abordés. Enfin, à l'initiative du Comité du programme scientifique et de divers partenaires, le programme est complété par 15 symposiums thématiques sur invitation. En conséquence, pendant chaque session orale parallèle, les participants auront l'opportunité de choisir entre une grande variété de présentations parmi six à huit différentes sessions simultanées par période. Vu ce grand nombre de sessions parallèles, des sessions de rapporteurs ont été planifiées le

dernier jour de la conférence afin de permettre aux participants d'être informés des principaux résultats de recherche des présentations auxquelles ils n'auront pas pu assister.

Environ 60 participants, incluant des chercheurs de pays en voie de développement et des étudiants gradués, assistent à la conférence en bénéficiant d'une bourse, financée par les généreuses contributions de la Fondation Bill & Melinda Gates, le « Office of AIDS Research », les « National Institutes of Health », et le Centre de recherches pour le développement international. Nous désirons aussi remercier les nombreuses compagnies, agences gouvernementales et organisations non gouvernementales pour leurs dons qui contribuent à faire de cette conférence un succès. Nous vous encourageons à assister aux symposiums sponsorisés et à visiter les kiosques d'exposition de nos différents donateurs. Nous désirons aussi remercier toutes les personnes qui ont si généreusement investi de leur temps et énergie intellectuelle pour le succès de cette conférence, en particulier les membres du comité organisateur local, des comité et sous-comités du programme scientifique, de même que les réviseurs de résumés impliqués dans le comité scientifique international. Nous sommes aussi reconnaissants envers les membres du comité des bourses et ceux du comité des carrières en développement dont le dévouement a permis de sélectionner les meilleurs candidats à des bourses sur un total de plus de 130 propositions reçues et pour l'organisation des activités de formation pour nos boursiers et autres jeunes chercheurs assistant à la conférence. Enfin, nous désirons remercier tous les membres du comité exécutif de l'ISSTD pour leur support, leur expérience des conférences antérieures nous ayant été d'une grande utilité. Les membres de chacun de ces groupes sont listés dans les pages suivantes et nous encourageons tous les participants à la conférence à les remercier personnellement.

Enfin, nous espérons que vous apprécierez notre merveilleuse ville, que vous aurez l'occasion d'apprécier certaines des activités de notre programme social et que vous aurez l'opportunité de participer à notre festival d'été qui est en cours durant toute la période de la conférence. Nous espérons que votre participation à la 19^{ième} conférence de l'ISSTD sera des plus plaisantes, à la fois scientifiquement et personnellement, et nous avons hâte de vous rencontrer.

Michel Alary et Marie-Claude Boily

TABLE OF CONTENTS

2	Welcome • Mot de bienvenue
5	Board of Directors
6	Conference Committees
14	Contributors & Sponsors
18	Program at a Glance
22	General Information
23	Social program
24	Venue Floor Plans
27	Exhibition Information
32	Scientific Program
32	PLENARY PROGRAM
40	SYMPOSIUM PROGRAM
50	EARLY CAREER DEVELOPMENT PROGRAM
52	SUNDAY SATELLITE SYMPOSIA
57	MAIN PROGRAM
57	Sunday, July 10 • Opening Ceremony
57	Monday, July 11
68	Tuesday, July 12
79	Wednesday, July 13
91	Poster Presentations

BOARD OF DIRECTORS 2009 - 2011

**Michel Alary, Current President and Chair,
19th Meeting, 2011**

Professeur Titulaire Unité de recherche en santé des populations, Centre hospitalier *affilié* universitaire de Québec et Université Laval Québec, Canada

**Angelika Stary, President Elect and Chair
of 20th Meeting, 2013**

Ambulatorium Pilzfektionen und andere Infektiöse Venero-dermatologische Erkrankungen Vienna, Austria

**Catherine Ison, Immediate Past President
and Chair, 18th Meeting, 2009**

Professor & Director, Sexually Transmitted Bacteria Reference Laboratory Health Protection Agency Centre for Infections London, United Kingdom

**Hunter Handsfield, Past President and Chair,
17th Meeting, 2007**

Senior Research Leader Battelle Centers for Public Health Research and Evaluation Clinical Professor of Medicine University of Washington Center for AIDS and STD Seattle, USA

Xiang-Sheng Chen

Professor & Deputy Director National Center for STD Control, China CDC Institute of Dermatology, CAMS & PUMC Nanjing, China

Sevgi Aral, Observer

Associate Director for Science National Center for HIV, STD and TB Prevention Centers for Disease Control and Prevention Atlanta, USA

Charlotte A. Gaydos

Associate Professor of Medicine Johns Hopkins University Division of Infectious Diseases International STD Laboratory Baltimore, USA

Graham J. Hart, PhD

Research Department of Infection & Population Health University College London Mortimer Market Centre London, United Kingdom

Sharon L. Hillier

Professor of Obstetrics, Gynecology and Reproductive Sciences and of Molecular genetics and Biochemistry Magee-Womens Hospital Dept OB/Gyn/RS Pittsburgh, USA

Jørgen Skov Jensen

Statens Serum Institut Mycoplasma Laboratory Copenhagen, Denmark

David A. Lewis

Head of the Sexually Transmitted Infections Reference Centre National Institute of Communicable Diseases National Health Laboratory Service Private Bag X4 Sandringham, South Africa

Jeanne Mrazzozzo, MD, MPH

Associate Professor Division of Allergy & Infectious Diseases University of Washington Harborview Medical Center Seattle, USA

Nancy S. Padian, PhD

Professor of Epidemiology University of California Berkeley School of Public Health Berkeley, USA

Cornelis A. Rietmeijer

Director, Sexually Transmitted Disease Control Program Denver Public Health Department Professor, Department of Medicine and Preventive Medicine and Biometrics University of Colorado Denver, School of Medicine Denver, USA

Barbara Van Der Pol, PhD, MPH

Assistant Professor of Epidemiology & Medicine Director, Infectious Diseases Laboratory Indiana University School of HPER Indiana University School of Medicine Indianapolis, USA

King K. Holmes, Observer

Liaison, International Union against Sexually Transmitted Infections Professor of Medicine and Epidemiology Director, Center for AIDS and STD University of Washington Seattle, USA

LOCAL ORGANIZING COMMITTEE

Chair



Dr Michel Alary,
Unité de recherche en
santé des populations,
Centre hospitalier *affilié*
universitaire de Québec
and Université Laval,
Québec, Canada



Dr. Michael Libman,
McGill University,
Montréal, Canada



Dr. Michel G. Bergeron,
Université Laval,
Québec, Canada



Dr. Joanne Otis,
Université du Québec
à Montréal,
Montréal, Canada



Dr. James Blanchard,
University of Manitoba,
Winnipeg, Canada



Dr. Frank Plummer,
Public Health Agency
of Canada,
Ottawa, Canada



Dr. Gaston Godin,
Université Laval,
Québec, Canada



Dr. Robert S. Remis,
University of Toronto,
Toronto, Canada




Dr. Annie-Claude Labbé,
Université de Montréal,
Montréal, Canada



Dr. Marc Steben,
Université de Montréal,
Montréal, Canada



Dr. Gilles Lambert,
Institut national de santé
publique du Québec,
Montréal, Canada



Dr. Mark A. Wainberg,
McGill University,
Montréal, Canada

BIOGRAPHY OF THE MEMBERS OF THE LOCAL ORGANIZING COMMITTEE

Michel Alary obtained his M.D. at *Université de Sherbrooke* in 1974. After eight years of general practice, he re-oriented his career towards public health. He completed a Ph.D. in epidemiology at *Université Laval*, Québec, in 1991. After a post-doctoral fellowship with Professor Peter Piot in Antwerp, Belgium, he became professor of epidemiology at *Université Laval* in 1992 and is also involved with the *Institut national de santé publique du Québec*. Most of his academic career has been devoted to epidemiologic and prevention research on HIV and STI among the most vulnerable populations, both in Canada and in developing countries. Since 2004, he is responsible for the impact assessment of Avahan, the India AIDS Initiative of the Bill & Melinda Gates Foundation, one of the largest HIV prevention programmes ever implemented. In 2008, he was also in charge of a major review of HIV epidemiology and response in West Africa for the World Bank. He is currently president of the International Society for STD Research and chair of the 19th Conference of this Society, to be held in Quebec City from July 10 to 13, 2011.

Dr. Michel G. Bergeron is professor of microbiology and infectious diseases (ID) as well as the founder and director of the Centre de recherche en infectiologie of *Université Laval* in Québec City, one of the largest infectious diseases research centres in North America (250 researchers). A world renowned researcher, he is the author of more than 400 publications. Dr. Bergeron and his team were the first to develop innovative DNA-based tests which allow the specific identification, directly from a clinical sample, of microbes and their antibiotic resistance genes in less than one hour instead of 2 to 3 days using standard microbiology techniques (Bergeron et al., *NEJM* 343:175-9, 2000). Several FDA approved real-time PCR tests to diagnose and better control hospital-acquired infections due to methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and *Clostridium difficile*, as well as neonatal infections due to Group B streptococci, are derived from his research laboratory. These “personalized medicine” tests, insuring real-time diagnostics and treatment, are saving many lives and preventing the spread of nosocomial infections and antimicrobial resistance while reducing healthcare costs. In 1995, to transform discoveries into products, he created Infectio Diagnostic (IDI) Inc. which was acquired by Becton Dickinson (BD) in 2006. These high clinical value tests are fabricated in Québec City (350 employees) and commercialized throughout the world by BD. Dr. Bergeron is now developing, with his transdisciplinary team, a simple “lab-on-a-chip” device on a compact disc (CD) platform that reads DNA rapidly and which will allow the detection of infections at point-of-care (POC). The innovativeness of Québec City’s researchers and entrepreneurs has elevated the region as a world class academic and industrial leader in molecular diagnostics.

James F. Blanchard, MD, MPH, PhD is an epidemiologist and public health specialist who obtained his medical degree from the University of Manitoba in 1986. He subsequently received a Master of Public Health (1990) and Ph.D. in Epidemiology (1997), both from the Johns Hopkins University. He is currently Professor of Community Health Sciences and Medical Microbiology at the University of Manitoba (Canada) and Director of the University’s Centre for Global Public Health. He also holds the Canada Research Chair in Epidemiology and Global Public Health. From 2001-2007, Dr. Blanchard lived and worked in India as Resident Coordinator of the University of Manitoba’s HIV programs. In addition to his project-related work, Dr. Blanchard has been active in applied research related to HIV and STI in India, Pakistan, China and elsewhere in Asia. He provides technical assistance and strategic advice to a number of government and non-government associations, including the governments of Canada, India, Sri Lanka, Bhutan and Pakistan, the Canadian International Development Agency, the World Bank and the Bill & Melinda Gates Foundation.

Gaston Godin, Ph.D. (community Health) is Full professor at *Université Laval*, Quebec City. He holds the Canada Research Chair on Behaviours and Health, funded by the Canadian Institutes of Health Research (Tier 1; CIHR: 2004-2011). He was visiting professor at various institutions such as at Harvard University (public health: behaviour sciences), Boston, USA (1987-1988), Maastricht University (prevention and health promotion), The Netherlands (1994-1995), Sheffield (psychology) and Leeds (psychology) Universities, England (2002), and Paul-Verlaine University (psychology) in Metz, France (2009). He is the author and the co-author of more than 200 peer-reviewed scientific publications.

Annie-Claude Labbé is a medical microbiologist at Hôpital Maisonneuve-Rosemont and clinical associate professor at the Department of microbiology and immunology of Université de Montréal. She trained under Michel Alary's supervision for her post-doctoral fellowship in 2000-2002 in Benin, working with female sex workers and their clients. She is member of the "Comité sur les infections transmissibles sexuellement et par le sang (ITSS)" and president of the "Comité sur les analyses de laboratoire en lien avec les ITSS", two public health committees of the province of Quebec.

Gilles Lambert MD, Médecin conseil, Direction des risques biologiques et occupationnels, Institut national de santé publique du Québec; Direction de santé publique, Agence de la santé et des services sociaux de Montréal, Canada.

Dr. Michael Libman is Director of the Division of Infectious Diseases at McGill University, and Interim Director of the J.D. MacLean Centre for Tropical Medicine at McGill University. He works as a consultant in Infectious Diseases and Medical Microbiology for the region of Nunavik in the eastern arctic, and is a regular visiting faculty member at the Christian Medical College in Vellore, India, and at Addis Ababa University in Ethiopia. He was also Director of the McGill residency training programs in infectious disease and medical microbiology for 10 years.

Joanne Otis Ph.D., professor at the Sexology Department of Université du Québec à Montréal (UQÀM) and associate professor at Université de Montréal, is renowned for her expertise in health promotion and her work in partnership with HIV/AIDS community organizations. Since October 2004, she has been the Chairholder of the Canada Research Chair in Health Education (CReCES). She is particularly interested in sexual health promotion and preventive sexual education and interventions, from conceptualization to evaluation. She also works on the psychosocial and socio-cultural factors associated to risk or preventive behaviours related to HIV infection or other STI.

Dr. Frank Plummer is the Chief Science Officer of the Public Health Agency of Canada and the Scientific Director General of the National Microbiology Laboratory in Winnipeg. Dr. Plummer is recognized in Canada and abroad for his work in public health and science, having received numerous honors. In 2001, he was named Canada Research Chair of the Canadian Institutes of Health Research. He has also been elected to the American Society of Clinical Investigation and the Association of American physicians, has served as an advisor to the National Academy of Sciences in the US, and as a consultant to the World Bank, the World Health Organization, and the Governments of Kenya, India and Lesotho. Dr. Frank Plummer received his medical degree from the University of Manitoba in 1976 and trained in internal medicine and infectious diseases at the University of Southern California, the University of Manitoba, the University of Nairobi, and the Centers for Disease Control in Atlanta. He joined the University of Manitoba faculty in 1984 and is currently Distinguished Professor at that University of Manitoba, as well as Professor of Medical Microbiology and Community Health Sciences.

Dr. Robert S. Remis received his MD from McGill University in 1972. Following a rotating internship, he worked as a physician in Northern Saskatchewan, a community clinic near Montreal, and a rural hospital in eastern Africa. Subsequently, he studied epidemiology at the Harvard School of Public Health (MPH) and trained at the US Centers for Disease Control (EIS). From 1983-1996, Dr. Remis coordinated communicable disease control in Montreal. Since 1997, he has worked to help monitor the HIV epidemic in Ontario. He has published 70 peer-reviewed articles and is currently collaborating in an epidemiologic and intervention study among female sex workers in Shanghai, China and a study of HIV/STI coinfection among African-Caribbean women and men and homosexual men in Toronto.

Dr. Marc Steben, M.D., C.C.M.F., F.C.M.F. As a family practitioner he currently works at Quebec's National Institute of Public Health on sexually transmitted infections. He is a member of both Social and Preventive Medicine and obstetrics and gynecology departments of the faculty of medicine at Université de Montréal. He chairs the Québec province committee on STI. He was an investigator for the quadrivalent HPV vaccine. He is a member of the Canadian STI guidelines expert group and lead author on the HPV and genital ulceration chapters. He was the 2010 recipient of the Gilles Des Rosiers award for his contribution to continuing medical education. He will chair the International papillomavirus society meeting of 2010 and is co chair of the policy and health services track of the International society for STD research congress of 2011.

Dr. Mark A. Wainberg is Professor of Microbiology and Director of the McGill University AIDS Centre. He was President of the International AIDS Society between 1998-2000 and helped organize the International Conference on AIDS in Durban, South Africa, 2000, that led to access to anti-HIV drugs in developing countries. He is well-known for his initial identification of 3TC as an anti-viral drug, and for multiple contributions to the fields of HIV drug resistance and HIV pathogenesis. He is an author of over 400 research papers and 100 reviews and commentary articles that have appeared in the scientific literature.

SCIENTIFIC ORGANIZING COMMITTEE

Committee co-chairs



Michel Alary,
Unité de recherche en
santé des populations,
Centre hospitalier *affilié*
universitaire de Québec
and Université Laval,
Québec, Canada



Marie-Claude Boily,
Unité de recherche en
santé des populations,
Centre hospitalier *affilié*
universitaire de Québec
and Imperial College,
London, UK

Committee members



Gilles Lambert,
Direction de la santé
publique de Montréal-
Centre, Montréal, Canada



Annie-Claude Labbé,
Université de Montréal,
Montréal, Canada



Joanne Otis,
Université du Québec
à Montréal, Montréal,
Canada



Jeanne Marrasso,
University of Washington,
Seattle, USA



Sevgi Aral,
Centers for Disease
Control and Prevention,
Atlanta, USA



Jo-Ann Dillon,
University of
Saskatchewan,
Saskatoon, Canada



Max Chernesky,
McMaster University,
Hamilton, Canada



Thomas Wong,
Public Health Agency
of Canada, Ottawa,
Canada



Marc Steben,
Institut national de santé
publique du Québec,
Montréal, Canada

Scientific sub-committees

Epidemiology track

Marie-Claude Boily, Unité de recherche en santé des populations, Centre hospitalier affilié universitaire de Québec and Imperial College, London, UK (co-chair)

Gilles Lambert, Direction de la santé publique de Montréal-Centre, Montréal, Canada (co-chair)

James Blanchard, University of Manitoba, Winnipeg, Canada

Anne Buvé, Institute of Tropical Medicine, Antwerp, Belgium

Benoît Mâsse, Fred Hutchison Cancer Institute, Seattle, USA

Gabriela Paz-Bailey, Del Valle University of Guatemala, Guatemala City, Guatemala

Robert Remis, University of Toronto, Toronto, Canada

Social and behavioural aspects of prevention track

Joanne Otis, Université du Québec à Montréal, Montréal, Canada (co-chair)

Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA (co-chair)

Ann O'Leary, Centers for Disease Control and Prevention, Atlanta, USA

Kaye Wellings, London School of Hygiene & Tropical Medicine, University of London, London, UK

Pamina Gorbach, UCLA Department of Epidemiology, Los Angeles, USA

Clinical sciences track

Annie-Claude Labbé, Université de Montréal, Montréal, Canada (co-chair)

Jeanne Marrasso, University of Washington, Seattle, USA (co-chair)

Michel G. Bergeron, Centre hospitalier universitaire de Québec and Université Laval, Québec City, Canada

Christopher K Fairley, University of Melbourne; Melbourne Sexual Health Centre, Melbourne, Australia

Khalil Ghanem, Johns Hopkins Medical School, Baltimore, USA

Patricia Kissinger, Tulane University School of Public Health and Tropical Medicine, New Orleans, USA

Ina Park, California Department of Health, Oakland, USA

Janet Wilson, The General Infirmary at Leeds; Leeds Teaching Hospitals NHS Trust, Leeds, UK

Basic sciences track

Jo-Anne Dillon, University of Saskatchewan, Saskatoon, Canada (co-chair)

Max Chernesky, McMaster University, Hamilton, Canada (co-chair)

Caroline E. Cameron, University of Victoria, Victoria, Canada

François Coutlée, Centre hospitalier de l'Université de Montréal, Montréal, Canada

Health services and policy track

Marc Steben, Institut national de santé publique du Québec, Montréal, Canada (co-chair)

Thomas Wong, Public Health Agency of Canada, Ottawa, Canada (co-chair)

Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA

Rafael Mazin, PAHO, Washington, D.C., USA

Angela Robinson, University College London, UK

BIOGRAPHY OF THE MEMBERS OF THE SCIENTIFIC ORGANIZING COMMITTEE

Dr. Sevgi Aral is the Associate Director for Science in the Division of STD Prevention where she is responsible for the oversight and direction of all scientific activities including the intramural and extramural research programs and science-program interactions. In addition to her appointment at CDC, Dr. Aral has served as a professor of sociology in the United States and Turkey. She currently serves as a clinical professor at the University of Washington School Of Medicine; and has adjunct professorial appointments at Emory University and University of Manitoba. Dr. Aral has served on the editorial boards of several scientific journals including Sexually Transmitted Diseases, AIDS Education and Prevention, Sexually Transmitted Infections, American Journal of Public Health, and AIDS. Currently, she is the Associate Editor of Sexually Transmitted Diseases and Sexually Transmitted Infections.

Jeanne Marrazzo, MD, MPH, FACP, FIDSA. Dr. Marrazzo is Professor in the Division of Infectious Diseases at the University of Washington in Seattle. She is the Medical Director of the Seattle STD/HIV Prevention Training Center, president of the American STD Association, and an Associate Editor of the journal Sexually Transmitted Diseases. She serves on several national committees related to control of infectious diseases, particularly in the area of women's health, and is the Protocol Co-Chair of the VOICE Study, a large study implemented by the Microbicides Trial Network that is evaluating HIV pre-exposure prophylaxis administered vaginally and orally to women at high risk for HIV infection in sub-Saharan Africa. She is a Fellow of the American College of Physicians and of the Infectious Disease Society of America, and has been the Principal Investigator for numerous studies of clinical and epidemiologic aspects of genital chlamydial infections, vaginal infections, and cervicitis. Major areas of research interest include molecular epidemiology, pathogenesis, and management of bacterial vaginosis, and diagnosis and screening of chlamydial infection.

Jo-Anne R. Dillon, is a Professor of Biology and Research Scientist at the Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada. Dr Dillon has provided extensive academic and public sector administrative leadership, has led several national and international scientific organizations and has consulted widely in the area of STIs and public health. She currently is co-ordinator for the Gonococcal Antimicrobial Surveillance Program (GASP) in Latin America and the Caribbean. Dr. Dillon has authored numerous publications with a special focus on international trends in antimicrobial resistance, molecular typing and the cell biology of *Neisseria gonorrhoeae*.

Max Chernesky is Professor Emeritus at McMaster University, Hamilton, Canada. He was Head of Microbiology Laboratories and Director of Microbiology/Infectious Diseases in the Hamilton Regional Laboratory Medicine Program (HRLMP). He has served as President of CSM, CCM, PASCV and chaired the Scientific Committee of the SDI (WHO). His achievements include FIDSA, FAAM, FCCM, Diagnostic Virology Award (PASCV) and Distinguished Microbiology Award (CCM). His research interests are STI Diagnostics (572 scientific articles).

Dr. Thomas Wong, MD, MPH, FRCPC is the Director of Community Acquired Infections Division, Centre for Communicable Diseases & Infection Control at the Public Health Agency of Canada. He was trained in internal medicine, public health and infectious diseases at McGill, Harvard and Columbia. His scientific interests focus on HIV, sexually transmitted infections, hepatitis C, tuberculosis and other infectious diseases, especially among underserved populations. Dr. Wong has academic appointments at both the University of Ottawa and the University of Toronto. He is the Chair of the Expert Working Group on Canadian Guidelines for Sexually Transmitted Infections, Editor-in-Chief of the Canadian Guidelines on Sexually Transmitted Infections, Member of the Canadian Paediatric Surveillance Program Steering Committee, Member of the Federal/Provincial/Territorial Advisory Committee on AIDS, and Co-Chair of the Federal/Provincial/Territorial Sexually Transmitted Bloodborne Infections.

SCHOLARSHIP COMMITTEE

Catherine M. Lowndes, Health Protection Agency, London, United Kingdom (Chair)

Dr. Michel G. Bergeron, Université Laval

Dr. James Blanchard, University of Manitoba

Dr. Gaston Godin, Université Laval

Dr. Robert S. Remis, University of Toronto

Dr. Mark A. Wainberg, McGill University

EARLY CAREER DEVELOPMENT COMMITTEE

Barbara Van Der Pol, Assistant Professor of Epidemiology & Medicine, Indiana University School of Medicine, Indianapolis, USA (Chair)

Dr. Charlotte Gaydos, Johns Hopkins University School of Medicine, Baltimore, USA

Dr. John Douglas, Chief Medical Officer, National Center for HIV/AIDS, Centres for Disease Control and Prevention, Atlanta, GA, USA

Dr. Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA

Dr. Marc Steben, Institut national de santé publique du Québec, Montréal, Canada

Dr. Nancy Padian, University of California, Berkeley, USA

INTERNATIONAL SCIENTIFIC COMMITTEE

Michael Apicella, USA

Laura Bachmann, USA

Jared Baeten, USA

Francisco Inacio Bastos, Brazil

Michel Bergeron, Canada

Stuart M Berman, USA

Martin Blais, Canada

James Blanchard, Canada

Marie-Claude Boily, United Kingdom

Anne Buvé, Belgium

Caroline Cameron, Canada

William Cameron, Canada

Mike Carey, USA

Willard Cates, USA

David Celentano, USA

Max Chernesky, Canada

Harrell W. Chesson, USA

Barbara Clarke, Canada

Ian Clarke, United Kingdom

Myron Cohen, USA

Chris Coleman, USA

François Coutlee, Canada

Joe Cox, Canada

Nicole Crepaz, USA

Ralph DiClemente, USA

Jo-Anne Dillon, Canada

Harold Dion, Canada

Marc Dionne, Canada

John Doorbar, United Kingdom

Ann Duerr, USA

Christopher Fairley, Australia

Kevin Fenton, USA

Bill Fisher, Canada

David Fisman, Canada

Elizabeth Foley, United Kingdom

Dennis Fortenberry, USA

Claude Fortin, Canada

Geoffrey Garnett, United Kingdom

Charlotte Gaydos, USA

Khalil Ghanem, USA

Gaston Godin, Canada

Matthew Golden, USA

Pamina Gorbach, USA

Sammi Gottlieb, USA

Heiner Grosskurth, United Kingdom

Sarah Guerry, USA

Nancy Haley, Canada

H. Hunter Handsfield, USA

Sharon Hillier, USA

Matthew Hogben, Canada

King Holmes, USA

Catherine Ison, United Kingdom

John Jemmott, USA

Rupert Kaul, Canada

Peter R. Kerndt, USA

Patricia Kissinger, USA

Jeffrey D. Klausner, USA

Joan Knapp, USA

Linda Koenig, USA

Peter K Kohl, Germany

Rhonda Kropp, Canada

Annie-Claude Labbe, Canada

Claude Laberge, Canada

Gilles Lambert, Canada

Jami Leichter, USA

Peter Leone, USA

Robert Lerch, Canada

Bernard Lessard, Canada

David Lewis, South Africa

Catherine Lowndes, United Kingdom

Sheila Lukehart, USA

Lauri Markowitz, USA

Jeanne Marrazzo, USA

Benoît Masse, Canada

Amalia MeierMagaret, USA

Steve Moses, Canada

Nicolas Nagot, France

Ann O'Leary, USA

Joanne Otis, Canada

Nikki Pai, Canada

Ina Park, USA

Dorothy Patton, USA

Gabriela Paz-Bailey, Guatemala

Jacques Pepin, Canada

Sam Phiri, Malawi

Michael L. Rekart, Canada

Robert S. Remis, Canada

Cornelis A Rietmeijer, USA	Ron Stall, USA	Kaye Wellings, United Kingdom
Angela Robinson, United Kingdom	Marc Steben, Canada	Harold C Wiesenfeld, USA
Barbara Romanowski, Canada	Peter Timms, Australia	Janet Wilson, United Kingdom
Allan Ronald, Canada	Patricia Totten, USA	Rich Wolitski, USA
Julius Schachter, USA	Benoît Trottier, Canada	Tom Wong, Canada
Theresa Seen, USA	Ariane vanderStraten, USA	Kimberly A Workowski, USA
Rita Shahin, Canada	Judith Wasserheit, USA	Jonathan Zenilman, USA
Ameeta Singh, Canada	Charlotte Watts, United Kingdom	Gregory Zimet, USA

PAST PRESIDENTS AND CONGRESS LOCATION

International Society for Sexually Transmitted Diseases Research Previous meetings

- 18th Meeting 2009 • London, United Kingdom; Chair: Catherine Ison
- 17th Meeting 2007 • Seattle, Washington, USA; Chair: H. Hunter Handsfield
- 16th Meeting 2005 • Amsterdam, The Netherlands; Chair: Roel Coutinho
- 15th Meeting 2003 • Ottawa, Canada; Chair: Jo-Anne Dillon
- 14th Meeting 2001 • Berlin, Germany; Chair: Peter Kohl
- 13th Meeting 1999 • Denver, Colorado, USA; Chair: Franklyn N. Judson
- 12th Meeting 1997 • Seville, Spain; Chair: Evelio Perea
- 11th Meeting 1995 • New Orleans, Louisiana, USA; Chair: David H. Martin
- 10th Meeting 1993 • Helsinki, Finland; Chair: Jorma Paavonen
- 9th Meeting 1991 • Banff, Alberta, Canada; Chair: Allan Ronald
- 8th Meeting 1989 • Copenhagen, Denmark; Chair: Inga Lind
- 7th Meeting 1987 • Atlanta, Georgia, USA; Chair: Sumner E. Thompson
- 6th Meeting 1985 • Brighton, United Kingdom; Chair: JRW Harris
- 5th Meeting 1983 • Seattle, Washington, USA; Chair: King K. Holmes
- 4th Meeting 1981 • Heidelberg, Germany; Chair: Detlef Petzoldt
- 3rd Meeting 1980 • Antwerp, Belgium; Chair: Peter Piot
- 2nd Meeting 1979 • Helsinki, Finland; Chair: Alan Lassar
- 1st Meeting 1977 • Rotterdam, The Netherlands; Chair: Ernst Stoltz

CONTRIBUTORS & SPONSORS

Hosted by:



Under the aegis of:




In conjunction with:



MAJOR CONTRIBUTORS



CONTRIBUTORS



SPONSORS

Platinum



Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck. Be well. For more information, visit www.merck.com.



Diagnostic Systems is the global leader of products and instruments used for diagnosing infectious diseases. Our products are used in the clinical market to screen for microbial presence, grow and identify organisms, and test for antibiotic susceptibility. In the industrial market, Diagnostic Systems' products are used for the testing of sterile and non-sterile pharmaceuticals and medical devices, for environmental monitoring and to detect food pathogens.

Gold



Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies. RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and

oncology, microbiology and sexually transmitted infections. Roche's cobas® 4800 System allows you to run the cobas® CT/NG Test which features a double target CT test and the new generation NG test designed for high specificity.

Silver



Since its founding in 1983, Gen-Probe has been at the forefront of the molecular diagnostics industry. The Company's patented technologies are used to diagnose sexually transmitted diseases and microbial infectious diseases and include the APTIMA® products for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) testing, as well as human papillomavirus (HPV). Several of Gen-Probe's current and future molecular tests can be performed on our TIGRIS® DTS® system, a fully automated, high-throughput NAT system for diagnostics and blood screening, and the next-generation PANTHER™ system, a versatile, fully automated NAT system for low- to mid-volume laboratories. Be sure to visit the Gen-Probe booth for a demonstration of the new PANTHER system, designed to be a smaller footprint, fully automated instrument for molecular diagnostics.



Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritional, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries. Abbott Molecular, a division of Abbott, is a leader in molecular diagnostics — the analysis of DNA, RNA, and proteins at the molecular level. Abbott Molecular's tests can also detect subtle but key changes in patients' genes and chromosomes and have the potential for earlier detection or diagnosis, can influence the selection of appropriate therapies, and may improve monitoring of disease progression. Abbott Molecular is committed to the sexual health industry by providing assays to detect STDs. www.abbottmolecular.com

SIEMENS

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately

diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.

Bronze



Graceway Pharmaceuticals is contributing to therapeutic advancements focusing in Dermatology, Pediatric and Adult Respiriology. We strive to better understand the needs of patients and healthcare providers delivering valued products to improve the health of Canadians.



STANDARD DIAGNOSTICS, INC.
www.standarddiag.com

Standard Diagnostics, Inc. (SD) has been engaged in the research, development, and commercialization of in-vitro diagnostic products since 1999. SD supplies the company's flagship products, ICA rapid test kits, which are available through 160 distributors in 100 countries for the point -of-care testing (POCT) of infectious diseases, Respiratory diseases tumor and cardiac markers, hormones, and forensics.

All SD products are manufactured in-house under strict quality controls to meet the international standards (ISO 13485:2003, etc.).

PROGRAM AT A GLANCE

SUNDAY JULY 10, 2011

Room	200B	200C	202	206B	302A
08:45 - ...				Satellite Symposium Key population and Their Role in STD/HIV Transmission Dynamics	Satellite Symposium 11th International Symposium on <i>Haemophilus ducreyi</i> Pathogenesis and Chancroid
09:00 - ...					
12:00 - 13:30	ROCHE Satellite Symposium				
14:00 - 17:00			Satellite Symposium Oh...Canada! The Current Context: STI Epidemiology, Guidelines and Partner Notification Practices		
17:30 - 19:00		Opening Ceremony Reconfiguring the AIDS response - <i>Dr. Paul De Lay</i>			
19:00 - 20:00					

MONDAY JULY 11, 2011

Room	200AB	200C	202	203	301A
7:00 - 8:30	ABBOTT Satellite Symposium				
8:30 - 10:00		Plenary Session 1 Global Syphilis Prevention and Control: Challenges & Opportunities			
10:00 - 10:30	Break - Exhibition Hall - Room 400ABC				
10:30 - 12:00			Epidemiology OS 1 Chlamydia	Behavioural aspects of prevention OS 1 Changes over time: Evolution of individual and population level patterns	Clinical sciences OS 1 Syphilis: Enhanced Approaches for Detection & Characterization
12:00 - 13:30	MERCK Satellite Symposium				
13:30 - 14:15		Plenary Session 2 Concentrated, mixed and generalized epidemics - typologies and effectiveness of core group interventions - <i>David Wilson</i>			
14:15 - 14:45	Break - Exhibition Hall - Room 400ABC				
14:45 - 16:15			Symposium 4 Speeding up Elimination of Congenital Syphilis with Rapid Syphilis Testing: Progress and Challenges	Behavioural aspects of prevention OS 2 Innovative STI and HIV preventive interventions: intended and unintended consequences	Clinical sciences OS 2 Genital Human Papillomaviruses & Trichomoniasis
16:15 - 17:00		Special Plenary Session Antiretroviral therapy for the prevention of HIV: where are we now and where are we going? - <i>Myron S. Cohen</i>			
17:00 - 18:30	Poster Session - Exhibition Hall - Room 400ABC				

302B	Main Hall
Satellite Symposium Meeting of the International Collaboration on Gonococci	
	Welcome Reception

301B	302A	302B	303AB	304AB	200ABC
				Training Session Scholarship Recipients & Young Investigators	
Health services & policy OS 1 Innovation technology	Basic sciences OS 1 Genomics, replication and pathogenesis	Epidemiology OS 2 Human Papillomavirus	Symposium 2 Rapid Tests as Tools to Transform Policy, strengthen Health Systems and Save Lives	Symposium 1 Measurement of sensitive behavior	
Epidemiology OS 4 STI and HIV among youth	Basic sciences OS 2 Immunity and animal models	Epidemiology OS 3 Bacterial resistance	Symposium 3 Evaluation of large-scale and complex public health interventions	Symposium 5 Unsolved Challenges in Women's Sexual and Genital Health	

PROGRAM AT A GLANCE

TUESDAY JULY 12, 2011

Room	200AB	200C	202	203	301A
7:00 - 8:30	GEN-PROBE Satellite Symposium				
8:30 - 10:00		Plenary Session 3 The Perfect Storm : STD Control and the Emergence of HIV - <i>Jacques Pépin</i> Plenary Session 4 Evolution of STI Pathogens in Context of Changing Environment: Biology and Behaviour - <i>Max Essex, Jane Carlton</i>			
10:00 - 10:30	Break - Exhibition Hall - Room 400ABC				
10:30 - 12:00			Symposium 7 In the quest for HIV prevention Scale up: Avahan's India experience. Program Approaches and Emerging Evaluation Results	Epidemiology OS 6 Planning of HIV preventive interventions	Clinical sciences OS 3 Diagnostic Testing: Chlamydia & Gonorrhoeae
12:00 - 13:30	BD - Satellite Symposium				
13:30 - 14:15		Plenary Session 5 Trichomoniasis: Why is It the Neglected STD? - <i>Marcia Hobbs</i>			
14:15 - 14:45	Break - Exhibition Hall - Room 400ABC				
14:45 - 16:15			Epidemiology OS 8 STIs and HIV in female sex workers	Symposium 9 Applications of Program Science in the Field of STI	Clinical sciences OS 4 Treatment: Chlamydia, Gonorrhoea & Related Syndromes
16:15 - 18:00	Poster Session - Exhibition Hall - Room 400ABC				

WEDNESDAY JULY 13, 2011

Room	200AB	200C	202	203	301A
7:00 - 8:30	SIEMENS Satellite Symposium				
8:30 - 10:00		Plenary Session 6 Sex, Science and Social Politics: Implications for STI and HIV Prevention in the 21st Century			
10:00 - 10:30	Break - Exhibition Hall - Room 400ABC				
10:30 - 12:00			Epidemiology OS 9 Use of observational data and mathematical modelling for impact evaluation	Behavioural aspects of prevention OS 5 Individual, Structural and Contextual Coping Strategies: Diverse causes and solutions	Clinical sciences OS 5 Treatment: Syphilis, Herpes, & Bacterial Vaginosis
12:00 - 13:30	American STD Association Award Presentations & Luncheon The 30 Year War Against HIV/AIDS: Have We Reached The Tipping Point				
13:30 - 15:00			Epidemiology OS 11 Various topics of special interest	Behavioural aspects of prevention OS 6 STI and HIV Risk: geographic, demographic and behavioural heterogeneity	Clinical sciences OS 6 Clinical Advances in Diagnosis & Screening
15:00 - 15:15	Break - Exhibition Hall - Room 400ABC				
15:15 - 16:30		Summary and Highlights			
16:30 - 17:30		Closing Ceremony Responding to STI and HIV in the digital age? - <i>Jeffrey Klausner</i>			

301B	302A	302B	303AB	304AB	200ABC
				Training Session Scholarship Recipients & Young Investigators	
Health services and policy OS 2 Evaluation of services and policies	Epidemiology OS 5 Vaginal infections	Behavioural aspects of prevention OS 3 Sexual and diagnostic behaviours: issues in measurement	Symposium 6 Updates and perspectives on STI and HIV issues among MSM	Symposium 8 The Global Public Health Challenge of Untreatable Multidrug-resistant Neisseria gonorrhoeae (MDR-GC) "Superbug"	
Health services and policy OS 3 Partner notification	Epidemiology OS 7 Neglected issues in anal STIs and transmission	Behavioural aspects of prevention OS 4 STI and HIV Risk Reduction Strategies: Considerations of cost, cost-effectiveness and potential impact	Symposium 10 Strategic Approaches for Addressing Sexual Health: Lessons, Challenges and Opportunities	Symposium 11 Controversies in Serologic Testing for Syphilis	
301B	302A	302B	303AB	304AB	200ABC
				Training Session Scholarship Recipients & Young Investigators	
Health services and policy OS 4 Screening	Symposium 13 Respondent Driven Sampling: where we are and where should we be going?	Late Breaker Symposium Questioning Azithromycin for Uncomplicated Genital Chlamydial Infection	Symposium 12 Current Topics on Human Papillomavirus	Epidemiology OS 10 Men who have sex with men	
Late breaker abstracts session		Symposium 14 Research in Progress: Updates from American STD Association Developmental Award Recipients		Symposium 15 STI epidemiology in Europe: challenges for prevention and control	
	Training Session Publishing in Clinical and Public Health Research				

GENERAL INFORMATION



BADGES

Please wear your name badge at all times.

BUSINESS CENTRE

For tourist information, reservations, souvenirs, and tours, the skilled concierge staff can handle a wide variety of needs in addition to providing fax and photocopy services. The Business Centre is located on the 4th level and has the same open from 8:00 – 17:00.

CERTIFICATE OF ATTENDANCE

Certification of attendance will be handout upon registration.

CURRENCY

The official currency in Canada is the Canadian Dollar. All major credit cards are accepted in most hotels, restaurants and shops.

INTERNET

Free Wi-Fi Internet access is available throughout the Québec City Convention Centre.

LANGUAGE

The official language of the Conference is English.

LOST PROPERTY

Please hand in lost property to the Registration Desk where it will be made available for collection.

VENUE

Québec City Convention Centre
1000, boul. René-Lévesque Est
Québec, QC G1R 5T8
Canada

OPENING HOURS OF THE REGISTRATION DESK

Registration will take place in the Main Hall.

Sunday:	8:00 – 16:00	Exhibitor Registration
	8:00 – 20:00	Registration Open
Monday:	6:30 – 17:30	
Tuesday:	6:30 – 17:30	
Wednesday:	6:30 – 15:00	

BREAKFAST AND LUNCHESES

Courtesy of the Conference Sponsors, breakfast and lunch will be offered to those attending Industry Sponsored Satellite Symposia.

MESSAGE BOARD

The contact number for people wishing to leave a message for you during the Conference opening hours is: 418-649-5231

Names of those for whom a message has been left will be posted on the message board located at the Registration Desk.

MOBILE PHONES

As a courtesy to the speakers and other delegates, please note that mobile phones must be switched off during all sessions.

SMOKING

Smoking is not permitted in any part of the Québec City Convention Centre.

SPEAKER READY ROOM

The Speaker Ready Room is located in the third level of the Convention Centre in Room 200C. All speakers must check into the Speaker Ready Room 201C at least 4 hours prior to their session time. The Speaker Ready Room will be staffed with technicians that can assist with any compatibility or formatting issues.

USEFULL PHONE NUMBERS

Secretariat of the Conference –
Québec City conference Centre: 418-649-5231

Emergencies on local telephones
(land line and mobile): 911


Long distance calls to most North America:
1 plus 10 digits

Long distance call to elsewhere than
North-America: 011, country code and local digits.

SOCIAL PROGRAM

Opening Ceremony & Welcome Reception (Sunday July 10, 17:30 – 20:00)

Registered participants and registered
accompanying persons are invited to the Opening
Ceremony that will take place in Room 200C
followed by the Reception in the Main Hall.



President's Dinner (Monday July 11)

By invitation only –
The President's Dinner
will take place at the
Québec Garrison Club.



Banquet

(Tuesday July 12, 2011)

The banquet will take place
in the Ball Room of the
the magnificent Fairmont
Le Château Frontenac.
Please ensure you bring
your Banquet Ticket
with you.


Closing Ceremony

(Wednesday July 12, 16:30 – 17:30)


Registered participants and registered accompanying
persons are invited to the Closing Ceremony that
will take place in Room 200C.

VENUE FLOOR PLANS


Second Floor



Third Floor



Fourth Floor



EXHIBITION INFORMATION

EXHIBITION OPENING HOURS


The Exhibition Hall is located in Room 400.

Monday July 11 8:30 – 18:30

Tuesday July 12 8:30 – 18:00

Wednesday July 13 8:30 – 15:00

ISSTD R QUÉBEC 2011



EXHIBITORS LIST

BOOTH No.	EXHIBITOR	BOOTH No.	EXHIBITOR
11	ABBOTT MOLECULAR	10	MERCK
13	BD DIAGNOSTICS	9	MSSS/INSPQ QUÉBEC
14	BMJ JOURNALS	5	PUBLIC HEALTH AGENCY OF CANADA
16	ECDC	2	ROCHE MOLECULAR SYSTEM
8	GEN-PROBE	18	SEKISUI DIAGNOSTICS
3	GRACEWAY PHAMACEUTICALS	7	SIEMENS HEALTHCARE DIAGNOSTICS
1	HOLOGIC	20	STANDARD DIAGNOSTICS
17	INESSS	12	STD DIAGNOSTICS INITIATIVE
6	IUSTI 2012 World Congress, Australia	15	STI VIENNA 2013 (ISSTD R/IUSTI)
19	MIKKOM LIMITED	4	TRINITY BIOTECH

EXHIBITOR PROFILES

Abbott Molecular**Stand 11**

7115 Millcreek Dr.
Mississauga, ON L5N3R3
Canada
Tel.: 647 227-8656
Email: jim.douey@abbott.com
www.abbottmolecular.com

Abbott Molecular is a rapidly growing molecular diagnostics business that provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. The business includes instruments and reagents used to conduct sophisticated analysis of patient nucleic acids.

BD Diagnostics**Stand 13**

7 Loveton Circle
Sparks, MD 21152
USA
Tel.: 410 316-4024
Fax: 410 316-4906
Email: bonnie_grimes@bd.com
www.bd.com

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

BMJ Journals**Stand 14**

BMA House, Tavistock Square
London, WC1H 9JP
United Kingdom
Tel.: 44 02207 383 6706
Fax: 44 0207 383 6661
Email: labbott@bmjgroup.com
www.bmj.com

Sexually Transmitted Infections (STI) is the world's longest running international journal dealing with issues of sexual health and medicine. STI publishes original work on the clinical, epidemiological, and laboratory aspects of sexual health, sexually transmitted infections, and HIV and AIDS. Visit STI online to subscribe, view free editor's choice articles, access the online archive, sign up for email alerts and listen to podcasts.
Email: subscriptions@bmjgroup.com
Web: sti.bmj.com

ECDC**Stand 16**

E-171 83 Stockholm
Sweden
Tel.: 46 858 60 7457
Fax: 46 858 60 1294
Email: Caroline.Daamen@ecdc.europa.eu
www.ecdc.europa.eu

The European Centre for Disease Prevention and Control (ECDC) was established by the EU to identify, assess and communicate current and emerging threats to human health posed by infectious diseases. To achieve this, ECDC works with national health protection bodies to strengthen disease surveillance and early warning systems across Europe.

Gen-Probe**Stand 8**

10210 Genetic Center Dr
San Diego, CA 92121
USA
Tel.: 858 410-8997
Fax: 858 410-8185
karen.capps@gen-probe.com
www.gen-probe.com

Gen-Probe is a leader in molecular diagnostics for STDs and microbial infectious diseases, including the recently FDA-approved APTIMA® Trichomonas vaginalis assay, and APTIMA assays for Chlamydia, gonorrhea, and HPV*. Visit our booth to view the next-generation PANTHER™*, a fully automated NAT system for low- to mid-volume laboratories (*not available for use in the U.S. or Canada).

GRACEWAY PHARMACEUTICALS **Stand 3**

252 Pall Mall Street, Suite 302
London, ON N5A 5P6
Canada
Tel.: 519 432-7373
Fax: 519 732-8097
Email: paula.ballard@gracewaypharma.com
www.gracewaypharma.com

Graceway Pharmaceuticals is contributing to therapeutic advancements focusing in Dermatology, Pediatric and Adult Respiriology. We strive to better understand the needs of patients and healthcare providers delivering valued products to improve the health of Canadians.

HOLOGIC® **Stand 1**

35 Crosby Drive
Bedford, MA 01730
USA
Tel.: 781-999-7771
Fax: 781-280-0668
Email: ryan.carney@hologic.com
www.hologic.com

HOLOGIC® is a leading developer, manufacturer and supplier of premium medical diagnostic tests, medical imaging equipment and surgical products dedicated to serving the healthcare needs of women throughout the world. Hologic's molecular solutions are based on the company's versatile Invader® chemistry, and include Cervista™ HPV HR, Cervista™ HPV 16/18 and InPlex® CF, as well as other genetic tests.

INESSS **Stand 17**

1195 Avenue Lavigerie, bureau 60
Québec, QC G1V 4N3
Canada
Tel.: 418 646-4779
Email: olivia.jacques@inesss.qc.ca
www.inesss.qc.ca

L'INESSS a pour mission de promouvoir l'excellence clinique et l'utilisation efficace des ressources dans le secteur de la santé et des services sociaux. L'Institut conçoit divers outils cliniques, dont des guides de pratique pour le traitement pharmacologique des ITSS. Pour plus d'information sur ces guides, venez nous visiter au kiosque 17!

IUSTI 2012 Congress, Australia **Stand 6**

Level 7/46 - 56 Kippax Street
Surry Hills, NSW 2100
Australia
Tel.: 61 2 8204 0774
Fax: 61 2 9212 4670
Email: nicole.robertson@ashm.org.au
www.ashm.org.au

The International Union against Sexually Transmitted Infections (IUSTI) Congress will be held in Melbourne, Australia from 15 – 17 October 2012 in conjunction with the Australasian Sexual Health and HIV/AIDS Conferences.

Join internationally renowned scientists and clinicians to share information on sexually transmitted infections and control. Visit www.iusti2012.com for information.

Merck **Stand 10**

1 Merck Drive
Whitehorse Station, NJ 08889-0100
USA
Tel.: 908-423-6868
Fax: 207 305-1266
Email: nand.kumar@merck.com
www.merck.com

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Merck. Be well. For more information visit www.merck.com

Mikkom Limited **Stand 19**

13-15 Sheet Street
Windsor, Berkshire SL4 1BN
United Kingdom
Tel.: 08707106675
Email: brenda.pope@mikkom.com
www.mikkom.eu

Mikkom provides mobile/Internet based solutions to the private and public sectors in the UK and abroad. Building on over a decade of cooperative development, Mikkom's inbound and outbound communications solutions are trusted by the UK NHS and MoD to deliver highly secure, 365/24/7 service and accessibility.

MSSS/INSPQ Québec**Stand 9**

190 boul Crémazie Est,
Montréal, QC H2P1E2
Canada
Tel.: 514 864-1600 (3311)
Email: Delphine.Descamps@inspq.qc.ca
www.inspq.qc.ca

The mission of the Ministère de la Santé et des Services sociaux is to maintain, improve, and restore the health and well-being of Quebecers by providing access to a set of integrated and high-quality health services and social services, thereby contributing to the social and economic development of Québec.

The Institut national de santé publique du Québec (INSPQ) supports the Ministre de la Santé et des Services sociaux du Québec, regional public health authorities and health and social services institutions in carrying out their public health responsibilities, by offering its expertise as well as its specialized laboratory and screening services.

Public Health Agency of Canada**Stand 5**

130 Colonnade Road
Ottawa, ON K1A 0K9
Canada
Tel.: 613-960-4524
Email: elizabeth.jarvis@phac-aspc.gc.ca
www.phac-aspc.gc.ca

The Public Health Agency of Canada is responsible for public health (PH) issues in Canada. It has a leadership role in promoting health; preventing and controlling chronic and infectious diseases; responding to PH emergencies; and strengthening PH capacity. This includes decreasing the incidence and transmission of communicable diseases and infections.

Roche Molecular System**Stand 2**

4300 Hacienda Drive
Pleasanton, CA 94588
USA
Tel. : 925-730-8793
Email : april.falcone@roche.com
www.roche.com

Roche Molecular Diagnostics (RMD) offers a unique range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies. Roche's cobas® 4800 System allows you to run the cobas® CT/NG Test which features a double target CT test and the new generation NG test designed for high specificity.

Sekisui Diagnostics**Stand 18**

31 New York Avenue
Framingham, MA 01701
USA
Tel.: 800 332 1042
Email: maureen.trickett@sekisuidiagnostics.com
www.sekisuidiagnostics.com

Sekisui Diagnostics OSOM® rapid tests line includes Influenza A & B, Pregnancy, Strep A, Mononucleosis, Trichomonas, Bacterial Vaginosis, H. pylori, C. Difficile and other infectious disease assays. For more information please visit our web site at www.sekisuidiagnostics.com

Siemens Healthcare Diagnostics**Stand 7**

511 Benedict Ave
Tarrytown, NY 10591
USA
Tel.: 914 524-5149
Email: julie.wojda@siemens.com
www.siemens.com

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.

Standard Diagnostics, Inc.**Stand 20**

156-68 Hagal-dong, Giheung-ku
Yongin, Gyeonggi 446-930
South Korea
Tel.: 81-31-899-2873
Fax: 81-31-899-2840
Email: steve@standardia.com
www.standardia.com

Standard Diagnostics, Inc. (SD) has been engaged in the research, development, and commercialization of in-vitro diagnostic products since 1999. SD supplies the company's flagship products, ICA rapid test kits, which are available through 160 distributors in 100 countries for the point-of-care testing (POCT) of infectious diseases, Respiratory diseases tumor and cardiac markers, hormones, and forensics. All SD products are manufactured in-house under strict quality controls to meet the international standards (ISO 13485:2003, etc.).

STD Diagnostics Initiative**Stand 12**

Keppel Street
London, WC1E 7HT
United Kingdom
Tel.: 44 20 7927 2010
Fax: 44 20 7637 4314
Email: elisabeth.downe@lshtm.ac.uk
www.lshtm.ac.uk

The Sexually Transmitted Diseases Diagnostics Initiative (SDI) aims to promote the development, evaluation and application of diagnostic tests for STDs appropriate for use in primary health care settings in developing countries. Tools which have been developed for the introduction of rapid syphilis tests with our partner countries will be available.

STI World Congress Vienna 2013 **Stand 15**

c/o Vienna Medical Academy
Alser Strasse 4, 1090 Vienna
Austria
Tel: 0043 1 405 13 83 11
Fax: 0043 1 407 82 74
Email: STIvienna2013@medacad.org
www.STIvienna2013.com

Professor Angelika Stary, chair of the joint Meeting of the 20th ISSTD and 14th IUSTI, is pleased to invite you to the beautiful city of Vienna, Austria. The conference will take place from July 14 to July 17, 2013. Our booth is awaiting you for further information. See you there!

Trinity Biotech**Stand 4**

2823 Grits Road
Jamestown, NY 14701
USA
Tel.: 3125434241
Fax: 7164871419
Email: heidi.maxwell@trinityusa.com
www.trinityusa.com

Trinity Biotech specializes in the development, manufacture and marketing of diagnostic test kits used in the clinical laboratory and point-of-care segments of the world wide diagnostic market. Our kits are used to detect infectious diseases, sexually transmitted diseases, autoimmune and hemoglobin disorders, for the detection, monitoring and control of diabetes.

SCIENTIFIC PROGRAM

PLENARY PROGRAM

SUNDAY 10 JULY 2011

17:30 – 19:00

OPENING CEREMONY



Reconfiguring the AIDS response
Keynote Speaker: Dr. Paul De Lay
Deputy Executive Director
UNAIDS

MONDAY 11 JULY 2011

8:30 – 10:00

PLENARY SESSION 1: GLOBAL SYPHILIS PREVENTION AND CONTROL: CHALLENGES & OPPORTUNITIES

Co-chairs:

Dr Thomas Wong, Public Health Agency of Canada, Ottawa, Canada

Dr Rafael Mazin, Pan American Health Organization/Regional Office of the World Health Organization for the Americas, Washington, USA



The global epidemiology of syphilis and the challenges and opportunities to address maternal and congenital syphilis

Dr. Francis J. Ndowa
Coordinator, STI Team,
Department of Reproductive Health and Research,
World Health Organization,
Geneva, Switzerland



Syphilis: Advances in the diagnosis, antimicrobial resistance and management

Barbara Romanowski MD, FRCPC, FACP
Clinical Professor,
Division of Infectious Diseases, Department of Medicine, University of Alberta
Associate Clinical Professor,
Department of Community Health Sciences, University of Calgary, Canada



Preventing syphilis: new approaches in light of shifting key populations

Gail Bolan, MD
Director of the Division of STD Prevention,
Centers for Disease Control and Prevention (CDC)
Atlanta, Georgia, USA

13:30 – 14:15

PLENARY SESSION 2:

CONCENTRATED, MIXED AND GENERALIZED EPIDEMICS - TYPOLOGIES AND EFFECTIVENESS OF CORE GROUP INTERVENTIONS

Co-chairs:

Dr Marie-Claude Boily, Imperial College, London, UK

Dr Francis Plummer, Public Health Agency of Canada, Ottawa, Canada



David Wilson

Program Director, AIDS Team,
Health Nutrition & Population,
World Bank
Washington, D.C., USA

16:15 – 17:00

SPECIAL PLENARY SESSION:

ANTIRETROVIRAL THERAPY FOR THE PREVENTION OF HIV: WHERE ARE WE NOW AND WHERE ARE WE GOING?

Co-chairs:

Dr Benoît Mâsse, Fred Hutchison Cancer Institute, Seattle, USA & Université de Montréal, Canada

Dr Michel Alary, Université Laval, Québec, Canada



Myron S. Cohen, MD

J. Herbert Bate Professor of Medicine, Microbiology and Immunology
and Public Health at the University of North Carolina, Chapel Hill, NC, USA
Associate Vice Chancellor for Medical Affairs-Global Health
Director of the UNC Division of Infectious Disease and the UNC Institute
for Global Health and Infectious Disease

TUESDAY 12 JULY 2011

8:30 – 10:00

PLENARY SESSION 3:

THE PERFECT STORM: STD CONTROL AND THE EMERGENCE OF HIV (30 MIN)

Co-chairs:

Dr Michel Alary, Université Laval, Québec, Canada

Dr David Lewis, National Institute for Communicable Diseases, Johannesburg, South Africa



Jacques Pépin, MD, FRCPC, MSc

Professor of Infectious Diseases,
University of Sherbrooke,
Sherbrooke, Canada

PLENARY SESSION 4:

EVOLUTION OF STI PATHOGENS IN CONTEXT OF CHANGING ENVIRONMENT: BIOLOGY AND BEHAVIOUR (1 HOUR)

Co-chairs:

Dr Jo-Anne Dillon, University of Saskatchewan, Saskatoon, Canada

Dr Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA



Evolution of the HIV-1C epidemic in southern Africa and lessons for controlling an uncontrollable virus

Max Essex DVM, PhD

Lasker Professor, Health Sciences at Harvard University, Boston, MA
Chair of the Harvard School of Public Health AIDS Initiative,
Chair of the Botswana–Harvard AIDS Institute in Gaborone, Botswana



A Trich-y parasite: genomics, population genetics and evolution of Trichomonas vaginalis

Jane Carlton PhD

Director of Genomics and Associate Professor of Parasitology,
New York University School of Medicine, USA

13:30 – 14:15

PLENARY SESSION 5:

TRICHOMONIASIS: WHY IS IT THE NEGLECTED STD?

Co-chairs:

Dr Jeanne Marrazzo, University of Washington, Seattle, USA

Dr Annie-Claude Labbé, Université de Montréal, Montréal, Canada



Marcia Hobbs PhD

Professor of Medicine and Microbiology & Immunology
School of Medicine at the University of North Carolina, Chapel Hill
Member of the faculty of the Division of Infectious Diseases and director
of the Clinical and Microbiology Laboratory Core of the NIAID-funded
Southeastern Sexually Transmitted Infections Cooperative Research Center, USA

WEDNESDAY 13 JULY 2011

8:30 – 10:00

PLENARY SESSION 6:

SEX, SCIENCE AND SOCIAL POLITICS: IMPLICATIONS FOR STI AND HIV PREVENTION IN THE 21ST CENTURY

Chair:

Dr Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA



The “black box” between research and intervention

Alain Poirier MD, FRCP (C)

Professor for the department of public preventive internal medicine, Faculty of Medicine, University of Montreal
National Director of Public Health and Assistant Deputy Minister to the Ministry of Health and Social Services, Québec, Canada



HIV/STI Prevention: Using Epidemiology to Change Behavior

Mary Ann Chiasson M.S., M.P.H., Dr. P.H.

Vice President for Research and Evaluation at Public Health Solutions (PHS)
Associate Professor of Clinical Epidemiology (in Medicine)
at Columbia University, New York, USA



Prevention of STBBIs. Do we know where we’re going?

Do we know how we’re getting there?

Margaret Fast B.Sc. (Medicine), MD, DTCH, FRCP(C)

Departments of Medical Microbiology, Community Health Sciences, and Pediatrics and Child Health,
University of Manitoba, Winnipeg, Canada

15:15 – 16:30

SUMMARY AND HIGHLIGHTS



Rapporteur for track 1 (Epidemiology)

Dr. Anne Buvé

Institute of Tropical Medicine
Antwerp, Belgium



Rapporteur for track 2 (Behavioural aspects of prevention)

Dr. Jami S. Leichter

Centers for Disease Control and Prevention
Atlanta, GA, USA



Rapporteur for tracks 3 and 4 (Clinical and basic sciences)

Dr. Barbara Van Der Pol

Indiana University School of Medicine
Indianapolis, IN, USA



Rapporteur for track 5 (Health services and policy)
Dr. Ameeta Singh
University of Alberta
Edmonton, AB, Canada

17:30 – 19:00

CLOSING CEREMONY



Responding to STI and HIV in the digital age
Keynote Speaker: Jeffrey D. Klausner, MD, MPH
Chief of the HIV and TB Care and Treatment Branch,
US CDC, South Africa
Associate Clinical Professor of Medicine in the Divisions of AIDS
and Infectious Diseases
University of California, San Francisco

BIOGRAPHY OF THE PLENARY SPEAKERS

Paul De Lay joined UNAIDS in February 2003 and was appointed the Deputy Executive Director, Programme, in June 2009. Since 1988, Dr De Lay has been engaged in strategic planning, implementing and monitoring national and international AIDS programmes. During his previous role as Director of the Department for Evidence, Monitoring and Policy (EMP), Dr De Lay led UNAIDS work to promote a comprehensive, evidence informed and adequately resourced response to the HIV epidemic. This included providing strategic information and policy guidance, monitoring programmatic coverage and behavioural trends, building country capacity, and evaluating the effectiveness of the response at the country, regional and global levels. The Department also coordinates the annual reporting to the UN Secretary General on progress toward achieving the UN General Assembly Special Session Declaration of Commitment. As Deputy Executive Director, Dr De Lay will work on implementing the new vision for UNAIDS, which includes the priorities of the new Executive Director and will reflect the findings and recommendations of the Second Independent Evaluation and other current analyses of roles, responsibilities, and functions within the joint Programme. He is a medical doctor with training and experience in family practice, infectious and tropical diseases, epidemiology, preventive medicine and public health. He practiced clinical medicine for 15 years. He previously worked with the Global Programme on AIDS at the World Health Organization and served as Chief of the HIV/AIDS Division at USAID. He has a medical degree from the University of California, Board Certification in Preventive Medicine and Public Health, and holds a Diploma of Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine. He is married to Karen Stannecki, who works as a bio-statistician.

Dr. Francis Ndowa is a Medical Officer in the Department of Reproductive Health and Research of the World Health Organization (WHO) in Geneva. He is the Coordinator of the Controlling Sexually Transmitted and Reproductive Tract Infections (STI) Team which has its primary role divided into thematic areas under: (1) Control of sexually transmitted infections; (2) Global elimination of congenital syphilis initiative; (3) Prevention of mother-to-child transmission of HIV research; (4) Microbicides; (5) Human papillomavirus vaccines and cervical cancer prevention; and (6) Safety and standards for male circumcision and male and female condoms. In 1996 he joined the Joint United Nations Programme on HIV/AIDS (UNAIDS) as the STI and Reproductive Health Advisor, and subsequently moved in 2000 with the STI unit from UNAIDS into WHO in the Department of HIV/AIDS where he was primarily responsible for STI work within the Prevention Team of the Department. In 2002 STI-related activities were incorporated into the WHO Department of Reproductive Health and Research. Dr. Ndowa qualified as a medical doctor in 1977 at the University of Birmingham, England, and holds postgraduate Diploma Dermatology and a Diploma Genito-urinary Medicine (London, UK). He worked extensively in the areas of chest infections and diseases, rheumatology, dermatology, STI, HIV and AIDS in the United Kingdom before returning to Zimbabwe in 1983.

Dr. Barbara Romanowski, MD, FRCPC, FACP, is a Clinical Professor in the Division of Infectious Diseases, Department of Medicine, University of Alberta, with a cross appointment in the Department of Medical Microbiology and Immunology. She is also Associate Clinical Professor, in the Department of Community Health Sciences, University of Calgary. She attended the University of Alberta and earned her BSc in Medicine and her Doctor of Medicine from the same university. She completed her postgraduate training in Internal Medicine and Infectious Disease in 1978 at the University of Alberta. She held the post of Director of the Sexually Transmitted Disease Program for the Province of Alberta from 1979 to 1998. Dr. Romanowski has published extensively on STD. She is a member of a large number of medical societies, on the editorial board of national and international scientific journals, a member of reviewing bodies for national granting agencies in Canada and the United States, and has held national and international posts in the area of STD.

Dr. Gail Bolan is Director of the Division of STD Prevention at the Centers for Disease Control and Prevention (CDC). A graduate of Dartmouth Medical School, she completed her training in internal medicine at the University of Virginia, in infectious diseases at Tufts New England and Stanford Medical Centers and in medical epidemiology as a CDC EIS officer in the Respiratory and Special Pathogens Branch. Prior to joining CDC, she served as the Chief of the STD Control Branch at the California Department of Public Health. Bolan is a leader in the field of STD Prevention and is recognized for her contributions in applied STD prevention research and implementation of science-based STD programs. Dr. Bolan has over 125 scientific publications. She has served on the CDC HIV/STD Prevention Advisory Committee and OID Board of Scientific Counselors, the Executive Committee of ASTDA, and Board of Directors of NCS and ASHA.

Mr. David Wilson is the World Bank's Global AIDS Program Director. He has worked on AIDS for almost 25 years, as a scientist and program manager, in over 50 countries in all regions, including the Middle East. His interests lie in AIDS epidemiology, HIV prevention science and program impact evaluation.

Myron S. Cohen is J. Herbert Bate Professor of Medicine, Microbiology and Immunology and Public Health at the University of North Carolina at Chapel Hill. He is Associate Vice Chancellor for Medical Affairs-Global Health. Dr. Cohen is Director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease. Dr. Cohen serves on the Leadership Groups of the NIH Center for HIV Vaccine Immunology (CHAVI) and the NIH HIV Prevention Trials Network (HPTN). Dr. Cohen's research focuses on the transmission and prevention of transmission of HIV; he is the author of more than 500 publications. Much of Dr. Cohen's research has been conducted in Malawi and the People's Republic of China.

Jacques Pepin is Professor of Infectious Diseases at the University of Sherbrooke, Canada. After working as a district medical officer in Zaire for 4 years, he completed a residency in internal medicine and infectious diseases, worked for the Medical Research Council in The Gambia and returned to Canada in 1990. For many years his research interests have focused on African trypanosomiasis, HIV and STIs in sub-Saharan Africa. He has also managed large HIV control projects in West Africa. More recently, he has investigated the role of medical interventions for the control of tropical diseases in the emergence of HIV-1 and HIV-2 in the early 20th century. He has written a book on the origins of AIDS which will be published in August 2011.

Max Essex, DVM, PhD, is Lasker Professor of Health Sciences at Harvard University, Chair of the Harvard School of Public Health AIDS Initiative, and Chair of the Botswana-Harvard AIDS Institute in Gaborone, Botswana. He was one of the first to link animal and human retroviruses to immunosuppressive disease. For this he shared the Lasker Award, the highest medical research award given in the United States, with Gallo and Montagnier in 1986. With his student, T. H. Lee, he was also the first to identify gp120, the surface protein of HIV-1 that is used for blood screening and diagnosis of AIDS, as well as various vaccine designs. He has received numerous other awards and 9 honorary degrees, and holds 15 patents. He has published over 500 papers and 10 books, the latest being *Saturday Is for Funerals*. His current research includes comprehensive "test-and-treat" approaches to controlling the HIV epidemic, molecular epidemiology, the role of host genetics factors, and chemoprophylaxis, with emphasis on southern Africa.

Jane Carlton is Director of Genomics and Associate Professor of Parasitology at New York University School of Medicine. She received her doctorate in Genetics at the University of Edinburgh, and has spent the past 12 years on the faculty of several institutions in the United States, including the University of Florida and The Institute for Genomic Research (TIGR). Dr. Carlton is passionate about genomics and the power that this technology has to revolutionize medicine. Her own research involves decoding the DNA of important human pathogens - in particular species of malaria, as well as parasites prevalent in the U.S. such as the common STD 'trich'. She has published more than 80 articles and book chapters, is the recipient of multi-million dollar federal grants, and her work has been profiled by several media organizations including CNN, BBC, The Economist and USA Today.

Marcia M. Hobbs, PhD is Professor of Medicine and Microbiology & Immunology in the School of Medicine at the University of North Carolina at Chapel Hill. She is a member of the faculty of the Division of Infectious Diseases and director of the Clinical and Microbiology Laboratory Core of the NIAID-funded Southeastern Sexually Transmitted Infections Cooperative Research Center. Core laboratory activities support a variety of research projects aimed directly at diagnosis, treatment and prevention of sexually transmitted infections or the use of these infections as bio-markers in evaluating biomedical or behavioral interventions aimed at STI/HIV prevention. Dr. Hobbs serves as a laboratory advisor on several NIH, CDC and USAID-supported projects in Jamaica, Malawi, China and Madagascar and is co-investigator on multiple STI clinical research projects in the US.

Alain Poirier is assistant Professor for the department of public preventive internal medicine in the Faculty of Medicine with the University of Montreal. He is a specialist in community health; he has worked in public health for more than twenty years. He has also participated internationally as an international health consultant and teacher. Since January, 2003, he has worked as National Director of Public Health and Assistant Deputy Minister to the Ministry of Health and Social Services. Previously, Dr Poirier worked as medical Advisor to Quebec's National Institute for Public Health and as Public Health Advisor for Quebec's Ministry of Water and Environment.

Mary Ann Chiasson, M.S., M.P.H., Dr. P.H. is Vice President for Research and Evaluation at Public Health Solutions (PHS), a New York City non-profit, and an Associate Professor of Clinical Epidemiology (in Medicine) at Columbia University. Before joining PHS in 1999, Dr. Chiasson served for fourteen years in various capacities at the New York City Department of Health including nine years as an Assistant Commissioner of Health with responsibility for AIDS Surveillance, HIV/AIDS Research, and Vital Statistics and Epidemiology. Dr. Chiasson's research interests include the epidemiology of sexually transmitted infections, women's reproductive health, infant mortality, and early childhood obesity. Her current HIV/STI-related research focuses on the relationship between the Internet and high risk sexual behavior among men who have sex with men. The HIV prevention videos produced by the research collaboration she leads are available at www.hivbigdeal.org.

Dr. Margaret Fast, B.Sc. (Medicine), MD, DTCH, FRCP(C), earned her Medical Degree from the University of Manitoba and, in addition to training in infectious diseases, completed Fellowships in pediatrics and community medicine. She has worked in Viet Nam and in Kenya. Most of Dr. Fast's professional life has been devoted to public health in Canada; she has been the Scientific Director of the National Collaborating Centre for Infectious Diseases since November 2008. Dr. Fast holds appointments in the Departments of Medical Microbiology, Community Health Sciences, and Pediatrics and Child Health at the University of Manitoba.

Anne Buvé graduated as a medical doctor in 1978. In 1980 she obtained the Diploma in Tropical Medicine at the Institute of Tropical Medicine in Antwerp. Between 1980 and 1989 she worked as a district medical officer in Zambia and in Sierra Leone. In 1989-1990 she did the Msc Epidemiology at the London School of Hygiene and Tropical Medicine. In 1993 she joined the Department of Microbiology at the Institute of Tropical Medicine as pre-doctoral researcher. Her main research interest was the heterogeneity of HIV epidemics in sub-Saharan Africa. In 2001 she defended her PhD entitled "Factors determining the differential spread of HIV in sub-Saharan Africa." (University of Antwerp, Belgium). In October 2005 she was appointed Senior Lecturer. Currently she is Assistant Director for Research of the HIV/STI Epidemiology and Control Unit (Head: Prof Marie Laga), Department of Microbiology, Institute of Tropical Medicine. Since October 2006 she is chairperson of the Institutional Review Board of the Institute of Tropical Medicine.

Jami Leichter is a research behavioral scientist in the Division of STD Prevention at the U.S. Centers for Disease Control and Prevention (CDC). Her research interests include high risk, marginalized populations and impoverished communities in the U.S. and South Africa. She has experience with national probability surveys including the U.S. National Survey of Family Growth (NSFG). Dr. Leichter received her PhD in applied experimental psychology from Southern Illinois University (SIU). She joined CDC in 1999 after serving as an associate scientist at SIU. She has co-authored numerous publications and presentations at national and international conferences.

Dr. Barbara Van Der Pol is an Assistant Professor of Epidemiology & Medicine in the Division of Epidemiology & Biostatistics with joint appointments in the Division of Infectious Disease and the African Studies Program at Indiana University. Dr. Van Der Pol has been active in the field of STI biology, epidemiology and diagnostics for more than 25 years. Her laboratory is focused on development, evaluation and application of diagnostic assays for STI, particularly molecular diagnostics. Her research interests include understanding the biological and behavioral factors that affect susceptibility to these infections. Her experience has involved multiple interacting disciplines that all contribute to our understanding of the transmission of STI. She has been a member of research teams involved in studies related to women's reproductive health in the US and in sub-Saharan African where she has also supported technology transfer projects in conjunction with local laboratories.

Dr. Ameeta Singh, BMBS (UK), MSc, FRCPC, is a Clinical Professor in the Division of Infectious Diseases and has been the Medical Director of the Edmonton Sexually Transmitted Infections Clinic since 1998. She completed her undergraduate medical degree in the United Kingdom in 1989. This was followed by an internal medicine residency and infectious diseases fellowship at the University of Alberta, which she completed in 1996. In 2002, she completed a Masters of Science in Epidemiology at Harvard University. From 1998 to 2008, she was the provincial consultant for sexually transmitted and blood borne infections in Alberta. Provincially, nationally and internationally, she has served on a number of committees and contributed to the development of a wide range of guidelines, programs, and policies for HIV, STI and viral hepatitis, and has published extensively in these areas.

Jeffrey D. Klausner is Chief of the HIV and TB Care and Treatment Branch for the US CDC, South Africa and Associate Clinical Professor of Medicine in the Divisions of AIDS and Infectious Diseases at the University of California San Francisco. Jeffrey D. Klausner, MD, MPH, is an infectious disease specialist and medical epidemiologist currently working in South Africa as the Chief of the HIV and TB Care and Treatment Branch for the US CDC, South Africa. From 1998-2010 he was the Director of the STD Prevention and Control Services Section for the San Francisco Department of Public Health. He is an Associate Clinical Professor of Medicine in the Divisions of AIDS and Infectious Diseases at the University of California San Francisco. A well known speaker and author, he is the Senior Editor of *Lange Current Diagnosis and Management of Sexually Transmitted Disease* and has over 250 peer-reviewed publications.

SYMPOSIUM PROGRAM

MONDAY 11 JULY 2011

10:30 – 12:00

Room: 304AB

Symposium 1 - Measurement of sensitive behaviour

Co-chairs:

Geoff Garnett, Imperial College, London, UK

Benoit Mâsse, Fred Hutchinson CRC, USA & Université de Montréal, Canada

Synopsis

Understanding and measuring high-risk behaviours and adherence to intervention is important to understand HIV/STI epidemiology and to design and evaluate interventions. However, the measurement of these behaviours is often challenging due to the sensitive nature of the questions, social desirability bias, recall bias, denial, the limits of our measurement tools and others. Much research has been done in recent years to improve the measurement of sensitive behaviours. This symposium aims to review and discuss the most recent methods used to collect, improve and validate these measurements in surveys and clinical trials. It will also include discussions on how biological or pharmacological markers can be used to measure and validate these behaviours more objectively. The symposium should generate an overall discussion of priorities and efforts required to improve the measurement of sensitive behaviours, the level of improvement that can realistically be expected with better tools, given the different sources of biases, and what level of precision and accuracy is really needed in different contexts.

Presentations

Improving the validity of sexual behaviour measurement: using computer assisted methods

Frances M Cowan, University College London, UK & University of Zimbabwe College of Health Sciences, Zimbabwe

Applying Semen Biomarkers to HIV/STI Research

Maria F. Gallo, Centers for Disease Control and Prevention, Atlanta, USA

Measurement of adherence: where are we?

Ariane Van der Straten, University of California, San Francisco, USA

Pharmacological assessment of medication adherence – Oral PrEP and Microbicides

Craig Hendrix, Johns Hopkins University School of Medicine, Baltimore, USA

10:30 – 12:00

Room: 303AB

Symposium 2 - Rapid Tests as Tools to Transform Policy, strengthen Health Systems and Save Lives (sponsored by WHO/TDR and the London School of Hygiene and Tropical Medicine)

Co-chairs:

King Holmes, University of Washington, Seattle, USA

David Mabey, London School of Hygiene and Tropical Medicine, London, UK

Synopsis

Affordable rapid point-of-care (POC) tests are available to support STI screening and syndromic management. This symposium will feature presentations on the feasibility and cost-effectiveness of introducing rapid tests into syphilis screening programmes for prenatal and high risk populations in vastly different health infrastructures, economic levels, and geographic locations. New POC technologies on the horizon will be previewed, followed by a panel discussion on how to use rapid tests to transform policy, overcome health system constraints and save lives in the developing world.

Presentations

Introduction of Rapid Syphilis Tests in Antenatal Care Services in Tanzania: Clients' and Service Providers' Acceptability and Uptake of Testing

Jacklin Mosh¹, John Changalucha, Julius Mngara, Clemens Masesa, Leocardia Kabalila, Engiribeta Makaranga, Kimberly Sollis, Saidi Kapiga, David Mabey, Rosanna Peeling;
(1) National Institute for Medical Research (Mwanza, Tanzania)

Increasing Access to HIV and Syphilis Screening in Remote Areas using Rapid Tests

Adele Benzaken¹, Valdir Monteiro Pinto, Carlos Henrique Carvalho, Rosanna Peeling;
(1) Fundacao Alfredo da Matta (Manaus, Brasil);

Screening High Risk Populations using Rapid Syphilis Tests: The Importance of Social and Cultural Contexts

Xiang-Sheng Chen¹, Yue-Ping Yin, Wan-Hui Wei, Rosanna Peeling;
(1) National Center for STD Control, China CDC (Nanjing, China);

New Technologies to Support STI Screening and Syndromic Management in Resource-limited Settings

Rosanna Peeling, London School of Hygiene and Tropical Medicine, London, UK

14:45 – 16:15

Room: 303AB

Symposium 3 - Evaluation of large-scale and complex public health interventions

Co-chairs:

Lalit Dandona, Public Health Foundation of India, India
Nancy Padian, Pangaia Global AIDS Foundation, Oakland, California, USA

Synopsis

In the world of public health, increasing attention is being placed on the evaluation of the population-level impact of large-scale HIV/STI interventions in order to inform policy makers. The evaluation of such intervention is challenging and often precludes the use of community based randomised control trials (C-RCT) (considered as gold standard) because most individuals in the population simultaneously receive the intervention. In addition, as C-RCT are difficult to conduct and their results often difficult to interpret, their usefulness has also been challenged. Current research is being done to improve impact evaluation studies, outside the context of randomised experiments, that would provide the strength of evidence required for decision making in a timely fashion. This symposium includes an introduction that will summarise the challenges and key issues in the evaluation of public health interventions. The talks will present current thinking on the role of C-RCT, transmission dynamics models, and multi-level strategies to evaluate public health intervention. The symposium will also include a discussion on the type and level of evidence that is required for implementation and scaling up of intervention. The symposium aims to generate discussion on the way forward and research gaps on intervention evaluation in order to provide reliable and objective results for public health decision making.

Presentations

Challenges and key issues in evaluation of public health interventions

Lalit Dandona, Public Health Foundation of India, India

The Role of Community Based Randomized Trials in the Evaluation of Public Health Interventions

Allan Donner, University of Western Ontario, Toronto, Canada

Use of transmission dynamics models to design and evaluate the impact of large scale HIV/STI prevention intervention: how, why and when?

Marie-Claude Boily, Imperial College, London, UK

Multi-level strategies to evaluate the impact of HIV prevention programmes in Zimbabwe

Dr. Simon Gregson, Imperial College, London, UK

Scaling up novel biomedical HIV prevention strategies: evidence for action

Catherine Hankins, UNAIDS, Geneva, Switzerland

14:45 – 16:15

Room: 202

Symposium 4 - Speeding up Elimination of Congenital Syphilis with Rapid Syphilis Testing: Progress and Challenges (sponsored by WHO)

Co-chairs:

Francis Ndowa, World Health Organization, Geneva, Switzerland

Rosanna Peeling, London School of Hygiene & Tropical Medicine, London, England

Synopsis

This session reviews progress and challenges for the global elimination of congenital syphilis initiative, focusing on the role of rapid point-of-care syphilis testing. The first speaker will present updated regional and global estimates of maternal syphilis and associated data limitations. The next speakers will summarize data from Uganda, Zambia, and Peru from the multisite study of impact of rapid syphilis testing on prevention of mother to child transmission of HIV and antenatal care services (the Accessible Quality-assured Diagnostic Tests for STI Project). Finally, speakers will review progress in development of dual non-treponemal and treponemal rapid syphilis tests and discuss global progress and challenges with maternal syphilis testing.

Presentations

Challenges in Global Estimates of Syphilis in Pregnancy

Lori Newman¹, Sarah Hawkes, Mary Kamb, Igor Toskin, Lale Say, Nathalie Broutet;

(1) World Health Organization (WHO), Geneva, Switzerland);

Introduction of Rapid Syphilis Testing Strengthens Health Systems and Health Worker Capacity to Provide Integrated PMTCT Services

Susan Strasser¹, Namwinga Chintu, Tabitha Sripipatana, Katherine Shelley, Othiniel Musana, Anne Phiri, Alexander Tshaka Ncube, Michelle Gill, Heather Hoffman, Edward Bitarakwate;

(1) Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Lusaka, Zambia

Implementation of rapid tests for prenatal syphilis screening: overcoming health system constraints

Garcia PJ¹, Peeling R, Mabey D, Holmes KK, The CISNE team (Spanish word for SWAN);

(1) Universidad Peruana Cayetano Heredia, Lima, Peru

Progress in development of dual rapid syphilis test technology

Dr. David L. Cox, Centers for Disease Control and Prevention, Atlanta, USA

Maternal syphilis testing and treatment to improve maternal and child health services: progress and challenges

Mary Kamb, Centers for Disease Control and Prevention, Atlanta, USA

14:45 – 16:15

Room: 304 AB

Symposium 5 - Unsolved Challenges in Women's Sexual and Genital Health

Co-chairs:

Janet Wilson, University of Leeds, Leeds, United Kingdom

Catriona Bradshaw, Melbourne Sexual Health Centre, Melbourne, Australia

Synopsis

While scientific advances have enhanced prevention and management of several STIs that adversely affect women, other areas relevant to women's genital health remain poorly understood. This symposium will provide state-of-the-art overviews of persistently challenging issues, including recognition and management of non-Trichomonas, non-BV vaginitis; current understanding of vaginal microbiota and contribution to health and disease; new information on pelvic inflammatory disease and implications at public health and individual levels; and evidence supporting rescreening for chlamydia and gonorrhoea.

Presentations

The Other Vaginitides: Update on DIV and Refractory Candida Vaginitis

Jack D Sobel, Wayne State University School of Medicine, Detroit, USA

Action Heroes or Casual Observers: Vaginal Microflora and STI/HIV Risk

Dr. Sharon Hillier, University of Pittsburgh School of Medicine, Pittsburgh, USA

New data on Pelvic Inflammatory Disease: Implications for screening and management

Professor Jonathan Ross, British Association for Sexual Health and HIV – BASHH, London, UK

Identifying Knowledge Gaps in the Evidence Base for Repeat Screening of Women with Chlamydia and Gonorrhea: Challenges to Public Health Action

Dr. Kyle Bernstein, San Francisco Department of Public Health, San Francisco, USA

TUESDAY 12 JULY 2011

10:30 – 12:00

Room: 303AB

Symposium 6 - Updates and perspectives on STI and HIV issues among MSM

Co-chairs:

Gilles Lambert, Institut national de santé publique du Québec, Montréal, Canada

Robert Remis, University of Toronto, Toronto, Canada

Synopsis

This symposium will focus on the current epidemiology of Sexually Transmitted and Blood Borne Infections (STBBI) among men who have sex with men. Particular attention will be paid to reemerging STBBI and to the dynamics of coinfection. The symposium will also focus on the evolution of MSM sexual behaviours over the past few years, among seronegative and seropositive MSM living in low / moderate income countries as well as in developed countries. A review of effective behavioural interventions and of the contribution of antiretroviral chemoprophylaxis in HIV prevention will also be on the agenda.

Presentations

Evolution of the Epidemiology among MSM in low and moderate income countries

Jorge Sanchez, University of Washington, USA and IMPACTA, Lima, Peru

Dangerous Liaisons – Risk in MSM in Developed Countries

Graham J Hart, University College (London, UK)

Behavioral interventions among MSM: where do we go from here?

Matthew R. Golden, Harborview Medical Center Madison Clinic, Seattle, USA

Antiretroviral chemoprophylaxis: New opportunities and new challenges

Kenneth H. Mayer, Harvard University's School of Public Health, Boston, USA

10:30 – 12:00

Room: 202

Symposium 7 - In the quest for HIV prevention Scale up: Avahan's India experience. Program Approaches and Emerging Evaluation Results

Co-chairs:

Gina Dallabetta, Bill & Melinda Gates Foundation, Washington DC, USA

Somesh Gupta, India Institute of Medical Sciences, New Delhi, India

Synopsis

Avahan, in partnership with the Government of India, provides HIV prevention services to 220,000 sex workers, 80,000 high risk men who have sex with men and transgenders in four states in south India and two in the north-east. This session will (1) provide details on program approach to achieve scale and coverage with outreach and clinical services; (2) describe approaches to foster wide spread social norm and behavior change, improved health-seeking behavior and enhance the enabling environment; (3) present estimates of the impact of these interventions among high risk groups and the general population; and (4) provide costs and cost-effectiveness.

Presentations

Achieving high coverage of HIV prevention services for MARPs: Avahan's experience in six states in India
Sameer Kumta, Bill & Melinda Gates Foundation, New Delhi, India

Measurement and Community Mobilization Do Not Have to be Mutually Exclusive: Preliminary Analysis from a Scaled Programme

Tisha Wheeler, Bill & Melinda Gates Foundation, Washington DC, USA

Impact of the Avahan intervention on HIV/STI transmission amongst high and low-risk groups: An interim modelling assessment

Peter Vickerman¹, Michael Pickles, Catherine M Lowndes, BM Ramesh, Reynold Washington, Stephen Moses, Kathleen Deering, Sushena Reza-Paul, Anna Vassall, Janet Bradley, James Blanchard, Michel Alary, Marie-Claude Boily;

(1) London School of Hygiene and Tropical Medicine, London, UK

Cost-effectiveness of targeted HIV preventions for female sex workers: an economic evaluation of the Avahan programme in southern India

Sudhashree Chandrashekar¹, Anna Vassall, Lorna Guinness, Michael Pickles, Bhaskar Reddy, Govindraj Shetty, Marie-Claude Boily, Kathy Lowndes, Michel Alary, Peter Vickerman;

(1) London School of Hygiene and Tropical Medicine, London, UK

10:30 – 12:00

Room: 304AB

Symposium 8 - The Global Public Health Challenge of Untreatable Multidrug-resistant *Neisseria gonorrhoeae* (MDR-GC) "Superbug"

Co-chairs:

Barbara Romanowski, University of Alberta, Edmonton, Canada

Stephanie Totten, Public Health Agency of Canada, Ottawa, Canada

Synopsis

A confluence of factors, including the use of antibiotics, microbiological, behavioural as well as global traffic, has resulted in the rapid spread of gonorrhoea antimicrobial resistance (AMR), compromising effective treatment and disease control efforts. Resistance to antibiotics such as penicillin, tetracycline and fluoroquinolones have long been established. Of increasing concern, however, is the detection of gonorrhoea treatment failures and the reducing susceptibility of *Neisseria gonorrhoeae* to azithromycin and the 3rd generation cephalosporins. Increased resistance to the last line of currently available treatment raises the issue of whether gonorrhoea will be treatable in the future.

Presentations

Lessons learned from global HIV drug resistance initiative: implications for MDR-GC

Dr. Donald Sutherland, Global Public Health, Ottawa, Canada

Synergy: public health, clinicians, laboratories and management guidelines

Irene Martin and Thomas Wong; Public Health Agency of Canada, Ottawa, Canada

Research and training needs

Jo-Ann Dillon, University of Saskatchewan, Saskatoon, Canada

Laboratory harmonization and quality-assurance issues: challenges and opportunities

Catherine Ison, Health Protection Agency Centre, London, United Kingdom

Global action plan to combat antimicrobial resistance in *Neisseria gonorrhoeae*: challenges and opportunities
Francis Jim Ndowa, World Health Organization, Geneva, Switzerland

14:45 – 16:15

Room: 203

Symposium 9 - Applications of Program Science in the Field of STI

Co-chairs:

Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA
James Blanchard, University of Manitoba, Winnipeg, Canada

Synopsis

This symposium focuses on a scientific approach to the planning, design, implementation, evaluation and continuous improvement of STD and HIV prevention programs. At a time when prevention efforts are faced with declining resources it is imperative that prevention programs maximize their return on investment, and population level impact. Program Science helps facilitate the achievement of these goals through science based strategic planning, strategic targeting and choice of intervention packages most appropriate for specific epidemiologic contexts.

Presentations

The role of mathematical models in planning and evaluating programmes

Geoff Garnett, Imperial College, London, UK

Monitoring and Evaluation: linking programming and research

Anna Vassall, London School of Hygiene and Tropical Medicine, London, UK

The programme science of scale – the Avahan experience

Aparajita RamaKrishnan, Bill & Melinda Gates Foundation, India

International AIDS policy choices for a changing financing landscape

David Wilson, World Bank, Washington DC, USA

Rapporteur

Caroline Ryan, Office of US Global AIDS Coordinator, Washington, USA

14:45 – 16:15

Room: 303AB

Symposium 10 - Strategic Approaches for Addressing Sexual Health: Lessons, Challenges and Opportunities (sponsored by the CDC¹)

Co-chairs:

Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA
Angela Robinson, Camden Provider Services (CNWL) and UCL, London, UK

Synopsis

Public health disciplines related to sexual behavior may benefit by identifying common parameters of health related to sexuality and promoting an overarching framework of sexual health. This symposium will bring together leaders from several nations and international health organizations that have developed approaches to advancing a sexual health framework to complement historical vertical disease prevention programs. The objectives are to:

1. Compare and contrast models used to address sexual health in selected nations.
2. Discuss and understand experiences of international organizations in promoting regional approaches
3. Share experiences including lessons learned, ongoing challenges, and potential opportunities to improve sexual health.

¹ "Funding for this conference was made possible in part by PR #2011-94371 from the Division of Sexually Transmitted Disease Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government."

Presentations

Addressing Sexual Health in Canada

Lisa Smylie and Barbara Clarke, Public Health Agency of Canada, Ottawa, Canada

Developing and Implementing a Public Health Approach to Improve Sexual Health in the U.S.

John Douglas and Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA

Sexual Health in MSM – Coordination and Agenda Setting in Europe

Marita Van de Laar, European Centre for Disease Prevention and Control, Stockholm, Sweden

Sexual Health and Public Policy in Latin America and the Caribbean (LAC)

Rafael Mazin, Pan American Health Organization/Regional Office of the World Health Organization for the Americas, Washington DC, USA

14:45 – 16:15

Room: 304AB

Symposium 11 - Controversies in Serologic Testing for Syphilis (sponsored by the CDC²)

Co-chairs:

Brad Stoner, Centers for Disease Control and Prevention, Atlanta, USA

Karen Hoover, Washington University Medical School, St. Louis, Missouri, USA

Synopsis

The public health agencies of Canada, Europe, and the United States each have published guidelines for the diagnosis and treatment of sexually transmitted infections. Recommendations for serologic testing for syphilis differ markedly among them. For example, the U.S. guidelines recommend screening with a nontreponemal test and confirming reactive nontreponemal tests with a treponemal test. In contrast, the European guidelines recommend screening with a treponemal test and confirming reactive treponemal tests with a second, different treponemal test, and testing serologic activity with a quantitative nontreponemal test if the confirmatory test is reactive. The Canadian guidelines provide recommendations for the use of both nontreponemal and treponemal testing algorithms.

The proposed symposium will address some of the controversies involved in the selection of a syphilis screening algorithm, and will propose a research agenda to provide the evidence needed to generate more refined guidance for the use of treponemal tests for syphilis screening.

Presentations

Problems encountered with reverse sequence syphilis screening

Karen W. Hoover, Centers for Disease Control and Prevention, Atlanta, USA

Which algorithm performs better, screening with a nontreponemal or treponemal test?

Claude Fortin, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada

Performing a treponemal test to confirm a reactive EIA test: before or after the non-treponemal test?

Catherine Ison, Health Protection Agency, London UK

Serological screening for syphilis: research needs

Sheila A. Lukehart, University of Washington, Seattle, USA

WEDNESDAY 13 JULY 2011

10:30 – 12:00

Room: 303AB

Symposium 12 - Current Topics on Human Papillomavirus

Co-chairs:

Max Chernesky, McMaster University, Hamilton, Canada

Basil Donovan, University of New South Wales, Coogee, Australia

² "Funding for this conference was made possible in part by PR #2011-94371 from the Division of Sexually Transmitted Disease Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government."

Synopsis

Enormous advances have been made in our understanding of HPV and in the development of HPV care and prevention methods. However, a significant barrier that we now face in realizing the full benefits of these advances is the lack of awareness and the persistence of inaccurate information. The aim of this symposium is to provide health professionals with a current, balanced, clinically relevant and evidence-based summary of the essential HPV knowledge that is required to provide proper care, treatment, and counseling as well as apply efficiently preventive measures.

Presentations

Transmission of Human Papillomavirus Infections

Burchell AN¹, Coutlée F, Tellier P, Hanley J, Franco EL;

(1) Department of Oncology, Faculty of Medicine, McGill University, Montreal, Canada

Screening for cervical cancer in the era of HPV vaccination

Eduardo L. Franco, McGill University, Montreal, Canada

What is the latest data from the 2 commercially available prophylactic cervical cancer vaccines?

Suzanne Garland, Royal Women's hospital, Victoria, Australia

Genital warts: prevention, diagnosis, treatment and counseling

Marc Steben, Institut national de santé publique du Québec, Montréal, Canada

10:30 – 12:00

Room: 302A

Symposium 13 - Respondent Driven Sampling: where we are and where should we be going?

Chair:

Richard White, London School of Hygiene and Tropical Medicine, London, UK

David Wilson, World Bank Group, Washington DC, USA

Synopsis

RDS is a variant of snowball sampling that is primarily used to estimate the characteristics of hard-to-reach groups, such as the HIV prevalence of drug users. RDS has quickly become popular, because of rapid recruitment and the potential of unbiased estimation. However, RDS is not without its critics. If estimates are biased or variance high, RDS will be less useful. This symposium asks what should RDS be used for? It reports on two robust evaluations of RDS and its most high-profile application - monitoring HIV behaviours among IDUs in the US by CDC. It will end with a discussion including the hot topics for RDS research.

Presentations

Respondent Driven Sampling: Uses, Assumptions, Limits and Prospects

Simon Frost, University of Cambridge, Cambridge, UK

Assessing Respondent-Driven Sampling

Sharad GOEL, Yahoo Research, New-York, USA

An empirical evaluation of Respondent-Driven Sampling

White, RG¹, Frost, S, McCreesh, N, Seeley, J, Katongole, J, Ndagire Tarsh, M, Ndungutse, R, Jichi, F, Maher, D, Sonnenberg, P, Copas, A, Hayes, RJ;; (1) London School of Hygiene and Tropical Medicine, London, UK;

Use of respondent-driven sampling for monitoring HIV behaviors among injecting drug users in the United States

Amy Lansky¹, Elizabeth A. DiNenno, Cyprian Wejnert;

(1) Centers for Disease Control and Prevention, Atlanta, USA

10:30 – 12:00

Room: 302B

Late Breaker Symposium - Questioning Azithromycin for Uncomplicated Genital Chlamydial Infection

Chairs:

H. Hunter Handsfield, MD, University of Washington Center for AIDS and STD and Battelle Centers for Public Health Research and Evaluation, Seattle, Washington, USA

Dr. Janet Wilson MB ChB, FRCP, Centre for Sexual Health, The General Infirmary at Leeds, Leeds, UK

Synopsis

The results of recent studies question the efficacy of single-dose azithromycin for uncomplicated genital chlamydial infection. The available data, controversies, possible interim treatment recommendations, and potential research agendas will be addressed, with ample opportunity for audience participation.

Presentations

Biological and Molecular Aspects of Chlamydia trachomatis Antimicrobial Resistance and Persistence

Dr. Patrick Horner, MBBS, FRCP, MD

Consultant Senior Lecturer in Genitourinary Medicine

University of Bristol and University Hospitals Bristol NHS Foundation Trust
Bristol, UK

Efficacy of Azithromycin for Uncomplicated Chlamydial Infection: Early Studies and New Doubts

H. Hunter Handsfield, MD

Professor of Medicine

University of Washington Center for AIDS and STD
Seattle, Washington, USA

Chlamydia trachomatis Treatment Efficacy: Review of Treatment Studies in the Nucleic Acid Amplification Era

William M. Geisler, MD, MPH

Associate Professor of Medicine and Epidemiology

University of Alabama at Birmingham
Birmingham, Alabama, USA

Panel Discussion (with audience participation): Research Agenda and Interim Recommendations: Where Do We Go from Here?

Panelists

Dr. Horner

Dr. Handsfield

Dr. Geisler

Kimberly A Workowski, MD, Professor of Medicine, Emory University, Division of STD Prevention, National Center for HIV, Viral Hepatitis, and STD Prevention, CDC, Atlanta, Georgia, USA

13:30 – 15:00

Room: 302B

Symposium 14 - Research in Progress: Updates from American STD Association Developmental Award Recipients

Co-chairs:

Jeanne Marrazzo, University of Washington, Seattle, USA

Cornelis A. Rietmeijer, University of Colorado, Denver, USA

Synopsis

This symposium will highlight contributions from recipients of Career Development Awards from the American Sexually Transmitted Disease Association (ASTDA). The ASTDA started funding promising young investigators with these 2-year awards through a competitive process in 2008. In this session, recipients from the program's first 3 years of funding will discuss preliminary findings from their work. This session is intended to highlight the value of and need for promoting the entry of junior researchers into the field STD field.

Presentations

Genital and Oral Human Papillomavirus in Adolescent Males

Bree A. Weaver¹, Darron Brown, J.Dennis Fortenberry;

(1) Indiana University School of Medicine, Indianapolis, USA

A study of African American and Latina Women and Human Papillomavirus: Lessons Learned

Loida Bonney¹, Michael Fost, Yun F. Wang, Victoria L. Green, Gina Wingood, Carlos del Rio, Richard Rothenberg; (1) Emory University School of Medicine, Atlanta, USA;

Evaluating the Internet as an STD Risk Environment for Teens: Findings from the Communication, Health, and Teens (CH@T) Study

Buhi ER¹, Klinkenberger N, Blunt H, Daley EM, Baldwin J, Rietmeijer C;

(1) University of South Florida, College of Public Health, Tampa, USA

Detecting Chlamydial and Gonococcal Infections through Social and Sexual Networks

AA Al-Tayyib¹, CA Rietmeijer; (1) Denver Public Health, Denver, USA

Treponema pallidum Sigma24 Regulon and Envelope Stress Response

Lorenzo Giacani¹, Oleg Denisenko, Martin Tompa, Barbara Molini, Arturo Centurion-Lara;

(1) University of Washington, Seattle, USA

Prevalence and predictors of Trichomonas Infection in Incarcerated Women

Ank Nijhawan¹, Rachel Salloway, Sarah Andrea, Jesse Champion, Michaela Seadale, Kimberle Chapin, Jennifer G Clarke; (1) Harvard Medical School, Boston, USA

13:30 – 15:00

Room: 304AB

Symposium 15 - STI epidemiology in Europe: challenges for prevention and control

Co-chairs:

Marita Van De Laar, European Centre for Disease Prevention and Control, Stockholm, Sweden

Catherine Ison, Health Protection Agency, London, UK

Synopsis

The symposium covers the coordination of European-wide STI and HIV surveillance and an update of the specific LGV situation in MSM. Results from the first MSM internet survey to collect information on current sexual practices, attitudes & beliefs and access to testing and care will be presented. This symposium will bring together the leaders from several EU-funded programmes with special focus on MSM.

The objectives are to present:

1. European STI and HIV expert networks; implementation of enhanced surveillance for these diseases in Europe; surveillance activities covering 20 years of STI and 2 years of gonococcal AMR surveillance;
2. First results from the European MSM Internet Survey with respect to access to STI testing;
3. An update on the on-going LGV epidemic in European countries, the public health response and the key factors that affect transmission.

Presentations

Sexually Transmitted Infections in Europe – coordinating the European STI network

Marita van de Laar, European Centre for Disease Prevention and Control, Stockholm, Sweden

European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP): Towards Timelier Monitoring

M. J. Cole¹, S. A. Chisholm, M. Unemo, S. Hoffmann, M. J. W. van de Laar, C. A. Ison;

(1) Health Protection Agency, London, United Kingdom;

European MSM Internet Survey (EMIS) - Differences in STI testing in European countries

Ulrich Marcus¹, Axel J. Schmidt, Michele Breveglieri, Percy Fernandes Davila, Laia Ferrer, Cinta Folch, Ford Hickson, Harm J. Hospers, Massimo Mirandola, David Reid, Peter Weatherburn, for the EMIS network;

(1) Robert Koch Institute, Department for Infectious Disease Epidemiology, Berlin, Germany)

Re-emergence of Lymphogranuloma venereum in Europe and the public health response

Helen Ward¹, Henry J.C. de Vries, Marita van de Laar;

(1) Imperial College, London, United Kingdom

EARLY CAREER DEVELOPMENT PROGRAM

Early Career Development sessions have been designed for people receiving scholarships to attend the conference and to other students and young investigators in the early years of their career.

MONDAY JULY 11, 2011

7:00 – 8:30

Early Career Development Session 1 – ROOM 304AB

Developing a professional network and finding mentors that suit your research focus

In this session, faculty will discuss their own path to building a network of colleagues in the STI/HIV research field. A part of the discussion will focus on how to assess your mentors to be certain that you are getting everything you need from that relationship. The first portion of the session will be short talks followed by the major portion of the session: the question and answer period. Faculty will include speakers and several other experts in the field. Be prepared to ask the faculty anything related to this topic!

Speakers:

Hunter Handsfield, MD, University of Washington Center for AIDS and STD & Battelle Seattle Center for Public Health Research and Evaluation

J. Dennis Fortenberry, MD, MS, Indiana University School of Medicine

TUESDAY JULY 12, 2011

7:00 – 8:30

Early Career Development Session 2 – ROOM 304AB

Building an interdisciplinary research team and then building capacity

In this session, the faculty will describe their experiences of identifying colleagues that have shared interests and managing a diverse group in order to accomplish shared research goals. The first portion of the session will be short talks followed by the major portion of the session: the question and answer period. Faculty will include speakers and several other experts in the field. Be prepared to ask the faculty anything related to this topic!

Speakers:

Jeanne Marrazzo, MD, MPH, University of Washington School of Medicine

Gregory D. Zimet, PhD, Indiana University School of Medicine

WEDNESDAY JULY 13, 2011

7:00 – 8:30

Early Career Development Session – ROOM 304AB

Meet the funders

This session will provide an opportunity to hear from people working for funding agencies about what they are looking for in proposals for research. The first portion of the session will be short talks followed by the major portion of the session: the question and answer period. Faculty will include speakers and several other experts in the field. Be prepared to ask the faculty anything related to this topic!

Speakers:

John Douglas, MD, Centers for Disease Control & Prevention
Carolyn Deal, PhD, Sexually Transmitted Diseases Branch, National Institute of Allergy & Infectious Diseases, National Institutes of Health

13:30 – 16:15**Early Career Development Satellite Short Course – ROOM 302A****Publishing in Clinical and Public Health Research****Instructor:**

Dr. Eduardo L. Franco, James McGill Professor, Departments of Oncology and of Epidemiology, Biostatistics, and Occupational Health; Acting Chair, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal, Canada.

The objectives of this course are:

- 1) to provide an overview of principles of good scientific practice as applied to research on human subjects;
- 2) to discuss elements of scientific reasoning that are used in clinical and public health research and mentorship;
- 3) to discuss the process of research communication and publishing;
- 4) to discuss the key features that enhance the quality of a paper and its value to the scientific community.

Instruction will be via interactive lecture to take advantage of students' own experiences as authors; emphasis on issues pertaining to study design, ethics, data analysis, scientific integrity, and strategies of communicating and interpreting results of clinical and public health research.

This course is intended for public health practitioners, epidemiologists, and other clinical researchers in the early stages of their careers or those who are switching from clinical or public health practice to research. Public health practitioners and policymakers may also find the contents valuable in understanding the process of scientific research and publishing. Researchers whose mother tongue is not English may find the course particularly helpful in assisting them to navigate the process of preparing, submitting, and revising manuscripts for publication in international biomedical journals.

Note about the instructor:

Dr. Franco has extensive experience as an author, editor, and overseeing the publication process in epidemiology and clinical research in oncology. He has published over 320 scientific articles, 50 chapters, and two books on cancer epidemiology and prevention. He has served as Guest Editor for nine journal supplement issues on the topic of his research (HPV and associated diseases). He has served in the editorial board of the following journals: American Journal of Epidemiology (1993-98); Cancer Detection and Prevention (2001-08), Cancer Epidemiology, Biomarkers & Prevention (1995-); Epidemiology (1993-2009), International Journal of Cancer (2009-11), Medical and Pediatric Oncology (2000-04), Oral Diseases (2005-), PLoS-Medicine (2004-), Preventive Medicine (2008-) among other journals. He has also served as ad hoc manuscript reviewer for dozens of other biomedical journals.

His awards and distinctions include: The McLaughlin-Gallie Visiting Professorship Award, Royal College of Physicians and Surgeons of Canada (2011); Lifetime Achievement Award of the American Society for Colposcopy and Cervical

Pathology (2010), Honourary President, EUROGIN Congress, Monaco (2010), Women in U.S. Government's Presidential Leadership Award (2008), EUROGIN Society's Distinguished Services Award (2006), Canadian Cancer Society's Harold Warwick Prize in cancer control research (2004), Medical Research Council of Canada's Distinguished Scientist Award (2000), Educational Excellence at McGill University (2000), and twice Montreal's "Ambassadeur" (2000, 2007).

SUNDAY SATELLITE SYMPOSIA - JULY 10, 2011

8:45 - 17:00

Key Population and Their Role in STD/HIV Transmission Dynamics – ROOM 206B

Co-chairs: Sevgi Aral and James Blanchard

This one-day meeting will focus on the role played by “key populations” such as sex workers, injection drug users, men who have sex with men, in the transmission dynamics, epidemiology and prevention of STI and HIV.

AGENDA

Time	Topic	Chair / Presenter
8:45 – 12:00		Chair: Sevgi Aral Centers for Disease Control & Prevention (CDC), Atlanta, GA, U.S.A.
8:45 – 9:00	Welcome	
9:00 – 9:30	Importance of Key Populations in STD/HIV Transmission Dynamics	James Blanchard University of Manitoba Winnipeg, Manitoba, Canada
9:30 – 10:00	Socio-demographic, contextual and behavioural factors leading to a risk of STIs and HIV among female sex workers in Pakistan	Faran Emmanuel University of Manitoba Winnipeg, Manitoba, Canada
10:00 – 10:30	Integrated biological and behavioural surveillance for HIV and STIs among female sex workers in Germany – results and lessons learned from the first round of data collection and a call for input on future plans	Stine Nielsen Robert Koch-Institut, Berlin, Germany
10:30 – 11:00	Break	
11:00 – 11:30	Female sex workers and male clients: Recent temporal trends and their Role in STI transmission in the U.S.	Jami Leichter Centers for Disease Control & Prevention (CDC), Atlanta, GA, U.S.A.
11:30 – 12:00	The brothers’ study (HPTN) 061): A feasibility study of a multi-component intervention for American Black men who have sex with men	Kenneth Mayer Brown University Providence, RI, U.S.A.
12:00 – 13:00	Lunch	
13:00 – 17:00		Chair: Geoff Garnett Imperial College London, United Kingdom
13:00 – 13:30	HIV epidemics among men who have sex with men are emerging in the Middle East and North Africa: Epidemiologic context and transmission links with other high risk-groups	Laith J. Abu-Raddad Weill Cornell Medical College New York, NY, U.S.A.

13:30 – 14:00	Comparison of venue-based and respondent driven sampling methods for surveillance of sex workers	Sharon Weir University of North Carolina at Chapel Hill, North Carolina, U.S.A.
14:00 – 14:30	Group sex events as sites which bridge key at-risk populations: A little-studied aspect of STI transmission networks and dynamics	Samuel Friedman National Development & Research Institutes, Inc. New York, NY, U.S.A.
14:30 – 14:45	Break	
14:45 – 15:15	The distribution of STDs across age groups, changes in STD rates among youth across birth cohorts, and sexual mixing patterns by age: An analysis of STD surveillance data	Harrell Chesson Centers for Disease Control & Prevention (CDC), Atlanta, GA, U.S.A.
15:15 – 15:45	Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users	Anneke de Vos University Medical Centre Utrecht, The Netherlands
15:45 – 16:15	Estimating sources of infection in HIV epidemics: A comparative modeling analysis	Sharmistha Mishra Imperial College London, United Kingdom
16:15 – 16:45	Neighborhood drug markets: A nexus for core groups and STI transmission?	Jacky Jennings Johns Hopkins University Baltimore, MD, U.S.A.
16:45 – 17:00	Concluding Remarks	James Blanchard & Sevgi Aral

9:15 am – 5:00 pm

11th International Symposium on *Haemophilus ducreyi* Pathogenesis and Chancroid – ROOM 302A

8:30 am **Registration**

Morning Topics: Molecular Pathogenesis of *Haemophilus ducreyi*

9:15 am	Welcome and Introduction Margaret E. Bauer, Indiana University School of Medicine
Session 1	Mechanisms of Survival of Host Defenses - Moderator: Isabelle Leduc
9:20 am	Mechanisms of immune evasion used by <i>Haemophilus ducreyi</i> during infection Wei Li, Indiana University School of Medicine
9:55 am	Transporter-mediated resistance of <i>Haemophilus ducreyi</i> to human antimicrobial peptides Sherri D. Rinker, Indiana University School of Medicine
10:30 am	<i>Haemophilus ducreyi</i> LspA proteins inhibit actin-dependent processes in macrophages Dana Dodd, University of Texas Southwestern Medical Center at Dallas
11:05 am	Coffee and Tea Break
Session 2	Structure/Function Studies of Virulence Factors - Moderator: Stan Spinola
11:20 am	Defining the motifs and amino acids of the <i>Haemophilus ducreyi</i> HgbA protein involved in binding hemoglobin and in acquisition of heme Bill Fusco, University of North Carolina at Chapel Hill

11:55 am **Defining in vitro functions of monoclonal antibodies developed to the *Haemophilus ducreyi* trimeric autotransporter DsrA**
Isabelle Leduc, University of North Carolina at Chapel Hill

12:30 pm **Lunch (on your own)**

Afternoon Topics: Regulation, Nutrient Acquisition, Novel Therapeutics, and Feasibility of Eradication

Session 3 **Regulation and Heme Acquisition** - Moderator: Margaret Bauer

2:00 pm **Regulation of gene expression in *Haemophilus ducreyi***
Maria Labandeira-Rey, University of Texas Southwestern Medical Center at Dallas

2:35 pm **Molecular characterization of the heme-binding protein hHbp of *Haemophilus ducreyi***
Renee Robinson, University of Ottawa

3:10 pm **Coffee and Tea Break**

Session 4 **Chancroid: Novel Therapeutics and Eradication?** - Moderator: Eric Hansen

3:30 pm **Using *Haemophilus ducreyi* pathogenesis to guide antimicrobial drug discovery for highly resistant Gram-negative bacteria**
Stanley M. Spinola, Indiana University School of Medicine

4:05 pm **Eradicating chancroid—a feasible, reasonable goal?**
Allan Ronald, University of Manitoba

4:40 pm **Discussion**

5:00 pm **Dismissal**

This symposium is supported by the ISSTD and by grant R13AI1094924 from the National Institute of Allergy and Infectious Diseases (NIAID). The content is the sole responsibility of the speakers and does not necessarily represent the views of NIAID or the National Institutes of Health.

12:00 – 13:30

ROCHE Industry Sponsored Symposium – ROOM 200B

See Industry Sponsored Symposium Program for details.

14:00 – 17:00

Meeting of the International Collaboration on Gonococci (ICG) – ROOM 302B

Chairs: Magnus Unemo and Jo-Anne Dillon

The International Collaboration on Gonococci (ICG) is an informal international collaboration which provides a focus and resource for those with an interest in the control of gonorrhoea through the application of laboratory-based approaches. The particular areas of interest of the ICG are laboratory diagnosis of gonococcal disease, typing of *Neisseria gonorrhoeae* and surveillance of antimicrobial resistance in the gonococcus. The website for the ICG is www.icngngo.org

14:00 - 14:20 Commemoration of Dr. John Tapsall, Inaugural Director of the ICG
Magnus Unemo and Jo-Anne Dillon

14:20 - 14:40 Mechanisms of emergence and international spread of antimicrobial resistance (AMR) in *N. gonorrhoeae*: Magnus Unemo, Gonococcal Reference Laboratory, Sweden

14:40 - 15:00 The global predicament with GC AMR: the need of enhanced surveillance!
Ye Tun, CDC, USA

15:00 - 15:20 WHO perspectives and global response plan: Francis Ndowa, WHO HQ, Switzerland

15:20 - 15:40 **Coffee Break**

- 15:40 - 16:00 US response to the emergence of cephalosporin resistant gonorrhoea
Hillard Weinstock/Robert Kirkcaldy, CDC, USA
- 16:00 - 16:20 Gonococcal Antimicrobial Susceptibility Surveillance Program (GASP) in Latin America and the Caribbean: Emerging trends in AMR and research needs in strain typing and resistance determinant characterization
Jo-Anne R. Dillon, University of Saskatchewan, Canada
- 16:20 - 16:40 Possible treatment strategies in an era of multi-drug resistant gonorrhoea:
David Lewis, STIRC, South Africa
- 16:40 - 17:00 General discussion

14:00 – 17:00

Oh...Canada! The Current Context: STI Epidemiology, Guidelines and Partner Notification Practices – ROOM 202
Organised by the Public Health Agency of Canada (PHAC)

Chair: Dr. Catherine Dickson, Public Health Agency of Canada

SYNOPSIS

Partner notification, testing, and treatment comprise one of the largest cornerstones of STI prevention. Partners can be reached through several different strategies including those led by infected patients, by health care providers, or by a combination of approaches. This symposium will examine various methods currently used for partner notification, and discuss the barriers in public health management of STIs, including HIV faced in Canada.

This 3-hour symposium will provide a forum for delegates to explore and discuss important issues relevant to the public health management of STIs/HIV, within a Canadian context. The session will highlight current STI epidemiology, guidelines, and partner notification practices in Canada.

AGENDA

- 2:00 - 2:10 **Opening remarks**
Speaker: Dr. Rainer Engelhardt, Assistant Deputy Minister (PHAC)
- 2:10 - 2:25 **Epidemiology of sexually transmitted and blood-borne infections in Canada & update on the Canadian guidelines on sexually transmitted infections**
Dr. Thomas Wong, Public Health Agency of Canada
- 2:25 – 2:45 **Review of evidence relating to the effectiveness of various partner notification methods**
Dr. Matthew Golden, University of Washington
- 2:45 – 3:00 **National partner notification initiatives**
NCCID partner notification project
Dr. Eve Cheuk, National Collaborating Centre for Infectious Diseases
Partner notification in correctional facilities
Dr. Sue Pollock, Public Health Agency of Canada
- 3:00 – 3:10 **Discussion**
- 3:10 – 3:40 **Innovative methods to engage in partner notification**
- **InSPOT Toronto**
Dr. Rita Shahin, Toronto Public Health
 - **Development of Guidelines for Contact Tracing via Facebook**
Representative from Yukon Communicable Disease Control
 - **Partner Notification via Online Dating Sites**
Debbie Loughton, Hastings and Prince Edward County Health Unit

- 3:40 – 3:55 **Break**
- 3:55 – 4:15 **Expedited partner therapy (EPT)**
Dr. Matthew Golden, University of Washington
- 4:15 – 4:35 **Innovative approaches to testing options**
- **New Brunswick “Safe Sex” Campaign**
Céline Couturier, New Brunswick Department of Health
 - **“Get Tested, Why Not” Campaign**
Zhaida Uddin, Ottawa Public Health
- 4:35 – 4:45 **Discussion**
- 4:45 – 5:00 **Wrap-up**
Closing remarks

MAIN PROGRAM

SUNDAY JULY 10, 2011

17:30 – 19:00

Opening Ceremony – ROOM 200C

Chaired by: Michel Alary, President ISSTD

Keynote Speaker: Dr. Paul De Lay, UNAIDS, Geneva

Title: Reconfiguring the AIDS response

19:00 – 20:00

Welcome Reception – MAIN HALL

MONDAY JULY 11, 2011

7:00 – 8:30

ABBOTT Industry Sponsored Symposium – ROOM 200AB

See Industry Sponsored Symposium Program for details.

7:00 – 8:30

Early Career Development Session 1 – ROOM 304AB

See Early Career Development Program for details, p. 50

8:30 – 10:00

Plenary Session 1: Global Syphilis Prevention and Control: Challenges & Opportunities – ROOM 200C

Co-chaired by:

Dr Thomas Wong, Public Health Agency of Canada, Ottawa, Canada

Dr Rafael Mazin, Pan American Health Organization/Regional Office of the World Health Organization for the Americas, Washington, USA

The global epidemiology of syphilis and the challenges and opportunities to address maternal and congenital syphilis - Francis J. Ndowa, World Health Organization, Geneva

Syphilis: Advances in the diagnosis, antimicrobial resistance and management - Barbara Romanowski, Department of Community Health Sciences, University of Calgary, Canada

Preventing syphilis: new approaches in light of shifting key populations - Gail Bolan, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

10:30 – 12:00

Symposium 1: Measurement of sensitive behavior – ROOM 304AB

Co-chaired by:

Geoff Garnett, Imperial College, London, UK

Benoit Mâsse, Fred Hutchinson CRC, USA & Université de Montréal, Canada

Presentations

Improving the validity of sexual behaviour measurement: using computer assisted methods

Frances M Cowan, University College London, UK & University of Zimbabwe College of Health Sciences, Zimbabwe

Applying Semen Biomarkers to HIV/STI Research

Maria F. Gallo, Centers for Disease Control and Prevention, Atlanta, USA

Measurement of adherence: where are we?

Ariane Van der Straten, University of California, San Francisco, USA

Pharmacological assessment of medication adherence – Oral PrEP and Microbicides

Craig Hendrix, Johns Hopkins University School of Medicine, Baltimore, USA

10:30 – 12:00

Symposium 2: Rapid Tests as Tools to Transform Policy, strengthen Health Systems and Save Lives (sponsored by WHO/TDR and the London School of Hygiene and Tropical Medicine) – ROOM 303AB

Co-chaired by:

King Holmes, University of Washington, Seattle, USA

David Mabey, London School of Health and Tropical Medicine, London, UK

Presentations

Introduction of Rapid Syphilis Tests in Antenatal Care Services in Tanzania: Clients' and Service Providers' Acceptability and Uptake of Testing

Jacklin Mosh¹, John Changalucha, Julius Mngara, Clemens Masesa, Leocardia Kabalila, Engiribeta Makaranga, Kimberly Sollis, Saidi Kapiga, David Mabey, Rosanna Peeling;

(1) National Institute for Medical Research (Mwanza, Tanzania)

Increasing Access to HIV and Syphilis Screening in Remote Areas using Rapid Tests

Adele Benzaken¹, Valdir Monteiro Pinto, Carlos Henrique Carvalho, Rosanna Peeling;

(1) Fundacao Alfredo da Matta (Manaus, Brasil);

Screening High Risk Populations using Rapid Syphilis Tests: The Importance of Social and Cultural Contexts

Xiang-Sheng Chen¹, Yue-Ping Yin, Wan-Hui Wei, Rosanna Peeling;

(1) National Center for STD Control, China CDC (Nanjing, China);

New Technologies to Support STI Screening and Syndromic Management in Resource-limited Settings

Rosanna Peeling, London School of Health and Tropical Medicine, London, UK

10:30 – 12:00

Epidemiology oral session 1: Chlamydia – ROOM 202

Co-chaired by:

Nicola Lowe, University of Bern, Switzerland

Hunter Handsfield, University of Washington, Seattle, USA

01-S01.01 Chlamydia Trends in the United States: Results from Multiple Data Sources

Catherine Satterwhite (1), Hillard Weinstock (1), Deblina Datta (2); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) GAVI Alliance (Switzerland)

01-S01.02 The incidence of genital Chlamydia trachomatis in a Cohort of Young Australian Women.

Jennifer Walker (1), Christopher Fairley (1), Catriona Bradshaw (2), Sepehr Tabrizi (3), Marcus Chen (2), Jimmy Twin (3), Nicole Taylor (3), Basil Donovan (4), John Kaldor (4), Jane Hocking (1); (1) University of Melbourne (University of Melbourne, Australia); (2) Melbourne Sexual Health Centre (Carlton, Australia); (3) The Royal Women's Hospital (Parkville, Australia); (4) National Centre in HIV Epidemiology and Clinical Research (Coogee, Australia)

01-S01.03 High Yield in Reinfections During a Chlamydia Screening Programme When Automatically Sending Testkits After Six Months to Previously Infected.

Hannelore M Götz (1), CIPA Hoebe (2), JEAM van Bergen (3), EEHG Brouwers (2), ELM Op de Coul (4), JSA Fennema (5), RH Koekenbier (5), LL Pars (3), SM van Ravesteijn (1), IVF van den Broek (4); (1) Rotterdam Rijnmond Public Health Service (Rotterdam, Netherlands); (2) South Limburg Public Health Service (Geleen, Netherlands); (3) STI AIDS Netherlands (Amsterdam, Netherlands); (4) Centre for Infectious Disease Control, National Institute of Public Health and the Environment (Bilthoven, Netherlands); (5) Public Health Service Amsterdam (Amsterdam, Netherlands)

01-S01.04 Suboptimal repeat testing of women with positive chlamydia tests in the United States, 2008-2010

Karen Hoover (1), Guoyu Tao (1), Barbara Body (2), Mindy Nye (2), Charlotte Kent (1); (1) CDC (Atlanta, USA); (2) Laboratory Corporation of America (USA)

01-S01.05 Estimating the Rate of Annual Chlamydia Screening Uptake in US Women

Janneke Heijne (1), Christian Althaus (1), Sereina Herzog (1), Guoyu Tao (2), Charlotte Kent (2), Nicola Low (1); (1) University of Bern (Bern, Switzerland); (2) Centers for Disease Control & Prevention (CDC) (Atlanta, USA)

01-S01.06 Estimation of the Burden of Disease and Costs of Genital Chlamydia trachomatis Infection in Canada

Ashleigh Tuite (1), David Fisman (1); (1) University of Toronto (Toronto, Canada)

10:30 – 12:00

Behavioural aspects of prevention oral session 1:

Changes over time: Evolution of individual and population level patterns – ROOM 203

Co-chaired by:

Graham Hart, University College of London, London, UK
Edward Hook, University of Alabama Birmingham, Birmingham, USA

02-S1.01 Developmental Changes in Masculinity, Sexual Behavior, and STI Risk Among Adolescent Boys

Mary Ott (1), David Bell (2), J. Dennis Fortenberry (1); (1) Indiana University School of Medicine (Indianapolis, USA); (2) Columbia University Medical Center (New York, USA)

02-S1.02 Is concurrency the new serial monogamy? Evidence from a large survey of people attending contrasting genitourinary medicine (GUM) clinics in England.

Catherine H Mercer (1), Catherine RH Aicken (1), Nicola Low (2), Claudia S Estcourt (3), Peter J White (4), Frances Keane (5), Gary Brook (6), Greta Rait (1), Jackie A Cassell (7); (1) University College London (London, United Kingdom); (2) University of Bern (Bern, Switzerland); (3) Barts and the London School of Medicine and Dentistry (London, United Kingdom); (4) Health Protection Agency (London, United Kingdom); (5) Royal Cornwall Hospitals NHS Trust (Truro, Cornwall, United Kingdom); (6) Central Middlesex Hospital (London, United Kingdom); (7) Brighton and Sussex Medical School (Brighton, United Kingdom)

02-S1.03 ABC for people with HIV: a longitudinal qualitative study of responses to sexual behaviour recommendations among people receiving antiretroviral therapy in Jinja, Uganda

Caroline Allen (1), Martin Mbonye (2), Janet Seeley (3), Josephine Birungi (4), Brent Wolff (5), Alex Coutinho (6), Shabbar Jaffar (7); (1) Caribbean HIV&AIDS Alliance (St Michael, Barbados); (2) Medical Research Council /Uganda Virus Research Institute (Entebbe, Uganda); (3) University of East Anglia (Kampala, United Kingdom); (4) The AIDS Support Organisation (Kampala, Uganda); (5) Medical Research Council /Uganda Virus Research Institute (Entebbe, Uganda); (6) Infectious Diseases Institute (Kampala, Uganda); (7) London School of Hygiene and Tropical Medicine (London, United Kingdom)

02-S1.04 Effective ART, Viral Load And Sexual Behaviour of HIV Positive Men Who Have Sex with Men: Changes from 2000 to 2010

Sonali Woyal (1), Jackie Cassell (2), Andrew Copas (1), Catherine Mercer (1), Simon Edwards (3), Graham Hart (1); (1) UCL (London, United Kingdom); (2) Brighton and Sussex Medical School (Brighton, United Kingdom); (3) Mortimer Market Centre, NHS Camden PCT (, United Kingdom)

02-S1.05 Vulnerability Re-Assessed: The Changing Face of Sex Work in Guntur District, Andhra Pradesh

Tara Beattie (1), Janet Bradley (2), Uma Devi Vanta (3), Anu Shetty (2), Catherine M. Lowndes (4), Michel Alary (5); (1) London School of Hygiene and Tropical Medicine (London, United Kingdom); (2) CHARME-India Project (Québec, Canada); (3) Indian Institute of Health and Family Welfare (IIHFW) (Hyderabad, India); (4) Health Protection Agency (London, United Kingdom); (5) Universitaire de Québec (Quebec, Canada)

02-S1.06 Community Responses to an HIV Epidemic in South India: Knowledge, Moral Panic and Cultural Inertia

Janet Bradley (1), S Rajaram (2), BM Ramesh (3), Parinita Bhattacharjee (3), Shajy Isac (3), Anil Lobo (3), Stephen Moses (4), James Blanchard (4), Reynold Washington (3), Michel Alary (1); (1) Laval University (Bangalore , India); (2) CHARME Project (Bangalore, India); (3) Karnataka Health Promotion Trust (Bangalore, India); (4) University of Manitoba (Winnipeg, Canada)

10:30 – 12:00

Clinical sciences oral session 1: Syphilis: Enhanced Approaches for Detection & Characterization – ROOM 301A

Co-chaired by:

Sheila Lukehart, University of Washington, Seattle, USA

Lori M. Newman, World Health Organization (WHO), Geneva, Switzerland

03-S1.01 British Ocular Syphilis Study (BOSS): National Surveillance Study of Intraocular Inflammation Secondary to Infectious Syphilis

Beng Goh (3), Rashmi Matthew (1), Ian Simms (2), Mark Westcott (1); (1) Moorfields Eye Hospital (London, United Kingdom); (2) Health Protection Agency (London, United Kingdom); (3) Barts & The London NHS Trust

03-S1.02 Deciphering the code of *Treponema pallidum* in the UK: implications for treatment and prevention

Craig Tipple (1), Graham Taylor (1); (1) Imperial College London (London, United Kingdom)

03-S1.03 Performance of Reverse Sequence Syphilis Screening in Jamaica

Marcia Hobbs (1), Floris Gordon (2), Carol Jones Cooper (2), Shashauna Eastman (3), Tina Hylton-Kong (3), Stephanie Watson-Grant (1), Sharon Weir (1), J Peter Figueroa (4); (1) University of North Carolina (Chapel Hill, USA); (2) Epidemiology Research and Training Unit of the Ministry of Health (, Jamaica); (3) Comprehensive Health Centre, Center of Excellence (, Jamaica); (4) University of the West Indies (, Jamaica)

03-S1.04 Performance Characteristics of BioPlex 2200 Syphilis IgG and Liaison *Treponema* Automated Assays for Detection of Antibodies to *Treponema pallidum*.

Yetunde Fakile (1), Susan Kikkert (1), Ron Ballard (1), David Cox (1); (1) Centers for Disease Control & Prevention (Atlanta, USA)

03-S1.05 Quality Assurance of Syphilis Testing in a Rural Health Facility Using Dried Tube Specimens (DTS)

Yaw Adu-Sarkodie (1), Albert Dompreeh (1), Baafuor Kofi Opoku (1), Agnes Dzokoto (2), David Mabey (2), Rosanna Peeling (2); (1) School of Medical Sciences (KUMASI, Ghana); (2) London School of Hygiene and Tropical Medicine (London, United Kingdom)

03-S1.06 Diagnostic accuracy of rapid point-of-care tests to detect syphilis: a meta-analysis.

Yalda Jafari (1), Rosanna Peeling (2), Sushmita Shivkumar (1), Gilles Lambert (3), Christiane Claessens (4), Jorge Cajas (5), Marina Klein (1), Lawrence Joseph (1), Nitika Pai (1); (1) McGill University (Montreal, Canada); (2) London School of Hygiene & Tropical Medicine (United Kingdom); (3) Institut national de santé publique du Québec (Canada); (4) Laboratoire de santé publique du Québec (INSPQ) (Canada); (5) Queen's University (Canada)

10:30 – 12:00

Basic sciences oral session 1: Genomics, replication and pathogenesis – ROOM 302A

Co-chaired by:

Jane Carlton, New York University Langone Medical Center, New York, USA
David Trees, Centers for Disease Control and Prevention, Atlanta, USA

04-S1.01 Rapid Array-Based Multilocus Genotyping of *Chlamydia trachomatis*:

The easy and economical alternative

Bjorn Herrmann (1), Linus Christerson (1), Anke Ruettinger (2), Kirsten Gravningen (3), Ralph Ehrlich (4), Konrad Sachse (2); (1) Uppsala University (Uppsala, Sweden); (2) Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health) (Jena, Germany); (3) University Hospital of Northern Norway (Tromsø, Norway); (4) Alere Technologies GmbH (Jena, Germany)

04-S1.02 Molecular Cloning and Expression of Hydrogenosomal Malate Dehydrogenase of *Trichomonas vaginalis*

Shahed Ardalan (1), Craig Lee (2), Gary Garber (2); (1) Faculty of Medicine, University of Ottawa, The Ottawa Hospital Research Institute (Ottawa, Canada); (2) Faculty of Medicine, University of Ottawa, Division of Infectious Diseases, The Ottawa Hospital (Ottawa, Canada)

04-S1.03 Defining the *in vitro* functions of monoclonal antibodies developed to the *Haemophilus ducreyi* trimeric autotransporter DsrA.

Isabelle Leduc (1); (1) UNC at Chapel Hill (Chapel Hill, USA)

04-S1.04 Rapid Spread of Herpes Simplex Virus-2 in the Human Genital Tract

Joshua Schiffer (1), David Swan (2), Amalia Magaret (3), Christine Johnston (3), Stacy Selke (3), Anna Wald (3), Lawrence Corey (1); (1) Fred Hutchinson Cancer Research Center (Seattle, WA, USA); (2) Fred Hutchinson Cancer Research Center (USA); (3) University of Washington (USA)

04-S1.05 RNA Helicases, p72 and p68 and HDAC1 Interact with HIV-1 Integrase and Affect Viral Replication.

Fadila Larguet (1), Éric Rassart (1), Elsy Edouard (1); (1) Université du Québec à Montréal (Montreal, Canada)

04-S1.06 HPV 16 predicts clinical outcome in oral cancer patients treated by radiotherapy

Rosa M Apolinario (1), Pedro C Lara (1), Luis A Henriquez (1), Marta Lloret (1), Beatriz Pinar (1); (1) Las Palmas University Hospital-Canarian Institute for Cancer Research (ICIC) (Las Palmas GC, Spain)

10:30 – 12:00

Health services and policy oral session 1: Innovation technology – ROOM 301B

Co-chaired by:

Marc Steben, Institut national de santé publique du Québec, Montréal, Canada
Vladimir Pinto, Secretaria de Saude de Sao Paulo, Sao Paulo, Brasil

05-S1.01 Employing School Nurses as a Healthcare Point of Contact for Male High School Students: A School-Based Intervention to Prevent STD, HIV, and Teen Pregnancy

Patricia Dittus (1), Christine De Rosa (2), Robin Jeffries (3), Abdelmonem Afifi (3), William Cumberland (3), Kathleen Ethier (1), Emily Chung (4), Esteban Martinez (5), Ric Loya (6), Peter Kerndt (4); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Los Angeles County Department of Public Health (USA); (3) UCLA (USA); (4) Los Angeles County Department of Health (USA); (5) Health Research Association (USA); (6) Los Angeles Unified School District (USA)

05-S1.02 Acceptability of inSPOT and patient-delivered partner therapy among men who have sex with men seeking medical care

Roxanne Kerani (1), Fleming Mark (2), Matthew Golden (3); (1) Public Health - Seattle & King County (Seattle, USA); (2) Public Health - Seattle and King County (, USA); (3) University of Washington (, USA)

05-S1.03 Young Adults' Views on Telemedicine Consultations for Sexual Health in Australia

Cameryn C Garrett (1), Maggie Kirkman (1), Jane Hocking (1), Marcus Chen (1), Christopher K Fairley (1); (1) University of Melbourne (The University of Melbourne, Australia)

05-S1.04 Social Media and Chlamydia Testing by University Students: A Pilot Study

Abigail Norris Turner (1), Tina Comston (1), John Davis (1), Zakia Nasrin (1), John Vaughn (1); (1) Ohio State University (Columbus, USA)

05-S1.05 Computer Assisted Self Interviewing in a Sexual Health Clinic as Part of Routine Clinical Care: Impact on Service and Patient and Clinician Views

Lenka Vodstrcil (1), Jane Hocking (1), Rosey Cummings (2), Marcus Chen (1), Catriona Bradshaw (1), Timothy Read (1), Jun Sze (2), Christopher Fairley (1); (1) The University of Melbourne (Parkville, Australia); (2) Melbourne Sexual Health Centre (Carlton, Australia)

05-S1.06 STD Clinic Triage Based on Computer-Assisted Self Interview: The King County Experience

Julia Dombrowski (1), Matthew Golden (2); (1) University of Washington & Public Health - Seattle & King County HIV/STD Program (Seattle, USA); (2) University of Washington and Public Health - Seattle & King County HIV/STD Program (Seattle, USA)

10:30 – 12:00

Epidemiology oral session 2: Human Papillomavirus – ROOM 302B

Co-chaired by:

Barbara Romanowski, University of Alberta, Edmonton, Canada
Suzanne Garland, Royal Women's Hospital, Victoria, Australia

01-S02.01 Epidemiology of, and Behavioural Risk Factors for, Sexually Transmitted Human Papilloma Virus Infection in a Sample of the British Population.

Catherine H. Mercer (1), Anne M. Johnson (1), Natasha de Silva (2), Simon Beddows (2), Sarika Desai (2), Rebecca Howell-Jones (2), Caroline Carder (3), Pam Sonnenberg (1), Catherine M. Lowndes (2), Kate Soldan (2); (1) University College London (London, United Kingdom); (2) Health Protection Agency (London, United Kingdom); (3) University College Hospitals NHS Foundation Trust (United Kingdom)

01-S02.02 Are There Mutual Associations Between the Incidence of HPV Infection and Other Sexually Transmitted Infections After Controlling for Sexual Behavior?

Thing Rinda Soong (1), PE Gravitt (1), SB Gupta (2), A Tadesse (2), E Kim (2), C Phongnarisorn (3), V Wootipoom (4), P Yuenyao (5), DD Celentano (1); (1) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA); (2) Merck & Co. Inc. (, USA); (3) Chiang Mai University (, Thailand); (4) Prince of Songkla University (HadYai, Thailand); (5) Khon Kaen University (, Thailand)

01-S02.03 Multiple Sex Partners and Lack of Condom Use for Anal Sex Are Associated with Multiple Anal HPV Infections among Men Having Sex with Men: The HIM Study

Alan Nyitray (1), Luisa L. Villa (2), Roberto J. Carvalho da Silva (3), Maria Luiza Baggio (4), Beibei Lu (1), Dan'elle Smith (1), Martha Abrahamsen (1), Mary Papenfuss (1), Eduardo Lazcano-Ponce (5), Anna R. Giuliano (1); (1) H. Lee Moffitt Cancer Center and Research Institute (Tampa, USA); (2) Ludwig Institute for Cancer Research (São Paulo, Brazil); (3) Centro de Referência e Treinamento em DST/AIDS (São Paulo, Brazil); (4) Ludwig Institute for Cancer Research, São Paulo, Brazil (São Paulo, Brazil); (5) Instituto Nacional de Salud Pública (Cuernavaca, Mexico)

01-S02.04 Evidence of HPV Vaccine Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007-2009

Heidi Bauer (1), Glenn Wright (1), Joan Chow (1); (1) California Department of Public Health (Richmond, USA)

01-S02.05 Population Based Surveillance for Cervical Intraepithelial Neoplasia Grade 3 and Adenocarcinoma in Situ in Three Central Cancer Registries, United States 2009

Elaine W. Flagg (1), S. Deblina Datta (2), Christopher Lyu (3), Jyothi Nagaraja (3), Glenn Copeland (4), Won Silva (4), Edward Peters (5), Lauren Cole (5), Thomas Tucker (6), Mary Jane Byrne (6), Elizabeth R. Unger (2), Mona Saraiya (2), Hillard Weinstock (2); (1) US Centers for Disease Control and Prevention (Atlanta, USA); (2) Centers for Disease Control and Prevention (, USA); (3) Battelle Memorial Institute (, USA); (4) Michigan Cancer Registry (, USA); (5) Louisiana Tumor Registry (, USA); (6) Kentucky Tumor Registry (, USA)

01-S02.06 Detection of Cervical Cancer Precursors and Associated HPV Types in the United States: HPV-IMPACT Preliminary Results.

Suzanne E. Powell (1), Susan Hariri (1), Martin Steinau (1), Heidi Bauer (2), Nancy Bennett (3), Karen Bloch (4), Sean Schafer (5), Linda Niccolai (6), Elizabeth R. Unger (1), Lauri Markowitz (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) California Department of Public Health (, USA); (3) University of Rochester Medical Center (, USA); (4) Vanderbilt University Medical Center (, USA); (5) Oregon Health Authority (, USA); (6) Yale University (, USA)

12:00 – 13:30

MERCK Industry Sponsored Symposium – ROOM 200AB

See Industry Sponsored Symposium Program for details.

13:13 – 14:15

Plenary Session 2: Concentrated, mixed and generalized epidemics - typologies and effectiveness of core group interventions – ROOM 200C

Co-chaired by:

Dr Marie-Claude Boily, Imperial College, London, UK

Dr Francis Plummer, Public Health Agency of Canada, Winnipeg, Canada

Speaker:

David Wilson, Health Nutrition & Population, World Bank, Washington, D.C., USA

14:45 – 16:15

Symposium 3: Evaluation of large-scale and complex public health interventions – ROOM 303AB

Co-chaired by:

Lalit Dandona, Public Health Foundation of India, New Delhi, India

Nancy Padian, Pangaea Global AIDS Foundation, Oakland, California, USA

Presentations

Challenges and key issues in evaluation of public health interventions

Lalit Dandona, Public Health Foundation of India, New Delhi, India

The Role of Community Based Randomized Trials in the Evaluation of Public Health Interventions

Allan Donner, University of Western Ontario, Toronto, Canada

Use of transmission dynamics models to design and evaluate the impact of large scale HIV/STI prevention intervention: how, why and when?

Marie-Claude Boily, Imperial College, London, UK

Multi-level strategies to evaluate the impact of HIV prevention programmes in Zimbabwe

Dr. Simon Gregson, Imperial College, London, UK

Scaling up novel biomedical HIV prevention strategies: evidence for action

Catherine Hankins, UNAIDS, Geneva, Switzerland

14:45 – 16:15

Symposium 4: Speeding up Elimination of Congenital Syphilis with Rapid Syphilis Testing: Progress and Challenges (sponsored by WHO) – ROOM 202

Co-chaired by:

Francis Ndowa, World Health Organization, Geneva, Switzerland

Rosanna Peeling, London School of Hygiene & Tropical Medicine, London, England

Presentations

Challenges in Global Estimates of Syphilis in Pregnancy

Lori Newman¹, Sarah Hawkes, Mary Kamb, Igor Toskin, Lale Say, Nathalie Broutet;

(1) World Health Organization (WHO), Geneva, Switzerland);

Introduction of Rapid Syphilis Testing Strengthens Health Systems and Health Worker Capacity to Provide Integrated PMTCT Services

Susan Strasser¹, Namwinga Chintu, Tabitha Sripipatana, Katherine Shelley, Othiniel Musana, Anne Phiri, Alexander Tshaka Ncube, Michelle Gill, Heather Hoffman, Edward Bitarakwate;

(1) Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Lusaka, Zambia

Implementation of rapid tests for prenatal syphilis screening: overcoming health system constraints

Garcia PJ¹, Peeling R, Mabey D, Holmes KK, The CISNE team (Spanish word for SWAN);

(1) Universidad Peruana Cayetano Heredia, Lima, Peru

Progress in development of dual rapid syphilis test technology

Dr. David L. Cox, Centers for Disease Control and Prevention, Atlanta, USA

Maternal syphilis testing and treatment to improve maternal and child health services: progress and challenges

Mary Kamb, Centers for Disease Control and Prevention, Atlanta, USA

14:45 – 16:15

Symposium 5: Unsolved Challenges in Women's Sexual and Genital Health – ROOM 304 AB

Co-chaired by:

Janet Wilson, University of Leeds, Leeds, United Kingdom

Catriona Bradshaw, Melbourne Sexual Health Centre, Melbourne, Australia

Presentations

The Other Vaginitides: Update on DIV and Refractory Candida Vaginitis

Jack D Sobel, Wayne State University School of Medicine, Detroit, USA

Action Heroes or Casual Observers: Vaginal Microflora and STI/HIV Risk

Dr. Sharon Hillier, University of Pittsburgh School of Medicine, Pittsburgh, USA

New data on Pelvic Inflammatory Disease: Implications for screening and management

Professor Jonathan Ross, British Association for Sexual Health and HIV – BASHH, London, UK

Identifying Knowledge Gaps in the Evidence Base for Repeat Screening of Women with Chlamydia and Gonorrhoea: Challenges to Public Health Action

Dr. Kyle Bernstein, San Francisco Department of Public Health, San Francisco, USA

14:45 – 16:15

Epidemiology oral session 3: Bacterial resistance – ROOM 302B

Co-chaired by:

David Fisman, University of Toronto, Toronto, Canada

Nitika Pant Pai, McGill University, Montréal, Canada

01-S03.01 Antimicrobial resistance to *Neisseria gonorrhoeae* in a cohort of young men in Kisumu, Kenya: 2002 - 2009

Supriya Mehta (1), Ian Maclean (2), Jeckoniah Ndinya-Achola (3), Ruth Murugu (4), Lawrence Agunda (4), Allan Ronald (2), Irene Martin (5), Robert Bailey (1), Stephen Moses (2), Johan Melendez (6), Jonathan Zenilman (6); (1) University of Illinois at Chicago (Chicago, USA); (2) University of Manitoba (Winnipeg, Canada); (3) University of Nairobi (Nairobi, Kenya); (4) UNIM Kenya (Kenya); (5) National Microbiology Laboratory Canadian Science Centre for Human and Animal Health (Canada); (6) The Johns Hopkins University (USA)

01-S03.02 Cephalosporin susceptibility of *Neisseria gonorrhoeae* isolates in the United States, 2000-2010

Robert Kirkcaldy (1), Erin Murray (1), Carlos Del Rio (2), Geraldine Hall (3), Edward Hook (4), Wil Whittington (5), John Papp (1), Hillard Weinstock (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Emory University (USA); (3) Cleveland Clinic (USA); (4) University of Alabama, Birmingham (USA); (5) University of Washington, Seattle (USA)

01-S03.03 Clonally related *Neisseria gonorrhoeae* isolates with decreased susceptibility to extended-spectrum cephalosporins in Amsterdam, the Netherlands

Raymond Heymans (1), Sylvia Bruisten (1), Daniel Golparian (2), Magnus Unemo (2), Henry de Vries (1), Alje van Dam (3); (1) Health Service of Amsterdam (GGD) (Amsterdam, Netherlands); (2) Örebro University Hospital (Sweden); (3) OLVG General Hospital (Netherlands)

01-S03.04 Core Groups, Antimicrobial Resistance and Rebound in Gonorrhoea

Christina Chan (1), David Fisman (2), Caitlin McCabe (1); (1) University of Toronto (Toronto, Canada); (2) University of Toronto, Faculty of Medicine (Toronto, Canada)

01-S03.05 Community-acquired methicillin-resistant and susceptible *Staphylococcus aureus* among men who have sex with men

Henri De Vries (1), Ivo Joore (1), Martijn van Rooijen (1), Maarten Schim van der Loeff (1), Alje van Dam (1), Henri De Vries (1); (1) GGD Amsterdam (Amsterdam, Netherlands)

01-S03.06 Evidence of circulating macrolide resistance in *Mycoplasma genitalium* infections and development of a rapid assay to detect resistance

Jimmy Twin (1), Catriona Bradshaw (2), Suzanne Garland (3), Christopher Fairley (2), Jorgen Jensen (4), Sepehr Tabrizi (3); (1) Murdoch Children's Research Institute (Melbourne, Australia); (2) Melbourne Sexual Health Centre (Australia); (3) Royal Women's Hospital (, Australia); (4) Statens Serum Institut (Denmark)

14:45 – 16:15

Behavioural aspects of prevention oral session 2: Innovative STI and HIV preventive interventions: intended and unintended consequences – ROOM 203

Co-chaired by:

Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA
David Wilson, The World Bank Group, Washington, USA

02-S2.01 The Project Connect Health Systems Intervention: STD Screening and HIV Testing Outcomes for Female Adolescents

Patricia Dittus (1), Christine De Rosa (2), Robin Jeffries (3), Abdelmonem Afifi (3), William Cumberland (3), Penny Loosier (1), Kathleen Ethier (1), Emily Chung (4), Esteban Martinez (5), Peter Kerndt (4); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Los Angeles County Department of Health (Los Angeles, USA); (3) UCLA (Los Angeles, USA); (4) Los Angeles County Department of Public Health (Los Angeles, USA); (5) Health Research Association (USA)

02-S2.02 Sex with stitches, the resumption of sexual activity during the post-circumcision healing period in Zambia

Paul Hewett (1), Barbara Mensch (1), Timothy Hallett (2), Geoffrey Garnett (2), Kumbutso Dzekedzeke (3), Petra Todd (4); (1) Population Council (Lusaka, Zambia); (2) Imperial College London (London, United Kingdom); (3) Dzekedzeke & Company (Lusaka, Zambia); (4) University of Pennsylvania (Philadelphia, USA)

02-S2.03 Feasibility of Giving HSV Serological Test Results by Mail and Phone

Mark Hayley (1), Tina Chikovani (1), Anne Rompalo (2); (1) Johns Hopkins University School of Nursing (Baltimore, USA); (2) Johns Hopkins University School of Medicine (, USA)

02-S2.04 Targeting HIV Prevention Efforts on HIV-Infected Men Using Conditional Cash Transfer (CCT): Does it Work?

Ayesha Khan (1), Rizwan Qazi (2), Neelofar Nazim (3), Adnan A Khan (1); (1) Research and Development Solutions (Islamabad, Pakistan); (2) The Pakistan Institute of Medical Sciences Hospital (Pakistan); (3) The Health Services Academy (Pakistan)

02-S2.05 Start with the social determinants of health to tailor sexual health promotion for First Nations, Inuit and Métis youth in Canada

Joyce Seto (1), Tihut Asfaw (2), Kelly Folz (3), Wayne Clark (4), Melissa Deleary (5), Amberine Sheikh (1); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Health Canada (, Canada); (3) Public Health Agency of Canada (, Canada); (4) National Aboriginal Health Organization (, Canada); (5) Assembly of First Nations (, Canada)

02-S2.06 Reducing sexual risk behaviour among youth: the development and effect evaluation of an interactive online intervention for individuals and their sexual network

Udi Davidovich (1), Hanna Uhr-Dall (2); (1) Amsterdam Public Health Service (Amsterdam, Netherlands); (2) Amsterdam Public Health Service (Netherlands)

14:45 – 16:15

Clinical sciences oral session 2: Genital Human Papillomaviruses & Trichomoniasis – ROOM 301A

Co-chaired by:

Jane Schwebke, University of Alabama at Birmingham, USA

Cécile Tremblay, Université de Montréal, Montréal, Canada

03-S2.01 Long-Term Efficacy of Human Papillomavirus Vaccination Against CIN3 and Invasive Cervical Carcinoma: A Registry Based Passive Follow-Up of the Phase III Trial (PATRICIA)

Jorma Pavonen(5),Matti Lehtinen (1), Mohsin Rana (2), Dan Apter (3), Tapio Luostarinen (4), Eero Pukkala (4); (1) University of Tampere (Tampere, Finland); (2) University of Tampere (, Finland); (3) Family Federation of Finland (, Finland); (4) Finnish Cancer Registry (, Finland); (5)Helsinki University Hospital

03-S2.02 Long-Term Efficacy of Human Papillomavirus Vaccination Against CIN3 and Invasive Carcinoma: Registry Based Follow Up of a Phase III Trial (FUTURE II)

Jorma Paavonen (1), Mohsin Rana (2), Dan Apter (3), Tapio Luostarinen (4), Eero Pukkala (4), Matti Lehtinen (2); (1) Helsinki University Hospital (Helsinki, Finland); (2) University of tampere (, Finland); (3) Family Federation of Finland (, Finland); (4) Finnish Cancer Registry (, Finland)

03-S2.03 The spectrum of genital HPV infection among men attending a Swedish STI Clinic: HPV typing and clinical presentation

Arne Wikström (1), Mari-Anne Hedblad (1), Stina Syrjänen (2); (1) Karolinska University Hospital (Stockholm, Sweden); (2) University of Turku (Turku, Finland)

03-S2.04 Cervical Ectopy Is Not Associated With Acquisition of HPV Infection

Loris Y Hwang (1), Jay Lieberman (1), Yifei Ma (1), Anna-Barbara Moscicki (1); (1) University of California, San Francisco (San Francisco, USA)

03-S2.05 Prevalence of Trichomonas vaginalis and Co-Infection with Chlamydia trachomatis and Neisseria gonorrhoea in the United States as Determined by the APTIMA Trichomonas vaginalis Nucleic Acid Amplification Assay

Christine C. Ginocchio (1), Kimberle Chapin (2), Jennifer S. Smith (3), Jaber Aslanzadeh (4), Janet Snook (5), Craig S. Hill (5), Charlotte A. Gaydos (6); (1) North Shore-LIJ Health System Laboratories (Lake Success, USA); (2) Rhode Island Hospital (Providence, USA); (3) University of North Carolina (Chapel Hill, USA); (4) Hartford Hospital and Clinical Laboratory Partners (Hartford, USA); (5) Gen-Probe Incorporated (San Diego, USA); (6) Johns Hopkins University School of Medicine (Baltimore, USA)

03-S2.06 The Effect of *Trichomonas vaginalis* (TV) Infection on the Vaginal Microbiome

David H. Martin (1), Marcela Zozaya-Hinchliffe (2), Rebecca Lillis (1), Julia Miller (1), Michael Ferris (2); (1) LSU Health Sciences Center (New Orleans, USA); (2) Research Institute for Children (New Orleans, USA)

14:45 – 16:15

Basic sciences oral session 2: Immunity and animal models – ROOM 302A

Co-chaired by:

Sharon Hillier, University of Pittsburgh, Pittsburgh, USA
Caroline Cameron, University of Victoria, Victoria, Canada

04-S2.01 The Host Response to Chlamydial Infection Results in Increased Gonococcal Colonization in a Novel Coinfection Model

Ann Jerse (1), Rachel Vonck (1), Toni Darville (2); (1) Uniformed Services University (Bethesda, USA); (2) University of Pittsburgh Medical Center (Pittsburgh, USA)

04-S2.02 Seroprevalence of Novel Immunogens of *Chlamydia trachomatis* And Their Cytokine Response in PBMC Cells Under in vitro Conditions

Daman Saluja (1), Achchhe Patel (1), Prashant Mishra (1), Divya Sachdev (1); (1) University Of Delhi (Delhi, India)

04-S2.03 An Anti-adhesive Approach to Prevention of *C. trachomatis* Infection

Lee Ann Campbell (1), Silvia Varate Zidal (1), Dorothy Patton (2), Cho-chou Kuo (3); (1) University of Washington (Seattle, USA); (2) Univeristy of Washington (Seattle, USA); (3) Univerisity of Washington (Seattle, USA)

04-S2.04 Can a Cervical Barrier Prevent Chlamydia Infection in the Pigtailed Macaque Cervical Challenge Model?

Dorothy Patton (1), Yvonne Cosgrove Sweeney (1), Thomas Moench (2); (1) University of Washington (Seattle, USA); (2) ReProtect, Inc (Baltimore, USA)

04-S2.05 Myd-88 Deficient Mice Show Evidence of Productive *T. pallidum* Infection

Dana Dunne (1), Adam Silver (1), Jennifer Fieber (1), Caroline Zeiss (2), Erol Fikrig (1); (1) Yale University School of Medicine (New Haven, USA); (2) Yale School of Medicine (New Haven, USA)

04-S2.06 A Primate Model of *Mycoplasma genitalium* Cervical Infection

Patricia Totten (1), Gwen Wood (1), Stefanie Iverson-Cabral (2), Peter Cummings (1), Yvonne Cosgrove Sweeney (1), Dorothy Patton (3); (1) University of Washington (Seattle, USA); (2) Univrsity of Washington (Seattle, USA); (3) Univerisity of Washington (Seattle, USA)

14:45 – 16:15

Epidemiology oral session 4: STI and HIV among youth – ROOM 301B

Co-chaired by:

Gilles Lambert, Institut national de santé publique de Québec, Montréal, Canada
Judith Glynn, London School of Hygiene & Tropical Medicine, London, UK

01-S04.01 Increasing Adolescent HIV Prevalence in Northeastern Zimbabwe: Evidence of Long-term Survivors of Mother to Child Transmission

Jeffrey Eaton (1), Felicia Takavarasha (2), Simon Gregson (1), Timothy Hallett (1), Peter Mason (2), Laura Robertson (1), Christina Schumacher (1), Constance Nyamukapa (2), Geoffrey Garnett (1); (1) School of Public Health, Imperial College London (London, United Kingdom); (2) Biomedical Research and Training Institute (, Zimbabwe)

01-S04.02 Regional HIV surveillance of youth MSM through multilevel analysis of RDS studies in Latin America

Jerry O. Jacobson (1), Monica Alonso-Gonzalez (1), Daesha Ramachandran (2), Gabriela Paz-Bailey (3), Ivan Balan (4), Sonia Morales-Miranda (5), Maria Elena Guardado (3), Roxana Salamanca-Kacic (1), Ana Isabel Nieto-Gomez (6), Matilde Maddaleno (1); (1) Pan American Health Organization (Bogota, Colombia); (2) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA); (3) Tephinet Inc., Atlanta Georgia and Del Valle University of Guatemala (Guatemala City, Guatemala); (4) Columbia

University (New York City, USA); (5) Del Valle University of Guatemala (Guatemala City, Guatemala); (6) Ministerio de Salud de El Salvador (San Salvador, El Salvador)

01-504.03 Co-infection with Sexually Transmitted Infections among Canadian Street-Involved Youth 2001-2006

C. Victoria Atwood (1), Lily Fang (1), Alain Demers (1), Jennifer Gratrix (2), Miriam Rossi (3), Darlene Taylor (4), Judith Wright (5), Thomas Wong (1), Gayatri Jayaraman (1), For the Enhanced Street Youth Surveillance Team (6); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Alberta Health Services (Edmonton, Canada); (3) Sick Kids Hospital, University of Toronto (, Canada); (4) BCCDC (Vancouver, Canada); (5) Public Health Observatory, Public Health Services, Saskatoon Health Region (Saskatoon, Canada); (6) Enhanced Street Youth Surveillance Team (, Canada)

01-504.04 Predictors of Repeat Chlamydia trachomatis and/or Neisseria gonorrhoeae Infections Among African-American Adolescent Females

Andrea Swartzendruber (1), Ralph DiClemente (1), Jessica Sales (1), Jennifer L. Brown (1), Eve Rose (1); (1) Emory University Rollins School of Public Health (Atlanta, USA)

01-504.05 Incidence and Prevalence of Sexually Transmitted Infections among School Students in the Eastern Cape, South Africa

Frans Radebe (1), Joh Jemmott III (2), Anthea Klopper (3), Loretta Jemmott (2), Ann O'Leary (4), Zolani Ngwane (5), Craig Carty (2), Joanne Tyler (6), Venessa Maseko (1), David Lewis (1); (1) National Institute for Communicable Diseases, National Health Laboratory Service (Sandringham, South Africa); (2) University of Pennsylvania (Philadelphia, USA); (3) Private General Practice (East London, South Africa); (4) Centers for Disease Control and Prevention (Atlanta, USA); (5) Haverford College (Haverford, USA); (6) University of Fort Hare (Alice, South Africa)

01-504.06 Pelvic Inflammatory Disease Occurring between the Time of Testing and Treatment for Gonorrhea and Chlamydia

William Risser (1), Jan Risser (2); (1) Univ. of Texas Medical School at Houston (Houston, USA); (2) Univ. of Texas School of Public Health (USA)

16:15 – 17:00

Special Plenary Session: Antiretroviral therapy for the prevention of HIV: where are we now and where are we going? – ROOM 200C

Co-chaired by:

Dr Benoît Mâsse, Fred Hutchison Cancer Institute, Seattle, USA & Université de Montréal, Canada
Dr Michel Alary, Université Laval, Québec, Canada

Speaker:

Myron S. Cohen, MD, University of North Carolina, Chapel Hill, NC, USA, Associate Vice Chancellor for Medical Affairs-Global Health, Director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease

17:00 – 18:30

Poster Session – Exhibition Hall – ROOM 400ABC

TUESDAY JULY 12, 2011

7:00 – 8:30

GEN-PROBE Industry Sponsored Symposium – ROOM 200AB

See Industry Sponsored Symposium Program for details.

7:00 – 8:30

Early Career Development Session 2 – ROOM 304AB

See Early Career Development Program for details, p. 50

8:30 – 9:00

Plenary Session 3: The Perfect Storm: STD Control and the Emergence of HIV – ROOM 200C

Co-chaired by:

Dr Michel Alary, Université Laval, Québec, Canada

Dr David Lewis, National Institute for Communicable Diseases, Johannesburg, South Africa

Speaker:

Jacques Pépin, University of Sherbrooke, Sherbrooke, Canada

9:00 – 10:00

Plenary Session 4: Evolution of STI Pathogens in Context of Changing Environment: Biology and Behaviour – ROOM 200C

Co-chaired by:

Dr Jo-Anne Dillon, University of Saskatchewan, Saskatoon, Canada

Dr Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA

Evolution of the HIV-1C epidemic in southern Africa and lessons for controlling an uncontrollable virus

Max Essex, Health Sciences at Harvard University, Boston, MA, Chair of the Harvard School of Public Health AIDS Initiative, Chair of the Botswana–Harvard AIDS Institute in Gaborone, Botswana

A Trich-y parasite: genomics, population genetics and evolution of Trichomonas vaginalis

Jane Carlton, New York University School of Medicine, USA

10:30 – 12:00

Symposium 6: Updates and perspectives on STI and HIV issues among MSM – ROOM 303AB

Co-chaired by:

Gilles Lambert, Institut national de santé publique du Québec, Montréal, Canada

Robert Remis, University of Toronto, Toronto, Canada

Presentations

Evolution of the Epidemiology among MSM in low and moderate income countries

Jorge Sanchez, University of Washington, USA and IMPACTA, Lima, Peru

Dangerous Liaisons – Risk in MSM in Developed Countries

Graham J Hart, University College, London, UK

Behavioral interventions among MSM: where do we go from here?

Matthew R. Golden, Harborview Medical Center Madison Clinic, Seattle, USA

Antiretroviral chemoprophylaxis: New opportunities and new challenges

Kenneth H. Mayer, Harvard University's School of Public Health, Boston, USA

10:30 – 12:00

Symposium 7: In the quest for HIV prevention Scale up: Avahan's India experience. Program Approaches and Emerging Evaluation Results – ROOM 202

Co-chaired by:

Gina Dallabetta, Bill & Melinda Gates Foundation, Washington DC, USA

Somesh Gupta, India Institute of Medical Sciences, New Delhi, India

Presentations

Achieving high coverage of HIV prevention services for MARPs: Avahan's experience in six states in India

Sameer Kumta, Bill & Melinda Gates Foundation, New Delhi, India

**Measurement and Community Mobilization Do Not Have to be Mutually Exclusive:
Preliminary Analysis from a Scaled Programme**

Tisha Wheeler, Bill & Melinda Gates Foundation, Washington DC, USA

**Impact of the Avahan intervention on HIV/STI transmission amongst high and low-risk groups:
An interim modelling assessment**

Peter Vickerman (1), Michael Pickles, Catherine M Lowndes, BM Ramesh, Reynold Washington, Stephen Moses, Kathleen Deering, Sushena Reza-Paul, Anna Vassall, Janet Bradley, James Blanchard, Michel Alary, Marie-Claude Boily; (1) Imperial College, London, UK

**Cost-effectiveness of targeted HIV preventions for female sex workers:
an economic evaluation of the Avahan programme in southern India**

Sudhashree Chandrashekar (1), Anna Vassall, Lorna Guinness, Michael Pickles, Bhaskar Reddy, Govindraj Shetty, Marie-Claude Boily, Kathy Lowndes, Michel Alary, Peter Vickerman; (1) London School of Hygiene and Tropical Medicine, London, UK

10:30 – 12:00

Symposium 8: The Global Public Health Challenge of Untreatable Multidrug-resistant *Neisseria gonorrhoeae* (MDR-GC) “Superbug” – ROOM 304AB

Co-chaired by:

Barbara Romanowski, University of Alberta, Edmonton, Canada
Stephanie Totten, Public Health Agency of Canada, Ottawa, Canada

Presentations

Lessons learned from global HIV drug resistance initiative: implications for MDR-GC

Dr. Donald Sutherland, Global Public Health, Ottawa, Canada

Synergy: public health, clinicians, laboratories and management guidelines

Irene Martin and Thomas Wong; Public Health Agency of Canada, Ottawa, Canada

Research and training needs

Jo-Ann Dillon, University of Saskatchewan, Saskatoon, Canada

Laboratory harmonization and quality-assurance issues: challenges and opportunities

Catherine Ison, Health Protection Agency Centre, London, United Kingdom

Global action plan to combat antimicrobial resistance in *Neisseria gonorrhoeae*: challenges and opportunities

Francis Jim Ndowa, World Health Organization, Geneva, Switzerland

10:30 – 12:00

Epidemiology oral session 5: Vaginal infections – ROOM 302A

Co-chaired by:

Jorgen S. Jensen, Statens Serum Institut, Copenhagen, Denmark
Reynold Washington, Karnataka Health Promotion Trust, Bangalore, India

O1-S05.01 The Epidemiological Associations of BV Candidate Bacteria in Sexually Experienced and Inexperienced Women with BV and Normal Vaginal Flora

Catriona Bradshaw (1), Katherine Fethers (1), Freya Fowkes (2), Jimmy Twin (3), Christopher Fairley (1), Suzanne Garland (3), Glenda Fehler (1), Anna Morton (1), Jane Hocking (2), Sepehr Tabrizi (4); (1) Melbourne Sexual Health Centre (Melbourne, Australia); (2) University of Melbourne (Australia); (3) Royal Women's Hospital (Australia); (4) Royal Women's Hospital (Australia)

O1-S05.02 Biological evidence of semen exposure is associated with incident bacterial vaginosis

Maria Gallo (1), Lee Warner (1), Caroline King (1), Jack Sobel (2), Anne Rompalo (3), Susan Cu-Uvin (4), Robert Klein (5), Ellie Schoenbaum (6), Denise Jamieson (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Wayne State University School of Medicine (Detroit, USA); (3) Johns Hopkins University School of Medicine (Baltimore, USA); (4) Brown University School of Medicine (Providence, USA); (5) Mount Sinai School of Medicine (New York, USA); (6) Albert Einstein College of Medicine (USA)

01-S05.03 Behavioural Factors Associated With Bacterial Vaginosis (BV) In Women Who Have Sex With Women (WSW): The Women On Women's (WOW) Health Study

Catriona Bradshaw (1), Jade Bilardi (2), Sandy Walker (2), Lenka Vodstrcil (2), Suzanne Garland (3), Jane Hocking (2), Marcus Chen (4), Suzanne Peterson (4), Glenda Fehler (4), Christopher Fairley (2); (1) Melbourne Sexual Health Centre and University of Melbourne (Melbourne, Australia); (2) University of Melbourne (Melbourne, Australia); (3) Royal Womens Hospital (, Australia); (4) Melbourne sexual health centre (Austria)

01-S05.04 Increased Risk for *T. vaginalis* in an urban population of young adults

Susan Rogers (1), Charles Turner (2), William Miller (3), Anthony Roman (4), Marcia Hobbs (3), Sylvia Tan (1); (1) Research Triangle Institute (Washington, USA); (2) City University of New York (Flushing, USA); (3) University of North Carolina (Chapel Hill, USA); (4) University of Massachusetts (Boston, USA)

01-S05.05 Association between *Trichomonas vaginalis* and vaginal bacterial community composition among asymptomatic reproductive-age women in the United States

Rebecca Brotman (1), L. Lately Jones (1), Joyce Sakamoto (1), Pawel Gajer (1), Kevin Ault (2), Ligia Peralta (1), Larry Forney (3), Zaid Abdo (3), Jacques Ravel (1); (1) University of Maryland School of Medicine (Baltimore, USA); (2) Emory University School of Medicine (, USA); (3) University of Idaho (, USA)

01-S05.06 Association between Prevalent Bacterial Vaginosis (BV) and HIV Infection among Female Sex Workers at 2 African and 2 Indian Sites

Fernand Aimé Guédou (1), Lut Van Damme (2), Florence M. Mirembe (3), Suniti Solomon (4), Marissa Becker (5), Jennifer Deese (2), Tania Crucitti (6), Doug Taylor (2), Michel Alary (1); (1) Centre hospitalier affilié universitaire de Québec (Quebec, Canada); (2) Family Health International (Durham, USA); (3) Makerere University (Kampala, Uganda); (4) Y.R. Gaitonde Center for AIDS Research and Education (Chennai, India); (5) University of Manitoba (Winnipeg, Canada); (6) Insitute of Tropical Medicine (Antwerp, Belgium)

10:30 – 12:00

Behavioural aspects of prevention oral session 3: Sexual and diagnostic behaviours: issues in measurement – ROOM 302B

Co-chaired by:

Kaye Wellings, London School of Hygiene & Tropical Medicine, London, UK
Frances M. Cowan, University College London, London, UK

02-S3.01 Feasibility and Acceptability of Self-Sampling for Rectal Sexually Transmitted Infections (STI) among Bisexual Men in the United States

Brian Dodge (1), Barbara Van Der Pol (1), Michael Reece (1), David Malebranche (2), Dennis Fortenberry (1); (1) Indiana University (Bloomington, USA); (2) Emory University (Atlanta, USA)

02-S3.02 Assessing the validity of sexual behaviour reports in a whole population survey in rural Malawi

Judith Glynn (1), Ndoliwe Kayuni (2), Emmanuel Banda (2), Fiona Parrott (1), Sian Floyd (1), Clare Tanton (3), Joanne Hemmings (1), Anna Molesworth (1), Amelia Crampin (1), Neil French (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) Karonga Prevention Study (Malawi); (3) University College London (United Kingdom)

02-S3.03 Duration of Recent Sexual Partnerships in Sexually Active Men and Women

Jami Leichliter (1), Sevgi Aral (1); (1) Centers for Disease Control & Prevention (Atlanta, USA)

02-S3.04 Web-based sex diaries and young men who have sex with men: assessing feasibility, reactivity, and data agreement

Sara Glick (1), Rachel Winer (1), Matthew Golden (1); (1) University of Washington (Seattle, USA)

02-S3.05 STIs and Neighborhood Drug Markets: First a foray into measurement

Jacky Jennings (1), Ralph Taylor (2), Debra Furr-Holden (1), Jonathan Ellen (1); (1) Johns Hopkins University (Baltimore, USA); (2) Temple University (USA)

02-S3.06 Area-Based Socioeconomic Measures Associated with Female Chlamydia and Gonorrhoea, San Francisco, 2009

Kyle Bernstein (1), Sandra Goldring (2), Julia Marcus (1), Susan Philip (1); (1) San Francisco Department of Public Health (San Francisco, USA); (2) University of Pittsburgh (San Francisco, USA)

10:30 – 12:00

Clinical sciences oral session 3: Diagnostic Testing: Chlamydia & Gonorrhoeae – ROOM 301A

Co-chaired by:

Lisa Manhart, University of Washington, Seattle, USA
Angelika Stary, Outpatients Center for STI, Vienna, Austria

O3-S3.01 Comparison of a New APTIMA Specimen Collection and Transportation Kit to L-Pap for Detection of *C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis* in Cervical and Vaginal Specimens

Max Chernesky (1); (1) McMaster University (Hamilton, Canada)

O3-S3.02 Performance of the Bio-Rad Dx CT/NG/MG Assay for simultaneous detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Mycoplasma genitalium* in urogenital samples.

Cécile Bébéar (1), Chloe Le Roy (1), Isabelle Le Hen (2), Maïthé Clerc (1), Véronique Arfel (2), Françoise Normandin (2), Bertille de Barbeyrac (1); (1) INRA-Université de Bordeaux2 (Bordeaux, France); (2) Maison départementale de la santé (Bordeaux, France)

O3-S3.03 Differing *Neisseria gonorrhoeae* Bacterial Loads In The Pharynx And Rectum: Implications For Gonococcal Detection, Transmission And Control

Melanie Bissessor (1), Sepehr Tabrizi (2), Christopher Fairley (1), J Danielewski (3), Bradley Whitton (1), Surbhi Bird (1), Suzanne Garland (3), Marcus Chen (1); (1) Melbourne Sexual Health Centre (Carlton, Australia); (2) Royal Womens hospital (Australia); (3) ROyal Women's Hospital (Australia)

O3-S3.04 Self-administered *Neisseria gonorrhoeae* and *Chlamydia trachomatis* testing in the pharynx and rectum among men who have sex with men in Washington, DC

Marybeth Sexton (1), Joseph Baker (2), Rodney Perkins (3), Keisuke Nakagawa (4), Brian Jucha (3), Danny Baker (3), Rebecca Slack (5), Sameer Arora (6), Michael Plankey (5); (1) Emory University School of Medicine (Atlanta, USA); (2) Fenway Institute (Boston, USA); (3) Whitman Walker Clinic (Washington, USA); (4) UC Davis School of Medicine (Sacramento, USA); (5) Georgetown University Medical Center (Washington, USA); (6) Johns Hopkins University School of Public Health (Baltimore, USA)

O3-S3.05 *Chlamydia trachomatis* Detection by Nucleic Acid Amplification Assay using Rectal Swabs

James Williams (2), Barbara Van Der Pol (1), Amy Pantone (2); (1) Indiana University School of Public Health (Bloomington, USA); (2) Indiana University School of Medicine (Indianapolis, USA)

O3-S3.06 Rescreening for chlamydial infection using home-based, self-obtained vaginal swabs: a randomized controlled trial in family planning clinic clients

Fujie Xu (1), Bradley Stoner (2), Stephanie Taylor (3), Leandro Mena (4), Linhui Tian (1), John Papp (1), Kathleen Hutchins (1), David Martin (3), Lauri Markowitz (1); (1) CDC (Atlanta, USA); (2) Washington University (St. Louis, USA); (3) Louisiana State University Health Sciences Center (New Orleans, USA); (4) University of Mississippi Medical Center and Mississippi (Jackson, USA)

10:30 – 12:00

Health services and policy oral session 2: Evaluation of services and policies – ROOM 301B

Co-chaired by:

Ameeta Singh, University of Alberta, Edmonton, Canada
Angela Robinson, Camden Provider Services (CNWL) and UCL, London, UK

O5-S2.01 A National Program with a National Impact: Quadrivalent HPV Vaccination and Genital Warts in Australia, 2004-2010

Basil Donovan (1), Rebecca Guy (1), Hammad Ali (1), Andrew Grulich (1), David Regan (1), Handan Wand (1), Christopher Fairley (2); (1) University of New South Wales (Sydney, Australia); (2) Melbourne Sexual Health Centre (Melbourne, Australia)

O5-S2.02 DELAY OF ENTRY INTO CARE IN HIV POSITIVE INDIVIDUALS

Maaike van Veen (1), Frank de Wolf (2), Titia Heijman (3), Sima Zaheri (2), Han Fennema (3), Hannelore Götz (4), Marianne van der Sande (1); (1) National Institute for Public Health and the Environment (RIVM) (Bilthoven, Netherlands); (2) HIV Monitoring Foundation (SHM) (Amsterdam, Netherlands); (3) Public Health Service (Amsterdam, Netherlands); (4) Municipal Health Service (Rotterdam-Rijnmond, Netherlands)

05-S2.03 Effect of improving the STI services in 7 provinces of China

Xiang-Dong Gong (1), Juan Jiang (1), Xiao-hong Su (1), Ning-xiao Cao (1), Xiao-li Yue (1); (1) Institute of Dermatology, Chinese Academy of Medical Sciences, National Center for STD Control (Nanjing, China)

05-S2.04 Evaluation of Sexually Transmitted Infection Clinical Services in Gauteng Province, South Africa: Knowledge, Attitudes, and Beliefs Among Health Care Providers

Jennifer Mark (1), Susan Hariri (1), Ricky Ilunga (2), Sara Forhan (1), Mupatal Likibi (3), Mary L Kamb (1), David Lewis (2); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) National Institute for Communicable Diseases of the National Health Laboratory Service (Johannesburg, South Africa); (3) Gauteng Department of Health (, South Africa)

05-S2.05 Role of Regional Reference Laboratories for Sexually Transmitted Infections in Improvement of Second Generation HIV Surveillance Experience from the Central America Region

Tun Ye (1), Lisa Steele (1), Sandra I. Juarez (1), Cheng Y Chen (1), Ronald C Ballard (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

05-S2.06 Withdrawn

10:30 – 12:00

Epidemiology oral session 6: Planning of HIV preventive interventions – ROOM 203

Co-chaired by:

Benoît Mâsse, Fred Hutchinson Cancer Research Center, USA & Université de Montréal, Canada
Catherine Hankins, UNAIDS, Geneva, Switzerland

01-S06.01 Impact of Targeted Interventions in HIV Epidemics as Predicted by Mathematical Models: a Systematic Review

Sharmistha Mishra (1), Marie-Claude Boily (1), Richard Steen (2), Ying Ru Lo (3), Antonio Gerbase (3); (1) Imperial College (London, United Kingdom); (2) Erasmus MC (Rotterdam, Netherlands); (3) World Health Organization (Geneva, Switzerland)

01-S06.02 Impact of pill sharing on drug-resistance and population-level effectiveness of a wide-scale oral PrEP intervention in resource-constrained settings

Dobromir Dimitrov (1), Marie-Claude Boily (2), Benoît Mâsse (3); (1) Fred Hutchinson Cancer Research Center (Seattle, USA); (2) Imperial College (London, United Kingdom); (3) University of Montreal (Montreal, Canada)

01-S06.03 Pre-Exposure Prophylaxis for HIV prevention

Ide Cremin (1), Timothy Hallett (1), Mark Dybul (2), Peter Piot (3), Geoffrey Garnett (1); (1) Imperial College London (London, United Kingdom); (2) Georgetown University (, USA); (3) London School of Hygiene and Tropical Medicine (, United Kingdom)

01-S06.04 Modeling the Effectiveness of Combination Prevention From A House-To-House HIV Testing Platform in KwaZulu Natal, South Africa

Ramzi Alsallaq (1), Jared Baeten (1), James Hughes (1), Laith Abu-Raddad (2), Connie Celum (1), Timothy Hallett (3); (1) University of Washington (Seattle, USA); (2) Weill Cornell Medical College – Qatar (Doha, Qatar); (3) Imperial College London (London, United Kingdom)

01-S06.05 Exploring the Potential Impact on HIV Incidence of a Reduction in Concurrency in Rural Uganda: a Modelling Study

Nicky McCreesh (1), Katie O'Brien (2), Rebecca Nsubuga (1), Leigh Anne Shafer (1), Roel Bakker (3), Janet Seeley (1), Richard White (2); (1) MRC/UVRI Uganda Research Unit on AIDS (Entebbe, Uganda); (2) London School of Hygiene and Tropical Medicine (, United Kingdom); (3) Erasmus MC, University Medical Center Rotterdam (, Netherlands)

01-S06.06 Patterns and Trends in Concurrency and Polygamy in Rural Zimbabwe, 1998-2008

Felicia Takavarasha (1), Simon Gregson (2), Jeff Eaton (2), Christina Schumacher (2), Phyllis Mushati (3), Geoffrey Garnett (2), Constance Nyamukapa (3); (1) Biomedical Research & Training Institute, Zimbabwe (Harare, Zimbabwe); (2) School of Public Health, Imperial College London, UK (Harare, United Kingdom); (3) Biomedical Research and Training Institute (Harare, Zimbabwe)

12:00 – 13:30

BD Industry Sponsored Symposium – ROOM 200AB

See Industry Sponsored Symposium Program for details.

13:30 – 14:15

Plenary Session 5: Trichomoniasis: Why is It the Neglected STD? – ROOM 200C

Co-chaired by:

Dr Jeanne Marrazzo, University of Washington, Seattle, USA

Dr Annie-Claude Labbé, Université de Montréal, Montréal, Canada

Speaker:

Marcia Hobbs, School of Medicine at the University of North Carolina, Chapel Hill

Member of the faculty of the Division of Infectious Diseases and director of the Clinical and Microbiology Laboratory Core of the NIAID-funded Southeastern Sexually Transmitted Infections Cooperative Research Center

14:45 – 16:15

Symposium 9: Applications of Program Science in the Field of STI – ROOM 203

Co-chaired by:

Sevgi Aral, Centers for Disease Control and Prevention, Atlanta, USA

James Blanchard, University of Manitoba, Winnipeg, Canada

Presentations

The role of mathematical models in planning and evaluating programmes

Geoff Garnett, Imperial College, London, UK

Monitoring and Evaluation: linking programming and research

Anna Vassall, London School of Hygiene and Tropical Medicine, London, UK

The programme science of scale – the Avahan experience

Aparajita RamaKrishnan, Bill & Melinda Gates Foundation, India

International AIDS policy choices for a changing financing landscape

David Wilson, World Bank, Washington DC, USA

14:45 – 16:15

Symposium 10: Strategic Approaches for Addressing Sexual Health: Lessons, Challenges and Opportunities (sponsored by the CDC) – ROOM 303AB

Co-chaired by:

Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA

Angela Robinson, Camden Provider Services (CNWL) and UCL, London, UK

Presentations

Addressing Sexual Health in Canada

Lisa Smylie and Barbara Clarke, Public Health Agency of Canada, Ottawa, Canada

Developing and Implementing a Public Health Approach to Improve Sexual Health in the U.S.

John Douglas and Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA

Sexual Health in MSM – Coordination and Agenda Setting in Europe

Marita Van de Laar, European Centre for Disease Prevention and Control, Stockholm, Sweden

Sexual Health and Public Policy in Latin America and the Caribbean (LAC)

Rafael Mazin, Pan American Health Organization/Regional Office of the World Health Organization for the Americas, Washington DC, USA

14:45 – 16:15

Symposium 11: Controversies in Serologic Testing for Syphilis (sponsored by the CDC) – ROOM 304AB

Co-chaired by:

Brad Stoner, Centers for Disease Control and Prevention, Atlanta, USA

Karen Hoover, Washington University Medical School, St. Louis, Missouri, USA

Presentations

Problems encountered with reverse sequence syphilis screening

Karen W. Hoover, Centers for Disease Control and Prevention, Atlanta, USA

Which algorithm performs better, screening with a nontreponemal or treponemal test?

Claude Fortin, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada

Performing a treponemal test to confirm a reactive EIA test: before or after the non-treponemal test?

Catherine Ison, Health Protection Agency, London UK

Serological screening for syphilis: research needs

Sheila A. Lukehart, University of Washington, Seattle, USA

14:45 – 16:15

Epidemiology oral session 7: Neglected issues in anal STIs and transmission – ROOM 302A

Co-chaired by:

Helen Ward, Imperial College, London, UK

Charlotte A. Gaydos, Johns Hopkins University, Baltimore, USA

01-S07.01 The relative contribution of anal intercourse and primary infection to mature heterosexual HIV epidemics

Marie-Claude Boily (1); (1) Imperial College (London, United Kingdom)

01-S07.02 Characteristics of Women Testing Positive for Rectal STIs Using Self-Collected Mailed Specimens

Jessica Ladd (1), Yu-Hsiang Hsieh (2), Mathilda Barnes (2), Patricia Agreda (2), Nicole Quinn (2), Pamela Whittle (3), Mary Jett-Goheen (2), Terry Hogan (2), Charlotte Gaydos (2); (1) Johns Hopkins School of Public Health (Baltimore, USA); (2) Johns Hopkins University (Baltimore, USA); (3) Baltimore City Health Department (Baltimore, USA)

01-S07.03 Prevalence and Correlates of Rectal Chlamydia and Gonorrhea Among Female STD Clinic Clients

Marjan Javanbakht (1), Sarah Guerry (2), Ali Stirland (2), Pamina Gorbach (3), Peter Kerndt (2); (1) University of California Los Angeles (Los Angeles, USA); (2) Los Angeles County Department of Public Health (USA); (3) University of California Los Angeles (USA)

01-S07.04 Many missed STI when only testing urogenitally without systematic anorectal and oropharyngeal screening in swingers and MSM.

Christian Hoebe (1), Geneviève van Liere (2), Anne-Marie Niekamp (3), Nicole Dukers-Muijters (1); (1) Department of Infectious Diseases, South Limburg Public Health Service and Department of Medical Microbiology, Maastricht University Medical Centre, School for Public Health and Primary Care (Geleen, Netherlands); (2) Department of Infectious Diseases, South Limburg Public Health Service (Geleen, Netherlands); (3) Centre for Sexual Health, Department of Infectious Diseases, Public Health Service South Limburg and Department of Medical Microbiology, Maastricht University Medical Centre, School for Public Health (Geleen, Netherlands)

01-S07.05 Rare event: rectal specimen collection from males for chlamydial infection in the United States

Guoyu Tao (1), Karen Hoover (1), Barbara Body (2), Mindy Nye (2), Charlotte Kent (1); (1) CDC (Atlanta, USA); (2) Laboratory Corporation of America (USA)

01-S07.06 Lymphogranuloma Venereum in the UK:

is there Evidence for Rectal to Rectal Transmission? Results of a Multicenter Case Control Study

Helen Ward (1), Neil Macdonald (2), Minttu Ronn (3), Gillian Dean (4), Sanjeeva Pallawela (5), Ann Sullivan (5), John White (6), Alan Smith (7), Patrick French (8), Catherine Ison (9); (1) Imperial College London (London, United Kingdom); (2) Imperial College London (London, United Kingdom); (3) Imperial College London (United Kingdom); (4) Brighton and Sussex University Hospital (United Kingdom); (5) Chelsea and Westminster Hospital (United Kingdom); (6) Guys and St Thomas's Trust (United Kingdom); (7) Imperial College Healthcare NHS Trust (United Kingdom); (8) Central and Northwest London Trust (United Kingdom); (9) Health Protection Agency (United Kingdom)

14:45 – 16:15

Behavioural aspects of prevention oral session 4: STI and HIV Risk Reduction Strategies: Considerations of cost, cost-effectiveness and potential impact – ROOM 302B

Co-chaired by:

Joanne Otis, Université du Québec à Montréal, Canada

Matthew Hogben, Centers for Disease Control and Prevention, Atlanta, USA

02-S4.01 Efficiency versus equity in screening: considerations in the scale-up of rapid syphilis testing in rural Tanzania

Sedona Sweeney (1), Jacklin Mosha (2), Fern Terris-Prestholt (1), Peter Vickerman (3), John Changalucha (2), Rosanna Peeling (1); (1) London School of Hygiene and Tropical Medicine (London, United Kingdom); (2) National Institute for Medical Research (Mwanza, Tanzania, United Rep. of); (3) LSHTM (United Kingdom)

02-S4.02 Cost-effectiveness of Screening for Chlamydia trachomatis in Dutch Pregnant Women

G Ingrid J G Rours (1), Roel P Verkooijen (1), Henri A Verbrugh (1), Maarten J Postma (2); (1) Erasmus Medical Centre (Rotterdam, Netherlands); (2) University of Groningen, Groningen (Netherlands)

02-S4.03 The Cost-Effectiveness of Human Papillomavirus Vaccination of Females over Age 12 Years in the United States

Harrell Chesson (1), Lauri Markowitz (1); (1) US Centers for Disease Control and Prevention (Atlanta, USA)

02-S4.04 The Cost of Expedited Partner Therapy Compared to the Cost of Standard Partner Referral for the Treatment of Chlamydia or Gonorrhea

Thomas Gift (1), Patricia Kissinger (2), Hamish Mohammed (3), Jami Leichter (1), Matthew Hogben (1), Matthew Golden (4); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Tulane University (New Orleans, USA); (3) Ross University School of Veterinary Medicine (Basseterre, Saint Kitts and Nevis); (4) University of Washington (Seattle, USA)

02-S4.05 Serosorting Behaviors and Beliefs among MSM at an Urban LGBT Health Center

Anna Hotton (1), Beau Gratzer (1), Daniel Pohl (2), Supriya D. Mehta (3); (1) Howard Brown Health Center/University of Illinois Chicago School of Public Health (Chicago, USA); (2) Howard Brown Health Center (Chicago, USA); (3) University of Illinois Chicago School of Public Health (Chicago, USA)

02-S4.06 Exploring Enema Practices among Men who Have Sex with Men in the United States: Implications for Sexual Health

Joshua G. Rosenberger (1), Debby Herbenick (1), Barbara Van Der Pol (2), David S. Novak (3), Michael Reece (1), J. Dennis Fortenberry (4); (1) Indiana University (Bloomington, USA); (2) Indiana University (Bloomington, USA); (3) Online Buddies Inc. (Cambridge, USA); (4) Indiana University School of Medicine (Indianapolis, USA)

14:45 – 16:15

Clinical sciences oral session 4: Treatment: Chlamydia, Gonorrhea & Related Syndromes – ROOM 301A

Co-chaired by:

Ina Park, University of California San Francisco, USA

David Fine, Center for Health Training, Seattle, USA

03-S4.01 The New Superbug *Neisseria gonorrhoeae* Makes Gonorrhea Untreatable? - First High-Level Ceftriaxone Resistance Worldwide and Public Health Importance

Makoto Ohnishi (2), Daniel Golparian (1), Ken Shimuta (2), Takeshi Saika (3), Shinji Hoshina (4), Kazuhiro Iwasaku (5), Shu-ichi Nakayama (2), Jo Kitawaki (5), Magnus Unemo (1); (1) Swedish Reference Laboratory for Pathogenic *Neisseria* (Orebro, Sweden); (2) National Institute of Infectious Diseases (Japan); (3) Mitsubishi Chemical Medience Corporation (Japan); (4) Hoshina Clinic (Japan); (5) Kyoto Prefectural University of Medicine (Japan)

03-S4.02 Is Single Dose Azithromycin Adequate For Asymptomatic Rectal Chlamydia?

Fraser Drummond (1), Nathan Ryder (2), Handan Wand (1), Rebecca Guy (1), Phillip Read (2), Anna McNulty (2), Lynette Wray (2), Basil Donovan (1); (1) National Centre in HIV Epidemiology & Clinical Research, University of New South Wales (Sydney, Australia); (2) Sydney Sexual Health Centre (Australia)

03-S4.03 Safety and Efficacy of WC2031 versus Vibramycin for the Treatment of Uncomplicated Urogenital Chlamydia trachomatis Infection

William M Geisler (1), Leandro Mena (2), Stephanie N Taylor (3), Byron E Batteiger (4), Andrea Thurman (5), Edward W Hook (1), William D Koltun (6), Nader Abdelsayed (7), Toby A Vaughn (8), Miriam P Annett (8), WC2031 Investigator Team (9); (1) University of Alabama at Birmingham (Birmingham, USA); (2) University of Mississippi Medical Center (USA); (3) Louisiana State University Health Science Center (USA); (4) Indiana University Department of Medicine (, USA); (5) Eastern Virginia Medical School (USA); (6) Medical Center for Clinical Research (USA); (7) Affiliated Clinical Research, Inc. (USA); (8) Warner Chilcott Pharmaceuticals (USA); (9) (USA)

03-S4.04 Time to cure Chlamydia: prospective study on detection of anorectal and cervicovaginal Chlamydia after directly observed treatment with Azithromycin

Nicole Dukers-Muijters (1), Marita Werner (2), Elfi Brouwers (2), Arjen Speksnijder (3), Laura Spauwen (2), Sylvia Bruisten (3), Ingrid van den Broek (4), Marianne van der Sande (5), Servaas Morré (6), Christian Hoebe (1); (1) Department of Infectious Diseases, South Limburg Public Health Service and Department of Medical Microbiology, Maastricht University Medical Centre, School for Public Health and Primary Care (Geleen, Netherlands); (2) Department of Infectious Diseases, South Limburg Public Health Service (Geleen, Netherlands); (3) Public Health Laboratory, Health Service Amsterdam (Amsterdam, Netherlands); (4) Epidemiology and Surveillance, Centre for Infectious Diseases Control, National Institute for Public Health and Environment (Bilthoven, Netherlands); (5) Epidemiology and Surveillance, Centre for Infectious Diseases Control, National Institute for Public Health and Environment and Julius Centre, UMCU (Bilthoven, Netherlands); (6) VUmc, Dept Pathology, Laboratory of Immunogenetics (Amsterdam, Netherlands)

03-S4.05 Treatment of Students Infected with Chlamydia and Gonorrhea in a School-wide Screening Program

Stephanie N Taylor (1), Christine Brennan (1), Lisa Longfellow (2), David H Martin (1), M Jacques Nsuami (1); (1) Louisiana State University Health Sciences Center (New Orleans, USA); (2) Louisiana Office of Public Health (, USA)

03-S4.06 Predictors of Clinical Treatment Failure among Men with Idiopathic NGU

Danny V Colombara (1), Lisa E Manhart (1), Catherine M Wetmore (1), M. Sylvan Lowens (2), Noa A Kay (1), Patricia A Totten (1), Matthew R Golden (2); (1) University of Washington (Seattle, USA); (2) Public Health-Seattle & King County / University of Washington (Seattle, USA)

14:45 – 16:15

Health services and policy oral session 3: Partner notification – ROOM 301B

Co-chaired by:

Margaret Fast, National Collaborating Center for Infectious Diseases, Winnipeg, Canada
Margaret Gale-Rowe, Public Health Agency of Canada, Ottawa, Canada

05-S3.01 Use and Effectiveness of Expedited Partner Therapy in an Inner-City STD Clinic

Theresa Mickiewicz (1), Alia Al-Tayyib (1), Christie Mettenbrink (1), Cornelis Rietmeijer (1); (1) Denver Public Health (Denver, USA)

05-S3.02 Implementation of an Expedited Partner Therapy (EPT) Program in an Inner-City STD Clinic

Theresa Mickiewicz (1), Alia Al-Tayyib (1), Christie Mettenbrink (1), Cornelis Rietmeijer (1); (1) Denver Public Health (Denver, USA)

05-S3.03 Incremental Cost-effectiveness of Introducing Partner Notification with Selective Screening for STD Control in Louisiana

Mohammad Rahman (1), Mahmud Khan (2), Lisa Longfellow (1); (1) Louisiana Office of Public Health (Metairie, USA); (2) Tulane University (New Orleans, USA)

05-S3.04 Individual and population level effects of partner notification for Chlamydia trachomatis

Christian L. Althaus (1), Janneke C.M. Heijne (1), Sereina A. Herzog (1), Adrian Roellin (2), Nicola Low (1), Partner Notification Modelling Project Group (1); (1) University of Bern (Bern, Switzerland); (2) National University of Singapore (Singapore)

05-S3.05 Partner Notification for STI And HIV: Patients' Views And Experiences of Notifying Partners

Sonali Wayal (1), Jackie Cassell (2), Graham Scambler (1), Graham Hart (1), Nicola Low (3); (1) UCL (London, United Kingdom); (2) Brighton and Sussex Medical School (United Kingdom); (3) Institute of Social and Preventive Medicine (Switzerland)

05-S3.06 Testing for STIs in population-based sexual health surveys without returning results: development of an ethical and pragmatic approach

Nigel Field (1), Clare Tanton (1), Catherine Mercer (1), Soazig Nicholson (2), Sven Sjordin (2), Kate Soldan (3), Simon Beddows (3), Catherine Ison (3), Anne Johnson (1), Pam Sonnenberg (1); (1) University College London (London, United Kingdom); (2) National Centre for Social Research (London, United Kingdom); (3) Health Protection Agency (London, United Kingdom)

14:45 – 16:15

Epidemiology oral session 8: STIs and HIV in female sex workers – ROOM 202

Co-chaired by:

Janet Bradley, CHARME Project, Bangalore, India, and Centre hospitalier affilié universitaire de Québec, Québec, Canada

Djimon Marcel Zannou, Université d'Abomey-Calavi, Cotonou, Benin

01-S08.01 High HIV prevalence within a generalized epidemic; condom use, violence, and sexually transmitted infections among female sex workers in Dar es Salaam, Tanzania

Neema Makyao (1), Alfred Kangolle (2), Arthur Gilly (2), Geoffrey Somi (1), Method Kazaura (3), Evelyn Kim (4), Mary Kibona (5), Switbert Kamazima (3); (1) National AIDS Control Programme (Dar es Salaam, Tanzania, United Rep. of); (2) Centers for Disease Control and Prevention (Tanzania, United Rep. of); (3) Muhimbili University of Health and Allied Sciences (MUHAS) (Tanzania, United Rep. of); (4) Centres for Disease Control and Prevention, Atlanta (USA); (5) Centres for Disease Control and Prevention (Tanzania, United Rep. of)

01-S08.02 Who are the Women at Risk of HIV infection in rural Zimbabwe and how many are there? Insights into their characteristics, locations, and behaviours

Jocelyn Elmes (1), Kundai Nhongo (2), Timothy Hallett (1), Peter White (1), Reggie Mutsindiri (2), Geoffrey Garnett (1), Constance Nyamukapa (2), Simon Gregson (1); (1) Imperial College (London, United Kingdom); (2) Biomedical Research and Training Institute (Zimbabwe)

01-S08.03 Condom use during work time among female sex workers in Benin

Souleymane Diabaté (1), Annie Chamberland (1), Nassirou Geraldo (2), Marcel Zannou D. (3), Marguérite Massinga Loembé (4), Sévérin Anagonou (5), Annie Claude Labbé (6), Cécile Tremblay (7), Michel Alary (8); (1) Centre de recherche, Centre hospitalier de l'Université de Montréal (Montréal, Canada); (2) Dispensaire IST, Centre de santé de Cotonou I (Cotonou, Benin); (3) Centre national hospitalier universitaire de Cotonou (Cotonou, Benin); (4) Institut de Médecine tropicale (Anvers, Belgium); (5) Centre national hospitalier universitaire (Cotonou, Benin); (6) Université de Montréal, Hôpital Maisonneuve-Rosemont (Montréal, Canada); (7) Centre de recherche du Centre hospitalier de l'Université de Montréal (Montréal, Canada); (8) URESP, Centre de recherche FRSQ du CHA universitaire de Québec (Québec, Canada)

01-S08.04 Central American Surveillance Survey of Sexual Behavior and Prevalence of HIV/STIs in Vulnerable Populations: Female Sex Workers, Nicaragua, 2009

Stephen Delgado (1), Berta Alvarez (1), Jana Goins (1), Luz María Romero (1), Enrique Javier Beteta Acevedo (2), Gabriela Paz-Bailey (3), Sonia Morales (1); (1) Universidad del Valle de Guatemala (Guatemala City, Guatemala); (2) Ministerio de Salud de Nicaragua (Nicaragua); (3) TEPHINET (USA)

01-S08.05 Recent trends in STIs and HIV among female sex workers and their clients in India: results from repeated cross-sectional surveys

Rajatashuvra Adhikary (1), Shreena Ramanathan (1), Abhishek Gautam (1), Prabuddhagopal Goswami (1), Lakshmi Ramakrishnan (1), Srinivasan Kallam (1), Mandar M Mainkar (2), GNV Brahmam (3), Thilakavathi Subramanaian (4), RS Paranjape (2); (1) FHI (New Delhi, India); (2) National AIDS Research Institute (NARI) (India); (3) National Institute of Nutrition (NIN) (India); (4) National Institute of Epidemiology (NIE) (India)

01-S08.06 Variability in the numbers and types of sex partners of female sex workers and its impact on HIV prevalence in southern India

Kathleen Deering (1), Jean Shoveller (1), Michael Pickles (2), Souradet Shaw (3), Stephen Moses (3), James Blanchard (3), Reynold Washington (4), B.M. Ramesh (4), Shajy Isac (4), Marie-Claude Boily (2); (1) University of British Columbia (Vancouver, Canada); (2) Imperial College (United Kingdom); (3) University of Manitoba (Winnipeg, Canada); (4) Karnataka Health Promotion Trust (Bangalore, India)

16:15 – 18:00

Poster Session – Exhibition Hall – ROOM 400ABC

WEDNESDAY JULY 13, 2011

7:00 – 8:30

SIEMENS Industry Sponsored Symposium – ROOM 200AB

See Industry Sponsored Symposium Program for details.

7:00 – 8:30

Early Career Development Session 3 – ROOM 304AB

See Early Career Development Program for details, p. 50

8:30 – 10:00

Plenary Session 6: Sex, Science and Social Politics:

Implications for STI and HIV Prevention in the 21st Century – ROOM 200C

Chaired by:

Dr Kevin Fenton, Centers for Disease Control and Prevention, Atlanta, USA

The “black box” between research and intervention

Alain Poirier, Faculty of Medicine, University of Montreal, Montréal, Canada,
National Director of Public Health and Assistant Deputy Minister to the Ministry of Health and Social Services, Québec, Canada

HIV/STI Prevention: Using Epidemiology to Change Behavior

Mary Ann Chiasson, Vice President for Research and Evaluation at Public Health Solutions (PHS)
Associate Professor of Clinical Epidemiology (in Medicine) at Columbia University, New York

Prevention of STBBIs. Do we know where we’re going? Do we know how we’re getting there?

Margaret Fast Departments of Medical Microbiology, Community Health Sciences, and Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada

10:30 – 12:00

Symposium 12: Current Topics on Human Papillomavirus – ROOM 303AB

Co-chaired by:

Max Chernesky, McMaster University, Hamilton, Canada
Basil Donovan, University of New South Wales, Coogee, Australia

Presentations

Transmission of Human Papillomavirus Infections

Burchell AN1, Coutlée F, Tellier P, Hanley J, Franco EL; (1) Department of Oncology, Faculty of Medicine, McGill University, Montreal, Canada

Screening for cervical cancer in the era of HPV vaccination

Eduardo L. Franco, McGill University, Montreal, Canada

What is the latest data from the 2 commercially available prophylactic cervical cancer vaccines?

Suzanne Garland, Royal Women's hospital, Victoria, Australia

Genital warts: prevention, diagnosis, treatment and counseling

Marc Steben, Institut national de santé publique du Québec, Montréal, Canada

10:30 – 12:00

Symposium 13: Respondent Driven Sampling: where we are and where should we be going? – ROOM 302A

Chaired by:

Richard White, London School of Hygiene and Tropical Medicine, London, UK
David Wilson, World Bank Group, Washington DC, USA

Presentations

Respondent Driven Sampling: Uses, Assumptions, Limits and Prospects

Simon Frost, University of Cambridge, Cambridge, UK

Assessing Respondent-Driven Sampling

Sharad GOEL, Yahoo Research, New-York, USA

An empirical evaluation of Respondent-Driven Sampling

White, RG1, Frost, S, McCreesh, N, Seeley, J, Katongole, J, Ndagire Tarsh, M, Ndungutse, R, Jichi, F, Maher, D, Sonnenberg, P, Copas, A, Hayes, RJ;; (1) London School of Hygiene and Tropical Medicine, London, UK;

Use of respondent-driven sampling for monitoring HIV behaviors among injecting drug users in the United States

Amy Lansky1, Elizabeth A. DiNenno, Cyprian Wejnert; (1) Centre for Disease Control and Prevention, Atlanta, USA

10:30 – 12:00

Late Breaker Symposium:

Questioning Azithromycin for Uncomplicated Genital Chlamydial Infection – ROOM 302B

Co-Chaired by:

H. Hunter Handsfield, MD, University of Washington Center for AIDS and STD and Battelle Centers for Public Health Research and Evaluation, Seattle, Washington, USA
Dr. Janet Wilson MB ChB, FRCP, Centre for Sexual Health, The General Infirmary at Leeds, Leeds, UK

Presentations

Biological and Molecular Aspects of Chlamydia trachomatis Antimicrobial Resistance and Persistence

Dr. Patrick Horner, MBBS, FRCP, MD, Consultant Senior Lecturer in Genitourinary Medicine, University of Bristol and University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Efficacy of Azithromycin for Uncomplicated Chlamydial Infection: Early Studies and New Doubts

H. Hunter Handsfield, MD, Professor of Medicine, University of Washington Center for AIDS and STD Seattle, Washington, USA

Chlamydia trachomatis Treatment Efficacy: Review of Treatment Studies in the Nucleic Acid Amplification Era

William M. Geisler, MD, MPH, Associate Professor of Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA

Panel Discussion (with audience participation): Research Agenda and Interim Recommendations: **Where Do We Go from Here?**

Panelists

Dr. Horner

Dr. Handsfield

Dr. Geisler

Kimberly A Workowski, MD, Professor of Medicine, Emory University, Division of STD Prevention, National Center for HIV, Viral Hepatitis, and STD Prevention, CDC, Atlanta, Georgia, USA

10:30 – 12:00

Epidemiology oral session 9: Use of observational data and mathematical modelling for impact evaluation – ROOM 202

Co-chaired by:

Simon Gregson, Imperial College London, London, UK

Christopher Fairley, University of Melbourne, Melbourne, Australia

01-S09.01 Increased Condom Use and Decreased HIV & STI Prevalence among Female Sex Workers Following a Targeted HIV Prevention Program in Karnataka, South India

Stephen Moses (1), B.M. Ramesh (2), Shajy Isac (3), Sushena Reza-Paul (1), Michel Alary (4), Janet Bradley (4), Reynold Washington (2), Tara Beattie (5), James Blanchard (1); (1) University of Manitoba (Winnipeg, Canada); (2) Karnataka Health Promotion Trust (Bangalore, India); (3) KHPT (Bangalore, India); (4) Centre hospitalier affilié universitaire de Québec (Quebec, Canada); (5) London School of Hygiene and Tropical Medicine (London, United Kingdom)

01-S09.02 HIV elimination without antiretroviral therapy (ART) in Southern India:

Modelling and projected costs

Michael Pickles (1), Peter Vickerman (2), Anna Vassall (2), BM Ramesh (3), Kathleen Deering (4), Sudha Chandrashekar (2), S Isac (3), Stephen Moses (3), Michel Alary (5), Marie-Claude Boily (1); (1) Imperial College (London, United Kingdom); (2) LSHTM (, United Kingdom); (3) KHPT (, India); (4) University of Manitoba (Winnipeg, Canada); (5) Centre Hospitalier affilié Universitaire de Québec (Quebec, Canada)

01-S09.03 Main results and impact analysis of annual Chlamydia screening in a large register-based programme in the Netherlands

Ingrid VF van den Broek (1), JAN EAM van Bergen (2), Han SA Fennema (3), Hannelore M Götz (4), Christian JPA Hoebe (5), Eelco Over (6), Marianne AB van der Sande (7), Boris V Schmid (8), Eline LM Op de Coul (8), on behalf of the CSI-Group - (9); (1) Centre for Infectious Diseases Control, National Institute of Public Health and the Environment (Bilthoven, Netherlands); (2) STI AIDS Netherlands (Amsterdam, Netherlands); (3) Cluster of Infectious Diseases, Department of Research, Online Research and Prevention Unit, Amsterdam Health Service (Amsterdam, Netherlands); (4) Division of Infectious Disease Control, Rotterdam Rijnmond Public Health Service (Rotterdam, Netherlands); (5) Department of Infectious Diseases, South Limburg Public Health Service (Geleen, Netherlands); (6) Centre for Prevention and Health Services Research, National Institute of Public Health and the Environment (Bilthoven, Netherlands); (7) Centre for Infectious Disease Control, National Institute of Public Health and the Environment and Julius Center for Health Sciences and Primary Health Care, University Medical Centre Utrecht (Bilthoven, Netherlands); (8) Epidemiology & Surveillance Unit, Centre for Infectious Disease Control, National Institute of Public Health and the Environment (Bilthoven, Netherlands); (9) - (, Netherlands)

01-S09.04 Modelled Impact of Changing Participation Rates on Effectiveness of Population Based Chlamydia Screening

Boris V. Schmid (1), Ingrid VF van den Broek (2), Eline LM Op de Coul (2), Jan EAM van Bergen (3), Johannes SA Fennema (4), Hannelore M Götz (5), Christian JPA Hoebe (6), Mirjam Kretzschmar (7); (1) National Institute for Public Health and the Environment (RIVM) (Bilthoven, Netherlands); (2) National Institute for Public Health and the Environment (Bilthoven, Netherlands); (3) STI AIDS Netherlands (Amsterdam, Netherlands); (4) Amsterdam Public Health Service (Amsterdam, Netherlands); (5) Rotterdam Rijnmond Public Health Service (Rotterdam, Netherlands); (6) South Limburg Public Health Service (Geleen, Netherlands); (7) National Institute for Public Health and the Environment, and University Medical Centre Utrecht (Netherlands)

01-S09.05 Decline in HIV prevalence among young people in the general population of Cotonou, Benin, 1998-2008

Luc Behanzin (1), Anne Buve (2), Catherine.M Lowndes (3), Djimon Marcel Zannou (4), Isaac Minani (5), Severin Anagonou (6), Marie-Claude Boily (7), Annie-Claude Labbe (8), Raphael Bitera (9), Michel Alary (1); (1) Centre hospitalier *affilié* universitaire de Québec (QUEBEC, Canada); (2) Institute of Tropical Medicine, Antwerp, Belgium (Belgium); (3) Health Protection Agency, London, UK. (United Kingdom); (4) Faculté des Sciences de la Santé de Cotonou, Université d'Abomey-Calavi, Cotonou, Bénin (Benin); (5) Dispensaire IST, Cotonou, Bénin. (Benin); (6) Faculté des Sciences de la Santé, Université d'Abomey-Calavi, Cotonou, Bénin (Benin); (7) Imperial College, London, UK (United Kingdom); (8) Hôpital Maisonneuve-Rosemont, Montréal, Canada (Canada); (9) Centre hospitalier *affilié* universitaire de Québec (Quebec, Canada)

01-S09.06 Assessing the Impact of a FSW Targeted HIV Intervention Programme on Incidence and Prevalence in Cotonou, Benin.

John Williams (1), Marie-Claude Boily (1), Catherine Lowndes (2), Stephanie Camden (3), Eric Demers (3), Isaac Minani (4), Marcel Zannou (4), Séverin Anagonou (5), Annie-Claude Labbé (6), Michel Alary (7); (1) Imperial College London (London, United Kingdom); (2) Health Protection Agency (London, United Kingdom); (3) Centre Hospitalier *affilié* Universitaire de Québec (CHA) (Quebec City, Canada); (4) Dispensaire IST (Cotonou, Benin); (5) Centre National Hospitalier Universitaire (Cotonou, Benin); (6) Hopital Maisonneuve-Rosemont (Montreal, Canada); (7) Centre Hospitalier *affilié* Universitaire de Québec (CHA) and Université Laval (Quebec City, Canada)

10:30 – 12:00

Behavioural aspects of prevention oral session 5: Individual, Structural and Contextual Coping Strategies: Diverse causes and solutions – ROOM 203

Co-chaired by:

Pamina Gorbach, University of California, Los Angeles, USA
Lisa Manhart, University of Washington, Seattle, USA

02-S5.01 Bonding, Bridging, Linking: Exploring Relationship between Social Capital and Migrants' HIV Risk Behaviour at Destination

Devender Singh (1), James Blanchard (2), John O'Neil (3), Javier Mignone (2), Stephen Moses (2); (1) PHFI - Public Health Foundation of India (New Delhi, India); (2) University of Manitoba (Winnipeg, Canada); (3) Simon Frazer University (Canada)

02-S5.02 The Association Between Alcohol Use and HIV Sexual Risk Behaviours

Aleefia Somji (1), Braimoh Bello (2), Sinead Delany-Moretlwe (2); (1) Center for Disease Dynamics, Economics & Policy (Washington, USA); (2) Wits Health Institute, University of the Witwatersrand (Johannesburg, South Africa)

02-S5.03 Sex, drugs and structural interventions: unstable housing associated with increased HIV risk behaviour in a cohort of people on treatment in British Columbia, Canada

Surita Parashar (1), Alexis Palmer (1), Nadia O'Brien (1), Keith Chan (1), David Milan (1), Hasina Samji (1), Julio Montaner (2), Robert Hogg (3); (1) BC Centre for Excellence in HIV/AIDS (Vancouver, Canada); (2) BC Centre for Excellence in HIV/AIDS; UBC, Department of Medicine (Canada); (3) BC Centre for Excellence in HIV/AIDS; SFU, Faculty of Health Sciences (Canada)

02-S5.04 Outlier populations: heightened risk for HIV, HCV and HIV/HCV co-infection among solvent-using injection drug users

Souradet Shaw (1), Kathleen Deering (2), Ann Jolly (3), John Wylie (1); (1) University of Manitoba (Winnipeg, Canada); (2) University of British Columbia (Canada); (3) Public Health Agency of Canada (Canada)

02-S5.05 Are MSM Looking for Lesions? Examining Self and Partners for Syphilis

Diya Surie (1), Emily Koumans (1), Bruce Furness (2), Rodney Perkins (3), Toye Brewer (4), Dwayne Turner (5), Patric Hernandez-Kline (6), Kandi Gamerdinger (6), Kimberly Workowski (7), Lauri Markowitz (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) District of Columbia Department of Health and Centers for Disease Control and Prevention (Washington, USA); (3) Whitman Walker-GMHW Clinic

(Washington, USA); (4) Florida Department of Health and Centers for Disease Control and Prevention (Miami, USA); (5) Broward County Health Department (Fort Lauderdale, USA); (6) FIT Health Care Clinic (Phoenix, USA); (7) Emory University and Centers for Disease Control and Prevention (Atlanta, USA)

02-S5.06 Health-seeking Behaviors among Female Sex Workers in a Community Randomized Trial in Peru (The Peru-PREVEN Study)

Pamela Kohler (1), Pablo E. Campos (2), Clara Buendia (2), Cesar Carcamo (2), Patricia J. Garcia (2), James Hughes (1), Carolina Mejia (1), Geoffrey Garnett (3), King Holmes (1); (1) University of Washington (Seattle, USA); (2) Universidad Peruana Cayetano Heredia (Lima, Peru); (3) Imperial College (London, United Kingdom)

10:30 – 12:00

Clinical sciences oral session 5: Treatment: Syphilis, Herpes, & Bacterial Vaginosis – ROOM 301A

Co-chaired by:

Jacques Pépin, Université de Sherbrooke, Sherbrooke, Canada

Khalil Ghanam, Johns Hopkins University, Baltimore, USA

03-S5.01 Impact of AIC316, a novel antiviral helicase-primase inhibitor, on genital HSV shedding: randomized, double-blind, placebo-controlled trial.

Anna Wald (1), Susanne Stoelben (2), Stephen Tyring (3), Terri Warren (4), Christine Johnston (5), Meei-Li Huang (1), Burkhard Timmler (2), Helga Ruebsamen-Schaeff (2), Lawrence Corey (6), Alexander Birkmann (2); (1) University of Washington (Seattle, USA); (2) AiCuris GmbH & Co. KG (Wuppertal, Germany); (3) University of Texas Health Science Center (Houston, USA); (4) Westover Heights Clinic (Portland, USA); (5) University of Washington / (Seattle, USA); (6) Fred Hutchinson Cancer Research Center / University of Washington (Seattle, USA)

03-S5.02 Frequent breakthrough genital HSV-2 shedding on standard and high dose valacyclovir

Christine Johnston (1), Misty Saracino (2), Steve Kuntz (3), Amalia Magaret (4), Joshua T. Schiffer (1), Stacy Selke (2), Meei-li Huang (5), Lawrence Corey (6), Anna Wald (1); (1) University of Washington (UW) & Fred Hutchinson Cancer Research Center (Seattle, USA); (2) University of Washington (USA); (3) Laboratory Medicine (USA); (4) University of Washington (UW) & Fred Hutchinson Cancer Research Center (USA); (5) University of Washington (UW) & Fred Hutchinson Cancer Research Center (USA); (6) Fred Hutchinson Cancer Research Center (FHCRC) and University of Washington (UW) (USA)

03-S5.03 High-dose Valacyclovir Decreases Plasma HIV-1 Levels More than Standard Dose Acyclovir in HIV-1, HSV-2 Positive Persons: a Randomized, Crossover Trial

Tara Perti (1), Jared Baeten (1), Christine Johnston (1), Kurt Diem (1), Negusse Ochbamiichael (1), Meei-Li Huang (1), Stacy Selke (1), Amalia Magaret (1), Lawrence Corey (1), Anna Wald (1); (1) University of Washington (Seattle, USA)

03-S5.04 The post-trial effect of periodic presumptive treatment for vaginal infections on the incidence of bacterial vaginosis and Lactobacillus colonization

Jennifer Balkus (1), Walter Jaoko (2), Kishorchandra Mandaliya (3), Barbra Richardson (4), Linnet Masese (1), Ruth Gitau (2), James Kiarie (5), Jeanne Mrazzozzo (6), Carey Farquhar (6), R. Scott McClelland (7); (1) University of Washington (Seattle, USA); (2) University of Nairobi (Kenya); (3) Coast Provincial General Hospital (USA); (4) University of Washington (Seattle, USA); (5) University of Nairobi Kenya; (6) University of Washington (USA); (7) University of Washington (USA)

03-S5.05 RPR Titer Variation Following Early Syphilis Therapy: A Potential Confounder of Treatment Outcome Assessment

Katherine Holman (1), Mark Wolff (2), Arlene Seña (3), David Martin (4), Frieda Behets (3), Kathleen Van Damme (5), Peter Leone (3), Linda McNeil (6), Jamie Winestone (2), Edward Hook III (1); (1) University of Alabama at Birmingham (Birmingham, USA); (2) Emmes Corporation (Rockville, USA); (3) University of North Carolina at Chapel Hill (Chapel Hill, USA); (4) Louisiana State University (Baton Rouge, USA); (5) University of North Carolina at Madagascar (, Madagascar); (6) Family Health International (Research Triangle Park, USA)

03-S5.06 Double-blind Randomized Placebo Controlled Trial of Oral Metronidazole in combination with either Vaginal Clindamycin or an Oestrogen-containing Vaginal Probiotic for the Treatment of Bacterial Vaginosis

Catriona Bradshaw (1), Marie Pirotta (2), Jane Hocking (2), Suzanne Garland (3), Deborah de Guigand (2), Glenda Fehler (4), Andrea Morrow (2), Sandy Walker (2), Lenka Vodstrcil (2), Christopher Fairley (5); (1) Melbourne Sexual Health Centre and University of Melbourne (Melbourne, Australia); (2) university of melbourne (Australia); (3) royal women's hospital (Australia); (4) melbourne sexual health centre (Australia); (5) university of melbourne and melbourne sexual health centre (Australia)

10:30 – 12:00

Health services and policy oral session 4: Screening – ROOM 301B

Co-chaired by:

Marc Dionne, Institut national de santé publique du Québec, Québec, Canada

Raphael Mazin, Pan American Health Organization/Regional Office of the World Health Organization for the Americas, Washington DC, USA

05-S4.01 Register-based Chlamydia Screening: does it make a difference if the invitation is sent by GP or by Municipal Health Service?

JEAM van Bergen (1), RH Koekenbier (2), JSA Fennema (2), EEHG Brouwers (3), HM Götz (4), CJPA Hoebe (3), ELM Op de Coul (5), LL Pars (1), SM van Ravensteijn (6), IVF van den Broek (5); (1) Soa Aids Nederland (Amsterdam, Netherlands); (2) Public Health Service Amsterdam (, Netherlands); (3) Public Health Service South-Limburg (, Netherlands); (4) Public Health Service Rotterdam Rijnmond (, Netherlands); (5) Centre for Infectious Disease Control (RIVM) (, Netherlands); (6) Public Health Service Rotterdam-Rijnmond (, Netherlands)

05-S4.02 Successful interventions to increase use of Patient Self Obtained Vaginal Swabs for chlamydia/ gonorrhea testing in WA State

Sarah Goldenkranz (1), David Fine (1), Chris Knutson (2), Rafael Loza (2); (1) Center for Health Training (Seattle, USA); (2) Washington State Department of Health (, USA)

05-S4.03 HIV Testing Among Patients Infected with Neisseria gonorrhoeae-STD Surveillance Network, United States, 2009-2010

Heather Bradley (1), Lenore Asbel (2), Kyle Bernstein (3), Melanie Mattson (4), Preeti Pathela (5), Raul Pino (6), Michael Samuel (7), Jane Schwebke (8), Mark Stenger (9), Irina Tabidze (10), Jonathan Zenilman (11), Debbie Dowell (1), Hillard Weinstock (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Philadelphia Department of Public Health (USA); (3) San Francisco Department of Public Health (USA); (4) Colorado Department of Public Health and Environment (USA); (5) New York City Department of Health and Mental Hygiene (USA); (6) Connecticut Department of Health (USA); (7) California Department of Public Health (USA); (8) University of Alabama at Birmingham (USA); (9) Washington State Department of Health (USA); (10) Chicago Department of Public Health (USA); (11) Johns Hopkins University School of Medicine (USA)

05-S4.04 TARGETED STD SCREENING AMONG HIGH-RISK MEN WHO HAVE SEX WITH MEN

Rodney Perkins (1), Bryce Furness (1), Michael Hager (1), Rachel McLaughlin (1), Justin Goforth (1), Meghan Davies (1); (1) Whitman-Walker Clinic (Washington, USA)

05-S4.05 Introduction of a Sexual Health Practice Nurse Increases STI Testing Among MSM in General Practice

Marcus Y Chen (1), Anthony F Snow (1), Rosey Cummings (1), Louise Owen (2), Carol El-Hyak (3), Margaret E Hellard (3), Lenka Vodstrcil (4), Christopher K Fairley (5), Marcus Y Chen (5); (1) Melbourne Sexual Health Centre (Melbourne, Australia); (2) Victorian AIDS Council/Gay Mens Health Centre (Australia); (3) Burnet Institute (Australia); (4) University of Melbourne (Australia); (5) Melbourne Sexual Health Centre /University of Melbourne (Australia)

05-S4.06 IMPROVING HIV SCREENING AT AN URBAN STD CLINIC

Bruce W. Furness (1), John Coursey (2), Toni Flemming (2), Paul Hess (2), Shukdeo Sankar (3), Nnemdi Kamanu Elias (3); (1) CDC/NCHHSTP/DSTDP/ESB/FEU (Washington, USA); (2) CDC/NCHHSTP/DSTDP (Washington, USA); (3) District of Columbia Department of Health (Washington, USA)

10:30 – 12:00

Epidemiology oral session 10: Men who have sex with men – ROOM 304AB

Co-chaired by:

Gabriella Paz, Del Valle University, Guatemala
Robert Remis, University of Toronto, Toronto, Canada

01-S10.01 High HIV incidence among MSM who were prescribed HIV-PEP: indications for further riskful sexual behaviour

José Heuker (1), Gerard Sonder (2), Ineke Stolte (1), Anneke van den Hoek (2); (1) Public Health Service Amsterdam (Amsterdam, Netherlands); (2) Public Health Service Amsterdam and Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center (University of Amsterdam) (, Netherlands)

01-S10.02 HIV and Bacterial STI Testing Among Men who have Sex with Men in the United States

Joshua G. Rosenberger (1), Barbara Van Der Pol (2), Debby Herbenick (2), David S. Novak (3), Michael Reece (2), J. Dennis Fortenberry (4); (1) Indiana University (Bloomington, USA); (2) Indiana University (Bloomington, USA); (3) Online Buddies Inc. (Cambridge, USA); (4) Indiana University School of Medicine (Indianapolis, USA)

01-S10.03 Lymphogranuloma Venereum, HIV and High-Risk Behaviour: Findings from LGV Enhanced Surveillance and Mathematical Modelling

Minttu Ronn (1), Geoffrey Garnett (1), Gwenda Hughes (2), Catherine Ison (2), Ian Simms (2), Sarah Alexander (2), Helen Ward (1); (1) Imperial College London (London, United Kingdom); (2) Health Protection Agency (, United Kingdom)

01-S10.04 Lifestyle As Marker Of Hepatitis C Infection In HIV Infected MSM In Amsterdam, The Netherlands

Amy Matser (1), Ronald Geskus (1), Titia Heijman (1), Anouk Urbanus (1), Jan Prins (2), Henry de Vries (1), Maria Prins (1), Maarten Schim van der Loeff (1); (1) Public Health Service (Amsterdam, Netherlands); (2) Academic Medical Centre (AMC) (Amsterdam, Netherlands)

01-S10.05 Cohort study to determine sexually transmitted rectal infections among high-risk men who have sex with men in India

Manish Ranjan (1), Anjana Das (1), Prakash Narayanan (1), Anup Gurung (1), Arun Risbud (2), Raman Gangakhedkar (2); (1) Family Health International (New Delhi, India); (2) National AIDS Research Institute (Pune, India)

01-S10.06 HIV/STI Prevalence Among Men Who Have Sex With Men in 4 Cities, China and Associated Risk Factors for HIV Infection

Xiangsheng Chen (1), Ning Jiang (1), Baoxi Wang (1); (1) National Center for STD Control, China CDC (Nanjing, China)

12:00 – 13:30

American STD Association Award Presentation & Luncheon – ROOM 200AB

Co-chaired by:

Jeanne Marrazzo, MD, MPH, University of Washington, Seattle, USA
Bradley Stoner, MD, PhD, Washington University, St-Louis, USA

Presentation of ASTDA Young Investigator Award
Presentation of ASTDA Achievement Award
Presentation of Thomas Parran Award

Parran Award Lecture: The 30 Year War Against HIV/AIDS: Have We Reached The Tipping Point?
Thomas Quinn, MD, MSc, NIAID, NIH and John Hopkins University, Baltimore, USA

13:30 – 15:00

Symposium 14: Research in Progress:

Updates from American STD Association Developmental Award Recipients – ROOM 302B

Co-chaired by:

Jeanne Marrazzo, University of Washington, Seattle, USA
Cornelis A. Rietmeijer, University of Colorado, Denver, USA

Presentations

Genital and Oral Human Papillomavirus in Adolescent Males

Bree A. Weaver¹, Darron Brown, J.Dennis Fortenberry; (1) Indiana University School of Medicine, Indianapolis, USA

A study of African American and Latina Women and Human Papillomavirus: Lessons Learned

Loida Bonney¹, Michael Fost, Yun F. Wang, Victoria L. Green, Gina Wingood, Carlos del Rio, Richard Rothenberg; (1) Emory University School of Medicine, Atlanta, USA;

Evaluating the Internet as an STD Risk Environment for Teens: Findings from the Communication, Health, and Teens (CH@T) Study

Buhi ER¹, Klinkenberger N, Blunt H, Daley EM, Baldwin J, Rietmeijer C; (1) University of South Florida, College of Public Health, Tampa, USA

Detecting Chlamydial and Gonococcal Infections through Social and Sexual Networks

AA Al-Tayyib¹, CA Rietmeijer; (1) Denver Public Health, Denver, USA

Treponema pallidum Sigma24 Regulon and Envelope Stress Response

Lorenzo Giacani¹, Oleg Denisenko, Martin Tompa, Barbara Molini, Arturo Centurion-Lara; (1) University of Washington, Seattle, USA

Prevalence and predictors of Trichomonas Infection in Incarcerated Women

Ank Nijhawan¹, Rachel Salloway, Sarah Andrea, Jesse Champion, Michaela Seadale, Kimberle Chapin, Jennifer G Clarke; (1) Harvard Medical School, Boston, USA

13:30 – 15:00

Symposium 15: STI epidemiology in Europe: challenges for prevention and control – ROOM 304AB

Co-chaired by:

Marita Van De Laar, European Centre for Disease Prevention and Control, Stockholm, Sweden
Catherine Ison, Health Protection Agency, London, UK

Presentations

Sexually Transmitted Infections in Europe – coordinating the European STI network

Marita van de Laar, European Centre for Disease Prevention and Control, Stockholm, Sweden

European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP): Towards Timelier Monitoring

M. J. Cole¹, S. A. Chisholm, M. Unemo, S. Hoffmann, M. J. W. van de Laar, C. A. Ison; (1) Health Protection Agency, London, United Kingdom;

European MSM Internet Survey (EMIS) - Differences in STI testing in European countries

Ulrich Marcus¹, Axel J. Schmidt, Michele Breveglieri, Percy Fernandes Davila, Laia Ferrer, Cinta Folch, Ford Hickson, Harm J. Hospers, Massimo Miranda, David Reid, Peter Weatherburn, for the EMIS network; (1) Robert Koch Institute, Department for Infectious Disease Epidemiology, Berlin, Germany)

Re-emergence of *Lymphogranuloma venereum* in Europe and the public health response

Helen Ward¹, Henry J.C. de Vries, Marita van de Laar; ⁽¹⁾ Imperial College, London, United Kingdom

13:30 – 15:00

Epidemiology oral session 11: Various topics of special interest – ROOM 202

Co-chaired by:

Stephen Moses, University of Manitoba, Winnipeg, Canada
Connie Celum, University of Washington, Seattle, USA

01-S11.01 Time evolution of the fraction of new HIV infections due to primary infection among high risk groups in southern India

Mike Pickles (1), Marie-Claude Boily (1), Peter Vickerman (2), Banadalkoppa M Ramesh (3), Reynold Washington (4), Kathleen Deering (5), Supriya Verma (3), James Blanchard (6), Stephen Moses (6), Michel Alary (7); ⁽¹⁾ Imperial College (London, United Kingdom); ⁽²⁾ LSHTM (, United Kingdom); ⁽³⁾ Karnataka Health Promotion Trust (Bangalore, India); ⁽⁴⁾ St John's Research Institute, Bangalore (, India); ⁽⁵⁾ University of British Columbia (, Canada); ⁽⁶⁾ University of Manitoba (Winnipeg, Canada); ⁽⁷⁾ Centre hospitalier affilié universitaire de Québec (Quebec, Canada)

01-S11.02 Determinants of Time Trends in HIV Prevalence in the Young Antenatal Population of Karnataka Districts

Uma Mahajan (1), Pradeep Banandur (2), Rajaram S (3), Thierry Duchesne (3), Belkacem Abdous (3), Ramesh BM (4), Stephen Moses (5), Michel Alary (6); ⁽¹⁾ CHARME II project (Bangalore, India); ⁽²⁾ 1 CHARME II project, 2 Rajarajeswari Medical College and Hospital (Bangalore, India); ⁽³⁾ 1 CHARME II project (Bangalore, India); ⁽⁴⁾ 3 Karnataka Health Promotion Trust (Bangalore, India); ⁽⁵⁾ 4 University of Manitoba (Winnipeg, Canada); ⁽⁶⁾ 5 Centre hospitalier affilié universitaire de Québec (Quebec, Canada)

01-S11.03 How many infections are averted by behaviour change after early HIV diagnosis & counselling of MSM? Estimates from a stochastic individual-based model

Peter White (1), Julie Fox (2), Neil MacDonald (1), Jonathan Weber (3), Myra McClure (3), Sarah Fidler (3), Helen Ward (1); ⁽¹⁾ Imperial College School of Public Health (London, United Kingdom); ⁽²⁾ Guys & St Thomas' NHS Trust / Kings College London (London, United Kingdom); ⁽³⁾ Imperial College London (, United Kingdom)

01-S11.04 Targeting the Use of HIV RNA Screening to Maximize Yield and Minimize Cost: NYC Health Department STD Clinics, 2008-2010

Susan Blank (1), Christine Borges (2), Alexis Kowalski (2), Samuel Sebiyam (2), Monica Sweeney (2); ⁽¹⁾ NYC DOHMH / CDC (New York, USA); ⁽²⁾ NYC DOHMH (New York, USA)

01-S11.05 Adolescent sexual intercourse and neighborhood social disorder

Sarah Wiehe (1), Mei-Po Kwan (2), Shawn Hoch (1), B'Wana Brooks (1), Aaron Burgess (1), Jeffrey Wilson (3), J Dennis Fortenberry (1); ⁽¹⁾ Indiana University School of Medicine (Indianapolis, USA); ⁽²⁾ The Ohio State University (, USA); ⁽³⁾ IUPUI (, USA)

01-S11.06 Burden of Genital Discharge Pathogens and Associated Characteristics of Asymptomatic HIV-Infected Patients in Johannesburg, South Africa

David Lewis (1), Tobias Chirwa (2), Veerle Msimang (1), Frans Radebe (1), Mary Kamb (3), Ian Sanne (4), Cynthia Firnhaber (4); ⁽¹⁾ National Institute for Communicable Diseases, National Health Laboratory Service (Sandringham, South Africa); ⁽²⁾ University of the Witwatersrand (Johannesburg, South Africa); ⁽³⁾ Centers for Disease Control and Prevention (Atlanta, USA); ⁽⁴⁾ Right to Care (Johannesburg, South Africa)

13:30 – 15:00

Behavioural aspects of prevention oral session 6: STI and HIV Risk: geographic, demographic and behavioural heterogeneity – ROOM 203

Co-chaired by:

Ayesha Khan, Research and Development Solutions, Islamabad, Pakistan

James Blanchard, University of Manitoba, Winnipeg, Canada

02-S6.01 Non-consensual Sex and Association with HIV Infection among Women: a Cohort Study in Rural Uganda, 1990-2008

Isolde Birdthistle (1), Billy Mayanja (2), Dermot Maher (2), Sian Floyd (1), Janet Seeley (3), Helen Weiss (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) MRC/UVRI Uganda Research Unit on AIDS (Entebbe, Uganda); (3) University of East Anglia (, United Kingdom)

02-S6.02 Occupational and intimate partner violence and inconsistent condom use with clients among female sex workers in southern India

Kathleen Deering (1), Parinita Bhattacharjee (2), H.L. Mohan (2), Janet Bradley (3), Kate Shannon (1), Marie-Claude Boily (4), B.M. Ramesh (2), Shajy Isac (2), Stephen Moses (5), James Blanchard (5); (1) University of British Columbia (Vancouver, Canada); (2) Karnataka Health Promotion Trust (Bangalore, India); (3) Laval University (Canada); (4) Imperial College (United Kingdom); (5) University of Manitoba (Winnipeg, Canada)

02-S6.03 Heterogeneity of HIV risk: female sex worker clients and their non-commercial sexual partners in south India

Souradet Shaw (1), Kathleen Deering (2), Shajy Isac (3), Banadakoppa Ramesh (3), Reynold Washington (3), Stephen Moses (1), James Blanchard (1); (1) University of Manitoba (Winnipeg, Canada); (2) University of British Columbia (Canada); (3) Karnataka Health Promotion Trust (Bangalore, India)

02-S6.04 An Exploratory Survey of Male Sex Workers and HIV Risk in an Urban Area of Southwest China

B. Nancy Yu (1), Xiaodong Alex Wang (2), Fei Yu (2), Jun Wang (3), James Blanchard (1); (1) University of Manitoba (Winnipeg, Canada); (2) Chengdu Gay Care Organization (Chengdu, China); (3) China Male Tongzhi Health Forum (Chengdu, China)

02-S6.05 Sexual violence against men who have sex with men and transgenders (MSM-T) in southern India

Souradet Shaw (1), Robert Lorway (1), Kathleen Deering (2), HL Mohan (3), Parinita Bhattacharjee (3), Shajy Isac (3), BM Ramesh (3), Reynold Washington (3), Sushena Reza-Paul (1), Stephen Moses (1), James Blanchard (1); (1) University of Manitoba (Winnipeg, Canada); (2) University of British Columbia (Canada); (3) Karnataka Health Promotion Trust (Bangalore, India)

02-S6.06 Sexual practices of Transgender community in Pakistan

Zia Ahmad (1); (1) Al-Aser (Muzaffargarh, Pakistan)

13:30 – 15:00

Clinical sciences oral session 6: Clinical Advances in Diagnosis & Screening – ROOM 301A

Co-chaired by:

Patricia Kissinger, Tulane University School of Public Health & Tropical Medicine, New Orleans, USA

Christopher Fairley, University of Melbourne, Melbourne, Australia

03-S6.01 Improved diagnostics of bacterial vaginosis with molecular techniques

Arjen Speksnijder (1), Paul Gruteke (2), Debby Jonker (1), Henry de Vries (1), Alje van Dam (1); (1) Health Service Amsterdam (Amsterdam, Netherlands); (2) Onze Lieve Vrouwe Gasthuis General Hospital (Amsterdam, Netherlands)

03-S6.02 SCREENING FOR MYCOPLASMA GENITALIUM, CHLAMYDIA TRACHOMATIS AND BACTERIAL VAGINOSIS IN A PUBLIC HOSPITAL, PREGNANCY TERMINATION SERVICE.

Suzanne Garland (1), Alex Marceglia (2), Sepehr Tabrizi (2), Anna Maria Costa (2); (1) The Royal Women's Hospital (Melbourne, Australia); (2) Royal Women's Hospital (Melbourne, Australia)

03-S6.03 The Diagnosis of Lymphogranuloma Venereum at One's Fingertips

Tania Crucitti (1), Hilde Smet (1); (1) Institute of Tropical Medicine (Antwerpen, Belgium)

03-S6.04 Multi-Site Screening for Lymphogranuloma venereum (LGV) in the United States

Justin Hardick (1), Nicole Quinn (1), Susan Eshelman (2), Estelle Piwowar-Manning (2), Vanessa Cummings (2), Vincent C. Marsiglia (3), The HPTN 061 Study Team (4), Charlotte A. Gaydos (2); (1) Johns Hopkins University School of Medicine (Baltimore, USA); (2) Johns Hopkins University, School of Medicine (Baltimore, USA); (3) Baltimore City Health Department (Baltimore, USA); (4) HIV Prevention Trials Network (Washington, USA)

03-S6.05 Perceptions on Point-of-Care Tests for Sexually Transmitted Infections - Disconnect between Frontline Clinicians and Professionals in Industry

Yu-Hsiang Hsieh (1), Charlotte Gaydos (1), Terry Hogan (1), O Uy (1), Joany Jackman (1), Mary Jett-Goheen (1), Anne Rompalo (1); (1) Johns Hopkins University (Baltimore, USA)

03-S6.06 Self-collection versus physician-collection for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium

Jessie Kwatampora (1), Virginia Senkomago (2), Nelly Mugo (3), Craig Hill (4), Jie Ting (2), Michael Chitwa (5), Suha Patel (1), Hannah Gukare (1), Joshua Kimani (1), Jennifer Smith (2); (1) University of Nairobi/University of Manitoba STI Collaboration (Nairobi, Kenya); (2) University of North Carolina at Chapel Hill (Chapel Hill, USA); (3) University of Nairobi/University of Manitoba STI Collaboration (Nairobi, Kenya); (4) Gen-Probe Incorporated, San Diego, CA. (San Diego, USA); (5) University of Nairobi/University of Manitoba STI Collaboration (Nairobi, Kenya)

13:30 – 15:00

Late breaker abstracts session – ROOM 301B

Co-chaired by:

Annie-Claude Labbé, Université de Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada
Marc Steben, Institut national de santé publique du Québec, Montréal, Canada

LBO - 1.1 Acyclovir Achieves Lower Concentration in African HIV-, HSV-2+ Women Compared to Non-African Populations, Possibly Explaining Lower Herpes Suppression

Yanhui Lu (1), Craig Hendrix (1), Connie Celum (2), Jared Baeten (2), Frances Cowan (3), Sinead Delany-Moretlwe (4), Stewart Reid (5), James Hughes (2), Anna Wald (2), Lawrence Corey (2); (1) Johns Hopkins University (Baltimore, USA); (2) University of Washington (, USA); (3) University of Zimbabwe & University College London (, Zimbabwe); (4) Women's Health Research Institute, University of Witwatersrand (, South Africa); (5) Center for Infectious Disease Research, Lusaka, Zambia & University of Alabama (, USA)

LBO - 1.2 The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men who Have Sex with Men in Lima, Peru

Annick Borquez (1), Gabriela B Gomez (1), Carlos F Caceres (2), Eddy R Segura (2), Robert M Grant (3), Geoffrey P Garnett (1), Timothy B Hallett (1); (1) Imperial College London (London, United Kingdom); (2) Instituto de Estudios en Salud, Sexualidad y Desarrollo Humano/Universidad Peruana Cayetano Heredia (, Peru); (3) J. David Gladstone Institutes, University of California at San Francisco (, USA)

LBO - 1.3 Syphilis Infection and Associated Behaviors Among Transgender Women, Chicago 2010

Beau Gratzner (1), Anna Hotton (2), Mark Pineda (3), Daniel Pohl (3), Letty Martinez (3); (1) Howard Brown Health Center/UIC School of Public Health (Chicago, USA); (2) Howard Brown Health Center/UIC-School of Public Health (Chicago, USA); (3) Howard Brown Health Center (Chicago, USA)

LBO - 1.4 Increasing macrolide resistance in *Mycoplasma genitalium*

Carin Anagrius (1), Britta Loré (1), Jörgen Skov Jensen (2); (1) Falu Hospital (Falun, Sweden); (2) SSI (Köpenhamn, Denmark)

LBO - 1.5 Men Who Have Sex With Men Have a 140-Fold Risk for HIV and Syphilis Compared With Other Men in New York City

Preeti Pathela (1), Sarah Braunstein (1), Julia Schillinger (2), Colin Shepard (1), Monica Sweeney (1), Susan Blank (2); (1) NYC Department of Health and Mental Hygiene (Queens, USA); (2) NYC Department of Health and Mental Hygiene/Centers for Disease Control and Prevention (Queens, USA)

LBO - 1.6 Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men

Stephen Goldstone (1); (1) Albert Einstein College of Medicine (New York, USA)

13:30 – 16:15

Early Career Development Satellite Short Course – Room 302A

See Early Career Development Program for details, p. 51

15:15 – 16:30

Summary and Highlights – ROOM 200C

Co-chaired by:

Gilles Lambert, Institut national de santé publique du Québec, Montréal, Canada
Angelika Stary, Outpatients Center for STI, Vienna, Austria

Conference rapporteurs:

Anne Buvé, Institute of Tropical Medicine, Antwerp, Belgium
Jami S. Leichter, Centers for Disease Control & Prevention, Atlanta, USA
Barbara Van der Pol, Indiana University, Bloomington, USA
Ameeta Singh, University of Alberta, Edmonton, Canada

16:30 – 17:30

Closing Ceremony – ROOM 200C

Co-Chaired by:

Michel Alary, Co-chair, Scientific Program Committee ISSTD 2011
Marie-Claude Boily, Co-chair, Scientific Program Committee ISSTD 2011

Keynote Speaker: Jeffrey Klausner, MD, MPH, Chief of the HIV and TB Care and Treatment Branch, US CDC, South Africa and Associate Clinical Professor of Medicine in the Divisions of AIDS and Infectious Diseases University of California, San Francisco, USA

Title: Responding to STI and HIV in the digital age

The abstract book is available as a Web supplement of the journal *Sexually Transmitted Infections*

http://sti.bmj.com/content/87/Suppl_1.toc



subscriptions@bmjgroup.com • sti.bmj.com

Sexually Transmitted Infections (STI) is the world's longest running international journal dealing with issues of sexual health and medicine. STI publishes original work on the clinical, epidemiological, and laboratory aspects of sexual health, sexually transmitted infections, and HIV and AIDS. Visit STI online to subscribe, view free editor's choice articles, access the online archive, sign up for email alerts and listen to podcasts.

POSTER PRESENTATIONS – ROOM 400ABC

Authors with odd poster numbers will be at their poster on Monday, July 11 and authors with even poster numbers will be at their poster on Tuesday, July 12.

Epidemiology poster session 1 - STI Trends

P1-S1.01 Trends in Chlamydia and Gonorrhea Positivity among Heterosexual Men and Men Who Have Sex With Men Attending a Large Urban Sexual Health Service in Australia, 2002-2009

Lenka Vodstrcil (1), Glenda Fehler (2), David Leslie (3), Jennifer Walker (1), Catriona Bradshaw (1), Jane Hocking (1), Christopher Fairley (1); (1) The University of Melbourne (Parkville, Australia); (2) Melbourne Sexual Health Centre (Carlton, Australia); (3) Victorian Infectious Diseases Reference Laboratory (North Melbourne, Australia)

P1-S1.02 Assessing heterogeneity in the incidence of chlamydia and gonorrhea in an urban Canadian setting: a population-based analysis

Souradet Shaw (1), Mandy Whitlock (2), Deborah Nowicki (2), Pierre Plourde (2), Salaheddin Mahmud (2); (1) University of Manitoba (Winnipeg, Canada); (2) Winnipeg Regional Health Authority (Canada)

P1-S1.03 Undiscovered Burden of STIs in Russia: Current System Shortcomings.

Natalia Anisimova (1), Tatiana Ivanova (1), Alexander Guschin (1), Elena Simonova (1), Anna Zakharova (2), Olga Novoschilova (2), Vartan Shakhzadov (2), Anna Shevchenko (2); (1) Central Research Institute for Epidemiology (Moscow, Russian Federation); (2) Skin and Venereal Disease Clinic #15 (Russian Federation)

P1-S1.04 The Pattern of STI Burden in the Central Region of Russia: Chlamydiosis VS Trichomoniasis. Which One Is the Leader?

Tatiana Ivanova (1), Natalia Anisimova (1), Alexander Guschin (1), Elena Simonova (1); (1) Central Research Institute for Epidemiology (Moscow, Russian Federation)

P1-S1.05 The Detection Rate of Chlamydia trachomatis and Mycoplasma genitalium Infections in STD Clinics in Novosibirsk, Russian Federation

Alexey KHRyanin (1), Oleg Reshetnikov (2); (1) Novosibirsk State Medical University, Ministry of Public Health (Novosibirsk, Russian Federation); (2) Institute of Internal Medicine (Russian Federation)

P1-S1.06 Rectal Health: Prevalence of Rectal STIs and Associations with Clinical Signs and Self-Reported Symptoms

Pamina M Gorbach (1), Marjan Javanbakht (1), Edward Fuchs (2), Robert E Weiss (1), Marjan Hezereh (3), Stephen Brown (3), Alen Voskanian (1), Peter Anton (1), Ross Cranston (4); (1) University of California, Los Angeles (Los Angeles, USA); (2) Johns Hopkins School of Medicine (USA); (3) AIDS Research Alliance (USA); (4) University of Pittsburgh School of Medicine (USA)

P1-S1.07 Multiple Bacterial Sexually Transmitted Infections in Ontario, Canada

Colin Lee (1), Michael Whelan (1), Camille Achonu (2), Wendy Bhanich-Supapol (1), Jennifer Christian (2); (1) Ontario Ministry of Health and Long-Term Care (Toronto, Canada); (2) Ontario Agency for Health Protection and Promotion (Canada)

P1-S1.08 Prevalence of Neisseria gonorrhoeae and Chlamydia trachomatis infection in men attending STD clinics in Brazil

Marcelo Barbosa (1), Valdir Monteiro Pinto (2), Fabio Moherdavi (2), Denis Ribeiro (2), Angelica Espinosa (3); (1) Federal District Government (Brasilia, Brazil); (2) Ministry of Health (Brazil); (3) UFES (Brazil)

P1-S1.09 Trends in the Aetiology of Sexually Transmitted Infections and HIV Co-Infections among STI Patients Attending Alexandra Health Centre, Johannesburg, South Africa (2007-2010)

David Lewis (1), Charles Ricketts (1), Neetha Bhojraj (1), Gloria de Gita (1), Precious Magooa (1), Ilze Venter (1), Lindiwe Mshibe (1), Alex Zezi (1), Etienne Muller (1), Frans Radebe (1); (1) NICD/NHLS (Sandringham, South Africa)

P1-S1.10 Microbiological Surveillance for Sexually Transmitted Infections in Windhoek and Oshakati, Namibia (2007)

Sarah Tobias (1), Shepherd Shonhiwa (2), Foster Norbert (1), Olufemi Oke (3), Christophine Ndjavera (4), Sydney Chikukwa (4), Frans Radebe (5), David Lewis (5); (1) Ministry of Health & Social Services (Windhoek, Namibia); (2) I-Tech Namibia (Namibia); (3) World Health Organisation

(Namibia); (4) Namibian Institute of Pathology (Namibia); (5) NICD/NHLS (South Africa)

P1-S1.11 Prevalence of *Trichomonas vaginalis*, *Chlamydia* and *Gonorrhoea* in Women at the Miami-Dade County Health Department STD Clinic

Hansel Tookes(1), Nina Hirsch (1), Chanelle Diaz (1), Olga Ponomareva (2), Jose Guillermo Castro (1); (1) University of Miami Miller School of Medicine (Miami, USA); (2) Miami Dade County Health Department (Miami, USA)

P1-S1.12 Age-specific incidence of chlamydia, gonorrhoea, and trichomoniasis infection in adolescent women

Wanzhu Tu (1), Byron Batteiger (1), Susan Ofner (1), Barbara Van Der Pol (2), Dennis Fortenberry (1); (1) Indiana University School of Medicine (Indianapolis, USA); (2) Indiana University (USA)

Epidemiology poster session 1 - STI trends - HIV

P1-S1.13 Heterogeneity of the HIV epidemic in the general population of Karnataka state, India

Pradeep Banandur (1), Rajaram Subramanian Potty (2), Sangameshwar B Mahagaonkar (3), Jan Bradley (4), Ramesh M Banadakoppa (5), Reynold G Washington (6), James F Blanchard (7), Stephen Moses (7), Catherine M Lowndes (8), Michel Alary (9); (1) CHARME II Project, India, Rajarajeswari Medical College and Hospital (Bangalore, India); (2) CHARME II project (Bangalore, India); (3) CHARME I project, India, Karuna Medical College (India); (4) CHARME I project, India (Bangalore, India); (5) Karnataka Health Promotion Trust (Bangalore, India); (6) St Johns Research Institute (India); (7) University of Manitoba (Winnipeg, Canada); (8) Health Protection Agency (United Kingdom); (9) Centre hospitalier *affilié* universitaire de Québec (Quebec, Canada)

P1-S1.14 Is HIV Prevalence Declining in Southern India?: Evidence From Two Rounds of General Population Surveys in Bagalkot District, Karnataka

Subramanian Potty Rajaram (1), JE Bradley (2), BM Ramesh (1), S Isac (1), RG Washington (1), S Moses (3), JF Blanchard (3), M Becker (3), M Alary (2); (1) Karnataka Health Promotion Trust (Bangalore, India); (2) Centre hospitalier *affilié* universitaire de Québec (Quebec, Canada); (3) University of Manitoba (Winnipeg, Canada)

P1-S1.15 The Status of the HIV Epidemic in Lebanon: Systematic Review and Synthesis

Ghina Mumtaz (1), Nahla Hilmi (2), Laith Abu-Raddad (1); (1) Weill Cornell Medical College in Qatar (Doha, Qatar); (2) World Bank (USA)

P1-S1.16 Estimating HIV Incidence Rate among Stable Sexual Partnerships in sub-Saharan Africa

Hiam Chemaitelly (1), Laith J. Abu-Raddad (1); (1) Weill Cornell Medical College- Qatar (Doha, Qatar)

P1-S1.17 HIV-1 molecular epidemiology in the Middle East and North Africa

Ghina Mumtaz (1), Nahla Hilmi (2), Francisca Ayodeji Akala (2), Iris Semini (3), Gabriele Riedner (4), David Wilson (2), Laith Abu-Raddad (1); (1) Weill Cornell Medical College in Qatar (Doha, Qatar); (2) World Bank (USA); (3) Joint United Nations Programme on HIV/AIDS Regional Support Team, Middle East and North Africa (Egypt); (4) Regional Office of the Eastern Mediterranean, World Health Organization (Egypt)

Epidemiology poster session 1 - STI trends - HSV

P1-S1.18 Investigating a Cluster of Neonatal Herpes at a Single Institution

Ninad Desai (1), Julia Schillinger (2), Simona Bratu (1), Antonella Eramo (1), Charles Bowers (1), Abha Agrawal (1); (1) Kings County Hospital Center (Brooklyn, USA); (2) New York City Department of Health and Mental Hygiene, New York, NY, USA, 3Centers for Disease Control and Prevention, Atlanta, GA, USA (NY, USA)

P1-S1.19 Herpes simplex virus type 2 infection: seroprevalence in Siberia

Alexey KHRYANIN (1), Oleg Reshetnikov (2), Marina Kandrushina (3); (1) Novosibirsk State Medical University (Novosibirsk, Russian Federation); (2) Institute of Internal Medicine (Russian Federation); (3) Vector-Best, Novosibirsk (Russian Federation)

P1-S1.20 Seroprevalence of herpes simplex virus type I and II infections in Russian Federation

Alexey KHRYANIN (1), Oleg Reshetnikov (2), Marina Kandrushina (3); (1) Novosibirsk State Medical University (Novosibirsk, Russian Federation); (2) Institute of Internal Medicine (Russian Federation); (3) Vector-Best, Novosibirsk (Russian Federation)

P1-S1.21 Incidence Rate of Herpes Simplex Virus type 2 (HSV-2) in the US, 1988-2008

Sarah Gerver (1); (1) Imperial College London (London, United Kingdom)

P1-S1.22 HSV-2 prevalence across a pastoral landscape: Transmission and transition among the Himba and Tjimba populations

Ashley Hazel (1), Betsy Foxman (1), Bobbi Low (2); (1) University of Michigan (Ann Arbor, USA); (2) University of Michigan (Ann Arbor, USA)

**Epidemiology poster session 1 - STI trends -
Syndromic approach**

P1-S1.23 Trend of Sexually Transmitted Diseases Diagnosed by Syndromic Approach in an Institute Setting

Amrinder Kanwar (1); (1) Postgraduate Institute of Medical Education and Research (Chandigarh, India)

P1-S1.24 Longitudinal Trends in Syndromic STI Diagnoses in Lilongwe, Malawi: 2006-2010

Gift Kamanga (1), Kimberly Powers (2), Clement Mapanje (1), Nkhafwire Mkandawire (1), Helen Milonde (1), Happiness Kanyamula (1), Patricia Wiyo (1), Francis Martinson (1), William Miller (2), Irving Hoffman (2); (1) UNC Project Malawi (Lilongwe, Malawi); (2) University of North Carolina at Chapel Hill (USA)

P1-S1.25 Trend of Sexually Transmitted Diseases Diagnosed by Syndromic Approach in an Institute Setting

Amrinder Kanwar (1); (1) Postgraduate Institute of Medical Education and Research (Chandigarh, India)

**Epidemiology poster session 1 - STI trends -
Trichomonas vaginalis**

P1-S1.26 Prevalence of trichomonas vaginalis infection during the first trimester of pregnancy in pregnant women on Maternal and Perinatal Institute

Luis Cortez (1); (1) Instituto Nacional Materno Perinatal (San Juan de Miraflores, Peru)

**Epidemiology poster session 1 - STI trends -
Vaginosis**

P1-S1.27 Intravaginal Practices, Lubrication, and Bacterial Vaginosis among Women in Los Angeles

Joelle Brown (1), Kristen Hess (1), Steve Brown (2), Colleen Murphy (2), Avalena Waldman (2), Marjan Hezareh (2); (1) University of California, Los Angeles (Los Angeles, USA); (2) AIDS Research Alliance (USA)

P1-S1.28 The Prevalence and Incidence of Bacterial vaginosis in a Cohort of Young Australian Women.

Jennifer Walker (1), Jane Hocking (1), Christopher Fairley (1), Sepehr Tabrizi (2), Marcus Chen (3), Francis Bowden (4), Jane Gunn (1), Basil Donovan (5), John Kaldor (5), Catriona Bradshaw (3); (1) University of Melbourne (University of Melbourne, Australia); (2) The Royal Women's Hospital (Parkville, Australia); (3) Melbourne Sexual Health Centre (Carlton, Australia); (4) Australian National University (Canberra, Australia); (5) National Centre in HIV Epidemiology and Clinical Research (Coogee, Australia)

P1-S1.29 Use of molecular sequencing to compare the vaginal microbiota of healthy women and women with bacterial vaginosis in India

Seema Kotian (1), Dr.Anjali Arun (1), Karl Krupp (1), Dr.Vijaya Srinivas (1), Dr.Purnima Madhivanan (1), Dr.Lee Riley (2), Eva Raphael (3), Dr.Arthur Reingold (4), Dr.Jeffrey Klausner (5); (1) Public Health Research Institute,India (Mysore, India); (2) School of Public Health,University of California,Berkeley (USA); (3) University of California,Berkeley (Berkeley, USA); (4) School of Public Health,University of California (USA); (5) University of California, San Francisco (USA)

**Epidemiology poster session 1 - STI trends -
Chlamydia trachomatis**

P1-S1.30 C. trachomatis Prevalence and Detection in Men Attending the Urologist's Office to Get Tested for Sexually Transmitted Infections in St. Petersburg

Vitaly Smelov (1), Sander Ouburg (2), Arnold Catsburg (2), Jolein Pleijster (2), Andrey Gorelov (1), Henry de Vries (3), Andrey Novikov (1), Servaas Morre (2); (1) Medical Academy of Postgraduate Studies (St. Petersburg, Russian Federation); (2) VU University Medical Center (Amsterdam, Netherlands); (3) University of Amsterdam (Amsterdam, Netherlands)

P1-S1.31 Chlamydia trachomatis in Norway, 1988-2009

Finn Egil Skjeldestad (1), Hilde Kløvstad (1); (1) Norwegian Institute of Public Health (Oslo, Norway)

P1-S1.32 Urogenital Chlamydia trachomatis is a Hyperendemic Disease in Paramaribo Suriname. Results from a Multiethnic Society.

Jannie van der Helm (1), Antoon Grunberg (2), Arjen Speksnijder (1), Henry de Vries (3), Leslie Sabajo (4); (1) Health Service Amsterdam (Amsterdam, Netherlands); (2) Lobi Foundation (Suriname); (3) Health Service Amsterdam, Academic Medical Center, University of Amsterdam, Centre for Infections and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, (Netherlands); (4) Dermatology Service, Ministry of Health (Suriname)

P1-S1.33 Timing of Progression of Chlamydia trachomatis Infection to Pelvic Inflammatory Disease: A Mathematical Modeling Study

Sereina A. Herzog (1), Christian L. Althaus (2), Janneke C.M. Heijne (2), Pippa Oakeshott (3), Sally Kerry (3), Philip Hay (4); (1) University of Bern (Bern, Switzerland); (2) University of Bern (Switzerland); (3) University of London (United Kingdom); (4) St George's Hospital (United Kingdom)

P1-S1.34 First Report of the Swedish New Variant of Chlamydia trachomatis (nvCT) in Russia

Elena Shipitsyna (2), Magnus Unemo (1), Ronza Hadad (1), Olga Ryzhkova (2), Alevtina Savicheva (2), Marius Domeika (3); (1) Swedish Reference Laboratory for Pathogenic Neisseria (Orebro, Sweden); (2) D.O. Ott Research Institute of Obstetrics and Gynaecology (Russian Federation); (3) Uppsala University (Sweden)

P1-S1.35 Declining positivity amongst 15-24 year olds screened for chlamydia in England: a sign of falling prevalence or a symptom of changing uptake?

Sarah C Woodhall (1), Catherine H Mercer (2), Kate Soldan (1); (1) Health Protection Agency (London, United Kingdom); (2) University College London (London, United Kingdom)

Epidemiology poster session 1 - STI trends - Neisseria gonorrhoeae

P1-S1.36 Prevalence of Neisseria gonorrhoeae Infections Among Men and Women Entering the National Job Training Program-United States, 2004-2009

Heather Bradley (1), Catherine Satterwhite (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P1-S1.37 Prevalence of and risk behaviors for Neisseria gonorrhoeae in parturient women aged 15 to 24 in Brazil

Angelica Miranda (1), Valdir Pinto (2), Celia Szwarcwald (3), Carla Baroni (1), Lorenzo Stringari (1), Lilian Inocencio (3); (1) Universidade Federal do Espirito Santo (Vitoria, Brazil); (2) Ministerio da Saúde (Brasilia, Brazil); (3) Ministério da Saúde (Rio de Janeiro, Brazil)

Epidemiology poster session 1 - STI trends - Neisseria gonorrhoeae - resistance

P1-S1.38 Emergence of Neisseria gonorrhoeae Isolates With Decreased Susceptibilities to Ceftriaxone and Cefixime in Canada: 2001-2010

Irene Martin (1), Pam Sawatzky (1), Vanessa Allen (2), Linda Hoang (3), Brigitte Lefebvre (4), Neil Mina (5), Matthew Gilmour (1); (1) Public Health Agency of Canada (Winnipeg, Canada); (2) Ontario Agency for Health Protection and Promotion, Public Health Laboratory (Toronto, Canada); (3) British Columbia Centres for Disease Control Public Health Microbiology & Reference Laboratory (Vancouver, Canada); (4) Laboratoire de santé publique du Québec (Ste-Anne-de-Bellevue, Canada); (5) University of Alberta, Department of Medical Microbiology (Edmonton, Canada)

P1-S1.39 Azithromycin Susceptibilities in Canadian Neisseria gonorrhoeae Isolates (2006-2010)

Pam Sawatzky (1), Irene Martin (1), Vanessa Allen (2), Linda Hoang (3), Brigitte Lefebvre (4), Marguerite Lovgren (5), Matthew Gilmour (1); (1) Public Health Agency of Canada (Winnipeg, Canada); (2) Ontario Agency for Health Protection and Promotion - Public Health Laboratory (Toronto, Canada); (3) British Columbia Centres for Disease Control, Public Health Microbiology & Reference Laboratory (Vancouver, Canada); (4) Laboratoire de santé publique du Québec (Ste-Anne-de-Bellevue, Canada); (5) Alberta Health Services (Edmonton, Canada)

P1-S1.40 Emerging Molecular Mutations of Reduced Susceptibility to Third-generation Cephalosporins in *Neisseria gonorrhoeae* Isolates from Saskatchewan, Canada

S.D. Thakur (1), E. Nagle (2), P.N. Levett (2), G.B. Horsman (2), Mingmin Liao (1), J. R. Dillon (1); (1) Vaccine and Infectious Disease Organization (Saskatoon, Canada); (2) Saskatchewan Disease Control Laboratory, Regina, SK, Canada (Canada)

P1-S1.41 Emergence of an African antimicrobial resistance genotype in *Neisseria gonorrhoeae* strains isolated in Guangzhou, China, 2001-2009

He-ping Zheng (1), Bin Yang (1), Xing-zhong Wu (1), Jin-mei Huang (1), Wei-ying Zeng (1), Yao-hua Xue (1), Han-ning Jiang (1), Jiang-li Ou (1); (1) Guangdong Provincial Center for Skin Diseases and STIs Control (Guangzhou, China)

P1-S1.42 Russian gonococcal antimicrobial susceptibility programme (RU-GASP) - resistance levels in 2010 and trends during 2005-2010

Nataliya Frigo (2), Magnus Unemo (1), A Kubanova (2), A Kubanov (2), V Solomka (2), S Polevshikova (2), I Lesnaya (3); (1) Swedish Reference Laboratory for Pathogenic *Neisseria* (Örebro, Sweden); (2) State Research Centre for Dermatology and Venereology Russian Ministry Health (Russian Federation); (3) Polevshikova (Russian Federation)

P1-S1.43 Antimicrobial Susceptibility and Molecular Epidemiological Characteristics of *Neisseria gonorrhoeae* in 2009-2010 in Belarus

Slavyana Glazkova(2), Magnus Unemo (1), Daniel Golparian (1), Leonid Titov (2), Nataliya Pankratova (3), Nataliya Suhabokava (4), Irina Shimanskaya (4), Gennadiy Ignatyev (2), Marius Domeika (5); (1) Swedish Reference Laboratory for Pathogenic *Neisseria* (Örebro, Sweden); (2) The Republican Research and Practical Center for Epidemiology and Microbiology (Belarus); (3) Mogilev Regional Dermato-Venerological Dispensary (Belarus); (4) Minsk City Dermato-Venerological Dispensary (Belarus); (5) Uppsala University (Sweden)

P1-S1.44 Antimicrobial Susceptibility Profile of *Neisseria gonorrhoeae* Isolates in the Province of Québec: 2010

Brigitte Lefebvre (1), Anne-Marie Bourgault (1); (1) Laboratoire de santé publique du Québec, Institut national de santé publique du Québec (Sainte-Anne-de-Bellevue, Canada)

P1-S1.45 *Neisseria gonorrhoeae* Antimicrobial Susceptibility in Latin America and the Caribbean (2000-2009): A Contribution to the Treatment Guidelines Revision.

Stefania Starnino (1), GASP-LAC Network* (1), Mingmin Liao (1), Martha Ruben (1), Ava Storey (1), Jo-Anne R. Dillon (1); (1) Vaccine and Infectious Disease Organization (University of Saskatchewan) (Saskatoon, Canada) - Authors contributed equally and are listed in an alphabetical order of country names. P. Galarza; I. Pagano; M. E. Trigos; A. Schwartz Benzaken; V. M. Pinto; A. Maldonado Ballesteros; O. M. Sanabria Cruz; A. Llop; E. Aguilar Jarrin; N. Aguayo; J. L. Portilla Carbajal; G. Borthagaray; A. Acevedo; D. Payares.

Epidemiology poster session 1 - STI trends - Syphilis

P1-S1.46 Withdrawn

P1-S1.47 Measuring and Prioritizing Congenital Syphilis Control in Guangdong China: A Markov Model to Inform Policy Implementation

Joseph Tucker(6) Nicholas Tan (1), Chara Rydzak (2), Li-Gang Yang (3), Rosanna Peeling (4), Xiang-Sheng Chen (5); (1) Harvard Institute for Global Health (Cambridge, USA); (2) Beth Israel Deaconess Medical Center (USA); (3) Guangdong Provincial STI Control Center (China); (4) London School of Hygiene and Tropical Medicine (United Kingdom); (5) National STD Control Center (China); (6) Harvard Medical School

P1-S1.48 Prevalence of Syphilis in Antenatal Clinic Attenders and Associated Risk Factors

Yaw Adu-Sarkodie (1), Paul Mensah (1), Baafuor Kofi Opoku (1), Philippe Mayaud (2), Rosanna Peeling (2); (1) School of Medical Sciences (KUMASI, Ghana); (2) London School of Hygiene and Tropical Medicine (London, United Kingdom)

P1-S1.49 Syphilis prevalence and risk factors in Brazilian Armed Forces conscripts, 2007

DENIS RIBEIRO (1), VALDIR MONTEIRO PINTO (1), Erika Rezende (2), ANGELICA ESPINOSA (3), Gerson Pereira (2); (1) MINISTRY OF HEALTH (BRASILIA, Brazil); (2) MINISTRY OF HEALTH (Brazil); (3) UFES (Brazil)

P1-S1.50 A Decade of Early Syphilis in East and Inner City London

Heather Anderson (1), Andy Williams (1), Matthias Zirngibl (1), Jaudat Fatima (1), Merle Symonds (1), Beng Goh (1); (1) Barts and The London NHS Trust (London, United Kingdom)

Epidemiology poster session 1 - STI trends - HPV

P1-S1.51 Prevalence of Anogenital Warts Among STD Clinic Patients-STD Surveillance Network, United States, January 2010- September 2010

eloisa llata (1), river Pugsley (2), Irina Tabidze (3), Lenore Asbel (4), Kyle Bernstein (5), Roxanne Kerani, PhD (6), Jane Schwebke (7), Lisa Longfellow (8), christie Mettenbrink (9), Sarah Guerry (10), Jonathan Zenilman (11), Ellen Klingler (12), Hillard Weinstock (13); (1) cdc (atlanta, USA); (2) Virginia Department of Health (Richmond, USA); (3) Chicago Department of Public Health (chicago, USA); (4) PDPH - Division of Disease Control (USA); (5) San Francisco Department of Public Health (San Francisco, USA); (6) Public Health - Seattle & King Co (Seattle, USA); (7) University of Alabama at Birmingham (Birmingham, USA); (8) Louisiana Office of Public Health (Metairie, USA); (9) Colorado Department of Health (USA); (10) LA County Dept of Public Health (Los Angeles, USA); (11) Johns Hopkins School of Medicine (Baltimore, USA); (12) NYC department of Health and mental hygiene (NYC, USA); (13) Centers for Disease Control and Prevention (USA)

P1-S1.52 Incidence of Anal HPV and HPV-Related Sequelae in HIV-Infected and - Uninfected US Adolescents

Tanya Mullins (1), Craig Wilson (2), Bret Rudy (3), Heidi Sucharew (1), Jessica Kahn (1); (1) Cincinnati Children's Hospital Medical Center (Cincinnati, USA); (2) University of Alabama at Birmingham (Birmingham, USA); (3) New York University School of Medicine (New York, USA)

P1-S1.53 Assessing HPV genotype prevalence in Australian women by Indigenous ethnicity pre-vaccination

Garland SM 1,2, 3, Brotherton JML1,4,5, Stevens M1, 3, Tabrizi SN1,2, 3, Condon J6, McIntyre P, Smith D7 on behalf of the WHINURS (Women, HPV, Indigenous Nonindigenous, Urban, Rural Study) Study Group. 1Department of Microbiology and Infectious Diseases, The Royal Women's

Hospital, Melbourne, Australia 2Department of Obstetrics and Gynaecology, University of Melbourne 3Murdoch Children's Research Institute, Victoria 4 Victorian Cytology Service 5 NCIRS, University of Sydney 6 Menzies Centre, Darwin 7 Pathwest, Perth, Western Australia.

P1-S1.54 High-risk Human Papilloma Virus (HPV) Types Prevalence in 20-64 Years Old Women; Slovenian National HPV Prevalence Study, 2010

Irena Klavs(1), Veronika Ucarar (1), Mario Poljak (2); (1) National Institute of Public Health (Ljubljana, Slovenia); (2) Institute of Microbiology & Immunology (Ljubljana, Slovenia)

P1-S1.55 Higher Seroprevalence is Associated with HPV Infections of Mucosal Epithelium and Infections at Multiple Sites in Men

BEIBEI LU (1), Raphael Viscidi (2), Yougui Wu (3), Alan Nyitray (1), Luisa Villa (4), Eduardo Lazcano-Ponce (5), Roberto J. Carvalho Silva (6), Maria Luiza Baggio (4), Manuel Quiterio (5), Jorge Salmerón (5), Danelle Smith (1), Martha Abrahamsen (1), Mary Papenfuss (1), Anna Giuliano (1); (1) H. Lee Moffitt Cancer Center and Research Institute (Tampa, USA); (2) School of Medicine, Johns Hopkins University (Baltimore, USA); (3) College of Public Health, University of South Florida (Tampa, USA); (4) Ludwig Institute for Cancer Research (São Paulo, Brazil); (5) Instituto Nacional de Salud Pública (Cuernavaca, Mexico); (6) 1Centre for Reference and Training in STD/AIDS (São Paulo, Brazil)

Epidemiology poster session 1 - STI trends - Mycoplasma genitalium

P1-S1.56 The Incidence of Mycoplasma genitalium in a Cohort of Young Australian Women.

Jennifer Walker (1), Christopher Fairley (1), Catriona Bradshaw (2), Sepehr Tabrizi (3), Marcus Chen (2), Jimmy Twin (3), Nicole Taylor (3), Basil Donovan (4), John Kaldor (4), Jane Hocking (1); (1) University of Melbourne (University of Melbourne, Australia); (2) Melbourne Sexual Health Centre (Carlton, Australia); (3) The Royal Women's Hospital (Parkville, Australia); (4) National Centre in HIV Epidemiology and Clinical Research (Coogee, Australia)

P1-S1.57 Epidemiology of *Mycoplasma genitalium* and Genital HIV-1 RNA: A Longitudinal Study Among HIV-infected Zimbabwean Women

Sue Napierala Mavedzenge (1), Etienne E Müller (2), David A Lewis (2), Tsungai Chipato (3), Charles Morrison (4), Helen A Weiss (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) Sexually Transmitted Infections Reference Centre (Johannesburg, South Africa); (3) University of Zimbabwe College of Health Science (Harare, Zimbabwe); (4) Family Health International (Research Triangle Park, USA)

Epidemiology poster session 2 - Population - Commercial sex worker

P1-S2.01 Prevalence of HIV and sexually transmitted infections among clients of female sex workers in Karnataka, south India

Souradet Shaw (1), Kathleen Deering (2), Sushena Reza-Paul (1), Shajy Isac (3), Banadakoppa Ramesh (3), Reynold Washington (3), Stephen Moses (1), James Blanchard (1); (1) University of Manitoba (Winnipeg, Canada); (2) University of British Columbia (Canada); (3) Karnataka Health Promotion Trust (Bangalore, India)

P1-S2.02 HIV prevalence in female sex workers in a focused HIV prevention project in Mumbai and Thane District, India

Samita Bhardwaj (1), Sudipto Roy (1), Sanjeevsingh Gaikwad (1), Virupax Ranebennur (1); (1) Family Health International (Mumbai, India)

P1-S2.03 Determinants of Condom Breakage among Female Sex Workers in Karnataka, India

Janet Bradley (1), S Rajaram (2), Michel Alary (1), Shajy Isac (2), Stephen Moses (3), BM Ramesh (2); (1) Laval University (Bangalore, India); (2) Karnataka Health Promotion Trust (Bangalore, India); (3) University of Manitoba (Winnipeg, Canada)

P1-S2.04 Impact of female sex worker turnover on HIV prevalence, incidence and core group intervention impact in Cotonou (Benin)

Marie-Claude Boily (1); (1) Imperial College (London, United Kingdom)

P1-S2.05 Clients of Street-based Female Sex Workers and Potential Bridging of HIV/STI in Russia

Linda Niccolai (1), Veronika Odinkova (2), Liliya Safiullina (2), Zinaida Bodanovskaya (2), Robert Heimer (1), Olga Levina (2), Maia Rusakova (2); (1) Yale School of Public Health (New Haven, USA); (2) NGO Stelit (Russian Federation)

P1-S2.06 HIV, Sexually Transmitted Infections, and Risk Behaviors among Clients of Sex Workers in Guatemala: are they a bridge in HIV transmission?

Meritxell Sabidó (1), María Lahuerta (2), Gabriela Hernández (3), Alexandra Montoliu (4), Victoria Gonzalez (4), Federica Giardina (5), José Ernesto Monzón (3), Maria Isabel Pedroza (6), Jordi Casabona (4), Rosa Guevara (6); (1) Fundació Sida i Societat, Barcelona, Catalonia, Spain; (2) CIBER Epidemiología y Salud Pública, (CIBERESP) (Barcelona, Spain); (3) International Center for AIDS Care and Treatment Programs, Columbia University-Mailman School of Public Health, New York, United States; (4) Fundació Sida i Societat (Barcelona, USA); (5) Fundació Sida i Societat, Escuintla, Guatemala (Guatemala); (6) Centre for Epidemiological Studies on HIV/AIDS and STI of Catalonia (CEEISCAT), ICO/Health Department, Generalitat de Catalunya, Badalona, Spain; (7) CIBER Epidemiología y Salud Pública, (CIBERESP) (Spain); (8) Fundació Sida i Societat, Barcelona, Catalonia, Spain (Spain); (9) Health District of Escuintla, Ministry of Health, Guatemala (Guatemala)

P1-S2.07 STI Rates and Risk Factors among Female Sex Workers Attending STI Testing Sites in Germany, January-December 2010

Stine Nielsen (1), Karin Haar (1), Andrea Sailer (1), Osamah Hamouda (1); (1) Robert Koch Institute (Berlin, Germany)

P1-S2.08 Geography, Mobility, Work Venue, and Sexually Transmitted Infections among 4,100 Female Sex Workers in 20 Cities in Peru

Carolina Mejia (1), Pablo Campos (2), Cesar Carcamo (2), Patricia Garcia (2), James Hughes (3), Diane Martin (3), Geoff Garnett (4), King Holmes (3); (1) Battelle (Seattle, USA); (2) Universidad Peruana Cayetano (Peru); (3) University of Washington (Seattle, USA); (4) Imperial College (United Kingdom)

P1-S2.09 Who is at Higher Risk of STIs and HIV: Brothel-based or Street-based Female Sex Workers? Evidence from Two Rounds of Bio-behavioral Surveys

Abhishek Gautam (1), Rajatashuvra Adhikary (1), Shreena Ramanathan (1), Prabuddhagopal Goswami (1), Sharmistha Khobragade (1), Sucheta M Deshpande (2), Shirin Khazi (2), Mandar M Mainkar (2), RS Paranjape (2); (1) FHI (New Delhi, India); (2) National AIDS Research Institute (NARI) (India)

P1-S2.10 Female Clients and Partners of MSM Sex Workers in a Resource-poor Setting, West Africa

Olusegun Busari (1), Martha Nakayima (2), Adebola Busari (3); (1) Federal Medical Centre (Ido-Ekiti, Nigeria); (2) The AIDS Support Organization (Masaka, Uganda); (3) Care AIDS International (Nigeria)

P1-S2.11 High Prevalence of HIV, Other Sexually Transmitted Infections and Risk Profile in Male Commercial Sex Workers Who Have Sex With Men in The Netherlands

Willem-Jan Cuypers (1), Anne-Marie Niekamp (1), Renee Keesmekers (1), Laura Spauwen (1), Dési Hollman (1), Daisy Telg (1), Nicole Dukers-Muijers (1), Christian Hoebe (1); (1) Public Health Service Southern Limburg NL (GELEEN, Netherlands)

P1-S2.12 Improving access to STI care among female sex workers by strengthening service provider networks in Bangalore, south India

Bharatesh Shetti (1), Sunil P (1), Parinita Bhattacharjee (1), Stephen Moses (2), Prakash K.H (1), Vidyacharan M (1); (1) Karnataka Health Promotion Trust (Bangalore, India); (2) Karnataka Health Promotion Trust (Bangalore, India)

P1-S2.13 The impact of the 2010 Winter Olympic Games on sex work patterns, safety and sex worker vulnerability to HIV and sexually transmitted infections

Kathleen Deering (1), Jill Chettiar (1), Keith Chan (2), Matthew Taylor (3), Julio Montaner (1), Kate Shannon (1); (1) University of British Columbia (Vancouver, Canada); (2) BC Centre for Excellence in HIV/AIDS (Canada); (3) HUSTLE, PEERS Vancouver Resource Society (Canada)

P1-S2.14 Neisseria gonorrhoea and Chlamydia trachomatis Re-infection and associated risk factors among cohort of Female sex workers in India

Arun R Risbud (1), Gururaj Rao Deshpande (1), Prakash Narayanan (2), Prabhakar parimi (3), Anjana Das (3); (1) National AIDS Research Institute (Pune, India); (2) Family Health International, India. (New Delhi, India); (3) Family Health International (New Delhi, India)

P1-S2.15 Prevalence of condyloma acuminatum and certain sexually transmitted diseases among female sex workers (FSWs) in a cohort study at sexually transmitted diseases dispensary (DIST) in Cotonou, Bénin.

Nassirou GERALDO (1); (1) DIST/Centre de santé de Cotonou 1 (Cotonou, Benin)

P1-S2.16 What do female sex workers do if they have genital symptoms?

Krystal Lee (1), KH Wong (2); (1) Stanley Ho Centre for Emerging Infectious Diseases (Hong Kong, Hong Kong); (2) Special Preventive Programme (Hong Kong, Hong Kong)

P1-S2.17 Modelling the impact of rapid test syphilis screening amongst female sex workers in China.

Kate Mitchell (1), Andrew Cox (1); (1) LSHTM (London, United Kingdom)

P1-S2.18 Syphilis Prevalence and Related Risk Factors among Female Workers at Social Venues in Liuzhou, China

Jing Li (1), Xiang-sheng Chen (1), Anisha Gandhi (2), Chirayath Suchindran (2), Sharon Weir (2); (1) The National Center for STD Control and the Chinese Academy of Medical Sciences Institute of Dermatology (Nanjing, China); (2) the Gillings School of Global Public Health and The Carolina Population Center, University of North Carolina at Chapel Hill (Chapel Hill, USA)

P1-S2.19 Unprotected Fellatio and Pharyngeal Gonorrhoea in Sydney Sex Workers

Phillip J Read (1), Handan Wand (2), Rebecca Guy (2), Anna McNulty (1), Basil Donovan (2); (1) Sydney Sexual Health Centre (Sydney, Australia); (2) National Centre in HIV Epidemiology and Clinical Research (Sydney, Australia)

P1-S2.20 Factors influencing cervical infection among female sex workers in Benin

Souleymane Diabaté (1), Annie Chamberland (1), Nassirou Géraldo (2), Marcel Zannou (3), Marguérite Massinga Loembé (4), Séverin Anagonou (5), Annie Claude Labbé (6), Cécile Tremblay (1), Michel Alary (7); (1) Centre de recherche du Centre hospitalier de l'Université de Montréal (Montréal, Canada); (2) Dispensaire IST, Centre de santé de Cotonou I (Cotonou, Benin); (3) Centre national hospitalier universitaire (Cotonou, Benin); (4) Institut de Médecine tropicale (Anvers, Belgium); (5) Centre national hospitalier universitaire (Cotonou, Benin); (6) Université de Montréal, Hôpital Maisonneuve-Rosemont (Montréal, Canada); (7) URESP, Centre de recherche FRSQ du CHA universitaire de Québec (Québec, Canada)

P1-S2.21 Integrating Public Health into the Sex Worker Community in Indianapolis

Alexis M. Roth, M.P.H. (1), Joshua G. Rosenberger, Ph.D.(c) M.P.H.(1), Janine Waters (2), Janet Arno M.D. (2), Barbara Van Der Pol, Ph.D., M.P.H. (1); (1) Indiana University (USA); (2) Marion County Health Dept (Indianapolis, USA)

P1-S2.22 Changes in HIV Knowledge & Risk Behaviors in Female Sex Workers in Rwanda: HIV Prevention Implications of Trend Analyses in Behavioral Surveillance

Catherine Kayitesi (1), R Hinda (1), A Gwiza (1), H Balisanga (1), S Nsanzimana (1), A Koleros (2), JMV Uwimana (3), M Mwumvaneza (1); (1) TRAC Plus (Kigali, Rwanda); (2) Futures Group International/MEASURE Evaluation (Kigali, Rwanda); (3) Rwanda National Reference Laboratory (Kigali, Rwanda)

Epidemiology poster session 2 - Population - transgender

P1-S2.23 Transgender Persons in Guatemala: Over-Exposed and Under-Protected: The Findings of an RDS Behavioral Survey

William Miller (1), Berta Alvarez (1), Sabrina Boyce (2), Andrés Alvarado (2), Clare Barrington (3), Gabriela Paz-Bailey (2); (1) Del Valle University of Guatemala (Guatemala City, Guatemala); (2) Tephinet, Inc. (Guatemala); (3) University of North Carolina at Chapel Hill (USA)

Epidemiology poster session 2 - Population - Injection drug users

P1-S2.24 HIV and hepatitis C risk factors, infection status awareness and access to care among people who inject drugs: Results from a national surveillance system, I-Track Phase 2 (2005-2008)

Jill Tarasuk(1), Anna-Maria Frescura (1), Susanna Ogunnaike-Cooke (1), Chris Archibald (1); (1) Public Health Agency of Canada (Ottawa, Canada)

P1-S2.25 HIV Serostatus Knowledge, Absence of Previous Testing and Sexual Behaviors among Injecting Drug Users

Karine Blouin (1), Raymond Parent (1), Pascale Leclerc (2), Caty Blanchette (3), Michel Alary (1), Carole Morissette (2), Élise Roy (4), Christiane Claessens (1); (1) Institut National de Santé Publique du Québec (Québec, Canada); (2) Direction de Santé Publique de Montréal (Montréal, Canada); (3) Centre de recherche du Centre hospitalier affilié universitaire de Québec (Québec, Canada); (4) Université de Sherbrooke à Longueuil (Longueuil, Canada)

P1-S2.26 Drug and Sexual HIV Risk among Injection Drug Users: A Latent Class Analysis

Syed Noor (1); (1) University of Texas School of Public Health (Houston, USA)

Epidemiology poster session 2 - Population - Vulnerable youth

P1-S2.27 Response of Troubled Youth and STIs

Arshad Iqbal Bhutta (1); (1) Al-Murid Surgical Hospital (Muzaffargarh, Pakistan)

P1-S2.28 Sexually Transmitted Infections in sexually abused children and adolescents in Ibadan, Nigeria

Samuel Adetona Fayemiwo (1), I. A. Ayede (1), O.O. Olusanya (2), O. F. Akinbami (2), R. A. Bakare (1); (1) University of Ibadan (Ibadan, Nigeria); (2) University College Hospital (Ibadan, Nigeria)

P1-S2.29 Risky Sexual Practices Among Youth In Quebec Care Centers

Gilles Lambert (1), Nancy Haley (2), Sandrine Jean (3), Claude Tremblay (4), Jean-Yves Frappier (5), Joanne Otis (6), Elise Roy (7); (1) Institut national de santé publique du Québec (Montréal, Canada);

(2) hospitalier Sainte-Justine, Université de Montréal (Canada); (3) Direction de santé publique, agence de la santé et des services sociaux de Montréal (Canada); (4) Direction de santé publique, agence de la santé et des services sociaux de Montréal (Canada); (5) Centre hospitalier Sainte-Justine, Université de Montréal (Canada); (6) Université du Québec à Montréal (Canada); (7) Université Sherbrooke (Canada)

P1-S2.30 STI AMONG VULNERABLES YOUTH ATTENDING FREE TARGETED HIV COUNSELING AND TESTING SERVICES INCLUDING AND STI DIAGNOSIS AND MANAGEMENT IN BENIN, WEST AFRICA

BEHANZIN NDOUR Marguerite (1), Balogoun A. Amour (2); (1) Population Service International-Benin (Cotonou, Benin); (2) Population Services International - Benin (Cotonou, Benin)

P1-S2.31 Mean Streets vs. Main Street: More Street Youth Report STIs, Multiple Sexual Partners and Lower Condom Use Compared to their Peers in the General Population.

Lily Fang (1), Salman A Klar (1), Caryll Tawse (2), Dara Friedman (3), Darlene Taylor (4), Jennifer Gratrix (5), John Wiley (6), Judith Wright (7), Miriam Rossi (8), Thomas Wong (1), Gayatri C Jayaraman (1), Team Enhanced Street Youth Surveillance (1); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Capital District Health Authority (Canada); (3) Ottawa Public Health (Canada); (4) BC Centre for Disease Control (Canada); (5) Alberta Health Services (Canada); (6) Cadham Provincial Laboratory (Canada); (7) Public Health Services, Saskatoon Health Region (Canada); (8) Sick Kids Hospital and University of Toronto (Canada)

P1-S2.32 Do As I Think, Not As I Do: The Discordance Between Perception of Risk for STBBIs and Sexual Risk Behaviours Among Canadian Street-Involved Youth

Lily Fang (1), Salman A Klar (1), Dara Friedman (2), Jennifer Gratrix (3), Miriam Rossi (4), Caryll Tawse (5), Darlene Taylor (6), Judith Wright (7), John Wylie (8), Thomas Wong (1), Gayatri C Jayaraman (1), Team for the Enhanced Street Youth Surveillance (9); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Ottawa Public Health (Ottawa, Canada); (3) Alberta Health Services (Edmonton, Canada); (4) Hospital for Sick Children (Toronto, Canada); (5) Capital District Health Authority (Halifax, Canada); (6) British Columbia Centre for Disease Control (Vancouver,

Canada); (7) Saskatoon Health Region (Saskatoon, Canada); (8) Cadham Provincial Laboratory (Winnipeg, Canada); (9) Enhanced Street Youth Surveillance (E-SYS) (Canada)

P1-S2.33 Criminal Justice Involvement in Adolescence and Sexually Transmitted Infection in Adulthood in the United States

Maria Khan (1), David Rosen (2), Matthew Epperson (3), Amanda Berger (4), Kristina Smyrk (4); (1) University of Maryland, College Park (College Park, USA); (2) University of North Carolina at Chapel Hill (Chapel Hill, USA); (3) University of Chicago (USA); (4) University of Maryland at College Park (Department of Behavioral and Community Health, USA)

Epidemiology poster session 2 - Population - Men who have sex with men

P1-S2.34 STI-Surveillance within AIDS Reference Centres in Belgium: High Consistent STI Incidence among HIV-positive Men having Sex with Men, 2008 - 2009.

Ruth Verbrugge (1), Dominique Van Beckhoven (1), André Sasse (1); (1) WIV-ISP (Brussels, Belgium)

P1-S2.35 Increased HIV and Primary and Secondary Syphilis Diagnoses among Young Men Who Have Sex with Men, 2004-2008

Elizabeth Torrone (1), Jeanne Bertolli (1), Jianmin Li (1), Patricia Sweeney (1), William Jeffries, IV (1), Thomas Peterman (1); (1) CDC (Atlanta, USA)

P1-S2.36 Prevalence and Risk Factors of HSV-2 Infection among Men Who Have Sex with Men in China

Shaochun Chen (1), Yue-ping Yin (1), Hong-chun Wang (1), Wan-hui Wei (1), Alberta L Wang (1), Yan Han (1), Rui-rui Peng (1), Xiang-sheng Chen (1), Bao-xi Wang (1); (1) National Center for STD Control, China CDC (Nanjing, China)

P1-S2.37 Incidence of Urethral Discharge Syndrome among men who have sex with men and associated risk factors in India; a cohort analysis of clinic attendees.

Anup Gurung (1), Anjana Das (1), Prakash Naryanan (1), Graham Neilson (2), Guy Morineau (3), Bitra George (2); (1) FHI (New Delhi, India); (2) FHI (Bangkok, Thailand); (3) FHI APRO (Thailand)

P1-S2.38 A situational analysis of MSM and HIV at AAS's Centre Oasis in Burkina Faso

Traore AbdouLazziz Soundiata (1), Koblavi Patrice (2), Dah Elias (3), Tiendrebeogo Pascal (3), Ouedraogo Filemon (2), Tiendrebeogo Issoufou (2); (1) Association African Solidarite (Ouagadougou, Burkina Faso); (2) A A S (Burkina Faso); (3) A A S (Canada)

P1-S2.39 Characteristics Of Lymphogranuloma Venereum (LGV) infection Among Homosexual Men in Melbourne.

Melanie Bissessor (1); (1) Melbourne Sexual Health (Carlton, Australia)

P1-S2.40 Human Immunodeficiency Virus (HIV) and Syphilis Co-Infection among Men Who Have Sex with Men, 34 states, United States - 2009

John Su (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P1-S2.41 SENTINEL SURVILLANCE FOR PHARYNGEAL CHLAMYDIA AND GONORRHEA AMONG MEN WHO HAVE SEX WITH MEN - SAN FRANCISCO, 2010

Jason Park (1), Julia Marcus (2), Kyle Bernstein (2), Mark Pandori (2), Ameera Snell (2), Susan Philip (2); (1) UC Berkeley (Berkeley, USA); (2) San Francisco Department of Public Health (USA)

P1-S2.42 STI Prevalence and Condom Use in Men who have Sex with Men attending STI Services, Honduras 2010

Freddy Tinajeros (1), Norma Artiles (1), Nasim Farach (1), Lesby Castro (2), Virgilio Maradiaga (2), Amanda Sevilla (3), Suyapa Mendoza (4), Marco Urquia (5), Hector Galindo (5), Gabriela Paz-Bailey (6); (1) TEPHINET (Tegucigalpa, Honduras); (2) Alonso Suazo Clinic, Tegucigalpa (Tegucigalpa, Honduras); (3) Miguel Paz Barahona Clinic, San Pedro Sula (San Pedro Sula, Honduras); (4) STI National Laboratory, Honduras (Tegucigalpa, Honduras); (5) Ministry of Health, National AIDS Program (Tegucigalpa, Honduras); (6) TEPHINET, Del Valle University of Guatemala, Guatemala (Guatemala, Guatemala)

P1-S2.43 Behavioral and Biological Surveillance among Man who Have Sex with Man Using Respondent-Driven Sampling Methodology in Manaus, Amazon, Brazil

Adele Schwartz Benzaken (1), Enrique Garcia Galban (2), Nina Schwatz Benzaken (3), Carl Kendall (4), Adriana Pinho (5), Maeve Mello (6), Felicien Vasquez (1), Carlos Alberto Barros (1),

Ligia Regina Franco Sansigolo Kerr (7); (1) Alfredo da Matta Foundation (Manaus, Brazil); (2) Instituto Nacional de Gastroenterologia (Habana, Cuba); (3) Nilton Lins University (Brazil); (4) Tulane University School of Public Health and Tropical Medicine (New Orleans, USA); (5) Escola Nacional de Saude Publica (Brazil); (6) CDC Brazil (Brazil); (7) Uversidade Federal do Ceara (Brazil)

P1-S2.44 Trends in STI in MSM visiting Dutch STI centres; does age matter?

Femke Koedijk (1), Paul van Beek (2), Kamiel Koops (2), Marianne AB van der Sande (3), On behalf of the Dutch STI centres (4); (1) National Institute for Public Health and the Environment (Bilthoven, Netherlands); (2) Schorer, Netherlands' institute for homosexuality, health and well-being (Netherlands); (3) National Institute for Public Health and the Environment. Also Academic Medical Centre Utrecht, University of Utrecht, Utrecht, the Netherlands (Netherlands); (4) A v Daal(East), P v Leeuwen(North-Holland Flevoland), F de Groot(North), A Niekamp(Limburg), M Langevoort(Utrecht), A v Camerijk (South-Holland North),J vd Sande(ZeeBRa),E vd Veen (South-Holland South) (Netherlands)

P1-S2.45 Clusters of Neisseria gonorrhoeae infected patients are not linked to HIV infection within the homosexual population in Amsterdam, the Netherlands

Raymond Heymans (1), Sylvia Bruisten (1), Amy Matser (1), Titia Heijman (1), Henry de Vries (1), Maarten Schim van der Loeff (1); (1) Health Service of Amsterdam (GGD) (Amsterdam, Netherlands)

P1-S2.46 Is group sex a setting for increased risk for HIV and other STI among HIV-negative men who have sex with men?

José Heuker (1), Ineke Stolte (1), Udi Davidovich (1); (1) Public Health Service Amsterdam (Amsterdam, Netherlands)

P1-S2.47 Serosorting and sexual risk behaviour during casual sex among MSM: from one-night stands to sex buddies

Ineke Stolte (1), Wijnand Van den Boom (1), Theo Sandfort (2), Udi Davidovich (3); (1) Public Health Service Amsterdam (Amsterdam, Netherlands); (2) HIV Center for Clinical and Behavioral Studies, Department of Psychiatry, Columbia University and New York State Psychiatric Institute (NY, USA); (3) Public Health Service Amsterdam (Netherlands)

P1-S2.48 Exponential growth of Lymphogranuloma venereum diagnoses in the UK: Investigation of the largest documented outbreak among men who have sex with men

Gwenda Hughes (1), Sarah Alexander (1), Ian Simms (1), Stefano Conti (1), Cassandra Powers (1), Catherine Ison (1); (1) Health Protection Agency (London, United Kingdom)

P1-S2.49 Chlamydia And Gonorrhoea Transmission Among Men Who Have Sex With Men In Amsterdam, Is Independent Of Network Factors Or Partnership Characteristics

Amy Matser (1), Titia Heijman (2), Ronald Geskus (1), Henry de Vries (1), Han Fennema (1), Maarten Schim van der Loeff (1); (1) Public Health Service (Amsterdam, Netherlands); (2) Cluster of Infectious diseases, department of research (Amsterdam, Netherlands)

P1-S2.50 Anal non-L Chlamydia trachomatis infection in Men who have sex with men, at l'Actuel, Montreal, Quebec

Louise Charest (1), Rejean Thomas (1), Benoit Trottier (1), Michel Boissonnault (1), Danielle Legault (1), Daniele Longpré (1), Jason Szabo (1), Pierre-Jean Maziade (1), Nima Machouf (1); (1) Clinique médicale l'Actuel (Montréal, Canada)

P1-S2.51 Sexually transmitted HCV in MSM in Montreal

Rejean Thomas (1), Sylvie Vezina (2), Nima Machouf (1), Robert O'Brien (1), Emmanuelle Huchet (1), Daniele Longpré (1), Stephane Lavoie (1), Michelle Milne (1), Francine Asselin (1), Benoit Trottier (1); (1) Clinique médicale l'Actuel (Montreal, Canada); (2) Clinique médicale l'Actuel (Canada)

P1-S2.52 Risk factors for STIs among MSM attending a sexually transmitted disease clinic in Montreal, Canada

Nima Machouf (1), Rejean Thomas (1), Robert O'Brien (1), Sylvie Vezina (1), Danielle Longpré (1), Daniele Legault (1), Michele Milne (1), Judith Fafard (1), Benoit Trottier (1); (1) Clinique médicale l'Actuel (Montreal, Canada)

P1-S2.53 Hepatitis C Virus in Men Who Have Sex with Men with No History of Injection Drug Use: Evidence for Sexual Transmission? A Canadian Perspective.

Stephanie Totten (1), Marissa McGuire (1), Joe Cox (2), Gilles Lambert (2), Murray Fyfe (3), Winston Husbands (4), Ted Myers (5), Robert Remis (5),

John Wylie (6), Thomas Wong (1); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Direction de la santé publique de Montréal, Institut national de santé publique du Québec (Montreal, Canada); (3) Vancouver Island Health Authority (Victoria, Canada); (4) AIDS Committee of Toronto (Toronto, Canada); (5) University of Toronto (Toronto, Canada); (6) Cadham Provincial Public Health Laboratory (Winnipeg, Canada)

P1-S2.54 Repeat Gonococcal and chlamydial infections in a cohort of Men who have sex with men in India

Gururaj Rao Deshpande (1), Arun R Risbud (1), Prakash Narayanan (2), Prabhakar parimi (3), Anjana Das (3); (1) National AIDS Research Institute (Pune, India); (2) Family Health International, India. (New Delhi, India); (3) Family Health International (New Delhi, India)

P1-S2.55 High Incidence of HIV and Low HIV Prevention Coverage Among Men Who Have Sex with Men in Managua, Nicaragua

Flor Hernandez (1), Nelson Arambú (2), Berta Alvarez (2), Luz Romero (2), Jana Goins (2), Enrique Beteta (3), Gabriela Paz-Bailey (4), Sonia Morales (5); (1) Del Valle University of Guatemala (Guatemala, Guatemala); (2) Del Valle University of Guatemala, Guatemala (Guatemala); (3) Ministerio de Salud de Nicaragua, Managua, Nicaragua (Nicaragua); (4) Del Valle University of Guatemala, Guatemala City and TEPHINET, Atlanta, Georgia, USA (Guatemala, Guatemala); (5) Del Valle University of Guatemala, Guatemala City (Guatemala)

P1-S2.56 Sexually Transmitted Diseases among HIV Positive MSM, Prior to HCV Infection

Ludwig Apers (1), Marc Vandenbruaene (1), Marjan Van Esbroeck (1), Tania Crucitti (1), Eric Florence (1); (1) Institute of Tropical Medicine (Antwerp, Belgium)

P1-S2.57 Using an Online Survey to Investigate Risk Behaviours and Social Networks in a Syphilis Outbreak Among Men Who Have Sex with Men in Toronto

Rita Shahin (2), Claudia Rank (1), Brooke Kiniburgh (1), Ann Jolly (1), Dana Al-Bargash (2), Bruce Clarke (2), Marianna Ofner (1), Marie-Line Gilbert (1); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Toronto Public Health (Canada)

P1-S2.58 The Role of Venues in Structuring STI and Risk Networks Among Men Who Have Sex With Men

Lydia Drumright (1), Sharon Weir (2), Simon Frost (3); (1) Imperial College London (London, United Kingdom); (2) UNC Chapel Hill (USA); (3) University of Cambridge (Cambridge, United Kingdom)

P1-S2.59 OROPHARYNGEAL HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE AND RISK FACTORS IN MEN HAVING SEX WITH MEN (MSM)

Tim Read (1), Lenka Vodstrcil (1), Sepehr Tabrizi (2), Suzanne Garland (2), Andrew Grulich (3), Jane Hocking (1), Bradshaw Catriona (4), Marcus Chen (4), Michael McCullough (1), Christopher Fairley (1); (1) University of Melbourne (Carlton, Australia); (2) Royal Women's Hospital (Melbourne, Australia); (3) University of New South Wales (Australia); (4) Alfred Hospital (Australia)

P1-S2.60 Prevalence and Correlates of Giving or Receiving Sex for Money, Drugs or Goods among Men who have Sex with Men in Vancouver, British Columbia

Warren Michelow (1), Robert Hogg (1), David Moore (1), Reka Gustafson (2), Terry Trussler (3), Marissa McGuire (4), Mark Gilbert (5), The ManCount Study Team (6); (1) BC Centre for Excellence in HIV/AIDS (Vancouver, Canada); (2) Vancouver Coastal Health Authority (Canada); (3) Community Based Research Centre (Canada); (4) Public Health Agency of Canada (Canada); (5) BC Centre for Disease Control (Canada); (6) M-Track (Canada)

P1-S2.61 High HIV Rates among Men Who Have Sex with Men in Jamaica despite Increased Prevention Efforts

J Peter Figueroa (1), Sharon Weir (2), Carol Jones Cooper (3), Lovette Byfield (4), Shashauna Eastman (4), Marcia Hobbs (2), Jacqueline Duncan (4); (1) University of the West Indies (Kingston, Jamaica); (2) University of North Carolina at Chapel Hill (USA); (3) Epidemiology and Research Training Unit (Kingston, Jamaica); (4) Ministry of Health (Jamaica)

P1-S2.62 Factors associated with high-risk penetrative sex in a cohort of treatment experienced HIV-positive men who have sex with men (MSM) in British Columbia

George Talany (1), Nadia O'Brien (2), James Forrest (2), Hong Wang (2), Warren Michelow (2), Alexis Palmer (2), Julio SG Montaner (2)(3), Robert Hogg (1)(2); (1) Faculty of Health Sciences, Simon Fraser University (Burnaby, Canada); (2)

British Columbia Centre for Excellence in HIV/AIDS (Vancouver, Canada); (3) Division of AIDS, Faculty of Medicine, University of British Columbia (Vancouver, Canada)

P1-S2.63 Association between Age and STI Among Men who Have Sex with Men (MSM) in Jamaica

Sharon Weir (1), Peter Figueroa (2), Carol Jones-Cooper (3), Tina Hylton-Kong (4), Marcia Hobbs (5), Kimberly Rich (5), Lovette Byfield (6); (1) University of North Carolina (Chapel Hill, USA); (2) University of the West Indies (Kingston, Jamaica); (3) Ministry of Health (Kingston, Jamaica); (4) Epidemiology & Research Training Unit (Kingston, Jamaica); (5) University of North Carolina (Chapel Hill, USA); (6) Ministry of Health (Kingston, Jamaica)

P1-S2.64 Demographic Characteristics and HIV Risk Behaviors among Men Who Have Sex With Men in Guatemala City, Guatemala, 2010

Alvarez B (1), Miller W (1), Hernández FM (1), Alvarado A (2), Boyce S (2-3), Morales S (1), Chen Sanny (4), Kim Andrea (4), Paz-Bailey G (1-2-3); (1) Del Valle University of Guatemala, Guatemala City; (2) Tephinet Inc., Atlanta, Georgia; (3) University of North Carolina, Chapel Hill, North Carolina; (4) Centers for Disease Control and Prevention, Atlanta, Georgia

P1-S2.65 Crack/cocaine use among MSM in Latin America: A Multilevel Analysis of RDS Studies to Identify Drug Use Patterns and Associated Factors Across Cities

Jerry O. Jacobson (1), Monica Alonso-Gonzalez (1), Daesha Ramachandran (2), Sonia Morales-Miranda (3), Alex Carballo-Dieguez (4), Jorge Medrano (5), Teresita Solano (6), Maria Dolores Rosales-Perez (1); (1) Pan American Health Organization (Bogota, Colombia); (2) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA); (3) Del Valle University of Guatemala (Guatemala City, Guatemala); (4) Columbia University (New York City, USA); (5) Ministerio de Salud y Deportes (La Paz, Bolivia); (6) Ministerio de Salud de Costa Rica (San Jose, Costa Rica)

Epidemiology poster session 2 -

Population - Adolescent

P1-S2.66 Risk assessment in a large cohort of urban public high school students infected with CT or GC - Philadelphia, 2009-2010

Felicia Lewis (1), Aaron Mettey (2), Greta Anschuetz (2), Lenore Asbel (2), Andrew De Los Reyes (2), Melinda Salmon (2); (1) CDC/Philadelphia Dept. of Public Health (Philadelphia, USA); (2) Philadelphia Dept. of Public Health (Philadelphia, USA)

P1-S2.67 Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among College Students who attended the Johns Hopkins University Health and Wellness Center from 2009-2010

Nicole Quinn (1), Patricia Agreda (1), Alain Joffe (1), Charlotte Gaydos (1); (1) Johns Hopkins University (Baltimore, USA)

Epidemiology poster session 2 -

Population - Ethnic minorities -

aboriginal population

P1-S2.68 Targeted interventions for remote Australians; trends in chlamydia and gonorrhoea notifications in Aboriginal and non-Indigenous Australians 2005-2009

Simon Graham (1); (1) National Centre in HIV Epidemiology and Clinical Research (Coogee, Australia)

P1-S2.69 Prevalence of HPV infections in Metis and First Nations living in Manitoba, Canada

Alain Demers (1), Brenna Shearer (2), Stephanie Totten (1), Lily Fang (1), Alberto Severini (3), Erich Kliewer (4), Yang Mao (1), Thomas Wong (1), Gayatri Jayaraman (1); (1) Public Health Agency of Canada (Ottawa, Canada); (2) International Centre for Infectious Diseases (Canada); (3) Public Health Agency of Canada (Canada); (4) CancerCare Manitoba (Canada)

P1-S2.70 The Detection and Management of Pelvic Inflammatory Disease in Aboriginal Women in Central Australia: Challenges of a Remote High Prevalence Setting

Bronwyn Silver (1), Janet Knox (2), Kirsty Smith (2), James Ward (2), Jacqueline Boyle (3), Rebecca Guy (4), John Kaldor (2), Alice Rumbold (5); (1) Menzies school of Health Research (Alice

SPRINGS, Australia); (2) National Centre in HIV Epidemiology and Clinical Research Unsw (Australia); (3) Menzies School of Health Research (Australia); (4) National Centre in HIV Epidemiology and Clinical Research UNSW (Australia); (5) Menzies School of Health Research. University of Adelaide (Australia)

Epidemiology poster session 2 -

Population - Prisoners

P1-S2.71 Sexually transmitted infections in Mexico-City's penitentiary centers: the Ponte a Prueba - Put Yourself to the Test" study"

Sergio Bautista (1), Araceli Fernández-Cerdeño (1), Luis Juárez-Figueroa (2), Andrea González-Rodríguez (2), Juan Sierra (3), Patricia Volkow (4); (1) Instituto Nacional de Salud Pública (Cuernavaca, Mexico); (2) Mexico City Program for HIV/AIDS (Mexico); (3) Instituto Nacional de Nutrición y Ciencias Médicas Salvador Zubirán (Mexico); (4) Instituto Nacional de Cancerología (Mexico)

P1-S2.72 Predictors of HSV-2 seroprevalence and willingness to accept a prescription for suppressive therapy among recently incarcerated women

Alexis Roth (1), Barbara Van Der Pol (2), Michael Reece (2), Brian Dodge (2), Gregory Zimet (2); (1) Indiana University School of Medicine (Indianapolis, USA); (2) Indiana University (Bloomington, USA)

Epidemiology poster session 2 -

Population - Migrants

P1-S2.73 Exploring the Relationship between Rural-to-Urban Circular Migration and HIV: A Qualitative Study of Migrants and Persons Living with HIV in North India

Tanvi Rai (1), Helen Lambert (2), Peter Piot (3), Kavita Agarwal (4), Helen Ward (1); (1) Imperial College London (London, United Kingdom); (2) University of Bristol (United Kingdom); (3) London School of Hygiene and Tropical Medicine (United Kingdom); (4) Kamala Nehru Memorial Hospital (Allahabad, India)

P1-S2.74 How patterns of migration may influence heterosexual HIV transmission

Maaïke van Veen (1), Maria Xiridou (1), Maria Prins (2), Roel Coutinho (1); (1) National Institute for Public Health and the Environment (RIVM)

(Bilthoven, Netherlands); (2) Public Health Service (Amsterdam, Netherlands)

P1-S2.75 Are sex/drug risk behaviors in sending countries predictive of sex/drug risk behaviors in receiving countries? - The case of Latino migrant men in New Orleans

Patricia Kissinger (1), Jennifer Mills (1), Norine Schmidt (1), Oscar Salinas (1), John Hembling (1), Alberto Aran (1), Michele Shedlin (2); (1) Tulane University School of Public Health and Tropical Medicine (New Orleans, USA); (2) New York University (USA)

P1-S2.76 Sexual concurrency among Latino migrant men in New Orleans

Patricia Kissinger (1), Colin Anderson-Smiths (1), Stephanie Kovacs (1), Oscar Salinas (1), John Hembling (1), Norine Schmidt (1); (1) Tulane University School of Public Health and Tropical Medicine (New Orleans, USA)

Epidemiology poster session 3 -

Burden of disease

P1-S3.01 Trends in the incidence of hospitalisation for chlamydia-related sequelae among women

Bette Liu (1), Basil Donovan (1), Handan Wand (1), Rebecca Guy (1), Jane Hocking (2), John Kaldor (1); (1) National Centre in HIV Epidemiology and Clinical Research (Coogee, Australia); (2) University of Melbourne (Australia)

P1-S3.02 The Economic Burden of Chlamydia and Gonorrhoea in Canada

Lisa Smylie (1), Patricia Lau (1), Robert Lerch (1), Christine Kennedy (1), Rachel Bennett (1), Barbara Clarke (1), Alan Diener (1); (1) Public Health Agency of Canada (Ottawa, Canada)

P1-S3.03 Mortality among Men Who Have Sex with Men Seen in an STD Clinic: High Rates of Suicide and Low Rates of Anal Cancer Death

Sara Glick (1), Roxanne Kerani (2), Matthew Golden (2); (1) University of Washington (Seattle, USA); (2) Public Health - Seattle and King County (Seattle, USA)

P1-S3.04 Death in the era of HAART: not all about AIDS

Ruth Smith (1), Meaghan Kall (1), Valerie Delpéch (1); (1) Health Protection Agency (London, United Kingdom)

P1-S3.05 Attributable Proportion of Tubal Factor Infertility caused by Chlamydia: An Estimate Based on Serological Evidence Adjusted for Test Resolution

Malcolm Price (1), AE Ades (1), John Macleod (1), Paddy Horner (1); (1) University of Bristol (Bristol, United Kingdom)

Epidemiology poster session 3 -

Burden of disease - PID

P1-S3.06 PREVALENCE AND DETERMINANTS OF NEISERIA GONORRHOEA AND CHLAMYDIA INFECTIONS AMONG GYNAECOLOGICAL PATIENTS WITH PELVIC INFLAMMATORY DISEASE AT UNIVERSITY TEACHING HOSPITAL, LUSAKA

Pierre Yassa (1), Bwalika (1), Kasanda (1); (1) University Teaching Hospital (Lusaka, Zambia)

P1-S3.07 Relation between female infertility and sexually transmitted genital infections

Caridad Almanza (1), Margarita Ricardo (1), Amada González (1); (1) Cira Garcia Clinic (Havana, Cuba)

P1-S3.08 Pelvic Inflammatory Disease (PID) in Adolescents after Treatment for Cervicitis

William Risser (1), Jan Risser (2); (1) Univ. of Texas Medical School at Houston (Houston, USA); (2) Univ. of Texas School of Public Health (USA)

P1-S3.09 Estimating the Incidence of PID Following Chlamydia Infection in Sex Workers

Bethan Davies (1), Sophie Day (2), Helen Ward (1); (1) Imperial College London (London, United Kingdom); (2) Goldsmith's College, University of London (United Kingdom)

P1-S3.10 The role of Chlamydia trachomatis in the development of symptomatic Pelvic Inflammatory Disease: a multi-parameter synthesis

Malcolm Price (1), Tony Ades (1), Nicky Welton (1), John Macleod (1), Kate Soldan (2), Daniela De Angelis (3), Ian Simms (2), Katy Turner (1), Paddy Horner (1); (1) University of Bristol (Bristol, United Kingdom); (2) Health Protection Agency (United Kingdom); (3) Medical Research Council Biostatistics Unit (United Kingdom)

Epidemiology poster session 3 -

Burden of disease - Neonatal herpes

P1-S3.11 Factors associated with death among infants with neonatal herpes reported in New York City, 2006-2010

Julia Schillinger (1), Shoshanna Handel (2), Kate Washburn (2), Ellen Klingler (2), Susan Blank (1), Preeti Pathela (2); (1) New York City Department of Health, and US Centers for Disease Control (New York, USA); (2) New York City Department of Health (New York, USA)

Epidemiology poster session 4 -

Methodological aspects

P1-S4.01 HIV/STD Co-infection in Arizona, 2000-2008: Identifying Opportunities for Integrated Surveillance and Partner Services

Melanie Taylor (1), Michelle Winscott (2), Julia Skinner (2), Roxanne Ereth (2), Kerry Kenney (1), Roberto Bailey (2); (1) CDC (Phoenix, USA); (2) Arizona Department of Health Services (Phoenix, USA)

P1-S4.02 Ethnicity based on the country of birth is better to identify the young population at high risk for Chlamydia infection than self-defined ethnicity.

Amanja Haasnoot (1), Femke DH Koedijk (1), Eline LM Op de Coul (1), Marianne AB van der Sande (1), Hannelore M Götz (2), Johannes FA Fennema (3), Ingrid VF van den Broek, on behalf of the CSI group (1); (1) National Institute for Public Health and the Environment (RIVM) (Bilthoven, Netherlands); (2) Rotterdam-Rijnmond Public Health Service (Rotterdam, Netherlands); (3) Amsterdam Public Health Service (Amsterdam, Netherlands)

P1-S4.03 Using Organism Load of Chlamydia trachomatis and Neisseria gonorrhoeae in Clinical Specimens as an Epidemiologic Tool

Barbara Van Der Pol (1), Amy Pantone (2), James Williams (3); (1) Indiana University School of Public Health (Bloomington, USA); (2) Indianapolis University School of Medicine (Indianapolis, USA); (3) Indiana University School of Medicine (Indianapolis, USA)

P1-S4.04 Biases in the Design of Studies Assessing the Role of Sexually Transmitted Infections as HIV Risk Factors

Justin O'Hagan (1), Marc Lipsitch (1); (1) Harvard School of Public Health (Boston, USA)

P1-S4.05 Quantifying social desirability biases in reported condom use among female sex workers in southern India

Mike Pickles (1), B M Ramesh (2), Rajatashuvra Adhikary (3), S Rajaram (2), Shajy Isac (2), Reynold Washington (4), Marie-Claude Boily (1), Janet Bradley (5), Stephen Moses (6), Michel Alary (7); (1) Imperial College (London, United Kingdom); (2) Karnataka Health Promotion Trust (Bangalore, India); (3) Family Health International, India (India); (4) St John's Research Institute, Bangalore (India); (5) CHARME-India Project (Bangalore, India); (6) University of Manitoba (Winnipeg, Canada); (7) Centre hospitalier affilié universitaire de Québec (Québec, Canada)

P1-S4.06 What impact does missing Quebec data have on national HIV surveillance data?

Kristina Lalonde Tomas (1), Raphael Bitera (2), Michel Alary (2), Micheline Fauvel (2), Raymond Parent (2), Diane Sylvain (2), Maureen Hastie (2), Christiane Claessens (2), Jessica Halverson (1), Chris Archibald (1); (1) Public Health Agency of Canada (Ottawa, Canada); (2) Institut national de sante publique du Quebec (Canada)

P1-S4.07 The Use of the Arizona Department of Health Services Surveillance Database to Identify Discordant Syphilis Treponemal Laboratory Results, Arizona

Michelle Winscott (1), Anita Betancourt (1), Roxanne Ereth (1); (1) Arizona Department of Health Services (Phoenix, USA)

P1-S4.08 Population size estimates for men who have sex with men in Guatemala City using time location sampling and respondent driven sampling

Gabriela Paz-Bailey (1), Berta Alvarez (2), William Miller (2), Boyce Sabrina (3), Clare Barrington (4), Andrea Kim (5), Sonia Morales (2), Sanny Chen (5); (1) Tephinet Inc (Guatemala, Guatemala); (2) Del Valle University of Guatemala (Guatemala, Guatemala); (3) Tephinet Inc. (Guatemala); (4) University of North Carolina (USA); (5) Centers for Disease Control and Prevention (USA)

P1-S4.09 Validation of the HEDIS measure of sexual activity in adolescents

Sarah Wiehe (1), J Dennis Fortenberry (1), Marc Rosenman (1), Wanzhu Tu (1); (1) Indiana University School of Medicine (Indianapolis, USA)

Epidemiology poster session 4 -

Methodological aspects - Network

P1-S4.10 The Use of Social Network Analysis to Quantify the Importance of Sex Partner Meeting Venues in an Infectious Syphilis Outbreak in Alberta, Canada

Rhonda Fur (1), Dr. Elizabeth A. Henderson (1), Dr. Ronald R. Read (1), Dr. Jenny Godley (1), Colleen Roy (2), kathryn Bush (1); (1) University of Calgary (Calgary, Canada); (2) Alberta Health Services (Canada)

Epidemiology poster session 4 -

Methodological aspects - Outbreak evaluation

P1-S4.11 The Use of the Historical Limits Method of Outbreak Surveillance to Retrospectively Detect a Syphilis Outbreak among American Indians in Arizona

Michelle Winscott (1), Anita Betancourt (1), Roxanne Ereth (1); (1) Arizona Department of Health Services (Phoenix, USA)

Epidemiology poster session 4 -

Methodological aspects - Neighbouring

P1-S4.12 Using Neighbourhood-level Population Data to Guide Gonorrhoea Intervention, Montréal, Québec, Canada, 2002-2009

Nashira Khalil (1), Robert Allard (2); (1) Public Health Agency of Canada (Montreal, Canada); (2) Direction de santé publique, Agence de la santé et des services sociaux de Montréal (Montreal, Canada)

Epidemiology poster session 4 -

Methodological aspects - Neighbouring / mapping

P1-S4.13 Mapping High Risk Activities of HIV/AIDS in Gaoxin and Yantan District of Zigong City

Juying Zhang (1), Yang Yang (2), Huan Zhou (3), Chunxia Yang (2), Qun Li (4), Guorong Song (4), Yan Xie (4), James Blanchard (5), Nancy Yu (5), Xiao Ma (2); (1) Sichuan University (ChengDu, China); (2) Sichuan University (China); (3) Sichuan University (China); (4) Zigong CDC (China); (5) University of Manitoba (Winnipeg, Canada)

P1-S4.14 Does Core Theory Apply in Rural Environments?

Dionne Gesink (1), Ashleigh Sullivan (1), Todd Norwood (2), Marc Serre (3), William Miller (3); (1) University of Toronto (Toronto, Canada); (2) Cancer Care Ontario (Canada); (3) University of North Carolina at Chapel Hill (USA)

Epidemiology poster session 4 - Modeling

P1-S4.15 Revisiting HIV epidemic appraisals for assisting in the design of effective HIV prevention programs

Sharmistha Mishra (1), Sema K. Sgaier (2), Laura Thompson (3), Stephen Moses (3), BM Ramesh (4), Michel Alary (5), James F. Blanchard (3); (1) Imperial College (London, United Kingdom); (2) Bill & Melinda Gates Foundation (India); (3) Centre for Global Public Health (Canada); (4) Karnataka Health Promotion Trust (Bangalore, India); (5) Centre de recherche FRSQ du CHA universitaire de Québec (Québec, Canada)

P1-S4.16 The UNAIDS Modes of Transmission Model: A Useful Tool for Decision Making?

Anna Foss (1), Holly Prudden (1), Alicia Mehl (1), Cathy Zimmerman (1), Kim Ashburn (2), Reshma Trasi (2), Michael Kiess (3), Grace Bantebya-Kyomuhendo (4), Katherine Fritz (2), Charlotte Watts (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) International Center for Research on Women (Washington DC, USA); (3) International Center for Research on Women-Cambodia (Phnom Penh, Cambodia); (4) Makerere University (Kampala, Uganda)

P1-S4.17 Interactive demonstration of a model to calculate costs and cost effectiveness of different strategies for chlamydia screening and partner notification

Katy Turner (1), Elisabeth Adams (2), Arabella Grant (3), John Macleod (1), Gill Bell (4), Jan Clarke (5), Paddy Horner (6); (1) University of Bristol (Bristol, United Kingdom); (2) Independent (London, United Kingdom); (3) Pathway Analytics (United Kingdom); (4) Royal Hallamshire Hospital (United Kingdom); (5) University of Leeds/Teaching Hospital (United Kingdom); (6) University of Bristol (United Kingdom)

P1-S4.18 Using mathematical modelling to investigate the role of the hidden" population of men who have sex with men (MSM) on the HIV epidemic in southern India."

Holly Prudden (1), Anna Foss (1), Kate Mitchell (1), Mike Pickles (2), Anna Phillips (2), BM Ramesh (3), Reynold Washington (4), Michel Alary (5), Catherine Lowndes (6), Peter Vickerman (1); (1) London School of Hygiene and Tropical Medicine (London, United Kingdom); (2) Imperial College London (London, United Kingdom); (3) Karnataka Health Promotion Trust, Bangalore, India and University of Manitoba (Winnipeg, Canada); (4) Karnataka Health Promotion Trust, Bangalore, India; University of Manitoba, Winnipeg, Canada; St John's Research Institute, Bangalore, India (Bangalore, India); (5) Centre hospitalier affilié universitaire de Québec, Québec, Canada (Québec, Canada); (6) Health Protection Agency, London, UK (Canada)

P1-S4.19 Stochastic Network Models

Pierre-André Noël (1), Antoine Allard (1), Laurent Hébert-Dufresne (1), Vincent Marceau (1), Louis J. Dubé (1); (1) Université Laval (Québec, Canada)

P1-S4.20 Mathematical modelling of HIV transmission and control amongst men who have sex with men: a review of 25 years of literature

Narat Punyacharoensin (1), William John Edmunds (1), Daniela De Angelis (2), Richard Guy White (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) Health Protection Agency and MRC Biostatistics Unit (United Kingdom)

P1-S4.21 Calibration of an Individual-Based Model of STI Transmission in Uganda: A Novel ABC-Bayesian Emulation Hybrid Approach

Helen Johnson (1), W. John Edmunds (2), Richard White (2); (1) London School of Hygiene and Tropical Medicine (London, United Kingdom); (2) London School of Hygiene & Tropical Medicine (United Kingdom)

P1-S4.22 Impact of a Hypothetical Chlamydia Vaccine on Population Prevalence: a Mathematical Modeling Study

Janneke Heijne (1), Christian Althaus (1), Sereina Herzog (1), Nicola Low (1); (1) University of Bern (Bern, Switzerland)

P1-S4.23 Describing the Progression from Chlamydia trachomatis to Pelvic inflammatory disease: Systematic Review of Mathematical Models

Sereina A. Herzog (1), Janneke C.M. Heijne (1), Christian L. Althaus (1), Nicola Low (1); (1) University of Bern (Bern, Switzerland)

P1-S4.24 Balancing the 'supply and demand' of sex acts: Implications for modelling the HIV epidemic among men who have sex with men in southern India

Kate Mitchell (1), Anna Foss (1), Holly Prudden (1), John Williams (2), Helen Johnson (1), Mike Pickles (2), Anna Phillips (2), Banadakoppa Ramesh (3), Reynold Washington (3), Peter Vickerman (1); (1) London School of Hygiene and Tropical Medicine (London, United Kingdom); (2) Imperial College London (London, United Kingdom); (3) Karnataka Health Promotion Trust (Bangalore, India)

P1-S4.25 Using mathematical models to understand the causes of the ecological association seen between HIV and HSV-2 in female sex workers in southern India

Kate Mitchell (1), Peter Vickerman (1), Mike Pickles (2), Maya Kaushik (2), Supriya Verma (3), Shajy Isac (3), Rajatashuvra Adhikary (4), Mandar Mainkar (5), Michel Alary (6), Marie-Claude Boily (2); (1) London School of Hygiene and Tropical Medicine (London, United Kingdom); (2) Imperial College London (London, United Kingdom); (3) Karnataka Health Promotion Trust (Bangalore, India); (4) Family Health International (New Delhi, India); (5) National AIDS Research Institute (Pune, India); (6) Centre Hospitalier affilié Universitaire de Québec (Québec, Canada)

P1-S4.26 Duration, incidence and prevalence of Chlamydia trachomatis in women: estimation by multi-parameter synthesis

Malcolm Price (1), AE Ades (1), Daniela De Angelis (2), Nicky Welton (1), John Macleod (1), Kate Soldan (3), Katy Turner (1), Ian Simms (1), Paddy Horner (1); (1) University of Bristol (Bristol, United Kingdom); (2) Cambridge University (United Kingdom); (3) Health Protection Agency (United Kingdom)

Epidemiology poster session 4 - Tests evaluation

P1-S4.27 Quality assurance of syphilis serological test in Guangdong, China, 2004-2009

He-ping Zheng (1), Xing-zhong Wu (1), Jin-mei Huang (1); (1) Guangdong Provincial Center for Skin Diseases and STIs Control (Guangzhou, China)

P1-S4.28 Survey of Methodology Used for the Identification and Antimicrobial Susceptibility Testing of *Neisseria gonorrhoeae* in Latin America and the Caribbean

Stefania Starnino (1), GASP-LAC Network* (1), Mingmin Liao (1), Martha Ruben (1), Ava Storey (1), Jo-Anne R. Dillon (1); (1) Vaccine and Infectious Disease Organization (University of Saskatchewan) (Saskatoon, Canada) - Authors contributed equally and are listed in an alphabetical order of country names. P. Galarza; I. Pagano; M. E. Trigos; A. Schwartz Benzaken; V. M. Pinto; A. Maldonado Ballesteros; O. M. Sanabria Cruz; A. Llop; E. Aguilar Jarrin; N. Aguayo; J. L. Portilla Carbajal; G. Borthagaray; A. Acevedo; D. Payares

P1-S4.29 Synthesis of evidence on implementation research on point-of-care syphilis tests: a systematic review.

Yalda Jafari (1), Mira Johri (2), Denis Ako-Arrey (3), Sushmita Shivkumar (1), Gilles Lambert (4), Christiane Claessens (5), Marina Klein (1), Jorge Cajas (6), Rosanna Peeling (7), Nitika Pai (1); (1) McGill University (Montreal, Canada); (2) Université de Montreal (Canada); (3) University of Saskatchewan (Canada); (4) Institut national de santé publique du Québec (Canada); (5) Laboratoire de santé publique du Québec (INSPQ) (Canada); (6) Queen's University (Canada); (7) London School of Hygiene & Tropical Medicine (United Kingdom)

P1-S4.30 Point-of-Care HIV Testing with OraQuick Advance HIV-1/2 antibody assay: A systematic review of Cost Outcomes

Bhairavi Balram (1), Mira Johri (2), Denis Ako-Arrey (2), Gilles Lambert (3), Christiane Claessens (3), Marina Klein (1), Jorge M Cajas (4), Rosanna Peeling (5), Nitika Pant Pai (1); (1) McGill University (Montreal, Canada); (2) Université de Montréal (Canada); (3) Institut national de santé publique du Québec (Canada); (4) Queen's University (Canada); (5) London School of Hygiene & Tropical Medicine (United Kingdom)

Epidemiology poster session 4 -

Methodological aspects - RDS & recruitment

P1-S4.31 Failure of respondent driven sampling in a transgender population due to inadequate formative work and non-network associated selection criteria

Jan Risser (1), Paige Padgett (1), Jane Montealegre (1); (1) University of Texas (Houston, USA)

P1-S4.32 Recruiting via social networking sites for sexual health research (assessing chlamydia and HPV knowledge)

Suzanne Garland (1), John Wark (2), Sepehr Tabrizi (1); (1) Royal Women's Hospital (Melbourne, Australia); (2) University of Melbourne (North Melbourne, Australia)

P1-S4.33 Effectiveness of Respondent Driven Sampling among Undocumented Central American Immigrant Women in Houston, Texas, 2010

Jane Montealegre (1), Jan Risser (1), Beatrice J. Selwyn (1), Keith Sabin (2); (1) The University of Texas School of Public Health (Houston, USA); (2) World Health Organization (Hanoi, Viet Nam)

P1-S4.34 Can RDS be used to recruit unbiased samples from the same population with repeated sampling?

Jan Risser (1), Paige Padgett (1), Jane Montealegre (1); (1) University of Texas School of Public Health (Houston, USA)

Epidemiology poster session 5 -

Transmission dynamic

P1-S5.01 Heterosexual Anal Sex, Lubrication, HIV, and HSV-2 infection among women

Joelle Brown (1), Kristen Hess (1), Steve Brown (2), Colleen Murphy (2), Avalena Waldman (2), Marjan Hezareh (2); (1) University of California, Los Angeles (Los Angeles, USA); (2) AIDS Research Alliance (Los Angeles, USA)

P1-S5.02 Towards more robust estimates of the per sex act transmission probability of Chlamydia trachomatis

Christian Althaus (1), Nicola Low (2); (1) University of Bern (Bern, Switzerland); (2) University of Bern (Switzerland)

P1-S5.03 Pattern of Sexually Transmitted Infections (STIs) In Hormonal Contraceptives And Intra-Uterine Devices (IUD) Users Attending Family Planning Clinics In Ibadan, Nigeria

Samuel Adetona Fayemiwo (1), A. A. Fatiregun (2), Rasheed A. Bakare (3); (1) University of Ibadan, Ibadan, Nigeria. (Nigeria, Nigeria); (2) University of Ibadan, Ibadan (Ibadan, Nigeria); (3) University of Ibadan, Ibadan, Nigeria (Ibadan, Nigeria)

P1-S5.04 HSV-2 Prevalence and Incidence among Stable HIV-1 Discordant Couples in Nairobi, Kenya.

Anthony Muiru (1), Rose Bosire (2), Brandon Guthrie (2), Robert Choi (2), Michele Merkel (2), Bhavna Chohan (2), James Kiarie (2), Barbara Lohman-Payne (2), Carey Farquhar (2); (1) Kenya Research Group/International AIDS Research and Training Program (Seattle, USA); (2) Kenya Research Group (Kenya)

P1-S5.05 The Emergence of HIV Pandemic: Who Lifted the Lid of the African SIV-HIV Pot? A Hypothesis.

Andrei Lovenetski (1); (1) NEARMEDIC PLUS (Moscow, Russian Federation)

**Epidemiology poster session 5 -
Transmission dynamic + behaviour**

P1-S5.06 Oral Sex and Risk of Sexually Transmitted Infections

Elaine Flagg (1), Hillard Weinstock (1), Kimberly Workowski (2), Thomas Peterman (1); (1) US Centers for Disease Control and Prevention (Atlanta, USA); (2) US Centers for Disease Control and Prevention, and Emory University (USA)

P1-S5.07 Ongoing Risk Behaviors: New STD diagnoses in persons known to be HIV-infected in Miami-Fort Lauderdale (South Florida), 2000-2009

Thomas A. Peterman (2), Toye H Brewer (1), Daniel R. Newman (2), Stacy Shiver (3); (1) CDC/Florida DOH (Miami, USA); (2) CDC (Atlanta, USA); (3) Florida Department of Health (Tallahassee, USA)

P1-S5.08 Attendance at Local and National Sex-Events Associated with STD Diagnosis, San Francisco, 2010

Kyle Bernstein (1), Hanna Hjord (1), Julia Marcus (1), Robert Kohn (1), Susan Philip (1); (1) San Francisco Department of Public Health (San Francisco, USA)

P1-S5.09 Withdrawn

P1-S5.10 Acute Genital Ulceration in South African Men: Importance of Age and Sexual Risk Behaviors

Jami Leichter (1), David Lewis (2), Gabriela Paz-Bailey (3); (1) Centers for Disease Control & Prevention (Atlanta, USA); (2) NICD/NHLS (South Africa); (3) Universidad del Valle de Guatemala (Guatemala)

P1-S5.11 High Prevalence of STIs and Risk Behaviors Among Persons Living with HIV in Nicaragua: Missed Opportunities for Prevention

Jana Goins (1), Luz María Romero (1), Flor de María Hernandez (1), Stephen Delgado (1), Berta Alvarez (1), Enrique Beteta (2), Gabriela Paz-Bailey (3), Sonia Morales (1); (1) Universidad del Valle (Guatemala City, Guatemala); (2) Ministerio de Salud de Nicaragua (Managua, Nicaragua); (3) Tephinet (Atlanta, USA)

P1-S5.12 Population attributable risk for chlamydia infection in a cohort of young international travellers (backpackers) and residents in Australia

Handan Wand (1); (1) University of New South Wales (Sydney, Australia)

P1-S5.13 Recreational Drug Use During Sex Is Associated With STI Among Clients of A Large STI Outpatient Clinic in Amsterdam, The Netherlands

Marlies Heiligenberg (1), Paulien Wermeling (1), Martijn van Rooijen (1), Anouk Urbanus (1), Maria Prins (1), Roel Coutinho (2), Maarten Schim van der Loeff (1); (1) Public Health Service Amsterdam (Amsterdam, Netherlands); (2) National Institute for Public Health and the Environment (Bilthoven, Netherlands)

P1-S5.14 Risk factors associated with HIV acquisition: a comparative analysis of older and younger women who participated in the MDP301 trial in Johannesburg

Sinead Delany-Moretlwe (1), Ananta Nanoo (1), Anjali Nagpal (2), Harry Moultrie (1), Sinead Delany (1), Helen Rees (1); (1) WHI (Hillbrow, South Africa); (2) LSHTM (United Kingdom)

P1-S5.15 Contribution of condom breakage to the HIV epidemic among men who have sex with men in Karnataka, India

Mike Pickles (1), Peter Vickerman (2), Janet Bradley (3), BM Ramesh (4), Shajy Isac (4), Reynold Washington (5), Holly Prudden (2), Kate Mitchell (2), Michel Alary (6), Marie-Claude Boily (1); (1) Imperial College (London, United Kingdom); (2) LSHTM (United Kingdom); (3) CHARME-India project (Bangalore, India); (4) Karnataka Health Promotion Trust (Bangalore, India); (5) St. John's Medical College Bangalore (India); (6) Centre Hospitalier *affilié* Universitaire de Québec (Quebec, Canada)

P1-S5.16 Investigating Self-reported Level of Condom Use and Condom Use in Last Act Amongst High-risk Groups in Southern India

Mike Pickles (1), Rajatashuvra Adhikary (2), Mandar Mainkar (3), Ramesh S Paranjape (3), Kathleen Deering (4), Supriya Verma (5), Marie-Claude Boily (1), Peter Vickerman (6), Michel Alary (7); (1) Imperial College (London, United Kingdom); (2) Family Health International India (India); (3) National AIDS Research Institute, Pune, India (India); (4) University of British Columbia (Canada); (5) Karnataka Health Promotion Trust (Bangalore, India); (6) LSHTM (United Kingdom); (7) Centre Hospitalier *affilié* Universitaire de Québec (Quebec, Canada)

P1-S5.17 The association between marital transition and HIV seroconversion in a cohort of young people in rural Tanzania.

Aoife M Doyle (1), John Changanlucha (2), Helen A Weiss (1), Deborah Watson-Jones (1), Saidi Kapiga (3), Richard J Hayes (1), Basia Zaba (1), David A Ross (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) National Institute for Medical Research, Mwanza Centre, Tanzania (Tanzania, United Rep. of); (3) Mwanza Intervention Trials Unit, National Institute for Medical Research, Tanzania (Tanzania, United Rep. of)

P1-S5.18 Withdrawn

P1-S5.19 MARRIAGE DISSOLUTION AND HIV PREVALENCE IN RURAL ZIMBABWE 2003-2008

Christina Schumacher (1), Constance Nyamukapa (2), Geoff Garnett (3), Simon Gregson (3); (1) Imperial College London (London, United Kingdom); (2) Biomedical Research and Training Institute (Zimbabwe); (3) School of Public Health, Imperial College London (United Kingdom)

P1-S5.20 Multi-Level Analysis of the Predictors of HIV Prevalence Among Pregnant Women Enrolled in Sentinel Surveillance in Four Southern India States

Usha Thamattoor (1), Tinku Thomas (1), Pradeep Banandur (2), Rajaram S (3), Thierry Duchesne (4), Belkacem Abdous (4), Reynold Washington (5), Ramesh BM (3), Stephen Moses (6), Michel Alary (4); (1) St John's Research Institute (Bangalore, India); (2) Charme II Project (Bangalore, India); (3) Karnataka Health Promotion Trust (India); (4) Centre hospitalier *affilié* universitaire de Québec (Quebec, Canada); (5) St John's Research Institute (India); (6) University of Manitoba (Winnipeg, Canada)

P1-S5.21 Self-esteem and STI/HIV Prevalence Among Residents of a Tanzanian Sugar Plantation

Cara Rice (1), Abigail Norris Turner (1), Alison Norris (2), Sabina Mtweve (3); (1) The Ohio State University (Columbus, USA); (2) Johns Hopkins University Bloomberg School of Public Health (USA); (3) Kilimanjaro Christian Medical College, Department of Social Welfare, Moshi (Tanzania)

P1-S5.22 Gender Differences in Behavioral Correlates of Biologically-Confirmed Sexually Transmitted Infections

Amanda Berger(1), Maria Khan (1); (1) University of Maryland, College Park (College Park, USA)

Epidemiology poster session 5 -

Transmission dynamic - coinfection

P1-S5.23 HIV Incidence And Time To Diagnosis Among Men With Bacterial Rectal Infections, New York City, 2008-2010

Preeti Pathela (1), Sarah Braunstein (1), Susan Blank (2), Julia Schillinger (2); (1) New York City Department of Health and Mental Hygiene (New York, USA); (2) New York City Department of Health and Mental Hygiene/Centers for Disease Control and Prevention (USA)

P1-S5.24 PREVALENCE OF CHLAMYDIA TRACHOMATIS AMONG WOMEN INFECTED BY HIV ATTENDING THE INSTITUTE OF TROPICAL MEDICINE IN AMAZONAS, BRAZIL.

Angelica Miranda(2), Leila Silva (1), Felipe Sardinha (1), Sinesio Talhari (1); (1) Fundação de Medicina Tropical do Amazonas (Manaus, Brazil); (2) Universidade Federal do Espírito Santo

P1-S5.25 Acyclovir and Transmission of HSV-2 from HSV-2/HIV-1 Dually Infected Persons

Andrew Mujugira (1), Amalia Margaret (1), Connie Celum (1), Jairam Lingappa (2), Jared Baeten (1), Kenneth Fife (3), Guy De Bruyn (4), Elizabeth Bukusi (5), Larry Corey (1), Anna Wald (1); (1) University of Washington (Seattle, USA); (2) University of Washington (USA); (3) Indiana University (USA); (4) University of the Witwatersrand (South Africa); (5) Kenya Medical Research Institute (Kenya)

P1-S5.26 Better-understanding of the dynamics of gonorrhoea and chlamydia through analysis of coinfection

Katy Turner (1), Peter White (2), Geoff Garnett (3), Nigel Gay (4), Nicola Low (5), Christian Althaus (5), Partner Notification Group (6); (1) University of Bristol (Bristol, United Kingdom); (2) Imperial College London & HPA (London, United Kingdom); (3) Imperial College London (London, United Kingdom); (4) None (United Kingdom); (5) University of Bern (Bern, Switzerland); (6) Many (United Kingdom)

P1-S5.27 Low Prevalence of Asymptomatic STI in HIV-Infected Heterosexual Males and Females, Visiting an HIV Outpatient Clinic in the Netherlands

Marlies Heiligenberg (1), Maarten Schim van der Loeff (1), Henry de Vries (2), Suzanne Geerlings (2), Maria Prins (1), Jan Prins (2); (1) Public Health Service Amsterdam (Amsterdam, Netherlands); (2) Academic Medical Centre (Amsterdam, Netherlands)

P1-S5.28 Cervical cytology and histopathologic abnormalities in women living with AIDS in São Paulo, Brazil

Valdir Pinto (1), Angelica Espinosa (2), Mariza Tancredi (3), Jonathan Golub (4), Rosa Alencar (3); (1) Ministry of Health (Brasilia, Brazil); (2) UFES (Brazil); (3) STD/AIDS State Program - Sao Paulo (Brazil); (4) Johns Hopkins School of Medicine (USA)

P1-S5.29 Relationship between incident bacterial vaginosis, gonorrhoea and chlamydial infection among women attending a sexually transmitted disease clinic

Maria Gallo (1), Maurizio Macaluso (1), Lee Warner (1), Michael Fleenor (2), Edward Hook, III (3), Ilene Brill (4), Mark Weaver (5); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Jefferson County Department of Health (Birmingham, USA); (3) Jefferson County Department of Health; University of Alabama at Birmingham (USA); (4) University of Alabama at Birmingham (USA); (5) FHI (USA)

P1-S5.30 Relationship between Syphilis and HIV: Lessons from a Nigerian Surveillance Survey

Adedayo Adeyemi (1), Kola Oyediran (1), Aderemi Azeez (2), Issa Kawu (2), Olubunmi Fakunle (3); (1) MEASURE Evaluation (Asokoro, Nigeria); (2) Federal Ministry of Health (Abuja, Nigeria); (3) University College Hospital (Ibadan, Nigeria)

P1-S5.31 Co-infection and concurrent Sexually Transmitted Infections (STIs) in Sexual Partnerships: Potential impact of partner notification and treatment in STD control

Fredy Canchihuaman (1), Stephen Hawes (2), King Holmes (2), Patricia Garcia (1), Cesar Carcamo (1); (1) UPCH (Lima, Peru); (2) University of Washington (Seattle, USA)

P1-S5.32 The Differential Associations of HPV Prevalence with Other Sexually Transmitted Infections in Hormonal and Non-hormonal Contraceptive Users.

Thing Rinda Soong (1), PE Gravitt (1), SB Gupta (2), K Liaw (3), A Tadesse (3), C Phongnarisorn (4), V Wootipoom (5), P Yuenyao (6), DD Celentano (1); (1) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA); (2) Merck & Co. Inc (USA); (3) Merck & Co. Inc. (USA); (4) Chiang Mai University (Thailand); (5) Prince of Songkla University, (Thailand); (6) Khon Kaen University, Khon Kaen (Thailand)

Epidemiology poster session 5 -

Transmission dynamic - partners - concurrency

P1-S5.33 Timing of Incident STI Relative to Sex Partner Change in Young Women

Mary Ott (1), Jaroslaw Harezlak (1), Susan Ofner (1), J. Dennis Fortenberry (1); (1) Indiana University School of Medicine (Indianapolis, USA)

P1-S5.34 Diffuse Distribution and Extensive Disassortative Mixing of Chlamydia trachomatis Genotypes between Ethnic Groups in Paramaribo, Suriname

Reinier Bom (1), Jannie van der Helm (1), Leslie Sabajo (2), Henry de Vries (1), Antoon Grunberg (3), Sylvia Bruisten (1); (1) Public Health Service of Amsterdam (Amsterdam, Netherlands); (2) Ministry of Health (Paramaribo, Suriname); (3) Lobi Foundation (Paramaribo, Suriname)

P1-S5.35 Multiple concurrent sexual partnerships among adolescents in Tanzania and South Africa: A comparison between areas with contrasting level of HIV magnitude

Elia Mmbaga (1), Arnfinn Helleve (2), Germana Leyna (1), Melkiory Masatu (3), Hans Onya (4), KnutInge Klepp (2); (1) Muhimbili University of Health Sciences (Dar Es Salaam, Tanzania, United Rep. of); (2) University of Oslo (Norway); (3) Center for Educational Development Arusha (Tanzania, United Rep. of); (4) University of Limpopo (South Africa)

P1-S5.36 Concurrency among Women <25 Years of Age Screened in Family Planning and Reproductive Health Clinics in U.S. Public Health Service Region X, January 2009 - June 2010

Wendy Nakatsukasa-Ono (1), David Fine (1); (1) Center for Health Training (Seattle, USA)

P1-S5.37 Evolution of Sexual Networks over Time in Manitoba, Canada

Ann Jolly (1); (1) Public Health Agency of Canada (Ottawa, Canada)

P1-S5.38 Concurrent Sexual Partnerships and Group Sex as Determinants of STI within Sexual Networks of Swingers

Anne-Marie Niekamp (1), Christian JPH Hoebe (1), Laura WL Spauwen (1), Nicole HTM Dukers-Muijters (1); (1) Public Health Service South Limburg (Geleen, Netherlands)

P1-S5.39 Triple Jeopardy? Sexual Networks of Syphilis & HIV Infection Among Heterosexuals, MSM, and Bisexual Men in North Carolina

Irene Doherty (1), Dana Pasquale (1), Aliza Liebman (1), Adaora Adimora (1), Peter Leone (1); (1) University of North Carolina at Chapel Hill (Chapel Hill, USA)

P1-S5.40 Sex cells: a pilot study investigating cell phone-based sexual networks among men who have sex with men in South India

Laura H. Thompson (1), Souradet Shaw (1), Kathleen Deering (2), Sushena Reza-Paul (3), Robert Lorway (1); (1) University of Manitoba (Winnipeg, Canada); (2) BC Centre for Excellence in HIV/AIDS (Canada); (3) Ashodaya-Disha (India)

P1-S5.41 Quantifying the contribution of re-infection within partnerships to persistent spread of Chlamydia

Mirjam Kretzschmar (1), Boris Schmid (2), Nicola Low (3), Janneke Heijne (3); (1) UMCU (Utrecht, Netherlands); (2) RIVM (Netherlands); (3) University of Bern (Switzerland)

P1-S5.42 Prevalence of Transitional and Embedded Concurrency Within a Prospective Cohort of Urban Adolescent Females

Pamela Matson (1), Shang-en Chung (1), J. Dennis Fortenberry (2), Jonathan Ellen (1); (1) Johns Hopkins School of Medicine (Baltimore, USA); (2) Indiana University-Purdue University Indianapolis (Indianapolis, USA)

Epidemiology poster session 5 -

Transmission dynamic - Income/race disparities

P1-S5.43 Disparities in Sexually Transmitted Diseases across Race-Income" Counties in the United States: A Race-Specific Morbidity Analysis"

Kwame Owusu-Edusei (1), Harrell Chesson (1), Jami Leichter (1), Charlotte Kent (1), Sevgi Aral (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P1-S5.44 STD Rates in the Eight Americas": Disparities in the Burden of Syphilis, Gonorrhea, and Chlamydia Across Race and County"

Harrell Chesson (1), Kwame Owusu-Edusei, Jr. (1), Charlotte Kent (1), Sevgi Aral (1); (1) US Centers for Disease Control and Prevention (Atlanta, USA)

P1-S5.45 Withdrawn

Epidemiology poster session 5 -

Transmission dynamic - Income disparities

P1-S5.46 Assessing the relationship between sexually transmitted infection rates, ethnic group and socio-economic deprivation in England

Emma Savage (1), Geraldine Leong (1), Lindsey Peters (1), Stephen Duffell (1), Gwenda Hughes (1); (1) Health Protection Agency (London, United Kingdom)

Epidemiology poster session 6 -

Preventive intervention

P1-S6.01 Controlling the Heterosexual HIV Epidemic in Low-Prevalence Domains

Clarence Lehman (1), Adrienne Keen (2), Benjamin Kerr (3); (1) University of Minnesota (St Paul, USA); (2) London School of Hygiene and Tropical Medicine (London, United Kingdom); (3) University of Washington (Seattle, USA)

P1-S6.02 Contraceptive discontinuation by rural Kenyan women in HIV discordant partnerships after exiting an HIV prevention trial

Kenneth Ngure (1), Jared Baeten (2), Jairam Lingappa (2), Renee Heffron (2), Paul Musingila (1), Elizabeth Irungu (2), Peterson Mwaniki (1), Lawrence Mwaniki (1), Ruth Wamae (1), Simon Mburu (1), Nelly Mugo (3); (1) Kenyatta National Hospital (Nairobi, Kenya); (2) University of Washington (USA); (3) Kenyatta National Hospital/University of Washington (Kenya)

P1-S6.03 Why are so many of our biomedical and behavioral prevention trials failing?

David Celentano (1), Chris Beyrer (1); (1) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA)

P1-S6.04 Education and Lifetime Risk of HIV infection in Manicaland, Zimbabwe

Laura Robertson (1), Phyllis Mushati (2), Jeffrey Eaton (1), Christina Schumacher (1), Simon Gregson (3), Constance Nyamukapa (4); (1) Imperial College London (London, United Kingdom); (2) Biomedical Research & Training Institute Zimbabwe (Zimbabwe); (3) Imperial College London, Biomedical Research & Training Institute, Zimbabwe (United Kingdom); (4) Biomedical Research & Training Institute, Zimbabwe (Zimbabwe)

P1-S6.05 Influence of Social Support Networks on the HIV Transmission Risk Behaviours of People Living with Human Immunodeficiency Virus in Manitoba, Canada

Alina Cameron (1); (1) University of Manitoba (Winnipeg, Canada)

P1-S6.06 What has been the effect of the Avahan HIV intervention on condom use among female sex workers? Insights from a fully Bayesian inference methodology

Joseph Dureau (1), Marie-Claude Boily (2), Peter Vickerman (3), Michael Pickles (2), Shajy Isac (4), Banadakoppa Ramesh (4), Supriya Verma (4), Stephen Moses (5), Michel Alary (6), Konstantinos Kalogeropoulos (1); (1) London School of Economics (London, United Kingdom); (2) Imperial College (United Kingdom); (3) London School of Hygiene & Tropical Medicine (United Kingdom); (4) Karnataka Health Promotion Trust (Bangalore, India); (5) University of Manitoba (Winnipeg, Canada); (6) Université Laval (Canada)

P1-S6.07 Ecological analysis of the factors influencing changes in HIV prevalence over time among FSW following a targeted intervention

Conghua wen (1), Marie-Claude Boily (2), Michael R E H Pickles (3), Supriya Verma (4), BM Ramesh (4), Shajy Isac (4), Rajatashuvry Adhinkari (5), Mandar K Mainkar (6), Michel Alary (7), Peter Vickerman (8); (1) Imperial college (London, United Kingdom); (2) Imperial college, Centre Hospitalier affilié Universitaire de Québec (United Kingdom); (3) Imperial College, LSHTM, (United Kingdom); (4) Karnataka Health Promotion Trust (Bangalore, India); (5) Family Health International (India); (6) National AIDS Research Institute (India); (7) Centre Hospitalier affilié Universitaire de Québec (Quebec, Canada); (8) LSHTM, University of Bristol (United Kingdom)

Epidemiology poster session 6 -

Preventive intervention - Screening

P1-S6.08 A multifaceted intervention to increase chlamydia testing in Australian general practice

Jane Hocking(1), Simone Poznanski (1), Alaina Vaisey (1), Jennifer Walker (1), Anna Wood (1), Dyani Lewis (1), Rebecca Guy (2), Meredith Temple-Smith (1); (1) The University of Melbourne (Melbourne, Australia); (2) University of New South Wales (Australia)

P1-S6.09 An Audit of Management of Prenatal Syphilis Serology in the STI Clinic, Calgary, AB, Canada

Angel Chu (1), Ron Read (1), Ron Scarrott (2); (1) University of Calgary (Calgary, Canada); (2) Alberta Health Services (Canada)

P1-S6.10 Acceptability of Anal Pap self-screening in high-risk women: Findings from English and Spanish focus groups in northern California

Candice McNeil (1), Cecilia Piñera (2), Yvonne Maldonado (1), Vivian Levy (3); (1) Stanford University (Stanford, USA); (2) Hospital González Cortez, Universidad de Chile (Santiago, Chile); (3) San Mateo County Health System (San Mateo, USA)

P1-S6.11 Prevention of Mother to Child Transmission of HIV (PMTCT) program in Burkina Faso: how high is the coverage of Voluntary Counselling and HIV Testing (VCT) services within a clinical trial supporting environment?

Hugues Asken TRAORE (1), Eric Some (1), Nicolas Meda (1), Nicolas Nagot (2), Philippe Van De Perre (3); (1) ANRS/Burkina Faso (Ouagadougou, Burkina Faso); (2) INSERM U 1058/France (France); (3) INSERM U 1058 (France)

P1-S6.12 The contribution of a Chlamydia screening programme to testing and case-finding in addition to regular STI-care in three regions of The Netherlands

Ingrid VF van den Broek (1), Hannelore M Götz (2), Elfi EHG Brouwers (3), Han SA Fennema (4), Christian JPA Hoebe (3), Rik H Koekenbier (4), Lydia L Pars (5), Sander M van Raveseijn (2), Eline LM Op de Coul (6), Jan EAM van Bergen (5); (1) Centre for Infectious Disease Control, National Institute of Public Health and the Environment (Bilthoven, Netherlands); (2) Division of Infectious Disease Control, Rotterdam Rijnmond Public Health Service (Rotterdam, Netherlands); (3) Department of Infectious Diseases, South Limburg Public Health Service (Geleen, Netherlands); (4) Cluster of Infectious Diseases, Department of Research, Online Research and Prevention Unit, Amsterdam Health Service (Amsterdam, Netherlands); (5) STI AIDS Netherlands (Amsterdam, Netherlands); (6) Epidemiology & Surveillance Unit, Centre for Infectious Disease Control, National Institute of Public Health and the Environment (Bilthoven, Netherlands)

P1-S6.13 A new approach to encourage HIV testing in high-risk populations at the Clinique l'Actuel.

Rejean Thomas(1), Nima Machouf (1), Benoit Trottier (1), Sylvie Vezina (1), Robert O'Brien (1), Michele Milne (1), Stephane Lavoie (1), Danielle Longpré (1), Emmanuelle Huchet (1), Vinh Kim Nguyen (1); (1) Clinique médicale l'Actuel (Montreal, Canada)

Epidemiology poster session 6 -

Preventive intervention - Screening - testing

P1-S6.14 Interventions to Increase Re-testing for Repeat Chlamydial Infection: a Systematic Review and Meta-analysis

Hammad Ali (1), Rebecca Guy (1), Nicola Low (2), Heidi Bauer (3), Jenny Walker (4), Jeffrey Klausner (5), Basil Donovan (1), John Kaldor (1), Jane Hocking (6); (1) National Centre in HIV Epidemiology and Clinical Research (Sydney, Australia); (2) Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern (Bern, Switzerland); (3) Program Development and Evaluation, STD Control Branch, California Department of Public Health (USA); (4) 4Centre for Women's Health, Gender and Society, Melbourne School of Population Health, University of Melbourne (Australia); (5) Department of Medicine, University of California (USA); (6) Centre for Women's Health, Gender and Society, Melbourne School of Population Health, University of Melbourne (Australia)

P1-S6.15 Characteristics and Predictors of Women Seeking Rescreening for STIs After Using the www.iwantthekit.org Program: Were They Infected or Uninfected?

Charlotte Gaydos (1), Yu-Hsiang Hsieh (1), Mathilda Barnes (1), Mary Jett-Goheen (1), Nicole Quinn (1), Patricia Agreda (1), Pamela Whittle (2), Terry Hogan (1); (1) Johns Hopkins University (Baltimore, USA); (2) Baltimore City Health Department (Baltimore, USA)

P1-S6.16 Australian Chlamydia Control Effectiveness Pilot - Preliminary Results from a Trial of Chlamydia Testing in General Practice

Jane Hocking (1), Meredith Temple-Smith (1), Simone Poznanski (1), Rebecca Guy (2), Nicola Low (3), Basil Donovan (2), Jane Gunn (1), Matthew Law (2), John Kaldor (2), Christopher Fairley (1); (1) University of Melbourne (Carlton, Australia); (2) University of New South Wales (Australia); (3) University of Bern (Switzerland)

P1-S6.17 Opting Out Testing for HIV in Dutch STI Clinics: Does It Work?

Femke Koedijk (1), Jan van Bergen (2), Nicole Dukers (3), Christian Hoebe (3), Marianne van der Sande (4), on behalf of the Dutch STI centres (5); (1) National Institute of Public Health and the Environment (Bilthoven, Netherlands); (2) STI AIDS Netherlands, Amsterdam, the Netherlands. Also

Centre for Infectious Diseases and Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands (Netherlands); (3) Department of Infectious Diseases, Public Health Service South Limburg. Also Department of Medical Microbiology, Maastricht University Medical Center, Maastricht, the Netherlands (Netherlands); (4) Centre for Infectious Diseases and Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. Also Academic Medical Centre Utrecht, Utrecht, the Netherlands (Netherlands); (5) A van Daal, P van Leeuwen, F de Groot, A Niekamp, M Langevoort, A van Camerijk, J van de Sande, E van der Veen (Netherlands)

P1-S6.18 Characteristics of Men Who Seek Rescreening for STIs After Once Using the www.iwantthekit.org Screening Program

Yu-Hsiang Hsieh (1), Mathilda Barnes (1), Mary Jett-Goheen (1), Nicole Quinn (1), Patricia Agreda (1), Pamela Whittle (2), Terry Hogan (1), Charlotte Gaydos (1); (1) Johns Hopkins University (Baltimore, USA); (2) Baltimore City Health Department (USA)

P1-S6.19 Comparing Two Methods of Estimating Chlamydia Screening Coverage in an Urban Neighborhood, 2009

Melissa Nelson (1), Preeti Pathela (2), Susan Blank (2), Julia Schillinger (2); (1) Cicatelli Associates, Inc. (New York, USA); (2) New York City Department of Health and Mental Hygiene (New York, USA)

P1-S6.20 Perinatal Screening for STIs in the US: Adherence to Preventive Screening Recommendations for HIV and Syphilis Among the Commercially Insured (2008)

Gail Janes (1), Alexander Beard (1), Guoyu Tao (1), Karen Hoover (1), Charlotte Kent (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P1-S6.21 Chlamydia trachomatis Screening Initiative among Female U.S. Army Soldiers Deployed to Korea.

Nikki Jordan (1), Nakia Clemmons (1), Joel Gaydos (2), Jodie Fishman (3), Tanya Jacobsmuhlen (3), Hee Choon Lee (3), Mitchell Meyers (3), Terry Klein (3); (1) US Army Public Health Command (Aberdeen Proving Grounds, Edgewood, USA); (2) Armed Forces Health Surveillance Center (Silver Spring, USA); (3) USA MEDDAC (Korea, Rép. of (South))

P1-S6.22 Characteristics of Chlamydia Testing by a Large Commercial Laboratory Corporation, United States, 2008-2010

Charlotte Kent (1), Guoyu Tao (1), Karen Hoover (1), Barbara Body (2), Mindy Nye (2); (1) CDC (Atlanta, USA); (2) Laboratory Corporation of America (USA)

P1-S6.23 Impact Evaluation of Performance-based Financing (PBF) for HIV Testing and Counseling for Individuals and Couples in Rwanda

Sergio Bautista (1), Agnes Binagwaho (2), Jean de Dieu Bizimana (3), Jeanine Condo (4), Damien de Walque (3), Paul Gertler (5), Ada Kwan (1), Jennifer Sturdy (3); (1) Mexico National Institute of Public Health (Cuernavaca, Mexico); (2) Republic of Rwanda Ministry of Health (Kigali, Rwanda); (3) The World Bank (Washington, DC, USA); (4) National University of Rwanda School of Public Health (Kigali, Rwanda); (5) University of California at Berkeley (Berkeley, USA)

P1-S6.24 Estimation of Prenatal Screening Rates for Chlamydia, Syphilis, and HIV Among Low-Income Women, California, 2007

Joan Chow (1), Glenn Wright (1), Gail Bolan (1); (1) California Department of Public Health (Richmond, USA)

P1-S6.25 The Male Reproductive Health Project: Using Research-Based Interventions to Increase Male Clients and STI Testing at Family Planning Clinics

David Fine (1), Sarah Goldenkranz (1), Janet Adamian (2), Samir Ranjan (2), Amy Pan (3), Jill Baker (4), Elizabeth Rink (5), Nhan Tran (6), David Johnson (6), Alfonso Carlon (1); (1) Center for Health Training (Seattle, USA); (2) Family Health Centers of San Diego (San Diego, USA); (3) San Diego State University (San Diego, USA); (4) Planned Parenthood of Montana (Great Falls, USA); (5) Montana State University (Bozeman, USA); (6) DHHS/OPA/OFP (Rockville, USA)

P1-S6.26 Modeling the Impact of Rapid Treponemal Tests on Syphilis Prevalence among Female Sex Workers in India

Sharmistha Mishra (1), Stephen Moses (2), Michael Pickles (1), BM Ramesh (3), Shajiy Isac (3), Reynold Washington (3), Marissa Becker (2), James Blanchard (2), Marie-Claude Boily (1); (1) Imperial College (London, United Kingdom); (2) Centre for Global Public Health (Canada); (3) Karnataka Health Promotion Trust (Bangalore, India)

P1-S6.27 Could a Peer Driven Intervention Increase Uptake of Chlamydia Screening? - Proof of principle

Jessica Loaring (1), Hickman Matthew (2), Isabel Oliver (3), Rona Campbell (2), Caroline Trotter (2), John Macleod (2), Karl Pye (4), Patrick Horner(2); (1) University of Birmingham (Birmingham, United Kingdom); (2) University of Bristol (United Kingdom); (3) Health Protection Agency (United Kingdom); (4) Bristol Primary Care Trust (United Kingdom)

P1-S6.28 Integrated HIV, Syphilis, and Other STI Testing in North Carolina County Jails

Jan Scott (1), Lynne A Sampson (2), Jacquelyn M Clymore (2), Peter R Moore (3), Peter A Leone (2); (1) Centers for Disease Control & Prevention (Raleigh, USA); (2) NC Division of Public Health (Raleigh, USA); (3) Centers for Disease Control and Prevention (Raleigh, USA)

P1-S6.29 Longitudinal Trends in HIV Testing and Prevalence among STI Clinic Patients in Lilongwe, Malawi: 2006-2010

Kimberly Powers (1), Gift Kamanga (2), Clement Mapanje (2), Jullita Kenala Malava (2), Mary Chindevuu (2), Hilex Kamzati (2), Francis Martinson (2), William Miller (1), Myron Cohen (1), Irving Hoffman (1); (1) University of North Carolina at Chapel Hill (Chapel Hill, USA); (2) UNC Project Malawi (Lilongwe, Malawi)

P1-S6.30 HIV Testing of Patients Receiving an STD Evaluation in a North Carolina Community Health Center

Pamela Klein (1), Al Bishop (2), Peter Leone (3); (1) UNC Gillings School of Global Public Health (Chapel Hill, USA); (2) Robeson Health Care Corporation (USA); (3) University of North Carolina School of Medicine (USA)

P1-S6.31 HIV Intertest Interval among MSM in King County, Washington

David Katz (1), Julia Dombrowski (2), Susan Buskin (2), Matthew Golden (2), Joanne Stekler (2); (1) University of Washington (Seattle, USA); (2) University of Washington / Public Health - Seattle & King County (Seattle, USA)

P1-S6.32 Optimising clinical systems to increase HIV/STI testing in gay men: the eTEST project

Fraser Drummond (1), Larissa Lewis (1), Chris Bourne (2), Vijay Ramanathan (3), Jane Hocking (4), Handan Wand (1), Basil Donovan (1), John Kaldor (1), Rebecca Guy (1); (1) National Centre

in HIV Epidemiology and Clinical Research (Sydney, Australia); (2) Sydney Sexual Health Centre (Australia); (3) Central Sydney GP Network (Australia); (4) Centre for Women's Health, Gender and Society (Australia); (5) University of New South Wales (Australia)

P1-S6.33 Monitoring chlamydia testing and positivity in the United States using data from a large commercial laboratory corporation, 2008-2010

Karen Hoover (1), Guoyu Tao (1), Mindy Nye (2), Barbara Body (2), Charlotte Kent (1); (1) CDC (Atlanta, USA); (2) Laboratory Corporation of America (USA)

P1-S6.34 Evaluation of risk-score algorithms for the detection of HIV infection and syphilis in North Carolina county jails.

Lynne A Sampson (1), William C Miller (2), Peter A Leone (1); (1) NC Division of Public Health (Raleigh, USA); (2) University of North Carolina (Chapel Hill, USA)

P1-S6.35 One finger stick, two tests: Integrating Syphilis and HIV Rapid tests for antenatal care and reproductive health services

Maria Valderrama (1), Marina Chiappe (1); (1) Universidad Peruana Cayetano Heredia (Lima, Peru)

P1-S6.36 Cost-effectiveness of rapid tests to improve access to syphilis prevention among pregnant women in Peru

Patricia Mallma (1), Cesar Carcamo (1), Maria Valderrama (1), Marina Chiappe (1), Sayda La Rosa (1), Patricia Garcia (1), Marcia Weaver (2), King Holmes (2), Fern Terris-Prestholt (3), Rossana Peeling (3); (1) School of Public Health - Universidad Peruana Cayetano Heredia (Lima, Peru); (2) University of Washington (Seattle, USA); (3) London School of Hygiene and Tropical Medicine (London, United Kingdom)

P1-S6.37 CAN RAPID SYPHILIS TESTS BE IMPLEMENTED AND IMPROVE SCREENING FOR MATERNAL SYPHILIS IN A THIRD LEVEL HOSPITAL?

Sayda La Rosa Roca (1), Patricia Garcia (1); (1) Cayetano Heredia University (LIMA, Peru)

P1-S6.38 Interpretation of Routine Data from a Youth Friendly Clinic in Region F, Johannesburg

SAMANTA TRESHA LALLA-EDWARD (1); (1) Wits Institute for Sexual and Reproductive Health, HIV and related diseases (JOHANNESBURG, South Africa)

P1-S6.39 Can professional midwives interpret rapid syphilis tests accurately?

Marina Angélica Chiappe Gutiérrez (1), Katherine Soto (1), Lorena Lopez-Torres (1), Cesar Cárcamo (1), María Isabel Valderrama Calderón (1), Sayda LaRosa (1), Patricia Mallma (1), Patricia Garcia (1), Rosanna Peeling (2); (1) School of Public Health and Administration, Universidad Peruana Cayetano Heredia. Lima, Peru, (2) London School of Hygiene & Tropical Medicine, UK

P1-S6.40 VCT sites in MSM from Mexico City: an opportunity to action

Carlos Magis-Rodríguez (1), Andrea González-Rodríguez (1), Enrique Bravo-García (2), Luis Juárez-Figueroa (1), Eduardo Rodríguez-Nolasco (1), Cristina De Azcárraga Urteaga (1); (1) Programme on HIV/AIDS in Mexico City (Mexico, Mexico); (2) Consultor (Mexico, Mexico)

Epidemiology poster session 6 -

Preventive intervention - Vaccination

P1-S6.41 Determinants of Human Papilloma Virus Vaccination (HPV) among Quebec (Canada) Teenagers

Maryse Guay (1), Paule Clément (2), Aïcha Hamid (1), Eve Dubé (2), Chantal Sauvageau (2), Nicole Boulianne (2), Monique Landry (3), Jacques Le-maire (1); (1) Université de Sherbrooke (Longueuil, Canada); (2) Institut national de santé publique du Québec (Canada); (3) Ministère de la Santé et des Services sociaux du Québec (Canada)

P1-S6.42 HPV Vaccine and Sexual Behavior among U.S. Adolescent and Young Adult Women

Nicole Liddon (1), Jami S Leichter (1), Julia Hood (1), Lauri E Markowitz (1); (1) U.S. Centers for Disease Control and Prevention (Atlanta, USA)

P1-S6.43 HPV Vaccine Coverage among High-Risk Women: Racial and Socioeconomic Disparities and Barriers

Linda Niccola (1), Niti Mehta (1), Pamela Julian (1), Alyssa Bilinski (2), Lynn Sosa (3), James Meek (1), Susan Hariri (4), Lauri Markowitz (4), James Hadler

(1); (1) Yale School of Public Health (New Haven, USA); (2) Yale College (New Haven, USA); (3) Connecticut Department of Public Health (Hartford, USA); (4) Centers for Disease Control and Prevention (Atlanta, USA)

P1-S6.44 HIV Vaccine Clinical Trial Adherence and Retention: High-Risk Drug-Using Women

Julie Becher (1), Sumedha Chhatre (1), Marlene Eisenberg (1), Danielle Fiore (1), Tiffany Dominique (1), Debora Dunbar (1), Ian Frank (1), David Metzger (1); (1) University of Pennsylvania (Philadelphia, USA)

Epidemiology poster session 6 -

Preventive intervention - Community action

P1-S6.45 Impact of a community level, diffusion based HIV/STI intervention on heterosexually-identified, socially marginalized men in urban, coastal Peru

Kelika Konda (1), Andres Lescano (2), David Celentano (3), Andre Maiorana (4), Ximena Salazar (5), Ana Maria Rosasco (5), Silvia Montano (2), Tadeusz Kochel (2), Eric Hall (2), Thomas Coates (1), Carlos Caceres (5), Susan Kegeles (4), NIMH Collaborative HIV/STD Prevention Trial Group (6); (1) UCLA (Lima, Peru); (2) NAMRU-6 (Callao, Peru); (3) Johns Hopkins University (Baltimore, USA); (4) UCSF (USA); (5) UPCH (Lima, Peru); (6) NIMH (USA)

P1-S6.46 The long-term impact of the MEMA kwa Vijana adolescent sexual and reproductive health intervention: Effects of dose and time since exposure to intervention

Aoife M Doyle (1), Helen A Weiss (1), Kaballa Maganja (2), Sheena McCormack (3), Deborah Watson-Jones (1), John Changalucha (2), Richard J Hayes (1), David A Ross (1); (1) London School of Hygiene & Tropical Medicine (London, United Kingdom); (2) National Institute for Medical Research, Mwanza Centre (Tanzania, United Rep. of); (3) MRC Clinical Trials Unit (United Kingdom)

P1-S6.47 Description and evaluation of a regional condom access program for community organizations

Genevieve Petit (2), Antony Bigras (1), Catherine Dubé (1), François-Charles Malo (1), Marie-Claude Surprenant (1), Mia Salvail (1), Maude Gagnon (2); (1) Université de Sherbrooke (Sherbrooke, Canada); (2) Direction de santé publique et de l'évaluation (Canada)

Epidemiology poster session 6 -

Preventive intervention - Counseling

P1-S6.48 Identifying women at risk: Can an STD diagnosis help target women for risk reduction counseling? Miami-Fort-Lauderdale, 2000-2009

Toye H Brewer (1), Thomas A Peterman (2), Daniel R Newman (2), Stacy Shiver (3); (1) CDC/Florida DOH (Miami, USA); (2) CDC (Atlanta, USA); (3) Florida Department of Health (Tallahassee, USA)

P1-S6.49 Developing and validating a risk scoring tool for chlamydia infection among sexual health clinic attendees in Australia A simple algorithm to identify those at high risk of Chlamydia infection

Handan Wand (1); (1) University of New South Wales (Sydney, Australia)

Epidemiology poster session 6 -

Preventive intervention - Partner notification

P1-S6.50 Chlamydia Partner Notification For Adolescent Females, San Francisco, 2010

Robert Kohn (1), Jacque McCright (1), Brandon Ivory (1), Ameera Snell (1), Kyle Bernstein (1); (1) San Francisco Department of Public Health (San Francisco, USA)

Epidemiology poster session 6 -

Preventive intervention - ARV

P1-S6.51 Antiretroviral Therapy, Sexual Behavior, and their Simulated Impact on HIV Epidemiologic Trends in Uganda

Leigh Anne Shafer (1), Rebecca Nsubuga (2), Ruth Chapman (3), Katie O'Brien (3), Billy Mayanja (2), Richard White (3); (1) University of Manitoba (Winnipeg, Canada); (2) Medical Research Council/Uganda Virus Research Institute (Entebbe, Uganda); (3) London School of Hygiene and Trop Med (London, United Kingdom)

P1-S6.52 Is PEP a Misused Therapy? Cross Sectional PEP Study in Sex Worker Outreach Program Clinic

Jane Mungai (1), Marion Kiguoya (1); (1) University of Nairobi (Nairobi, Kenya)

P1-S6.53 Antiretroviral Therapy Reduces HIV Transmission in Discordant Couples in Northern Malawi

Judith Glynn (1), Alison Price (1), Sian Floyd (1), Anna Molesworth (1), Ndoliwe Kayuni (2), Menard Chihana (2), Vitumbiku Nyirenda (2), Amelia Crampin (1), Neil French (1); (1) London School of Hygiene & Tropical Medicine (Chilumba, Malawi); (2) Karonga Prevention Study (Malawi)

Epidemiology poster session 6 -

Preventive intervention - Circumcision

P1-S6.54 Medical Male Circumcision may be protective of urogenital *Mycoplasma genitalium* infection: Results from a randomized trial in Kisumu, Kenya

Supriya Mehta (1), Charlotte Gaydos (2), Ian Maclean (3), Elijah Odoyo-June (4), Stephen Moses (3), Ruth Murugu (4), Lawrence Agunda (5), Edith Nyagaya (4), Nicole Quinn (2), Robert Bailey (1); (1) University of Illinois at Chicago (Chicago, USA); (2) The Johns Hopkins University School of Medicine (USA); (3) University of Manitoba (Winnipeg, Canada); (4) UNIM Project (Kenya); (5) UNIM Kenya (Kenya)

Social and behavioural aspects of prevention

poster session 1 - Adolescents

P2-S1.01 Beyond the ABC In HIV/AIDS Prevention: a Systematic Literature Review of Sexual Education Programs for Young People

John Harold Estrada-Montoya (1); (1) Universidad Nacional de Colombia (Bogotá, Colombia)

P2-S1.02 Safe Spaces - Youth friendly centre used to promote HIV education in Nairobi slums

Peter Chacha Baru Musya (1), Caitlin Johnston (2), Peter Mokaya (1), Lydia Mbenya (1), Hannah Nyambura (1), Victoria Nduku (1); (1) U-Tena Performing Artists-Youth Organization (Nairobi, Kenya); (2) U-Tena Arts and Education Society (Vancouver, Canada)

P2-S1.03 Our Adolescents! My Sexuality Matters (MSM) the Lessons we have learnt

Onyeigwe Daniel Obi Peter (1); (1) Asso. of Positive Youth Living with HIV/AIDS in Nigeria APYIN (Abuja, Nigeria)

P2-S1.04 Associations of Symptoms of Depression with Multiple Sexual Risk Behaviours in Nova Scotia Adolescents

Donald Langille (1), Mark Asbridge (1), Steve Kisely (2); (1) Dalhousie University Faculty of Medicine (Halifax, Canada); (2) Faculty of Medicine, University of Queensland (Brisbane, Australia)

P2-S1.05 Parental Acceptability of Contraceptive Methods Offered to their Teen During a Confidential Health Care Visit

Lauren Hartman (1), Mary-Ann Shafer (1), Lance Pollack (1), Chuck Wibbelsman (2), Fay Chang (1), Kathleen Tebb (1); (1) University of California San Francisco (San Francisco, USA); (2) Kaiser Permanente (USA)

P2-S1.06 Adolescents' Willingness to Participate in HIV Vaccine Clinical Trial Preparedness in Nigeria

Ngozi Otuonye (1), Rita Onwuatuelo (1), ChiKa Onwuamah (1); (1) Nigerian Institute of Medical Research (Yaba, Nigeria)

P2-S1.07 Sadness, Poor School Work, Running Away, and Sexual Risk Behavior Among Urban Female African American Adolescents

Marc Safran (1), Lin Hui Tian (2), Matthew Hogben (2), Jim Braxton (2), Rachel Robitz (2), Emily Koumans (2); (1) Centers for Disease Control and Prevention (CDC) (Atlanta, USA); (2) CDC (USA)

P2-S1.08 Dual Contraceptive Use among Adolescents and Young Adults: Correlates and Implications for Condom Use and STI Outcomes

Julia Hood (1), Matthew Hogben (1), Maggie Chartier (2), Gail Bolan (1), Heidi Bauer (3); (1) CDC (Atlanta, USA); (2) Department of Veteran Affairs (USA); (3) California Department of Public Health (USA)

P2-S1.09 Associations Between Early Sexual Debut and Two Types of Sexual Risk Behaviour in Nova Scotia Adolescents

Donald Langille (1), Pantelis Andreou (1), Kevin Wilson (1); (1) Dalhousie University (Halifax, Canada)

P2-S1.10 Identifying Key Elements Describing Sexual Behavior in the Danish Population: A Qualitative Study.

Marianne Johansson Jørgensen (1), Helle Terkildsen Maindal (2), Frede Olesen (2), Berit Andersen (1); (1) Randers Regional Hospital (Randers NØ, Denmark); (2) Aarhus University (Aarhus C, Denmark)

P2-S1.11 Withdrawn

P2-S1.12 Project Prepare Tanzania: Engaging Multiple Stakeholders to Develop a School-based Sexual Health Curriculum for Adolescents

Renicha McCree-Hale (1), Lusajo Kajula-Maonga (2), Tatizo Ramatu Sheya wa Mnyakaya (2), Juliana Joachim (2), Khalid Mrumbi (2), Elia John (2), Sylvia Kaaya (2); (1) Management and Development for Health (Dar es Salaam, Tanzania, United Rep. of); (2) Muhimbili University (Dar es Salaam, Tanzania, United Rep. of)

P2-S1.13 Why Individuals Do Not Return Their Requested Chlamydia trachomatis (CT) Home Collection Kit: Results from a Qualitative Study

Rik Koekenbier (1), Livia Kalma (1), Freke Zuure (1), Udi Davidovich (2), *On behalf of the Chlamydia Screening Implementation (CSI) project group - (3); (1) Amsterdam Public Health Service (Amsterdam, Netherlands); (2) Amsterdam Public Health Service (Netherlands); (3) - (Netherlands)

P2-S1.14 The Accuracy of Perceptions about Sexual Concurrency among Pregnant Adolescents and their Partners and the Influence of Self-reported Concurrency

Andrea Swartzendruber (1), Linda Niccolai (2), Jonathan Zenilman (3), Jacky Jennings (3), Heather Sipsma (2), Anna Arnold (2), Trace Kershaw (2); (1) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA); (2) Yale School of Public Health (USA); (3) Johns Hopkins University School of Medicine (USA)

P2-S1.15 Criminal Justice Involvement in Adolescence and Sexually Transmitted Infection in Adulthood in the United States

Maria Khan (1), David Rosen (2), Matthew Epperson (3), Amanda Berger (4), Kristina Smyrk (4); (1) University of Maryland, College Park (College Park, USA); (2) University of North Carolina at Chapel Hill (Chapel Hill, USA); (3) University of Chicago (USA); (4) University of Maryland at College Park (Department of Behavioral and Community Health, USA)

P2-S1.16 Social influences on relationship fidelity and concurrency patterns among Latino adolescents in San Francisco

Alexandra Minnis (1), Evan vanDommelen-Gonzalez (1); (1) RTI International (San Francisco, USA)

P2-S1.17 Evaluating Native STAND: a Peer Education Curriculum for Healthy Decision-Making for Native Youth

Lori de Ravello (2), Stephanie Craig Rushing (1), Sonal Doshi (2), Mike U. Smith (3), Scott Tulloch (2); (1) Northwest Portland Area Indian Health Board (Portland, USA); (2) Centers for Disease Control & Prevention (Atlanta, USA); (3) Mercer University (Macon, USA)

P2-S1.18 Accuracy of self-reported condom use assessed by the semen Y-chromosome biomarker for unprotected sex

Janet Rosenbaum (1), Johan Melendez (2), Eve Rose (3), Gina Wingood (3), Jonathan Zenilman (2), Ralph DiClemente (3); (1) University of Maryland School of Public Health (Washington, USA); (2) Johns Hopkins Medical Institutions (USA); (3) Emory School of Public Health (USA)

**Social and behavioural aspects of prevention
poster session 2 - Female sex workers**

P2-S2.01 Support groups as a strategy for reducing HIV vulnerability among female sex workers in Bellary, northern Karnataka, India

Dhanunjaya Rao Chintada (1), Priya Pillai (2), Suresh Mahadevapappa (1), Peer Mohammed (1), Shajy Isac (1), BM Ramesh (1), Venkata Ramappa (3), Parinita Bhattacharjee (1), Stephen Moses (4); (1) Karnataka Health Promotion Trust (Bellary, India); (2) Independent consultant (Bangalore, India); (3) MYRADA (Bellary, India); (4) University of Manitoba (Winnipeg, Canada)

P2-S2.02 Role of Decision Makers in the lives of Migrant Sex Workers-Focus on Families: An Qualitative Assessment

Satyanarayana Ramanaiik (1), Venkatesh Sabnis (1), Kavari Gurav (1), Pradeep Banandur (1), Raluca Buzdugan (1), Shiva Halli (2), James Blanchard (2); (1) Karnataka Health Promotion Trust (Bangalore, India); (2) Centre for Global Public Health, University of Manitoba (Winnipeg, Canada)

P2-S2.03 Reaching the New and Young Migrant Sex workers: Strategies for intervention

Satyanarayana Ramanaiik (1), Mahesh Doddamane (1), Srikantamurthy S (1), Ravindra I (1), Ravikant Meti (1), Tejswini Hiremath (1), Arjun Mirji (1), Gyanappa Holidasar (1), Mahesh Pudur (1), Ragavendra T (1), Parinita Bhattacharjee (1); (1) Karnataka Health Promotion Trust (Bangalore, India)

P2-S2.04 Sex Workers, Mobility and Migrant Latino Men in the US South: Findings from an Exploratory Rapid Ethnographic Assessment in North Carolina

Karen Kroeger (1), Thurka Sangaramoorthy (2), Petra Vallila-Buchman (2), Rachel Robitz (2), Pete Moore (3), Jacquelyn Clymore (3); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) CDC (USA); (3) North Carolina Department of Public Health (USA)

P2-S2.05 Mobilizing female sex workers to access outreach and medical services - a case study from Solapur district, Maharashtra, south India

Raghavendra T (1); (1) Karnataka Health Promotion Trust (Bangalore, India)

P2-S2.06 Becoming a Sex Worker: The Nexus between Violence, Gender Disadvantage and Poverty

Maryam Shahmanesh (1), Sonali Wayal (1), Frances Cowan (1); (1) University College London (London, United Kingdom)

P2-S2.07 Improving sexually transmitted infections (STI) prevention strategies: factors associated with STIs among female sex workers in India

Prakash Narayanan (1), Anjana Das (1), Anup Gurung (1), Prabhakar Parimi (2), Gururaj Rao (3), Arun Risbud (3) Manish Ranjan (1); (1) FHI (New Delhi, India); (2) India HIV/AIDS Alliance (Hyderabad, India); (3) National AIDS Research Institute (Pune, India)

P2-S2.08 Withdrawn

P2-S2.09 Profile of Clients of sex workers developed through imagery used with FSWs in six major Pakistani cities

Syed Sohail Abbas (1); (1) Margalla Clinic (Islamabad, Pakistan)

P2-S2.10 Sex Worker Collective Organization in the Absence of NGOs: A Qualitative Analysis of Female Sex Worker Hometown Social Networks in South China

Joseph Tucker (1), Hua Peng (2), Kaidi Wang (3), Helena Chang (4), Li-Gang Yang (2), SenMiao Zhang (2), Bin Yang (2); (1) Massachusetts General Hospital (Boston, USA); (2) Guangdong Provincial STI Control Center (China); (3) Harvard Medical School (USA); (4) University of Wisconsin Madison (USA)

P2-S2.11 Focused and Early Intervention in Rural Areas can Impact on HIV transmission in southern India

Reynold Washington (1), Parinita Bhattacharjee (1); (1) KHPT (Bangalore, India)

P2-S2.12 Condom use within intimate partnerships of female sex workers in southern India

Kathleen Deering (1), Parinita Bhattacharjee (2), Reynold Washington (2), Janet Bradley (3), Marie-Claude Boily (4), Souradet Shaw (5), Kate Shannon (1), B.M. Ramesh (2), S Rajaram (2), Stephen Moses (5), Michel Alary (3); (1) University of British Columbia (Vancouver, Canada); (2) Karnataka Health Promotion Trust (Bangalore, India); (3) Laval University (Canada); (4) Imperial College (United Kingdom); (5) University of Manitoba (Winnipeg, Canada)

P2-S2.13 A pilot study of the effectiveness of a vaginal washing cessation intervention among Kenyan female sex workers

Linnat Masese (1), R. Scott McClelland (1), Ruth Gitau (2), George Wanje (1), Juma Shafi (2), Francis Kashonga (2), Jeckoniah Ndinya-Achola (2), Barbra Richardson (1), Richard Lester (3), Ann Kurth (4); (1) University of Washington (Seattle, USA); (2) University of Nairobi (Kenya); (3) University of British Columbia (Canada); (4) New York University (USA)

P2-S2.14 Alcohol abuse and Sexual Victimization among female sex workers in China

Yan Hong (1), Chen Zhang (1), Xiaoming Li (2); (1) Texas A&M Health Science Center (College Station, USA); (2) Wayne State University School of Medicine (Detroit, USA)

P2-S2.15 Typology of female sex workers and association with HIV risks: evidence from China

Yan Hong (1), Xiaoming Li (2); (1) Texas A&M Health Science Center (College Station, USA); (2) Wayne State University School of Medicine (Detroit, USA)

P2-S2.16 Impact of duration of exposure to sex work on HIV prevalence in 23 districts of Southern India

Mike Pickles (1), Marie-Claude Boily (1), Kathleen Deering (2), Peter Vickerman (3), B M Ramesh (4), Reynold Washington (5), Shajy Isac (4), Rajatashuvra Adhikary (6), Ramesh S Paranjape (7), Michel Alary (8); (1) Imperial College (London, United Kingdom); (2) University of British Columbia (Canada); (3) LSHTM (United Kingdom); (4) Karnataka Health Promotion Trust (Bangalore, India); (5) St John's Research Institute, Bangalore (India); (6) Family Health International, India (India); (7) National AIDS Research Institute, Pune (India); (8) Centre hospitalier *affilié* universitaire de Québec (Quebec, Canada)

P2-S2.17 Community-Led Structural Intervention's promise for HIV prevention: a case study from the Ashodaya Samithi Sex Worker Collective of Mysore, India.

Nadia O'Brien (1), Sushena Reza-Paul (2), Pasha Akram (3), Seema Jai (3), Koppal T. Venukumarc (4), Mysore S. Venugopal (4), Mary P. Fatima (4), Robert Lorway (5); (1) BC-Centre for Excellence in HIV/AIDS (Vancouver, Canada); (2) University of Manitoba, Department of Community Health Sciences (Winnipeg, Canada); (3) Ashodaya Samithi (India); (4) Ashodaya Samithi (India); (5) University of Manitoba, Department of Community Health Sciences (Canada)

P2-S2.18 Are We Doing Enough to Cover Risk of STI/HIV Transmission from the Lovers" of Female Sexworkers (FSWs)? "

Mahesh Doddamane (1), Parinita Bhattacharjee (1), Dhanunjaya Rao (1); (1) Karnataka Health Promotion Trust (Bangalore, India)

P2-S2.19 Withdrawn

P2-S2.20 The Association Study of Job Mobility and HIV/STI prevention in female sex workers of Hunan province, China

Zhiju Zheng (1), Ning Jiang (1); (1) National Center for STD Control, China CDC (Nanjing City, China)

P2-S2.21 Traditional Devadasi" System Under Transition: Boon or Bane for HIV Prevention Programme?"

Kaveri Gurav (1), Elizabeth Cooper (2), Jennifer Junno (2), Derek Stein (2), Dhanujaya Rao Chintada (1), Mahesh Doddamane (1), Stephen Moses (2); (1) Karnataka Health Promotion Trust (Bangalore, India); (2) University of Manitoba (Winnipeg, Canada)

P2-S2.22 Innovations to Attract Young Female Sex Workers to Access STI Services in Drop in Centres (DIC): A Case Study from Bangalore, South India

Elizabeth Michael (1), Senthil Kumaran Murugan (2), Lakshmi Viswanatha (1), Pushpalatha R (3); (1) Karnataka Health Promotion Trust (Bangalore, India); (2) University of Manitoba (Winnipeg, Canada); (3) Swati Mahila Sangha (India)

P2-S2.23 Measuring the impact of HIV prevention programme on HIV/STI prevalence and condom use in Karnataka: A case-control approach

RAVI PRAKASH (1), Shajy Isac (1), BM Ramesh (1), Pradeep Banandur (1), Stephen Moses (1), Reynold Washington (1), Parinita Bhattacharjee (1); (1) Karnataka Health Promotion Trust (Bangalore, India)

Social and behavioural aspects of prevention

poster session 3 - General Population

P2-S3.01 STI Risk Among Persons Attending Burning Man in 2010

Julia L. Marcus (1), Kyle T. Bernstein (1), Susan S. Philip (1); (1) San Francisco Department of Public Health (San Francisco, USA)

P2-S3.02 Latent class analysis of sexual risk patterns among heterosexually-identified, socially marginalized men in urban, coastal Peru

Kelika Konda (1), David Celentano (2), Susan Kegeles (3), Thomas Coates (1), Carlos Caceres (4), NIMH Collaborative HIV/STD Prevention Trial Group (5); (1) UCLA (Lima, Peru); (2) Johns Hopkins University (USA); (3) UCSF (USA); (4) UPCH (Peru); (5) NIMH (USA)

P2-S3.03 Exploring Perceptions of the Social Determinants of STIs in African American Communities of the United States (U.S.)

Allison Friedman (1), Ann Forsythe (1), Jon Poehlman (2), Shelly Harris (2), Justin Smith (3), Jennifer Uhrig (2); (1) CDC (Atlanta, USA); (2) RTI International (USA); (3) University of North Carolina, Chapel Hill (USA)

P2-S3.04 Withdrawn

P2-S3.05 Association of STI-related Stigma and Shame to STI Testing and Partner Notification among Young Black Men in San Francisco

Sheri Lippman (1), Jessica Morris (1), Marguerita Lightfoot (1), Susan Philip (2); (1) University of California, San Francisco (San Francisco, USA); (2) San Francisco Department of Public Health, STD Prevention and Control Services (San Francisco, USA)

P2-S3.06 Exploring Sexual Identity Development of African American Male College Students Age 18-25 at a Historically Black College and University

Schenita Randolph (1), Carol Golin (2), Derrick Matthews (3); (1) North Carolina Agricultural and Technical State University (Greensboro, USA); (2) The University of North Carolina at Chapel Hill (Chapel Hill, USA); (3) The University of North Carolina at Chapel Hill (Chapel Hill, USA)

P2-S3.07 Responding to Problems of Sexual Violence and Vulnerability to HIV/AIDS within Crisis and Unstable Situations: A Case Study of Kenya's Post-election Violence

CHRISPUS MUSYOKA (1), Anita Mwendwa (2), Norah Kyalo (3); (1) Walden University/The Centre for Integrated Community Development and Outreach, CICDOT (Seattle, USA); (2) Moi University Teaching and Referral Hospital (Eldoret, Kenya); (3) University of Nairobi (Nairobi, Kenya)

P2-S3.08 Selling Sex on the Doorstep: Development Work for the Third British National Survey of Sexual Attitudes and Lifestyles (Natsal 3)

Clare Tanton (1), Andrew Phelps (2), Soazig Nicholson (2), Catherine Mercer (3), Pam Sonnenberg (3), Jessica Datta (4), Wendy Macdowall (4), Bob Erens (3), Kaye Wellings (4), Anne Johnson (3); (1) UCL (London, United Kingdom); (2) National Centre for Social Research (United Kingdom); (3) University College London (,United Kingdom); (4) London School of Hygiene & Tropical Medicine (United Kingdom)

P2-S3.09 MOBILITY AS PREDICTOR OF INVOLVEMNET IN HIGH RISK SEXUAL RISK BEHAVIOR

Zachary Kwena (1), Calvin Obuya (1); (1) Kenya Medical Research Institute (Kisumu, Kenya)

P2-S3.10 HSV-2 serologic testing and psychosocial harm: a systematic review

Kaile Ross (1), Anna Wald (1), Christine Johnston (1); (1) University of Washington (Seattle, USA)

P2-S3.11 STI-related risk behaviors and STI disparity between residents of Baltimore City and other urban cities in the U.S.

Maria Villarroel (1), Susan Rogers (2), Charles Turner (3); (1) Johns Hopkins University (Baltimore, USA); (2) RTI International (Washington, DC, USA); (3) City University of New York, (Queens College and the Graduate Center) (New York, USA)

P2-S3.12 CULTURE AND RESEARCH: HOW DO YOU MIX THEM?

Dionne Gesink (1), Priscilla McGilvery (2), Troy Tilley (3), Karen Saganiuk (3); (1) University of Toronto (Toronto, Canada); (2) Saddle Lake Health Center (Saddle Lake, Canada); (3) First Nations and Inuit Health, Health Canada (Saddle Lake, Canada)

P2-S3.13 Effective HIV and AIDs prevention: Is factors affecting the spread important?

Munir Bankole (1), Marian Bankole (2), Adeluola Adebawale (3), Godswill Iboma (4), Olorunfemi Olonire (5); (1) Ministry of Health Lagos (Alausa-Ikeja, Nigeria); (2) Nigerian Institute of Medical Research (Yaba, Nigeria); (3) University of Lagos (Idi-araba, Nigeria); (4) Ministry of Health Lagos State (Alausa-Ikeja, Nigeria); (5) Ministry of Health (Alausa-Ikeja, Nigeria)

Social and behavioural aspects of prevention

poster session 4 - Health Services Venue

Attendees

P2-S4.01 Epidemiological profile and motivations for HIV screening among people attending an anonymous HIV voluntary testing service in Cotonou, Benin

Djimon Marcel Zannou (1), Angèle Azon-Kouanou (1), Omodélé Marlène Alaye (1), Jocelyn Akakpo (1), Delore Azon (2), Evelyne Akinocho (2), Séverin Anagonou-Y (3); (1) Ambulatory treatment center of PLWHIV-CNHU (Cotonou, Benin); (2) National

Program to Fight against AIDS, Benin (Cotonou, Benin); (3) Microbiology laboratory-CNHU-Cotonou (Cotonou, Benin)

P2-S4.02 Don't look at your patients, look at their partners: Characteristics of sexual partnerships reported by people attending GUM clinics in England.

Catherine H Mercer (1), Catherine RH Aicken (1), Nicola Low (2), Claudia S Estcourt (3), Peter J White (4), Frances Keane (5), Gary Brook (6), Greta Rait (1), Jackie A Cassell (7); (1) University College London (London, United Kingdom); (2) University of Bern (Bern, Switzerland); (3) Barts and the London School of Medicine and Dentistry (London, United Kingdom); (4) Health Protection Agency (London, United Kingdom); (5) Royal Cornwall Hospitals NHS Trust (Truro, Cornwall, United Kingdom); (6) Central Middlesex Hospital (London, United Kingdom); (7) Brighton and Sussex Medical School (Brighton, United Kingdom)

P2-S4.03 Prevalence and Risk Factors for C. trachomatis (CT) Infection Among Female Medical Students and Women Attending Family Planning Clinics in Northern Italy

Alberto Bigliano (1), Giorgia Montrucchio (1), Roberta Moglia (2), Erika Concialdi (2), Cesare Bolla (2), Massimo Tramontano (3), Dennis V. Ferrero (4); (1) "Cardinal Massaja" Hospital / University of Torino (Asti, Italy); (2) "Cardinal Massaja" Hospital (Asti, Italy); (3) Family Planning Clinic, A.S.L. 19 (Asti, Italy); (4) University of the Pacific (Stockton, USA)

P2-S4.04 Motivational interviewing is effective for reducing high risk sexual behavior

Jens Boman (1), Helena Lindqvist (2), Astri Brandell-Eklund (3), Lars Forsberg (2), Elisabet Nylander (4); (1) Umeå University (Umeå, Sweden); (2) Karolinska Institute (Sweden); (3) Swedish National Institute of Public Health (Sweden); (4) Umeå University (Sweden)

P2-S4.05 Acceptability of Medical Male Circumcision among men attending an HIV voluntary counseling and testing center in Mysore, India

Purnima Madhivanan (1), Karl Krupp (1), Vijaya Srinivas (1), Jeffrey Klausner (2); (1) Public Health Research Institute of India (Mysore, India); (2) University of California, San Francisco (San Francisco, USA)

P2-S4.06 Knowledge of HSV-2 Serostatus in Asymptomatic Adults May Result in Change in Sexual Behavior and Possible Risk Reduction

Mary Gene Cuyugan (1), Wudeneh Mulugeta (1), Manju Thabolingam-Haridas (1), Tracey Wilson (1), Michael Augenbraun (1), Talie Elsass (1), Brett Cerniglia (1); (1) SUNY Downstate Medical Center (Brooklyn, USA)

P2-S4.07 Unsafe casual travel sex with discordant and concordant partners is common among visitors of a large STI outpatient clinic in Amsterdam; risk for international spread of STI

Anouk Urbanus (1), Titia Heijman (1), Gerard Sonder (2), Anneke van den Hoek (2); (1) Amsterdam Public Health Service (Amsterdam, Netherlands); (2) Amsterdam Public Health Service and Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center (AMC) (gsonder@ggd.amsterdam.nl, Netherlands)

P2-S4.08 Patterns and Correlates of Condom Use at Last Sex Episode in a Population Presenting for Voluntary HIV Counseling and Testing in Soweto, Johannesburg

Theogene Nshimiyimana (1), Essien Thandekile (1), Ingrid Katz (2), Neil Martinson (1), Glenda Gray (1), Guy de Bruyn (1); (1) Perinatal HIV Research Unit (Johannesburg, South Africa); (2) Harvard Medical School (USA)

P2-S4.09 Withdrawn

P2-S4.10 Characteristics associated with condom breakage/slippage or partial use during vaginal sex with main and non-main partners: findings from the Safe City Project Study

Laura D'Anna (1), Andrew Margolis (2), Lee Warner (2), Olga Korosteleva (1), Lydia O'Donnell (3), Cornelis Rietmeijer (4), Jeff Klausner (5), C. Kevin Malotte (1); (1) California State University, Long Beach (Long Beach, USA); (2) Centers for Disease Control and Prevention (Atlanta, USA); (3) Education Development Center (Boston, USA); (4) Denver Public Health (Denver, USA); (5) University of California San Francisco (San Francisco, USA)

Social and behavioural aspects of prevention

poster session 5 - High Risk Groups

P2-S5.01 A Qualitative Study of Barriers to Consistent Condom Use among HIV-1 Serodiscordant Couples in Kenya

Kenneth Ngure (1), Nelly Mugo (1), Connie Celum (2), Jared Baeten (2), Martina Morris (2), Owuor Olungah (3), Joyce Olenja (3), Harrison Tamooch (1), Bettina Shell-Duncan (2); (1) Kenyatta National Hospital (Nairobi, Kenya); (2) University of Washington (Washington, USA); (3) University of Nairobi (Nairobi, Kenya)

P2-S5.02 Confined Outreach Clinics: Increasing utilization of HIV/STI clinic services by IDUs in hard to reach rural settings - an example from North-East India

Collins Z Sono (1), Melody Lalawmpuii (1); (1) EHA-Project ORCHID (Dimapur, India)

P2-S5.03 Hyperfeminine and Vulnerable: Gender Identities and HIV/AIDS in Transgender Women in Bogotá, Colombia

John Harold Estrada-Montoya (1), Andrea García-Becerra (1); (1) Universidad Nacional de Colombia (Bogotá, Colombia)

P2-S5.04 Behavioral risks and HIV/AIDS knowledge in adolescent street children and their health implications

Faiza Naseem (1), Rana Ahmad (2), Audil Rashid (3); (1) Degree College for Women (Rawalpindi, Pakistan); (2) Street NGO (Quetta, Pakistan); (3) PMAS Arid Agriculture University (Rawalpindi, Pakistan)

P2-S5.05 Risk Profiles of Winnipeg Street Populations: A latent class analysis

Suellen Hopfer (1), John Wylie (2), Xianming Tan (1); (1) Pennsylvania State University (State College, USA); (2) Cadham Provincial Laboratory/University of Manitoba (Winnipeg, Canada)

P2-S5.06 Behavioral interventions for reducing HIV infection in workers in occupational settings, a Cochrane systematic review.

Olumuyiwa Ojo (1), Jos Verbeek (2), Kimmo Rasanen (1), Jarmo Heikkinen (1), Leena Isotalo (3), Nomusa Mngoma (4), Eija Ruotsalainen (5); (1) University of Eastern Finland (Kuopio, Finland); (2) Finnish Institute of Occupational health/Cochrane Occupational safety and health group (Kuopio, Finland); (3) Finnish Institute of Occupational Health

(Helsinki, Finland); (4) Queen's University (Kingston, Canada); (5) Kuopio University Hospital (Kuopio, Finland)

P2-S5.07 Cost of the Avahan HIV prevention programme for high risk groups: results from 23 districts from four southern states in India

Sudha Chandrashekar (1), Anna Vassall (2), Bhaskar Reddy (3), Govindraj Shetty (4), Michel Alary (5), Peter Vickerman (2); (1) London School of Hygiene and Tropical Medicine, St. John's Research Institutel(SJRI) (Bangalore, India); (2) London School of Hygiene and Tropical Medicine (London, India); (3) Karnataka Health Promotion trust (Bangalore, India); (4) Karnataka Health Promotion trust (Bangalore, India); (5) Centre hospitalier affilié universitaire de Québec (Quebec, Canada)

P2-S5.08 Knowledge about STD transmission and clinical characteristics among conscripts in Brazil, 2007

Denis Ribeiro (1), Valdir Monteiro Pinto (1), Angelica Espinosa (2), Erica Rezende (3), Gerson Pereira (1), Marcelo Barbosa (4); (1) Ministry of Health (Brasilia, Brazil); (2) UFES (Brazil); (3) Ministry of Health (Brazil); (4) Federal District Government (Brazil)

P2-S5.09 Transgenders and HIV: A Literature Review of HIV Risk Behaviors and Prevalence Rates

Saira Butt (1), Leandro Mena (1), Christina Muzny (2); (1) University of Mississippi Medical Center (Jackson, USA); (2) University of Alabama at Birmingham (Birmingham, USA)

P2-S5.10 Sexual behaviours among injecting drug users (IDUs) in North-East India

Ritu Kumar Mishra (1); (1) Emmanuel Hospital Association (Guwahati, India)

Social and behavioural aspects of prevention

poster session 6 - Men who Have Sex with Men

P2-S6.01 Social, behavioral characteristics, and seroprevalence of HIV infection among men who have sex with men (MSM): about 92 cases collected in a community medical center named Centre Oasis" of Association African Solidarité (AAS), Ouagadougou, Burkina Faso."

Ter Tiero Elias Dah (1), Tanga Samuel Koala (2); (1) Association African Solidarité (Ouagadougou, Burkina Faso); (2) GGlobal Fund, Burkina Faso (Ouagadougou, Burkina Faso)

P2-S6.02 Use of a computer alert increases detection of early, asymptomatic syphilis among higher risk men who have sex with men

Melanie Bissessor (1), Christopher Fairley (2), David Leslie (3), Marcus Chen (2); (1) Melbourne Sexual Health centre (Carlton, Australia); (2) MSHC (Australia); (3) VIDRL (Aruba)

P2-S6.03 Withdrawn

P2-S6.04 Needs Assessment on STI Prevention Services among Men Who Have Sex with Men with HIV in Guatemala City, 2010

Nasim Farach (1), Sabrina Boyce (1), Clare Barrington (2), Cesar Galindo (3), Gabriela Paz-Bailey (1); (1) TEPHINET (Tegucigalpa, Honduras); (2) University of North Carolina (Chapel Hill, USA); (3) Universidad del Valle (Guatemala City, Guatemala)

P2-S6.05 Exploring Dynamics around Female Condom Use for Anal Sex among MSM

Suresh Babu Kokku (1), Saroj Tucker (1), Sawrup Punyam (1); (1) India HIV/AIDS Alliance (Hyderabad, India)

P2-S6.06 Prevalence, Incidence and Predictors of Sexual Assault in the Community-based HIM Cohort of Sydney Homosexual Men

David Templeton (1), Fengyi Jin (1), Garrett Prestage (1), Mary Poynten (1); (1) National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales (Darlinghurst, Australia)

P2-S6.07 Intentional viral sorting as a frequently practiced HIV risk reduction strategy among HIV-positive MSM with HIV discordant and concordant partners

Udi Davidovich (1), Wijnand Van den Boom (1), Robert Witlox (2), Ineke Stolte (3); (1) Public Health Service Amsterdam (Amsterdam, Netherlands); (2) Dutch HIV Association (Amsterdam, Netherlands); (3) Public Health Service Amsterdam (Amsterdam, Netherlands)

P2-S6.08 Examining Risk in High Risk" Populations: Measuring Sexual behavior among Men who have Sex with Men"

Joshua G Rosenberger (1), Michael Reece (1), David S. Novak (2), Debby Herbenick (1), J. Dennis Fortenberry (3), Barbara Van Der Pol (1); (1) Indiana University (Bloomington, USA); (2) Online Buddies Inc. (Cambridge, USA); (3) Indiana University School of Medicine (Indianapolis, USA)

P2-S6.09 FACTORS ASSOCIATED WITH HIV SEXUAL RISK MANAGEMENT AMONG HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN LIVING IN QUEBEC AND WHO USE INTERNET TO FIND SEXUAL PARTNERS

Marie-Claude Drouin (1), Alain Léobon (2), Louis-Robert Frigault (3), Joseph J. Lévy (4); (1) Institut national de santé publique du Québec (Montréal, Canada); (2) CNRS: Centre national de recherche sociale (France); (3) Direction de santé publique de Montréal (Canada); (4) Université du Québec à Montréal (Canada)

P2-S6.10 Risks and Attributable Fractions for HIV Infection among MSM at a LGBT Health Center: Chicago, 2010

Anna Hotton (1), Beau Gratzner (1), Cameron Estrich (2), Supriya D. Mehta (2); (1) Howard Brown Health Center/University of Illinois Chicago School of Public Health (Chicago, USA); (2) University of Illinois Chicago School of Public Health (Chicago, USA)

P2-S6.11 The Cost-Effectiveness of Screening Men Who Have Sex with Men for Rectal Chlamydial and Gonococcal Infection to Prevent Human Immunodeficiency Virus (HIV) Infection

Thomas Gift (1), Kyle Bernstein (2), Harrell Chesson (1), Julia Marcus (2), Sharon Pipkin (2), Charlotte Kent (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) San Francisco Department of Public Health (San Francisco, USA)

P2-S6.12 Sexual debut and sexual health: Is early age of first anal intercourse associated with heightened HIV vulnerability among gay men?

Anthony Lyons (1), Marian Pitts (1), Jeffrey Grierson (1), Anthony Smith (1), Stephen McNally (1), Murray Couch (1); (1) La Trobe University (Melbourne, Australia)

P2-S6.13 Gay men's assessment of sexual and social risks in the context of a recent HIV-positive diagnosis

Daniel Grace (1), Michael Kwag (2), Malcolm Steinberg (3), Michael Rekart (2); (1) BC Centre for Disease Control; Simon Fraser University; University of British Columbia (Vancouver, Canada); (2) BC Centre for Disease Control; University of British Columbia (Canada); (3) BC Centre for Disease Control; Simon Fraser University (Canada)

P2-S6.14 Sexual behaviour, Vulnerabilities and Clinical intervention among Men who have Sex with Men (MSM) attending STI clinic; study from South India.

V Sam Prasad (1), shekhar s (2); (1) Strategic Partnerships (Chennai, India); (2) Swam (India)

P2-S6.15 Investigating the critical programme components of HIV prevention programme among MSM-Ts in Bangalore, Karnataka

Ravi Prakash (1), Shajy Isac (1), BM Ramesh (1), Stephen Moses (1), Reynold Washington (1), Parinita Bhattacharjee (1), Bharat Shetty (1), Sunil Kumar (1); (1) Karnataka Health Promotion Trust (Bangalore, India)

**Social and behavioural aspects of prevention
poster session 7 - Persons living with HIV/AIDS**

P2-S7.01 CONDOM USE AND THE DISPOSITION TO IT AMONG HIV POSITIVE WOMEN ACCESSING CARE AT AN ANTIRETROVIRAL CLINIC IN IBADAN, NIGERIA

Adeyinka O. Adefolarin (1), Oyedunni S. Arulogun (2), Isaac F. Adewole (1); (1) AIDS Prevention Initiative In Nigeria Plus (Ibadan, Nigeria); (2) UNUniversity of Ibadan, Faculty of Public Health (Ibadan, Nigeria)

P2-S7.02 Effectiveness of communication in tackling stigma and discrimination among people living with HIV and AIDS and health care providers in Nigeria

Funmilayo Olaosebikan (2), Charles Uwakwe (1); (1) University of Ibadan (Ibadan, Nigeria); (2) Harvard PEPFAR-APIN PLUS

P2-S7.03 Pregnancy and contraceptive experiences of women living with HIV in Mexico

Marieke van Dijk (1), Kate Wilson (1), Xipatl Contreras (1), Allison Ettenger (1), H. Dawn Fukuda (1), Sandra García (1); (1) Population Council Mexico Office (Mexico D.F., Mexico)

P2-S7.04 Maximizing the Impact of Positive Prevention Practices in People Living with HIV: Learning's from Karnataka, South India

Krishnamurthy Jayanna (1), Reynold Washington (1), Stephen Moses (2); (1) Karnataka Health Promotion Trust (Bangalore, India); (2) University of Manitoba (Winnipeg, Canada)

P2-S7.05 Assessing the Quality of Life of HIV/AIDS Patients on ARV Therapy and Their Caregivers at the National Hospital Abuja

Chioma Asuzu (1), Kingsley Arogunyo (2); (1) University of Ibadan, Ibadan (Ibadan, Nigeria); (2) I & R Communications

P2-S7.06 FACTORIAL VALIDITY AND INTERNAL CONSISTENCY OF THE SCALE OF ATTITUDE TOWARD PEOPLE LIVING WITH HIV AND AIDS

Marianne Beaulieu (1), Alix Adrien (2), Louise Potvin (1), Clément Dassa (1); (1) Université de Montréal (Montréal, Canada); (2) Direction de Santé Publique de Montréal (Montréal, Canada)

P2-S7.07 Adherence and difficulties with antiretroviral medication in an Australian sample of people living with HIV

Anthony Lyons (1), Jeffrey Grierson (1), Rachel Koelmeye (1), Anthony Smith (1), Marian Pitts (1); (1) La Trobe University (Melbourne, Australia)

P2-S7.08 Psychosocial support and therapeutic adherence of hiv positive pregnant women at HIV Treatment Hospital of Suru Léré in Cotonou (Benin)

KPATCHAVI Adolphe Codjo (1), SACCA SIDI Mistourath (2); (1) University of Abomey Calavi Benin (Cotonou, Benin); (2) University of Abomey Calavi (Cotonou, Benin)

**Social and behavioural aspects of prevention
poster session 8 - Technology and Media**

P2-S8.01 Withdrawn

P2-S8.02 Withdrawn

P2-S8.03 Did You Hear about the 2010 STD Treatment Guidelines? Re-strategizing How We e-Communicate about STD Guidance

Melissa A. Habel (1), Lisa Richman (1), Suzanne Haecker (1), Rohit Verma (1), Anne Meneghetti (2), Rachel Kachur (1), Blanche Collins (1), Rheta Barnes (1), Natarsha Thompson (1), Kimberly Workowski (1); (1) CDC (Atlanta, USA); (2) Epocrates (San Mateo, USA)

P2-S8.04 GYT (Get Yourself Tested) Campaign: Getting Young People Talking and Tested and Sparking a Social Movement

Allison Friedman (1), Melissa Habel (2), Rachel Kachur (2), Mary McFarlane (2), Lily Williamson (3), Meredith Mishel (4), Sarah Levine (5), Alexa Binns (5), Colleen Kapsimalis (2), Ashlesha Patel (6); (1) Centers for Disease Control & Prevention (Atlanta, USA); (2) CDC (Atlanta, USA); (3) MTV Networks (New York, USA); (4) Henry J. Kaiser Family Foundation (USA); (5) Kaiser Family Foundation (USA); (6) Planned Parenthood Federation of America (USA)

P2-S8.05 Use of Cellular Telephones in a Study of High-Risk Patients

Dottie Craig (1), Devon Hensel (1), J. Dennis Fortenberry (1), Jarek Harezlak (1), Kendra Jones (1); (1) Indiana University School of Medicine (Indianapolis, USA)

P2-S8.06 USING ELECTRONIC DIARIES PROSPECTIVELY TO CAPTURE STI-RELATED PHENOMENOLOGY

Devon Hensel (1), J. Dennis Fortenberry (1), Jarek Harezlak (1), Kendra Jones (1), Dottie Craig (1); (1) Indiana University School of Medicine (Indianapolis, USA)

P2-S8.07 Keeping participants on board: optimising uptake by automated respondent reminders in an Internet-based Chlamydia Screening in the Netherlands

Rik Koekenbier (1), Nynke Dokkum (1), Eline Op de Coul (2), Jan van Bergen (3), Elfi Brouwers (4), Han Fennema (1), Hannelore Götz (5), Christian Hoebe (4), Lydia Pars (3), Sander van Ravesteijn (5); (1) Amsterdam public health service (Amsterdam, Netherlands); (2) RIVM (Netherlands); (3) STI AIDS Netherlands (Netherlands); (4) South-Limburg public health service (Netherlands); (5) Rotterdam Rijnmond public health service (Netherlands)

P2-S8.08 Reducing the Stigma of Herpes Simplex Virus (HSV) Infection through Brief Publicly-Generated Videos

Lee S. Shearer (1), Lisa W. Simmons (2), Adrian Mindel (3), Lawrence R. Stanberry (2), Susan L. Rosenthal (2); (1) New York Presbyterian Hospital - Columbia University Medical Center (New York, USA); (2) Columbia University (New York, USA); (3) University of Sydney (Sydney, Australia)

P2-S8.09 What are they asking? An analysis of STD related calls to CDC-INFO.

Rachel Kachur (1), Natarsha Thompson (2), Suzanne Haecker (2), Rasaan Jones (2); (1) Centers for Disease Control & Prevention (Atlanta, USA); (2) CDC (USA)

P2-S8.10 Measuring Social Media Efforts: Beyond Click Throughs

Rachel Kachur (1), Lisa Richman (1), Melissa Hable (1), Rohit Verma (1), Allison Friedman (1), Colleen Kapsimalis (1), Mary McFarlane (1), Ashlesha Patel (2); (1) Centers for Disease Control & Prevention (Atlanta, USA); (2) Planned Parenthood Federation of America (USA)

P2-S8.11 Co-creating the Dutch Safe Sex Campaign 2011: Using social media and municipal health centres (MHC) to improve implementation intentions of condom use.

Filippo Zimbile (1), Erwin Fisser (1); (1) Sti Aids The Netherlands (Amsterdam, Netherlands)

P2-S8.12 Feasibility of Using Cell Phones for Daily Data Collection within Adolescent Cohort Studies

Charles Malotte (1), Allison Cutting (2), Steven Huettner (2), Pamela Matson (2), Jonathan Ellen (2); (1) Johns Hopkins University (Baltimore, USA); (2) Johns Hopkins University (USA)

**Social and behavioural aspects of prevention
poster session 9 - Women**

P2-S9.01 Withdrawn

P2-S9.02 Syphilis and Pregnancy: Social Portrait of the Disease in Belarus

Iryna Tsikhanouskaya (1); (1) Vitebsk State Medical University (Vitebsk, Belarus)

P2-S9.03 The Sex Lives of Emergency Contraception Users in the U.S., 2006-2008

Melissa Habel (1), Jami S. Leichter (1); (1) CDC (Atlanta, USA)

P2-S9.04 Condom Nonuse is Associated with Low Perception of Risk for STIs in Young Sexually Active Women

Cherrie Boyer (1), Lance Pollack (1), Mary-Ann Shafer (1); (1) University of California, San Francisco (San Francisco, USA)

P2-S9.05 Qualitative Assessment of Anal Intercourse and Rectal Lubricant Use Among Women in Los Angeles

Marjan Javanbakht (1), Joelle Brown (2), Bitu Amani (1), Shauna Stahlman (1), Pamina Gorbach (1), Stephen Brown (3), Colleen Murphy (3), Marjan Hezareh (3); (1) University of California Los Angeles (Los Angeles, USA); (2) University of California Los Angeles (USA); (3) AIDS Research Alliance (USA)

P2-S9.06 Vaginal Film Microbicides for HIV Prevention: A Mixed Methods Study of Women's Preferences

Maria Fan (1), Lindsay Ferguson (1), Lisa Rohan (1), Leslie Meyn (2), Sharon Hillier (1); (1) University of Pittsburgh (Pittsburgh, USA); (2) Magee-Womens Research Institute (Pittsburgh, USA)

P2-S9.07 Economic Risk Factors for Syphilis Infection Among Pregnant Women in Rural Haiti

Jennifer Mark (1), Lambert Wesler (2), Cate Oswald (3), Fernet Léandre (2), Patrice Nevil (2), Didi Bertrand (2), Jessye Bertrand (2), Frederick Boehm (3), Mary C Smith Fawzi (4); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Zanmi Lasante Sociomedical Complex (Cange, Haiti); (3) Partners In Health (Boston, USA); (4) Partners In Health / Harvard Medical School (Boston, USA)

P2-S9.08 Baby Daddy Sex as a Risk Factor for HIV/STDs

Paige Padgett (1), Jan Risser (1); (1) University of Texas School of Public Health (Houston, USA)

P2-S9.09 Help me understand your lab results": An exploratory, qualitative study of discordance between biologic and self-reported measures of semen exposure in Jamaica"

Althea Bailey (1), Margaret Snead (2), Elizabeth Costenbader (3), Malene Townsend (1), Clive Anderson (4), Lee Warner (2), Tina Hylton-Kong (4), Markus Steiner (3); (1) University of the West Indies Mona (Kingston, Jamaica); (2) Centres for Disease Control (Atlanta, USA); (3) Family Health International (Durham, USA); (4) Comprehensive Health Centre (Kingston, Jamaica)

P2-S9.10 HIV testing behaviors among undocumented Central American immigrant women in Houston, Texas, 2010

Jane Montealegre (1), Jan Risser (1), Beatrice J. Selwyn (1); (1) The University of Texas School of Public Health (Houston, USA)

P2-S9.11 HIV INFECTION AND VIOLENCE AGAINST MARRIED/COHABITING WOMEN: FINDINGS FROM A NATIONAL HOUSEHOLD SURVEY IN RWANDA

Jeanne Françoise KAYIBANDA (1), Michel Alary (1), Raphaël Bitera (1); (1) Centre de recherche FRSQ du CHA universitaire de Québec (Québec, Canada)

P2-S9.12 Descriptions of Behaviors by Partner Type for Ethnic Minority Female Adolescents with Histories of Abuse

Jennifer Collins (1), Jane Dimmitt Champion (1); (1) Texas Tech University Health Sciences Center (Lubbock, USA)

P2-S9.13 African-and Mexican-American Adolescent Women with STI and a History of Abuse: Biological Outcome of a Randomized Trial of Behavioral Intervention

Jane Dimmitt Champion (1), Jennifer Collins (1); (1) Texas Tech University Health Science Center (Lubbock, USA)

P2-S9.14 A Qualitative, Longitudinal Study of Post-diagnosis Reactions Among HSV-2 Serologic Positive Women

Juanita Ebert Brand (1), Barbara Van Der Pol (2), Gregory D. Zimet PhD (3), Kenneth H. Fife MD, PhD (3), Alexis Roth-Graneros MPH (3); (1) Ball State University/Marion County Public Health Department (New Palestine, USA); (2) Indiana University Medical Center & IU-Bloomington (Bloomington, USA) ; (3) Indiana University School of Medicine (Indianapolis, USA)

Clinical sciences poster session 1 -

Chlamydia trachomatis, Neisseria gonorrhoeae and related syndromes

P3-S1.01 Prevalence Of Genital Chlamydia And Gonococcal Infections In at-risk Women in the Kumasi Metropolis of Ghana

Baafuor Opoku (1); (1) KNUST-School of Medical Sciences (Kumasi, Ghana)

P3-S1.02 Evaluation of Screening Tests for Chlamydia Trachomatis: Bias Associated with the Patient Infected Status Algorithm

Alula Hadgu (1), Nandini Dendukuri (2), Liangliang Wang (3); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) McGill University (Montreal, Canada); (3) University of British Columbia (Vancouver, Canada)

P3-S1.03 Mixed infections in women with Chlamydial genital infection

Abbos Kasymov (1), Olim Kasymov (1); (1) Institute of Postgraduate Medical Education (Dushanbe, Tajikistan)

P3-S1.04 Abnormal Prostate Cancer Markers in a Man with Symptomatic C. trachomatis Infection

Vitaly Smelov (1), Andrey Novikov (1); (1) Medical Academy of Postgraduate Studies (St. Petersburg, Russian Federation)

P3-S1.05 Incidence of STI in patients with chronic prostatitis

Alena Khaikova (1), Sergei Sohar (1), Viktoryia Kazlouskaya (1); (1) Gomel State Medical University (Gomel, Belgium)

P3-S1.06 Withdrawn

P3-S1.07 Chlamydia trachomatis Serovar Distribution and Other Sexually Transmitted Coinfections in Subjects Attending a STD Outpatients Clinic in Italy.

Antonella Marangoni (1), Manuela Donati (1), Antonietta D'Antuono (1), Antonietta Di Francesco (1), Fabio Ostanello (1), Claudio Foschi (1), Paola Nardini (1), Nicoletta Banzola (1), Roberto Cevenini (1); (1) University of Bologna (Bologna, Italy)

P3-S1.08 Withdrawn

P3-S1.09 Validation of Cobas® 4800 HPV and CT/NG Test in Clinical Samples

Miren Basaras (1), Elisabete Arrese (1), Daniel Andia (2), Silvia Hernaez (2), Valentin Esteban (2), Marimar Camara (3), Ramón Cisterna (4); (1) Universidad del País Vasco (Leioa-Bizkaia, Spain); (2) Hospital de Basurto (Spain); (3) Cantro de ETS Bombero Etxaniz (Spain); (4) Hospital de Basurto. Universidad del País Vasco (Spain)

P3-S1.10 Using Electronic Medical Record Data To Guide Expedited Partner Therapy Implementation in an Urban STD Clinic System, 2009

Tiffani Mulder (1), Kimberly Johnson (2), Anne Lifflander (2), Julia Schillinger (3), Meighan Rogers (2), Susan Blank (4); (1) US Centers for Disease Control and Prevention (Atlanta, USA); (2) New York City Department of Health (New York, USA); (3) NYC Department of Health/US Centers for Disease Control (New York, USA); (4) NYC Department of Health/US Centers for Disease Control and Prevention (New York, USA)

P3-S1.11 Percent Additional Test Positive Following Positive Combo 2 Chlamydia (CT) and Gonorrhea (GC) Specimens: Assessing the Impact of Prevalence

Robert Johnson (1), Daphne Ware (2), Leandro Mena (3), Fujie Xu (1); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Mississippi State Public Health Laboratory (USA); (3) University of Mississippi Medical Center (USA)

P3-S1.12 High Concordance of Test Results of the Chlamydia trachomatis Detection and Genotyping Kit Compared to the COBAS Amplicor CT/NG Test

Laura van Dommelen (1), Antoinette A.T.P. Brink (2), Frank H. van Tiel (2), Wim G.V. Quint (3), Servaas A. Morré (4), Petra F. Wolffs (2), Christian C.J.P.A. Hoebe (5); (1) PAMM (Veldhoven, Netherlands); (2) Maastricht University Medical Centre (Netherlands); (3) DDL Diagnostic Laboratory (Netherlands); (4) VU University Medical Center (Netherlands); (5) South Limburg Public Health Service (Netherlands)

P3-S1.13 Establishment of a protocol for the detection of Chlamydia trachomatis in semen specimens using the cobas® 4800 CT/NG test

Bertille de Barbeyrac (1), Virginie Mehats (1), Aline Papaxanthos (2), Cécile Bébéar (1); (1) Inra-Université de Bordeaux (Bordeaux, France); (2) CHU Bordeaux (Bordeaux, France)

P3-S1.14 Evaluation of the platform cobas® 4800 CT/NG test for detecting Chlamydia trachomatis in urogenital samples

Bertille de Barbeyrac (1), Virginie Mehats (1), Maïthé Clerc (1), Chloé Le Roy (1), Cécile Bébéar (1); (1) Inra-Université de Bordeaux (Bordeaux, France)

P3-S1.15 THE MOLECULAR DIAGNOSIS OF RECTAL GC AND CT INFECTIONS USING THE FTA ELUTE CARD FOR SPECIMEN COLLECTION AND THE REAL-TIME MULTIPLEX PCR FOR DETECTION

Kai-Hua Chi (1), Cheng-Yen Chen (1), Tun Ye (1), Eli Nachamkin (1), Ron Ballard (1); (1) CDC (Atlanta, USA)

P3-S1.16 Comparison of the Abbott m2000 RealTime CT Assay for Chlamydia trachomatis monitoring in Tanzania compared to the Roche Amplicor CT Assay.

Patricia Agreda (1), Laura Dize (1), Sheila West (1), James A. Williams (2), Barbara Van Der Pol (2), Charlotte A. Gaydos (1), Mathilda Barnes (1); (1) Johns Hopkins University (Baltimore, USA); (2) Indiana University (USA)

P3-S1.17 Syndromic Management of Cervicitis and Vaginal Discharge at a STI Clinic in Jamaica: Low Cure Rates for Chlamydial Infection and Trichomoniasis

Marcia Hobbs (1), Clive Anderson (2), Tina Hylton-Kong (2), Shashauna Eastman (2), Kimberly Rich (1), Maria Gallo (3), Jennifer Legardy-Williams (3), Elizabeth Costenbader (4), Markus Steiner (4), Lee Warner (3); (1) University of North Carolina (Chapel Hill, USA); (2) Comprehensive Health Centre, Center of Excellence (Kingston, Jamaica); (3) Centers for Disease Control and Prevention (USA); (4) Family Health International (Research Triangle Park, USA)

P3-S1.18 Side Effects of Doxycycline in Adolescents Treated for Pelvic Inflammatory Disease

William Risser (1), Jan Risser (2); (1) Univ. of Texas Medical School at Houston (Houston, USA); (2) Univ. of Texas School of Public Health (USA)

P3-S1.19 Evaluation of the cobas® 4800 CT/NG Test using Clinician and Self-Collected Vaginal Swabs, Cervical Specimens in PreservCyt Solution, and Pharyngeal Throat Wash Specimens

Mark Krevolin (1), Art Sunhachawee (1), David Hardy (1), Jim Pane (1), Elizabeth Cervantes (1), Rashmi Kotadia (1), Snehal Joshi (1), Randi Puckett (1), Oliver Liesenfeld (1); (1) Roche Molecular Systems (Pleasanton, USA)

P3-S1.20 Etiology of Urethral Discharge syndrome and its association with sexual practices among males attending STI clinics in India

Ravi Kumar (1), Prabhakar Parimi (2), Prakash Narayanan (3), Anjana Das (3), Anup Gurung (3), Gururaj Rao (4), Arun Risbud (4); (1) Family Health International (New Delhi, India); (2) HIV AIDS Alliance (Hyderabad, India); (3) Family Health International (New Delhi, India); (4) National AIDS Research Institute (Pune, India)

P3-S1.21 Non-culture based Neisseria gonorrhoeae antimicrobial resistance surveillance.

Namraj Goire (1), Kevin Freeman (2), John Tapsall (3), Stephen Lambert (1), Michael Nissen (4), Theo Sloots (1), David Whiley (1); (1) Queensland Children's Medical Research Institute/Sir Albert Sakzewski Virus Research Centre (Brisbane, Australia); (2) Royal Darwin Hospital (Darwin, Australia); (3) Prince of Wales Hospital (Sydney, Australia); (4) Pathology Queensland Central, Royal Brisbane and Women's Hospital Campus (Brisbane, Australia)

P3-S1.22 Evaluation of performance of six commercial assays for detection of characterized isolates of *Neisseria gonorrhoeae* and other *Neisseria* species

Sepehr Tabrizi (1), Magnus Unemo (2), Athena Limnios (3), Stig-Ove Hjelmvoll (4), Suzanne Garland (1), John Tapsall (3); (1) The Royal Women's hospital (Parkville, Australia); (2) Örebro University Hospital (Örebro, Sweden); (3) The Prince of Wales Hospital (Randwick, Australia); (4) University Hospital of North Norway (Tromsø, Norway)

P3-S1.23 *Mycoplasma genitalium* in South African Men with and without Symptoms of Urethritis: Diagnosis and Bacterial Load

Marie Cecilia le Roux (1), Anvir Adam (2), Anwar Hoosen (3); (1) University of Limpopo (Medunsa Campus) (Pretoria, South Africa); (2) Private Medical Practice, Silverton (Pretoria, South Africa); (3) University of Pretoria

P3-S1.24 Cost Effectiveness of Self-taken Vaginal Swabs using GenProbe AC2 Assay vs Clinician Taken Urethral and Endocervical Swabs for Detection of Gonorrhoea

Janet Wilson (2), Claire Hulme (1), Catherine Stewart (2), Sarah Schoeman (2), Mark Wilcox (2); (1) University of Leeds (Leeds, United Kingdom); (2) Leeds General Infirmary (Leeds, United Kingdom)

P3-S1.25 Evaluation of Real time PCR for Detection of Five Sexually Transmitted Diseases in Abidjan, Ivory Coast

Solange KAKOU-NGAZOA (1), Solange Kakou-Ngazoa (2); (1) Institut Pasteur Abidjan (Abidjan, Côte d'Ivoire); (2) Institut Pasteur (Côte d'Ivoire)

P3-S1.26 Novel *Chlamydia trachomatis* Point of Care Rapid Test Shows Disappointingly Low Clinical Sensitivity in Urogenital Chlamydia Infections in Paramaribo, Suriname

Jannie van der Helm (1), Leslie Sabajo (2), Servaas Morré (3), Antoon Grunberg (4), Arjen Speksnijder (1), Henry de Vries (5); (1) Health Service Amsterdam (Amsterdam, Netherlands); (2) Dermatology Service, Ministry of Health (Suriname); (3) VU University Medical Center (Netherlands); (4) Lobi Foundation (Suriname); (5) Health Service Amsterdam, Academic Medical Center, University of Amsterdam (Netherlands)

P3-S1.27 Is Antimicrobial Resistance in *Chlamydia trachomatis* a Reality?

Rachel Pitt (1), Sarah Alexander (2), Paddy Horner (3), Catherine Ison (2); (1) Health Protection Agency -Cfl (London, United Kingdom); (2) Health Protection Agency - Cfl (United Kingdom); (3) University of Bristol (United Kingdom)

P3-S1.28 Is Urethritis of Unknown Etiology Caused by Bacteria Associated with Bacterial Vaginosis?

Maria Frølund (1), Raluca Datcu (1), Peter Ahrens (1), Peter Lidbrink (2), Eva Björnelius (2), Jørgen Skov Jensen (1); (1) Statens Serum Institut (Copenhagen S, Denmark); (2) Karolinska University Hospital (Sweden)

P3-S1.29 Effectiveness of Gentamicin for Gonorrhoea Treatment: a Systematic Review

Robert Kirkcaldy (1), Deborah Dowell (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P3-S1.30 Successful Use of Non-Invasive Self Obtained Glans/Meatal Dry FLOQSwabs (COPAN) For CT/NG Detection With The BD ProbeTec ET Assay In Northern Italy

Alberto Biglino (1), Giorgia Montrucchio (1), Roberta Moglia (1), Erika Concialdi (1), Cesare Bolla (1), Luca Oddone (1), Dennis V. Ferrero (2); (1) Infectious Diseases Unit, "Cardinal Massaja" Hospital, Asti (Italy); (2) University of the Pacific, Stockton, California, USA

P3-S1.31 Comparison of Copan UriSwab with BD ProbeTec Urine Preservative Transport Kit for preservation and detection of CT and NG In The ProbeTec assay

Santina Castriciano (1), Giorgia Montrucchio (2), Roberta Moglia (2), Erika Concialdi (2), Luca Oddone (2), Cesare Bolla (3), Alberto Biglino (3); (1) Copan Italia SpA (Brescia, Italy); (2) Cardinal Massaja" Hospital (Asti, Italy); (3) Cardinal Massaja Hospital (Asti, Italy)

P3-S1.32 A Validation Study of the Gen-Probe APTIMA Combo2 (AC2) Assay for Detecting *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in Dry Swabs

Lisa Cosentino (1), Jane R. Schwebke (2), Marcia M. Hobbs (3), Sharon L. Hillier (4); (1) Magee Womens Research Institute (Pittsburgh, USA); (2) University of Alabama (Birmingham, USA); (3) University of North Carolina (Chapel Hill, USA); (4) University of Pittsburgh/Magee Womens Research Institute (Pittsburgh, USA)

P3-S1.33 Evaluation of the Roche cobas 4800 for the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae using Minimally Invasive Samples in Women

Laura Hires (1), Barbara Van Der Pol (1), Stephanie Taylor (2), Rebecca Lillis (2), Barbara Body (3); (1) Indiana University School of Public Health (Bloomington, USA); (2) Louisiana State University Health Sciences Center (New Orleans, USA); (3) Laboratory Corporation of American (Burlington, USA)

P3-S1.34 Evaluation of the Roche cobas 4800 for the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae using Endocervical Specimens

Amy Pantone (1), Barbara Van Der Pol (1), Rebecca Lillis (2), Barbara Loyd (3), Melinda B. Nye (3), Stephanie Taylor (2); (1) Indiana University School of Public Health (Bloomington, USA); (2) Louisiana State University Health Sciences Center (New Orleans, USA); (3) Laboratory Corporation of America (Burlington, USA)

P3-S1.35 Systemic and Mucosal IgG and IgA Antibody Responses in Genital Chlamydia Trachomatis Infection

Rebecca Wiggins (1), Georgina Morris (2), Laura Habgood (3), Charles Lacey (2); (1) University of York (York, United Kingdom); (2) Hull York Medical School (United Kingdom); (3) Monksgate Health Centre (United Kingdom)

P3-S1.36 ASSESSING THE DIAGNOSIS AND TREATMENT OF URETHRITIS AMONG MEN ATTENDING AN URBAN STD CLINIC

Bruce W. Furness (1), Edward A. Sheriff (2), Shukdeo Sankar (3), Nnemdi Kamanu Elias (3); (1) CDC/NCHHSTP/DSTDP/ESB/FEU (Washington, USA); (2) George Washington University (Washington, USA); (3) District of Columbia Department of Health (Washington, USA)

P3-S1.37 The role of microscopy in the diagnosis of proctitis amongst men who have sex with men (MSM). A retrospective review of rectal screening.

Derval Harte (1), Paddy Horner (2); (1) University Hospital Bristol trust (Bristol, United Kingdom); (2) University of Bristol

P3-S1.38 Molecular detection of Chlamydia trachomatis and Neisseria gonorrhoea in rectal swabs and (self)collected vaginal swabs with the Cobas 4800 system

Servaas Morre (1); (1) VU University Medical Center Amsterdam (Amsterdam, Netherlands)

P3-S1.39 Comparison of Strategies for Empiric Chlamydia trachomatis (CT) Treatment in the Denver Metro Health Clinic: Treat MPC vs. Increased WBC on Wet Prep

Karen Peterson (1), Theresa Mickiewicz (1); (1) Denver Public Health (Denver, USA)

P3-S1.40 Frequency and predictors of recommended gonorrhea therapies in Washington State

Roxanne Kerani (1), Mark Stenger (2), Mark Aubin (2), Matthew Golden (3); (1) Public Health - Seattle & King County (Seattle, USA); (2) Washington State Department of Health (Olympia, USA); (3) University of Washington (Seattle, USA)

P3-S1.41 Coinfection of Neisseria gonorrhoeae and Chlamydia trachomatis in Symptomatic And Asymptomatic Women in India - Implications in Reproductive Health

Divya sachdev (1), subash Sonkar (1), Prashant Mishra (1), Achchhe Patel (2), Daman Saluja (3); (1) University of Delhi (Delhi, India); (2) University of Delhi (India); (3) University of Delhi (India)

P3-S1.42 Complex treatment of urogenital chlamydiosis with macrolids and immunostimulants

Tatyana Fartushok (1), Taras Dasyuk (1); (1) Danylo Halytsky Lviv Medical University (Lviv, Ukraine)

P3-S1.43 Women friendly gonorrhoea culture by self taken vaginal swabs for the purpose of surveillance of gonorrhoea resistance

Hannelore M Götz (1), A Luijendijk (2), B Nuradini (1), M van Westreenen (2); (1) Rotterdam Rijnmond Public Health Service (Rotterdam, Netherlands); (2) Erasmus University Medical Centre (Rotterdam, Netherlands)

P3-S1.44 Comparison of Self-taken Vulvo-vaginal Swabs and Clinician-taken Endocervical Swabs Using the Gen-Probe Aptima Combo 2 Assay versus Clinician-taken Urethral and Endocervical Swabs for Culture of Gonorrhoea

Janet Wilson (1), Catherine Stewart (1), Sarah Schoeman (1), Russell Booth (1), Susan Smith (1), Mark Wilcox (1); (1) Leeds Teaching Hospitals NHS Trust (Leeds, United Kingdom)

Clinical sciences poster session 2 -

Herpes simplex virus

P3-S2.01 Non sexually transmitted genital ulcers; patients referred to a STD clinic

Aparna Palit (1); (1) BLDE University (Bijapur, India)

P3-S2.02 Variations in Testing and Treatment Received by Infants with Possible Neonatal Herpes

Elissa Meites (1), Fujie Xu (1), Kathleen Hutchins (1), Bradley Ackerson (2), Julianne Gee (1), Eileen Eriksen (3), Allison Naleway (4), Lauri Markowitz (1), Kenneth Zangwill (3); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) Southern California Kaiser Permanente Medical Group (Los Angeles, USA); (3) UCLA Center for Vaccine Research (Torrance, USA); (4) Kaiser Permanente Northwest Center for Health Research (Portland, USA)

P3-S2.03 Clinical Evaluation of the BD HSV1 Qx Assay for the Direct Qualitative Testing of HSV1 as Compared to Viral Culture and a Laboratory-Based PCR Assay using Male and Female External Anogenital Lesions

Amy Pantone (1), Barbara Van Der Pol (1), James Williams (1), Larry Corey (2), Edward Hook (3), Barbara Body (4), Stephanie Taylor (5), Paul Fine (6), Savita Ginde (7), Joel Lebed (8); (1) Indiana University School of Medicine (Indianapolis, USA); (2) University of Washington (Seattle, USA); (3) University of Alabama Birmingham (Birmingham, USA); (4) LabCorp (Burlington, USA); (5) LSU Health Science Center (New Orleans, USA); (6) Planned Parenthood Gulf Coast (Houston, USA); (7) Planned Parenthood of the Rocky Mountains (Denver, USA); (8) Planned Parenthood Southeastern Pennsylvania (Philadelphia, USA)

P3-S2.04 Clinical Evaluation of the BD HSV2 Qx Assay for the Direct Qualitative Testing of HSV2 as Compared to Viral Culture and a Laboratory-Based PCR Assay using Male and Female External Anogenital Lesions

Laura Hires (1), Barbara Van Der Pol (1), James Williams (2), Larry Corey (3), Edward W. Hook (4), Melinda Nye (5), Stephanie Taylor (6), Mark Martens (7), Leandro Mena (8), Terri Warren (9); (1) Indiana University School of Medicine (Indianapolis, USA); (2) Indiana University (Indianapolis, USA); (3) University of Washington (Seattle, USA); (4) University of Alabama Birmingham (Birmingham, USA); (5) LabCorp (Burlington, USA); (6) LSU Health Science Center (New Orleans,

USA); (7) Planned Parenthood of Arkansas and Eastern Oklahoma (Tulsa, USA); (8) University of Mississippi Medical Center (Jackson, USA); (9) Westover Heights (Portland, USA)

P3-S2.05 Invasive Obstetric Procedures and Cesarean Sections in Women with Known Herpes Simplex Virus (HSV) Status During Pregnancy

Nicholas Moss (1), Carolyn Gardella (1), Linda Drolette (1), Amalia Magaret (1), Anna Wald (1); (1) University of Washington (Seattle, USA)

Clinical sciences poster session 3 - HIV

P3-S3.01 Anal Pap Smear Screening Among Drug Users Living with HIV in Miami, Florida

Isabella Rosa-Cunha (1), Thomas Hooton (1), Gabriel Cardenas (1), Lisa Metsch (1); (1) University of Miami (Miami, USA)

P3-S3.02 Reiter's syndrome in association with HIV infection: report of 3 cases

Arun Inamadhar (1); (1) BLDE University (Bijapur, India)

P3-S3.03 Clinical profile of Buschke-Lowenstein tumor in HIV infected patients

Ragunatha Shivanna (1); (1) BLDE University (Bijapur, India)

P3-S3.04 Clinical screening of sexually transmitted infections and risk factors among people living with HIV at the University Hospital of Cotonou.

Carin AHOuada (1), Jules BASHI (1), Marcel Djimon ZANNOU (2), Alice GOUGOUNON (1), Jocelyn AKAKPO (1), Rodolphe ZINSOU (1), Chrispina d'ALMEIDA (1), Christelle AHOMADEGBE (1), Angele AZON-KOUANOU (3), Gabriel ADE (3), Fabien HOUNGBE (3); (1) amulatory treatment center of academyc hospital (cotonou, Benin); (2) department of internal medicine (Benin); (3) department of internal medicine (Benin)

P3-S3.05 Cotrimoxazole Resistant Respiratory Opportunistic Pathogens in HIV and AIDS Patients in Lagos, Nigeria

Nneoma Idika (1), Maureen Anidobe (1), Dan Onwujekwe (1), Oni Idigbe (1); (1) Nigerian Institute of Medical Research (Lagos, Nigeria)

P3-S3.06 Quantifying Lactobacillae Species with Real Time PCR Methods for HIV prevention trials

Tania Crucitti (1), Vicky Jespers (1), Joris Menten (1), Hilde Smet (1), Anne Buvé (1), Sabrina Poradosú (1); (1) Institute of Tropical Medicine (Antwerpen, Belgium)

P3-S3.07 Withdrawn

P3-S3.08 Sensitivity and specificity of rapid HIV testing in a community setting

Benoit Trottier (1), Vinh Kim Nguyen (1), Rejean Thomas (1), Nima Machouf (1), Sylvie Vezina (1), Robert O'Brien (1), Stephane Lavoie (1), Danielle Longpré (1), Michel Boissonnault (1), Louise Charest (1); (1) Clinique médicale l'Actuel (Montreal, Canada)

P3-S3.09 New Drugs Targeting Toxicities Have Highest Hope of Impacting Patient Prognosis

Mikaela Smit (1), Colette Smit (2), Ide Cremin (1), Timothy Hallett (1), Frank de Wolf (2), Geoffrey Garnett (1); (1) Imperial College (London, United Kingdom); (2) HIV Monitoring Foundation (Amsterdam, Netherlands)

P3-S3.10 An Assessment of the Effects of Ancillary Services on CD4 Counts and Viral Loads of People Living with HIV/AIDS

Karen Ball (1), Robert Parrish (1), Alice Thornton (1); (1) University of Kentucky (Lexington, USA)

P3-S3.11 Withdrawn

P3-S3.12 Transmitted HIV Drug Resistance Mutations in Ontario, Canada, 2002-09

Ann Burchell (1), Ahmed Bayoumi (2), Carol Major (1), Sandra Gardner (1), Darien Taylor (3), Anita Rachlis (4), Paul Sandstrom (5), Sean Rourke (1), James Brooks (5); (1) Ontario HIV Treatment Network (Toronto, Canada); (2) St. Michael's Hospital (Toronto, Cape Verde); (3) Canadian AIDS Treatment Information Exchange (Toronto, Canada); (4) Sunnybrook Health Sciences Centre (Toronto, Canada); (5) Public Health Agency of Canada (Ottawa, Canada)

Clinical sciences poster session 4 -

Human papillomavirus

P3-S4.01 High-risk Human Papillomavirus (HR-HPV) Infection Detection in Russia: Need to Intensify Its Laboratory Proficiency With Standardization Programs?

Vitaly Smelov (1), Andrey Novikov (1), Sander Ouburg (2), Jolein Pleijster (2), Adylbek Allambergenov (1), Viktor Revzon (3), Andrey Gorelov (3), Servaas Morre (2); (1) Medical Academy of Postgraduate Studies (St. Petersburg, Russian Federation); (2) VU University Medical Center (Amsterdam, Netherlands); (3) St. Petersburg State University (St. Petersburg, Russian Federation)

P3-S4.02 High-Risk Human Papillomavirus (HR-HPV) Detection in Men With and Without the History of Chlamydia trachomatis Infection

Vitaly Smelov (1), Viktor Terekhov (2), Sander Ouburg (3), Jolein Pleijster (3), Andrey Gorelov (2), Andrey Novikov (1), Servaas Morre (3); (1) Medical Academy of Postgraduate Studies (St. Petersburg, Russian Federation); (2) St. Petersburg State University (St. Petersburg, Russian Federation); (3) VU University Medical Center (Amsterdam, Netherlands)

P3-S4.03 Impact of Comprehensive Management including Counselling on Health Related Quality of Life Index in Indian Patients with Anogenital Warts

Somesh Gupta (1); (1) All India Institute of Medical Sciences (New Delhi, India)

P3-S4.04 Topical 80% Trichloroacetic Acid (TCA) Shows Efficacy in the Treatment of Internal High-Grade Anal Intraepithelial Neoplasia (HGAIN)

Ken Ho (1), Esther Elishaev (1), Darlene Maciak (1), Jonathan Baker (1), Craig Parzynski (2), Chunming Zhu (2), Richard Day (2), Ross Cranston (1); (1) University of Pittsburgh (Pittsburgh, USA); (2) University of Pittsburgh Graduate School of Public Health (Pittsburgh, USA)

P3-S4.05 Missed Opportunities for Early Detection of Cervical Cancer in an STD Clinic

Janet Arno (1), Rebecca Graffis (1), Elizabeth Ferries-Rowe (1), Lisa Hess (1); (1) Indiana University School of Medicine (Indianapolis, USA)

P3-S4.06 Men with genital warts do consult later than women.

Patrick Dolcé (1), Valérie Séguin (1), Harold Bernatchez (1); (1) CSSS Rimouski-Neigette (Rimouski, Canada)

Clinical sciences poster session 5 - Other

P3-S5.01 Microbial Diversity of Genital Ulcer Disease in Men Enrolled in a Randomized Trial of Male Circumcision in Kisumu, Kenya

Supriya Mehta (1), Ian Maclain (2), Robert Baiely (1), Stephen Moses (2), Patrick Gillevet (3), Gregory Spear (4); (1) University of Illinois at Chicago (Chicago, USA); (2) University of Manitoba (Winnipeg, Canada); (3) George Mason University (USA); (4) Rush University (USA)

P3-S5.02 Is Urethral Smear Microscopy In Asymptomatic Men Effective In Reducing Major M genitalium Infection Sequelae In Women?

Peter White (5), Ruthie Birger (1), John Saunders (2), Claudia Estcourt (2), Timothy Hallett (1), Orla Caffrey (3), Catherine Mercer (4), Tracy Roberts (3), . . . (6); (1) Imperial College School of Public Health (London, United Kingdom); (2) St Bartholomew's Hospital (London, United Kingdom); (3) University of Birmingham (Birmingham, United Kingdom); (4) University College London (London, United Kingdom); (5) Health Protection Agency (London, United Kingdom); (6) . (United Kingdom)

P3-S5.03 Conflict of interest and point of care tests: an exploration of accuracy in Hepatitis C infection.

Sushmita Shivkumar (1), Yalda Jafari (1), Gilles Lambert (2), Christiane Claessens (2), Marina Klein (1), Jorge Martinez-Cajas (3), Rosanna Peeling (4), Lawrence Joseph (1), Nitika Pant Pai (1); (1) McGill University (Montreal, Canada); (2) INSPQ (Canada); (3) Queen's University (Canada); (4) LSHTM (United Kingdom)

P3-S5.04 The Diagnostic Accuracy of Rapid Point of Care Tests Used to Diagnose Hepatitis B: A Bayesian Meta-analysis.

Sushmita Shivkumar (1), Yalda Jafari (1), Gilles Lambert (2), Christiane Claessens (2), Marina Klein (1), Jorge Martinez-Cajas (3), Rosanna Peeling (4), Lawrence Joseph (1), Nitika Pant Pai (1); (1) McGill University (Montreal, Canada); (2) INSPQ (Canada); (3) Queen's University (Canada); (4) LSHTM (United Kingdom)

P3-S5.05 Rapid Point of Care Testing for Ten Sexually Transmitted Diseases

John Kriesel (1), Amiteshwar Bhatia (1), Mike Vaughn (2), Jordan Gardner (2), Cammie Barrus (3), Robert Crisp (2); (1) University of Utah School of Medicine (Salt Lake City, USA); (2) Idaho Technologies, Inc. (Salt Lake City, USA); (3) Salt Lake Valley Health Department (USA)

P3-S5.06 Surgery in the treatment of severe dyspareunia caused by vulvar vestibulitis syndrome-A longterm fol-low-up study

Jorma Paavonen (1), Thommola Päivi (1), Leila Unkila-Kallio (1); (1) Helsinki University Hospital (Helsinki, Finland)

P3-S5.07 Multidisciplinary clinic for the treatment of Hepatitis C: an useful tool for the management of the patients; review of the experience of a regional hospital

Patrick Dolcé (1), Sarah Brin-Clément (2), Harold Bernatchez (1), Philippe Jutras (1), Francine Tourangeau (1); (1) CSSS Rimouski-Neigette (Rimouski, Canada); (2) Université du Québec à Rimouski (Rimouski, Canada)

Clinical sciences poster session 6 - Syphilis

P3-S6.01 Validation of a treponemic antibodies quimioluminescence automated test for Syphilis detection among inmates of Mexico City.

Luis Juárez-Figueroa (1), Patricia Iracheta (2), Carlos Conde-Glez. (3), Sergio Bautista-Arredondo (3), Andrea González-Rodríguez (2); (1) HIV/STI Program of Mexico City (Mexico City, Mexico); (2) HIV/AIDS Program of Mexico City (Mexico); (3) National Institute of Public Health (Mexico)

P3-S6.02 Is Fourfold Drop Of the Nontreponemal Antibody Titers At Three Or Six Months After Early Syphilis Treatment An Effectiveness" Criterion?"

Pingyu Zhou (1), Xin Gu (1), Haikong Lu (1), Zhifang Guan (1), Yihong Qian (1); (1) Shanghai Skin Disease Hospital (Shanghai, China)

P3-S6.03 Seroreversion of Treponemal Tests in Cases meeting Canadian Surveillance Criteria for Confirmed Congenital Syphilis

Singh Ameeta (1), Tamara Guenette (2), Joshua Bergman (1), Jennifer Gratrix (1), Penny Parker (1), Barbara Anderson (1), Sabrina Plitt (3), Bonita Lee (4), Joan Robinson (4); (1) Alberta Health Services-Edmonton STI Clinic (Edmonton, Canada); (2)

Alberta Health Services- Edmonton STI Clinic (Edmonton, Canada); (3) Public Health Agency of Canada (Canada); (4) University of Alberta (Canada)

P3-S6.04 Use of a Point of Care Test Device to Detect Syphilis in a STD Clinic

Mathilda Barnes (1), Della Ducan (2), Patricia Agreda (3), Yu-Hsiang Hsieh (3), Jeffery Holden (3), Anne Rompalo (3), Charlotte Gaydos (3); (1) Johns Hopkins (Baltimore, USA); (2) Baltimore City Health Department (Baltimore, USA); (3) Johns Hopkins University (Baltimore, USA)

P3-S6.05 COMPARING THE ANALYTICAL SENSITIVITIES OF SIX TREPONEMAL TESTS

Heather Jost (1), Susan Kikkert (1), Yetunde Fakile (1), Arnold Castro (1), Tun Ye (1), Akbar Zaidi (1), Ronald Ballard (1), David Cox (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P3-S6.06 Does The Concept of Early And Late Latent Syphilis Hold Well in Today's Scenario?

Dipankar De (1), Amrinder Kanwar (1); (1) Postgraduate Institute of Medical Education and Research (Chandigarh, India)

P3-S6.07 Withdrawn

P3-S6.08 DETECTION OF THE 23S rRNA POINT MUTATIONS (A2058G AND A2059G) ASSOCIATED WITH AZITHROMYCIN RESISTANCE IN TREPONEMA PALLIDUM USING A TAQMAN-BASED REAL-TIME TRIPLEX-PCR ASSAY

Cheng-Yen Chen (1), Kai-Hua Chi (1), Allan Pillay (1), Eli Nachamkin (1), Ron Ballard (1); (1) CDC (Atlanta, USA)

P3-S6.09 Withdrawn

P3-S6.10 Analysis of systemic and cutaneous immune responses helps explain the duality of immune evasion and recognition in secondary syphilis

Adriana Cruz (1), Lady Ramirez (1); (1) CIDEIM (CALI, Colombia)

Clinical sciences poster session 7 -

Vaginal infections

P3-S7.01 Evaluation of a simple point-of-care rapid test for detecting *Trichomonas vaginalis* among women in Mysore, India

Keerthi Rao (1), Purnima Madhivanan (1), Jeffrey Klausner (2), Stephanie Trammell (2), Seema Kotian

(1), Kavitha Ravi (1), Karl Krupp (1), Vijaya Srinivas (1); (1) Public Health Research Institute of India (Mysore, India); (2) University of California (USA)

P3-S7.02 Performance of a Point-of-Care Diagnostic for Bacterial Vaginosis among young reproductive age women in Mysore, India

Kavitha Ravi (1), Seema Kotian (1), Keerthi Rao (1), Julia Selezneva (2), Vijaya Srinivas (1), Karl Krupp (1), Purnima Madhivanan (1); (1) Public Health Research Institute of India (Mysore, India); (2) Department of Molecular & Cell Biology, University of California Berkeley, Berkeley, USA (Berkeley, USA)

P3-S7.03 THE PREVALENCE OF BACTERIAL VAGINOSIS AMONG YOUNG WOMEN IN URBAN AREAS IN NIGERIA AND ITS MAJOR RISK FACTORS

Oluwagbenga Olawuyi (1); (1) Alafia Hospital (Ibadan, Nigeria)

P3-S7.04 *Candida* susceptibility to antifungals in Gomel region (Belarus)

Alena Khaikova (1); (1) Gomel State Medical University (Gomel, Belarus)

P3-S7.05 Phenotypic Characterization of Clinical *Trichomonas vaginalis* Isolates among AAWSW in Sexual Partnerships

Christina Muzny (1), Charles Rivers (1), Leandro Mena (2), Jane Schwebke (1); (1) University of Alabama at Birmingham (Birmingham, USA); (2) University of Mississippi Medical Center (Jacksonville, USA)

P3-S7.06 VAGINAL DISCHARGE IN WOMEN LIVING WITH HIV ATTENDING AN AIDS CLINIC IN MANAUS, BRAZIL.

Angelica Miranda (2) Leila Silva (1), João Vicente Braga (1), Rosicleia Montes (1), Sinesio Talhari (1); (1) Fundação de Medicina Tropical do Amazonas (Manaus, Brazil); (2) Universidade Federal do Espírito Santo

P3-S7.07 Detection of *Trichomonas vaginalis* in HIV Positive Women in Pretoria, South Africa

Marleen Kock (1), Ivy Rukasha (2), Anneke Dijkmans (3), Anwar Hoosen (1); (1) University of Pretoria/National Health Laboratory Service (Pretoria, South Africa); (2) University of Pretoria (Pretoria, South Africa); (3) University of Leiden (Netherlands)

P3-S7.08 Clinical Evaluation of the APTIMA® Trichomonas vaginalis Assay on the TIGRIS® DTS® System in Asymptomatic and Symptomatic Female Subjects

Jane Schwebke (1), Marcia Hobbs, Ph.D. (2), Stephanie Taylor, M.D. (3), Kimberle Chapin, M.D. (4), Michael Catania, Ph.D. (5), Barbara Weinbaum (6), Damon Getman, Ph.D. (5), Charlotte Gaydos, Ph.D. (7); (1) University of Alabama at Birmingham (Birmingham, USA); (2) University of North Carolina, Chapel Hill (Chapel Hill, USA); (3) LSU Health Sciences Center (New Orleans, USA); (4) Albert Brown Medical School (Providence, USA); (5) Gen-Probe Incorporated (San Diego, USA); (6) Gen-Probe Incorporated (San Diego, USA); (7) Johns Hopkins University (Baltimore, USA)

P3-S7.09 Mutations on gyrA or parC genes of Mycoplasma genitalium and efficacies of treatment with fluoroquinolones against M. genitalium-related urethritis

Ryoichi Hamasuna (1), Satoshi Takahashi (2), Masahiro Matsumoto (1), Takahiko Sho (1), Tetsuro Matsumoto (1); (1) University of Occupational and Environmental Health, Japan (Kitakyushu, Japan); (2) Sapporo Medical University of Medicine (Sapporo, Japan)

P3-S7.10 Composition of Vaginal Microbiota in Bacterial Vaginosis Patients and Healthy Women - Basis for Genetic Diagnosis of Bacterial Vaginosis?

Magnus Unemo (1), Annika Fahlen (2), Raluca Datcu (3), Anders Hallen (4), Hans Fredlund (1), Jörgen Jensen (5), Lars Engstrand (6); (1) Swedish Reference Laboratory for Pathogenic Neisseria (Örebro, Sweden); (2) Karolinska Institute (Sweden); (3) Statens Serum Institut, Copenhagen (Denmark); (4) Uppsala University Hospital (Sweden); (5) Statens Serum Institut (Denmark); (6) Swedish Institute for Infectious Disease Control (Sweden)

P3-S7.11 Factors associated with persistent bacterial vaginosis among young reproductive age women in Mysore, India

Purnima Madhivanan (1), Sujit Rathod (2), Karl Krupp (1), Anjali Arun (1), Arthur Reingold (2), Craig Cohen (3), Jeffrey Klausner (3); (1) Public Health Research Institute of India (Mysore, India); (2) University of California, Berkeley (USA); (3) University of California, San Francisco (USA)

P3-S7.12 Infections and Interventions in Pregnant Women at High Risk of Preterm Birth: A Cohort Study

Janet Wilson (1), Isabel Okpaluba (1), Nigel Simpson (2); (1) Leeds Teaching Hospitals NHS Trust (Leeds, United Kingdom); (2) University of Leeds (Leeds, United Kingdom)

P3-S7.13 EVALUATION OF THE AFFIRM VP8 MICROBIAL IDENTIFICATIONS TEST FOR THE DIAGNOSIS OF VAGINITIS AND BACTERIAL VAGINOSIS

Dumisile Venessa Maseko (1), Frans Madimetja Radebe (1), Lindy Gumede (1), Neetha Bhojraj Sewphershad (1), Sydney Khumalo (1), Ilze Basson (1), David Lewis (1); (1) National Institute for Communicable Diseases (NHLS) (Johannesburg, South Africa)

P3-S7.14 The Association of Ureaplasma urealyticum with Male Non-gonococcal Urethritis

Maria Frølund (1), Peter Lidbrink (2), Malin Cullberg (2), Arne Wikström (2), Peter Ahrens (1), Jørgen Skov Jensen (1); (1) Statens Serum Institut (Copenhagen, Denmark); (2) Karolinska University Hospital (Sweden)

P3-S7.15 Diagnostic Reliability of Wet Prep Microscopy for T. Vaginalis in Women Visiting a High-Volume STD Clinic

John Fitch (1), Teri Anderson (1), Mark Thrun (1), Christy Mettenbrink (1); (1) Denver Public Health Department (Denver, USA)

P3-S7.16 Lactobacillus crispatus Colonization Reduces Risk of Bacterial Vaginosis (BV) Acquisition

May Antonio (1), Melinda Petrina (1), Leslie Meyn (1), Sharon Hillier (2); (1) Magee-Womens Research Institute (Pittsburgh, USA); (2) Magee-Womens Research Institute/University of Pittsburgh (Pittsburgh, USA)

P3-S7.17 Noninvasive High Resolution Imaging with Optical Coherence Tomography for Vaginal Product Safety Assessment in Women

Kathleen Vincent (1), Lawrence Stanberry (2), Tom Moench (3), Carmen Radecki Breitkopf (4), Melissa Loza (1), Jingna Wei (1), Jeremy Paull (5), James Grady (6), Massoud Motamedi (1), Susan Rosenthal (2); (1) University of Texas Medical Branch (Galveston, USA); (2) Columbia University (USA); (3) ReProtect (USA); (4) Mayo Clinic (USA); (5) Starpharma (Australia); (6) University of Connecticut Health Center (USA)

P3-S7.18 Aetiological Agents of Infective Vaginal Discharge Among Women attending a STD Clinic in Kumasi, Ghana.

Thomas Agyarko-Poku (1); (1) University of Science and Technology (Kumasi, Ghana)

P3-S7.19 Diversity of the Vaginal Flora Determined by Molecular Methods in Healthy Women and Women with Bacterial Vaginosis in the Bay Area, California, USA

Eva Raphael (2), Purnima Madhivanan (1), Art Reingold (2), Jeff Klausner (3), Lee Riley (2), Stephanie Trammell (2); (1) Public Health Research Institute of India, Mysore (Mysore, India); (2) University of California, Berkeley (Berkeley, USA); (3) University of California, San Francisco (San Francisco, USA)

Basic sciences poster session 1 - Chlamydia

Trachomatis and Neisseria Gonorrhoea

P4-S1.01 Role of Chlamydia trachomatis heat shock proteins 60 and 10 in induction of apoptosis in endocervical epithelial cells

Aruna Singh nee Mittal (1), Rajneesh Jha (1), Sudha Salhan (2); (1) Institute of Pathology (New Delhi, India); (2) Safdarjung Hospital (New Delhi, India)

P4-S1.02 Coupling of electrochemical detection with PCR amplification for sensitive detection of N. gonorrhoeae

Seema Sood (1), Rachna Verma (1), Renu Singh (2), Gajala Sumana (2), Vinod Sharma (1), Jyotish Samantaray (1), Ravindra Pandey (1), Bansi Malhotra (2); (1) All India Institute of Medical Sciences (New Delhi, India); (2) National Physical Laboratory (India)

P4-S1.03 Demonstrating Performance of a Low-Cost, Ultra-Rapid PCR Device with True Point-of-Care Applications

David Pearce (1), Daniel Shenton (1), Simon Brake (1), Anais Larry (1), Marc Green (1), Charlotte Gaydos (2); (1) Atlas Genetics Ltd. (Trowbridge, United Kingdom); (2) Johns Hopkins University School of Medicine (Baltimore, USA)

P4-S1.04 11C-Choline Small Animal PET in Experimental Chlamydia muridarum Infection.

Antonella Marangoni (1), Cristina Nanni (2), Carmelo Quarta (2), Rita Aldini (1), Manuela

Donati (1), Paola Nardini (1), Claudio Foschi (1), Stefano Fanti (2), Roberto Cevenini (1); (1) University of Bologna (Bologna, Italy); (2) Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi (Italy)

P4-S1.05 Polymerase Chain Reaction-based Typing of penA Genes Exhibiting Elevated MIC Values to Cephalosporins in Isolates of Neisseria gonorrhoeae.

David Trees (1), Mark Burroughs (2), Sally Harris (2), Steve Johnson (2); (1) Centers for Disease Control and Prevention (Atlanta, USA); (2) CDC (USA)

P4-S1.06 High-resolution Multilocus Sequence Typing (MLST) of Chlamydia trachomatis from Three Catchment Areas in North and Central Norway

Bjorn Herrmann(1), Linus Christerson (1), Kirsten Gravningen (2), Anna Stahlsten (1), Kristina Ödman (1), Diem Nguyen (1), Jenny Isaksson (1), Ann-Sofie Furberg (2), Gunnar Skov Simonsen (3); (1) Uppsala University (Uppsala, Sweden); (2) University of Tromsø (Tromsø, Norway); (3) University Hospital of North Norway (Tromsø, Norway)

P4-S1.07 Chlamydia trachomatis DNA stability independent of preservation temperature, type of medium en storage duration

Laura van Dommelen (1), Frank H. van Tiel (2), Nicole H. Dukers (3), Petra F. Wolffs (2), Selma B. Hengreen (2), Christian J.P.A. Hoebe (3); (1) PAMM (Veldhoven, Netherlands); (2) Maastricht University Medical Centre (Netherlands); (3) South Limburg Public Health Service (Netherlands)

P4-S1.08 Performance Comparison of Neisseria gonorrhoeae (NG) Sequence Typing Methods NG-MAST and NG-MLVA on a Defined Panel of Isolates

Raymond Heymans (1), Daniel Golparian (2), Sylvia Bruisten (1), Magnus Unemo (2); (1) Health Service of Amsterdam (GGD) (Amsterdam, Netherlands); (2) Örebro University Hospital (Sweden)

P4-S1.09 Development of a Microwave - Accelerated Metal-Enhanced Fluorescence 40 seconds, < 100 cfu/mL Point of Care Assay for the Detection of Chlamydia trachomatis and Neisseria Gonorrhoea

Chris Geddes(1),Yongxia Zhang (1), Johan Melendez (1), Charlotte Gaydos (2); (1) University of Maryland Baltimore County (Baltimore, USA); (2) Johns Hopkins University Medical School (USA)

P4-S1.10 Longitudinal changes in cervicovaginal cytokine levels upon incident *Chlamydia trachomatis* infection among young women

Loris Y Hwang (1), Mark Scott (1), Yifei Ma (1), Janet Jonte (1), Anna-Barbara Moscicki (1); (1) University of California, San Francisco (San Francisco, USA)

Basic sciences poster session 2 - HIV and Hepatitis

P4-S2.01 A cross-sectional survey of Hepatitis B virus infections and natural immunity against Hepatitis B virus infections among HIV discordant heterosexual couples in Kisumu, Kenya

Raphael Ondondo (1); (1) Kenya Medical Research Institute (Kisumu, Kenya)

P4-S2.02 Withdrawn

P4-S2.03 Calculating BMI in HIV+ female adolescents: A case of Shaping the Health of Adolescents in Zimbabwe - Shaz! plus project.

Definate Nhamo (1); (1) Zimbabwe Aids Prevention Project - University of Zimbabwe (Harare, Zimbabwe)

Basic sciences poster session 3 -

Ureaplasma, Trichomonas and Syphilis

P4-S3.01 Macrolide-resistance testing and molecular subtyping of *Treponema pallidum* strains from South Africa

Etienne Muller (1), Gabriela Paz-Bailey (2), David Lewis (1); (1) National Institute for Communicable Diseases, National Health Laboratory Service (Johannesburg, South Africa); (2) Del Valle University of Guatemala (Guatemala City, Guatemala)

P4-S3.02 Subtyping of *Treponema pallidum* Strains by Sequence Analysis of *tp0279* and *tp0548*

Allan Pillay (1), Cheng Y. Chen (1), M.G. Morshed (2), S. Philip (3), R.C. Ballard (1); (1) CDC (Atlanta, USA); (2) British Columbia Centre for Disease Control Public Health Microbiology and Reference Laboratories (Atlanta, USA); (3) STD Prevention and Control Services, San Francisco Department of Public Health (San Francisco, USA)

P4-S3.03 Characterization of *Ureaplasma parvum* from Symptomatic and Asymptomatic Men Attending a Family Practice in Pretoria, South Africa

Marleen Kock (1), Ntutu Maningi (2), Anvir Adam (3), Anwar Hoosen (1); (1) University of Pretoria/National Health Laboratory Service (Pretoria, South Africa); (2) University of Pretoria (South Africa); (3) Private practitioner (Pretoria, South Africa)

P4-S3.04 *Treponema pallidum* Molecular Typing in China

Rui-Rui Peng (1), Yue-Ping Yin (1), Wan-Hui Wei (1), Hong-Chun Wang (1), Xiang-Sheng Chen (1); (1) National Center for STD Control, Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Dermatology (Nanjing, China)

P4-S3.05 Clinical Titers and Stability of *Trichomonas vaginalis* RNA in Urine Specimens

Michael Catania (1), Christine Bennett (1), Anabel Pae (1), Barbara Weinbaum (1), Damon Getman (1); (1) Gen-Probe Incorporated (San Diego, USA)

P4-S3.06 Study on early infection of the low genital tract of female mice by different serotypes *ureaplasma urealyticum*

Bin Yang (1); (1) Guangdong Provincial Center for Skin Disease and STD Control (Guangzhou, China)

P4-S3.07 Population Genomics of *Trichomonas vaginalis* Reveals a Globally Distributed Two-Phylotype Population Structure.

Melissa Conrad (1), Andrew Gorman (1), Julia Schilinger (2), Steven Sullivan (1), Jacqueline Upcroft (3), Jorge Gonzalez (4), Pier Luigi Fiori (5), Rossana Arroyo (6), Jacques Ravel (7), William E Secor (8), Jane Carlton (1); (1) New York University School of Medicine (New York, USA); (2) New York City Department of Health and Mental Hygiene (USA); (3) Queensland Institute of Medical Research (Australia); (4) University of Antofagasta (Chile); (5) University of Sassari (Italy); (6) Centro de Investigacion y de Estudios Avanzados del IPN (Mexico); (7) University of Maryland School of Medicine (USA); (8) Centers for Disease Control and Prevention (USA)

P4-S3.08 Development of a novel chimeric protein construct for improved diagnosis of syphilis

Brenden Smith (1), Caroline Cameron (1); (1) University of Victoria (Victoria, Canada)

P4-S3.09 The prevalence of *Trichomonas vaginalis* Virus (TVV) in globally distributed *Trichomonas vaginalis* isolates.

Lynchy Lezeau (1), Melissa Conrad (1), Andrew Gorman (1), Jane Carlton (1); (1) New York University School of Medicine (New York, USA)

P4-S3.10 A *Trichomonas vaginalis* Human Vaccine Candidate: Freund's Adjuvant Versus Aluminum Hydroxide Adjuvant in a BALB/c Mouse Vaginal Infection Model.

Jeffrey Smith (1), Gary Garber (2); (1) University of Ottawa (Ottawa, Canada); (2) University of Ottawa, Faculty of Medicine; OHRI Division of Infectious Disease (Canada)

Basic sciences poster session 4 -

Bacterial diversity

P4-S4.01 Investigation of the Bacterial Diversity in Urine of Urethritis Patients and Healthy Controls using 454 High-Throughput-Sequencing

Peter Ahrens (1), Maria Frølund (1), Waleed Abu Al-Soud (2), Arne Wikström (3), Peter Lidbrink (3), Malin Cullberg (3), Søren Johannes Sørensen (2), Jørgen Skov Jensen (1); (1) Statens Serum Institut (Copenhagen, Denmark); (2) University of Copenhagen (Denmark); (3) Karolinska University Hospital (Sweden)

P4-S4.02 A 22-Organism Microarray Approach for Detecting Microbiological Associations with Symptomatic Urethritis in Males.

Sheel Patel (2), Marcus Pond (1); (1) St George's, University of London (London, United Kingdom); (2) St George's Healthcare NHS Trust

P4-S4.03 A low-cost microfluidics-based diagnostic test for STDs

Samuel Sia (1); (1) Columbia University (New York, USA)

P4-S4.04 Temporal Dynamics of Vaginal Bacterial Communities

Jacques Ravel (1), Rebecca Brotman (1), Pawel Gajer (1), Joyce Sakamoto (1), Sara Koenig (1), Li Fu (1), Xia Zhou (2), Zaid Abdo (2), Larry Forney (2), Jacques Ravel (1); (1) University of Maryland School of Medicine (Baltimore, USA); (2) University of Idaho (USA)

**Health services and policy poster session 1 -
Stigmatization and Mental Health**

P5-S1.01 Perceptions and Practices of Employers of Labour in Ibadan North Local Government Area towards Persons Living with HIV/AIDS

Oluwafemi Dipeolu (1), Fredrick Oshiname (1); (1) University of Ibadan (Ibadan, Nigeria)

P5-S1.02 Sexual Risk Behaviors and Mental Health Concerns Among HIV-infected MSM

Marc Safran (1), Tao Guoyu (2), Mary Butler (3), Karen Hoover (2); (1) Centers for Disease Control and Prevention (CDC) (Atlanta, USA); (2) CDC (USA); (3) Private Consultant (USA)

P5-S1.03 HIV status disclosure in family and determinants of stigmatization in a conservative society

Audil Rashid (1), Mian Adnan (2); (1) PMAS Arid Agriculture University (Rawalpindi, Pakistan); (2) F.G. Postgraduate College (Men) (Rawalpindi, Pakistan)

P5-S1.04 THE IMPACT OF PELVIC INFLAMMATORY DISEASE ON SEXUAL, REPRODUCTIVE AND PSYCHOLOGICAL HEALTH

Jane Hocking (1), Danielle Newton (1), Christine Bayly (2), Christopher Fairley (3), Marcus Chen (3), Henrietta Williams (3), Louise Keogh (1), Meredith Temple-Smith (1), Kathy McNamee (4), Jane Fisher (1), Arthur Hsueh (1), Jane Hocking (1); (1) University of Melbourne (Melbourne, Australia); (2) The Royal Women's Hospital (Melbourne, Australia); (3) Melbourne Sexual Health Centre; Sexual Health Unit, School of Population Health, University of Melbourne (Australia); (4) Family Planning Victoria (Australia)

**Health services and policy poster session 2 -
Circumcision**

P5-S2.01 Survey on Knowledge, Attitude and Practices on Male circumcision in Rwanda

Jennifer Mbabazi (1); (1) TRACPlus (Kigali, Rwanda)

P5-S2.02 Survey on Knowledge, Attitude and Practices on Male circumcision in Rwanda

Jennifer Mbabazi (1), (1) TRACPlus (Kigali, Rwanda)

P5-S2.03 Phase one implementation of male circumcision as a comprehensive package of HIV prevention in Rwanda

Jennifer Mbabazi (1); (1) TRACPlus (Kigali, Rwanda)

P5-S2.04 Assessing comprehension of key informed consent concepts among clients undergoing male circumcision during scale up of services in Zambia and Swaziland

Barbara Friedland (1), Louis Apicella (1), Meredith Sheehy (1), Katie D. Schenk (1), Kelvin Munjile (1), Alfred Adams (1), Paul C. Hewett (1); (1) Population Council (New York, USA)

**Health services and policy poster session 3 -
Evaluation of Services and Policies**

P5-S3.01 Developing a Multi-Pronged Quality Improvement (QI) Strategy to Increase Chlamydia trachomatis (CT) Retesting Rates: Building a framework for success

Holly Howard (1), Aileen Barandas (2), Linda Creegan (3), Heidi Bauer (1), Joan Chow (1), Ina Park (1), Gail Bolan (4); (1) California Department of Public Health, STD Control Branch (Richmond, USA); (2) California Family Health Council, Inc. (Berkeley, USA); (3) California STD/HIV Prevention Training Center (Oakland, USA); (4) Department of Public Health, STD Control Branch (Richmond, USA)

P5-S3.02 Implementing Widespread Antenatal Syphilis Screening in Poor Regions of Guangdong, China: A Health Services Investigation of Implementation Barriers

Li-Gang Yang (1); (1) Guangdong Provincial Center for Skin Disease & STI Control, Guangzhou, China (Guangzhou, China)

P5-S3.03 Individual tracking amongst high risk groups for STI management in India: an analysis of 400,000 high risk groups followed from 2004 to 2009.

Anup Gurung (1), Prakash Narayanan (1), P. Mugundu (1), Manish Ranjan (2), Ravi Kumar (1), P Prabhakar (1), Anjana Das (2); (1) FHI (New Delhi, India); (2) FHI (India)

P5-S3.04 CONTINUED DECLINE IN GENITAL WARTS THREE YEARS AFTER INTRODUCTION OF QUADRIVALENT HUMAN PAPILLOMAVIRUS (HPV) VACCINATION PROGRAM.

Tim Read (1), Jane Hocking (1), Lyle Gurrin (1), Marcus Chen (2), Basil Donovan (3), Catriona Bradshaw (2), Christopher Fairley (1); (1) University of Melbourne (Carlton, Australia); (2) Alfred Hospital (Australia); (3) University of New South Wales (Australia)

P5-S3.05 A Clinical Practice Intervention to Increase Chlamydial Screening: Sustaining the Gain and Translating into Practice 4 Years Later

Kathleen Tebb (1), Mary-Ann Shafer (1); (1) University of California, San Francisco (San Francisco, USA)

**Health services and policy poster session 4 -
Innovation**

P5-S4.01 TRACNet: Sustaining mHealth at Scale in Rwanda

Jean Pierre Nyemazi (1); (1) Ministry of Health (Kigali, Rwanda)

P5-S4.02 Routine HIV testing of Family Members of Hospitalized Patients: a Novel Approach to HIV testing in Nigeria, sub Sahara Africa

Olusegun Busari (1), Adedayo Adeyemi (2), Martha Nakayima (3); (1) Federal Medical Centre (Ido-Ekiti, Nigeria); (2) Family Health International (Abuja, Nigeria); (3) The AIDS Support Organization (Masaka, Uganda)

P5-S4.03 Systematic Selection of Screening Participants by Risk Score in Chlamydia Screening Programme is Feasible and Effective

Christian J.P.A. Hoebe (1), Elfi E.H.G. Brouwers (1), Jan E.A.M. van Bergen (2), Johannes S.A. Fennema (3), Hannelore M. Gotz (4), Rik H. Koekenbier (3), Eline L.M. Op de Coul (5), Lydia Pars (2), Sander M. van Ravensteijn (4), Ingrid V.F. van den Broek (5); (1) South Limburg Public Health Service (Sittard-Geleen, Netherlands); (2) STI AIDS Netherlands (Amsterdam, Netherlands); (3) Amsterdam Health Service (Amsterdam, Netherlands); (4) Rotterdam Rijnmond Public Health Service (Rotterdam, Netherlands); (5) Centre for Infectious Disease Control, National Institute of Public Health and the Environment (Bilthoven, Netherlands)

P5-S4.04 Withdrawn

P5-S4.05 The Use of Financial Compensation as an Incentive for Infectious Syphilis Case Finding among Vulnerable Populations in Edmonton, Canada

Jennifer Gratrix (1), Shihe Fan (1), Barbara Anderson (1), Patsy Conroy (1), Sharyn Hewitt (1), Tracy Parnell (1), Joy Jaipual (2), Penny Parker (1), Ameeta E Singh (1), James Talbot (3); (1) Alberta Health Services (Edmonton, Canada); (2) Alberta Health Services (Canada); (3) Alberta Health and Wellness (Canada)

P5-S4.06 Sticking to it: the effect of Maximally Assisted Therapy on antiretroviral treatment adherence among a cohort of unstably housed people living with HIV in BC, Canada

Surita Parashar (1), Alexis Palmer (1), Nadia O'Brien (1), Keith Chan (1), Anya Shen (1), Suzy Coulter (2), Julio Montaner (3), Robert Hogg (4); (1) BC Centre for Excellence in HIV/AIDS (Vancouver, Canada); (2) Vancouver Coastal Health Authority (Canada); (3) BC Centre for Excellence in HIV/AIDS; UBC, Department of Medicine (Canada); (4) BC Centre for Excellence in HIV/AIDS; SFU, Faculty of Health Sciences (Canada)

P5-S4.07 SMS reminders increase re-testing for repeat chlamydial infection in heterosexuals at a sexual health clinic

Rebecca Guy (1), Handan Wand (1), Philip Read (2), Aurelie Kenigsberg (2), Vickie Knight (2), Anna McNulty (3); (1) National Centre in HIV Epidemiology and Clinical Research, Sydney (Sydney, Australia); (2) Sydney Sexual Health Centre, Sydney Hospital, Sydney (Sydney, Australia); (3) School of Public Health and Community Medicine, University of NSW; Sydney Sexual Health Centre, Sydney Hospital, Sydney (Sydney, Australia)

P5-S4.08 Integration of Syphilis Point-of-Care Test into Outreach Intervention Services at Commercial Sex Venues in Southern China

Yue-ping Yin (1), Jing Li (1), Wan-hui Wei (1), Hong-chun Wang (1), Rosanna W Peeling (2), Xiang-sheng Chen (1); (1) National Center for STD Control and the Chinese Academy of Medical Sciences Institute of Dermatology (Nanjing, China); (2) London School of Hygiene and Tropical Medicine (London, United Kingdom)

Health services and policy poster session 5 - Partner Notification

P5-S5.01 Factors Associated with Stated Willingness to Accept Expedited Partner Therapy From Sex Partners, NYC, 2007-2008

Diana Sanchez (1), Kristen L. Ricchetti-Masterson (2), Shoshanna Handel (3), Meighan Rogers (3), Julia A. Schillinger (3); (1) University of North Carolina Chapel Hill Gillings School of Global Public Health (Chapel Hill, USA); (2) University of North Carolina Chapel Hill Gillings School of Global Public Health (Chapel Hill, USA); (3) New York City Department of Health and Mental Hygiene (New York, USA)

P5-S5.02 OUTCOMES FOLLOWING THE INTRODUCTION OF HIV PARTNER NOTIFICATION GUIDELINES IN EDMONTON, CANADA

Joshua Bergman (1), Judith Brandley (1), Jennifer Gratrix (1), Kelsey Ross (1), Kerri Paradis (1), Penny Parker (1), Barbara Anderson (1), Stan Houston (1), Ameeta Singh (1); (1) Alberta Health Services (Edmonton, Canada)

P5-S5.03 Partner Notification and Treatment for Maternal Syphilis in Lima, Peru: Knowledge, Attitudes, and Practices of Health Providers and Patients

Beth Williams (1), Patricia Garcia (2), Cesar Carcamo (3), Marina Chiappe Guterrez (3), Sayda De la Rosa Roca (3), Maria Valderrama Calderon (3), Rosanna Peeling (4); (1) Columbia University Mailman School of Public Health (New York, USA); (2) Universidad Peruana Cayetano Heredia (Peru); (3) Universidad Peruana Cayetano Heredia (Peru); (4) London School of Hygiene and Tropical Medicine (United Kingdom)

P5-S5.04 Provider and Contract Referral for Bacterial STIs: Two Sides of the Same Coin?

Jacqueline Cassell (1), Claudia Estcourt (2), Merle Symonds (2), John Richens (3), Greta Rait (3), Stefania Lanza (1), Julia Dodds (4), Helen Smith (1); (1) Brighton and Sussex Medical School (Brighton, United Kingdom); (2) Queen Mary, University of London (United Kingdom); (3) University College London (United Kingdom); (4) MRC General Practice Research Framework (United Kingdom)

P5-S5.05 Partner Notification Uptake for Sexually Transmitted Infections in China: a Systematic Review

Alberta Wang (1), Ruirui Peng (2), Joseph Tucker (3), Xiang-Sheng Chen (2), Myron Cohen (4); (1) The University of Texas Medical School at Houston

(Houston, USA); (2) National Center for STD Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Dermatology (China); (3) Harvard University (USA); (4) University of North Carolina School of Medicine (USA)

P5-S5.06 Population-based Partner Services for Men Who Have Sex with Men (MSM) with Gonorrhea or Chlamydial Infection: A Missed HIV Prevention Opportunity

Matthew Golden (1), Mark Stenger (2), Roxanne Kerani (1), Julia Dombrowski (1), Joanne Stekler (1); (1) University of Washington (Seattle, USA); (2) Washington State Department of Health (Olympia, USA)

P5-S5.07 Withdrawn

P5-S5.08 Efficient Gonorrhea and Chlamydia Control and Prevention through Partner Notification in High Morbidity STD States - A Louisiana Perspective

Mohammad Rahman (1), Mahmud Khan (2), Lisa Longfellow (1); (1) Louisiana Office of Public Health (Metairie, USA); (2) Tulane University (New Orleans, USA)

Health services and policy poster session 6 - Services

P5-S6.01 Towards universal access to Prevention Mother To Child HIV-Transmission (PMTCT) services leading to Elimination of Mother To Child HIV-Transmission (MTCT) in Rwanda

Jean Pierre Nyemazi (1); (1) Ministry of Health (Kigali, Rwanda)

P5-S6.02 Sexual Education and Citizenship Construction: Colombia (2006-2008). What Does This Mean?

John Harold Estrada-Montoya (1); (1) Universidad Nacional de Colombia (Bogotá, Colombia)

P5-S6.03 Withdrawn

P5-S6.04 HIV TESTING OF HOMOSEXUAL MEN: CLINICIANS AS PART OF THE TESTING EQUATION

Marcus Chen (2), Teddy Petlo (1), Christopher Fairley (2), Bradley Whitton (2); (1) University of Melbourne (Carlton, Australia); (2) Melbourne Sexual Health Centre (Australia)

P5-S6.05 Withdrawn

P5-S6.06 Utilization and Cost of Diagnostic Methods for STD Screening among Insured American Youth, 2008

Kwame Owusu-Eduesei (1), Hang Nguyen (1), Thomas Gift (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P5-S6.07 The management of syphilis and gonococcal infections among Men who have Sex with Men (MSM) in a community medical center named "Centre Oasis, Ouagadougou, Burkina Faso."

Ter Tiero Elias Dah (1); (1) Association African Solidarité (Ouagadougou, Burkina Faso)

P5-S6.08 STD Surveillance and Control: Do STD and Family Planning Clinics Matter?

Sonal Doshi (1), kwame Owusu-Eduesei (1); (1) Centers for Disease Control and Prevention (Atlanta, USA)

P5-S6.09 Using Syndromic management of STI as an entry point to HIV prevention intervention in a resource poor setting

Victor Bassey (1), Andy Eyo (1); (1) ECEWS (Uyo, Nigeria)

P5-S6.10 Withdrawn

P5-S6.11 HIV Prevention with Positives Provider Training in a Resource-Constrained Setting: the US Virgin Islands

April Canete (1), Gowri Nagendra (1), Eunmee Chun (2), Rita Olans (3), Tiffany Ciprian (4), Susan Dreisbach (5); (1) Public Health Solutions (New York, USA); (2) NYC Department of Health & Mental Hygiene (New York, USA); (3) US Virgin Islands Department of Health (USA); (4) NYC Department of Health & Mental Hygiene (New York, USA); (5) University of Colorado (USA)

P5-S6.12 Control of Sexually Transmitted Infections (STI) in Guyana: Plan to Integrate into Existing Programmes

Shauna Scotland (1), Shanti Singh (1), Rosalinda Hernandez (2), Dereck Springer (3), Curtis LaFleur (4), Karen Boyle (5), Ameeta Singh (6); (1) Guyana Ministry of Health/National AIDS Programme Secretariat (Georgetown, Guyana); (2) Pan American Health Organization (Guyana); (3) Local consultant (Guyana); (4) U.S. Centers for Disease Control (Guyana); (5) Guyana HIV/AIDS Reduction and Prevention Project (Guyana); (6) External consultant (University of Alberta) (Canada)

P5-S6.13 Objective assessment of Patient Satisfaction with their HIV care

Lucy Land (1), Jonathan Ross (2); (1) Birmingham City University (Birmingham, United Kingdom); (2) University Hospital Birmingham (Birmingham, United Kingdom)

P5-S6.14 Qualitative Assessment of Facilitators and Barriers to HPV Vaccination Among Providers Serving a High-Risk Community

Marjan Javanbakht (1), Shauna Stahlman (1), Susan Walker (2), Sami Gottlieb (3), Lauri Markowitz (3), Nicole Liddon (3), Aaron Plant (2), Sarah Guerry (2); (1) University of California Los Angeles (Los Angeles, USA); (2) Los Angeles County Department of Public Health (USA); (3) Centers for Disease Control and Prevention (USA)

P5-S6.15 Social Work Services at New York City Health Department STD Clinics

Tiffany Ciprian (1), Anne Lifflander (1), Sean Sobin (1), Mediha Kosovrasti (1), Arien Muzacz (1), Gowri Nagendra (2); (1) New York City Department of Health and Mental Hygiene (New York, USA), (2) NYC Prevention Training Center (New York, USA)

P5-S6.16 Novel modular teaching of HIV patients in resource-limiting setting: effect of learning outcomes on adherence to highly active antiretroviral therapy (HAART)

Olusegun Busari (1), Olusogo Busari (1), Adedayo Adeyemi (2), Martha Nakayima (3); (1) Federal Medical Centre (Ido-Ekiti, Nigeria); (2) Family Health International (Abuja, Nigeria); (3) The AIDS Support Organization (Masaka, Uganda)

P5-S6.17 Facilitating Access to Sexual Health Services for Men Who Have Sex with Men and Transgender Persons in Guatemala City

Sabrina Boyce (1), Clare Barrington (2), Jose Herbert Bolanos (3), Cesar Galindo Arandi (4), Gabriela Paz-Bailey (5); (1) Tephinet Inc. (Atlanta, USA); (2) University of North Carolina (Chapel Hill, USA); (3) Universidad San Carlos (Guatemala City, Guatemala); (4) Del Valle University of Guatemala (Guatemala City, Guatemala); (5) Tephinet Inc., University of North Carolina, Del Valle University of Guatemala (Guatemala City, Guatemala)

P5-S6.18 Cost-effectiveness of Introducing Rapid Syphilis Testing in the Amazon Region, Brazil

Carlos Henrique Carvalho (1), Adele Benzaken (2), Rosanna Peeling (3), Andreia Santos (3), Fern Terris-Prestholt (3); (1) Alfredo da Matta Foundation

(Manaus, Brazil); (2) Alfredo da Matta Foundation (Manaus, Brazil); (3) London School of Hygiene and Tropical Medicine (London, United Kingdom)

5-S6.19 Prevalence and Incidence of Sexually Transmitted Infections among Female Sex Workers in Two Cities in India: Implications for STI Control Strategies

Anjana Das (1), Parimi Prabhakar (1), Prakash Narayanan (1), Graham Neilsen (1), Guy Morineau (1), Sanjay Mehendale (2), Arun Risbud (2); (1) FHI (New Delhi, India); (2) National AIDS Research Institute (India)

P5-S6.20 STIs and Healthcare Reform. Will it Really Improve America's Sexual Health?

Christie Mettenbrink (1), Rietmeijer Cornelis (1); (1) Denver Public Health Department (Denver, USA)

P5-S6.21 Acyclovir for Managing Genital Ulcer Disease in South Africa: Experiences of Guideline Introduction, Implementation and Uptake

Drew Emge (1), Sinead Delany-Moretllwe (2), Philippe Mayaud (3); (1) London School of Hygiene & Tropical Medicine and Reproductive Health & HIV Research Unit, University of the Witwatersrand (Bay City, USA); (2) Reproductive Health & HIV Research Unit, University of the Witwatersrand (Hillbrow, Johannesburg, South Africa); (3) London School of Hygiene & Tropical Medicine (London, United Kingdom)

P5-S6.22 Social-structural factors associated with supportive service use in a cohort of HIV-positive individuals on ARV therapy in British Columbia, Canada.

Nadia O'Brien (1), Alexis K. Palmer (1), Wendy Zhang (1), Warren Michelow (2), Anya Shen (1), Eric Roth (3), Chelsey L. Rhodes (4), Julio S.G. Montaner (5), Robert S. Hogg (5); (1) BC-Centre for Excellence in HIV/AIDS (Vancouver, Canada); (2) BC-Centre for Excellence in HIV/AIDS (Canada); (3) University of Victoria (Canada); (4) University of Waterloo (Canada); (5) BC Centre for Excellence in HIV/AIDS (Canada)

P5-S6.23 Barriers to Accessing Hepatitis C Treatment for Individuals Who Have Experience With Injection Drug Use

Caitlin Sinclair (1), Susan Kirkland (1), Mark Asbridge (1), Fiona Martin (2); (1) Dalhousie University (Halifax, Canada); (2) Dalhousie University (Canada)

P5-S6.24 Comprehensive, Competent and Compassionate Care for People Living with HIV in coastal Andhra Pradesh

Reynold Washington (1), Ram Babu (2); (1) KHPT (Bangalore, India); (2) Lepra Society (Secunderabad, India)

P5-S6.25 INTEGRATING HIV/AIDS, FAMILY PLANNING, AND REPRODUCTIVE HEALTH SERVICE INTO NIGERIAN COMMUNITIES

Chinomso Ibe Traffina (1); (1) Institute of Human Virology of Nigeria (Abuja, Nigeria)

P5-S6.26 Prevention with positives in Nigeria: what have we learnt?

Chinomso Ibe Traffina (1); (1) Institute of Human Virology of Nigeria (Abuja, Nigeria)

P5-S6.27 New Avenues to Increase Quality of STI-care in General Practice

JEAM van Bergen (1); (1) Soa Aids Nederland (Amsterdam, Netherlands)

P5-S6.28 HIV prevention based on the static Modes of Transmission synthesis for two Indian districts: insights from dynamical modeling

Sharmistha Mishra (1), Peter Vickerman (2), Michael Pickles (1), BM Ramesh (3), Reynold Washington (3), Shajy Issac (3), Stephen Moses (4), James Blanchard (4), Marie-Claude Boily (1); (1) Imperial College (London, United Kingdom); (2) London School of Hygiene and Tropical Medicine (United Kingdom); (3) Karnataka Health Promotion Trust (Bangalore, India); (4) Centre for Global Public Health (Canada)

P5-S6.29 Intensive use of a clinical documentation audit tool to bring about sustained improvement in the standard of record-keeping in a busy Genito-urinary Medicine (GUM) clinic

William Spice (1), Rachel Whitby (1), Sumit Bhaduri (1); (1) Worcestershire Primary Care Trust (Worcester, United Kingdom)

P5-S6.30 HPV catch-up vaccination among a community sample of young adult women

Lisa Manhart (1), Albert Burgess-Hull (1), Charles Fleming (1), Jennifer Bailey (1), Kevin Haggerty (2), Richard Catalano (1); (1) University of Washington (Seattle, USA); (2) University of Washington (USA)

P5-S6.31 Sexual health care among female sex workers working outside of the main entertainment district in Tijuana, Mexico

Melanie Rusch (1), Manuel Gallardo (2), Remedios Lozada (2), Ryan Lindsay (3), Valerie J Mercer (1), Mari L Zuniga (1), Thomas L Patterson (1), Steffanie A Strathdee (1); (1) UCSD (La Jolla, USA); (2) PrevenCasa A.C. (Mexico); (3) SDSU-UCSD (USA)

P5-S6.32 Using a Contingent Valuation Method to Understand Consumer Preferences for Care of Adolescents with Pelvic Inflammatory Disease (PID)

Maria Trent (1), Qiang Qian (2), Kevin Frick (3), Carol Thompson (3), Arlene Butz (4), Jonathan Ellen (4), Harold Lehmann (4); (1) Johns Hopkins University School of Medicine (Baltimore, USA); (2) University of Maryland (Towson, USA); (3) Johns Hopkins Bloomberg School of Public Health (Baltimore, USA); (4) Johns Hopkins School of Medicine (Baltimore, USA)

P5-S6.33 HIV/AIDS Impact Mitigation in Resource-Poor Settings: Scaling-up A Multi-Sectoral Response

Anita Mwendwa (1), Norah Kyalo (2), Winfred Kihara (3), Jackline Mburu (4), Maria Mutua (5); (1) Moi University Hospital Teaching and Referral Centre (Eldoret, Kenya); (2) University of Nairobi (Nairobi, Kenya); (3) Kenyatta National Hospital (Nairobi, Kenya); (4) Redeemed Gospel Church Development Programme (Nairobi, Kenya); (5) Centre for Integrated Community Development and Outreach, CICDOT (Nairobi, Kenya)

P5-S6.34 Provider Characteristics Associated with Gonorrhea Treatment Errors, Massachusetts, 2010

Jennifer Swails (1), Laura Smock (2), Yuren Tang (2), Katherine Hsu (2); (1) Brigham and Women's Hospital (Boston, USA); (2) Massachusetts Dept. of Public Health (USA)

P5-S6.35 Effectiveness of mobilizing medical facilities to participate in STD/HIV control activities

Guojun Liang (1); (1) National Center for STD Control, China CDC. (Nanjing, China)

P5-S6.36 Factors Affecting Quality of Life of People Living With HIV In Karnataka, India

Pradeep Banandur (1), Marissa L Becker (2), Lavanya Garady (3), Amaresh Yallappa (3), Shajy Isaac (3), Rajaram S Potty (3), Reynold G Washington (3), James F Blanchard (2), Stephen Moses (2), Ramesh M Banadakoppa (3); (1) Rajarajeswari Medical College and Hospital (Bangalore, India);

(2) University of Manitoba (Winnipeg, Canada);
(3) Karnataka Health Promotion Trust (Bangalore, India)

P5-S6.37 A community led decentralised and integrated approach for personalized prevention and care services to PLHIV in Karnataka, South India.

Manish Kumar P (1), Krishnamurthy Jayanna (1);
(1) Karnataka Health Promotion Trust (Bangalore, India)

P5-S6.38 NICE Guidance on Prevention of Sexually Transmitted Infections and Under 18 Conceptions; has it influenced service providers?

Angela Robinson (1), Kiri Dixon (2), Kimberley Forbes (3), Dawn Wilkinson (4), Elizabeth Foley (5); (1) Mortimer Market Centre, London (London, United Kingdom); (2) Southampton University Medical School (United Kingdom); (3) West Middlesex University Hospital Trust (United Kingdom); (4) St Mary's Hospital Foundation Trust, London (United Kingdom); (5) Royal South Hants Hospital Trust (United Kingdom)

P5-S6.39 Integrating Medication Assisted Therapy With Buprenorphine and Other Harm Reduction Interventions into an Urban Public Health Department STD Clinic in the Southwestern USA

Bruce Trigg (1), Mary Murphy (2), Ashley Tsang (3); (1) New Mexico Department of Health (retired) (Albuquerque, USA); (2) Stanford Buprenorphine Induction Program (Albuquerque, USA); (3) CDC Associate (Albuquerque, USA)

Health services and policy poster session 7 -

Screening

P5-S7.01 Exploring the Acceptability of Medical, Educational and Sport Settings for STI Screening: Stratified Random Probability Survey of Young Men in the UK.

Claudia Estcourt (1), John Saunders (1), Cath Mercer (2), Lorna Sutcliffe (1), Graham Hart (2); (1) Queen Mary University of London (London, United Kingdom); (2) University College London (London, United Kingdom)

P5-S7.02 Trends in Screening Females for Chlamydia in Juvenile Detention Centers US 2005-2009 Daniel R. Newman, MA; Thomas A. Peterman, MD, MSc; Dayne E. Collins, BS; Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta, GA, USA

Daniel Newman (1), Thomas Peterman (1), Dayne Collins (1); (1) CDC (Atlanta, USA)

P5-S7.03 Syphilis Screening for High-Risk Groups in a Large-Scale HIV Prevention Program in India - Uptake and Trends

Mugundu Parthasarathy (1), Narayanan Potty (1), Anup Gurung (1), Anjana Das (1), Prabhakar Parimi (2); (1) Family Health International (Chennai, India); (2) Alliance, India (Hyderabad, India)

P5-S7.04 Who participates in the Dutch Chlamydia Screening? A study on demographic and behavioural correlates of (repeated) participation and positivity

Eline Op de Coul (1), Hannelore Götz (2), Jan Van Bergen (3), Elfi Brouwers (4), Han Fennema (5), Christian Hoebe (6), Rik Koekenbier (5), Sander van Ravesteijn (2), Lydia Pars (3), Ingrid van den Broek (1); (1) RIVM (Bilthoven, Netherlands); (2) GGD Rotterdam-Rijnmond (Netherlands); (3) SOA AIDS Nederland (Netherlands); (4) GGD Oostelijk Zuid-Limburg (Netherlands); (5) GGD Amsterdam (Netherlands); (6) GGD Oostelijk Zuid-Limburg (Netherlands)

P5-S7.05 Chlamydia Screening in an International Resort Community: an Outreach Program to Expand Access

Marisa Collins (1), Rosanna Holehouse (2), Janusz Kaczorowski (1); (1) University of British Columbia (Whistler, Canada); (2) Options for Sexual Health BC (Canada)

P5-S7.06 Chlamydia screening implementation in the Netherlands is not cost-effective

Boris Schmid (1), Eelco Over (1), Ingrid van den Broek (1), Eline Op de Coul (1), Jan van Bergen (2), CSI Group (3), Mirjam Kretzschmar (1), Ardine de Wit (1); (1) RIVM (Bilthoven, Netherlands); (2) Soa Aids Nederland (Netherlands); (3) CSI Group (Netherlands)

P5-S7.07 Chlamydia screening in Cornwall: How often do young people get retested?

Katy Turner (1), Lea Trela-Larsen (1), Pam Gates (2), Margaret May (1), Paddy Horner (1); (1) University of Bristol (Bristol, United Kingdom); (2) Royal Cornwall Hospital Trust (Truro, United Kingdom)

P5-S7.08 Assessment of chlamydia testing coverage using HEDIS data - United States, 2009

Guoyu Tao (1), Karen Hoover (1), raul Romaguera (1), Charlotte Kent (1); (1) CDC (Atlanta, USA)

P5-S7.09 Is Abandoning Urethral Smear Microscopy For The Detection Of Non-Gonococcal Non-Chlamydial Urethritis In Asymptomatic Men A Cost Effective Strategy?

Orla Caffrey (1), John Saunders (2), Claudia Estcourt (2), Ruthie Birger (3), Peter White (3), Tracy Roberts (1); (1) University of Birmingham (Birmingham, United Kingdom); (2) Queen Mary University of London (London, United Kingdom); (3) Imperial College London (London, United Kingdom)

P5-S7.10 Chlamydia Screening Coverage among American Indian and Alaska Native Women in the United States

Scott Tulloch (1), Melanie Taylor (1); (1) Centers for Disease Control & Prevention (Albuquerque, USA)

P5-S7.11 Chlamydia and Gonorrhea Positivity among Females Aged 15-25 Years Tested in Community Health Centers in 12 Counties in CY2009, Region II Infertility Prevention Project, United States

Kelly Opdyke (1), Melissa Nelson (1), Dawn Middleton (1); (1) Cicatelli Associates Inc. (New York, USA)

P5-S7.12 STD Testing in Emergency Department: A Novel Method to Provide Test Results

Janet Arno (1), Frank Messina (2), Anthony Perkins (3), Andrea Allen (2); (1) Indiana University School of Medicine & Marion County Public Health Department (Indianapolis, USA); (2) Indiana University School of Medicine (Indianapolis, USA); (3) Anthony Perkins Statistical Consulting (Brownsburg, USA)

P5-S7.13 Royal Perth Hospital Emergency Department Screening Project For Chlamydia trachomatis

Christine Dykstra (1), Daniel Fatvich (1), James Flexman (1), Michael Phillips (2), Jenny McCloskey (1); (1) Royal Perth Hospital (Perth, Australia); (2) University of Western Australia (Perth, Australia)

P5-S7.14 High Chlamydia and Gonorrhea Incidence, Reinfection and HIV Infection Among Workers in the Adult Film Industry: Time to Regulate and Protect Workers

Cristina Rodriguez-Hart (1), Binh Goldstein (1), Getahun Aynalem (1), Peter Kerndt (1); (1) Los Angeles Department of Public Health (Los Angeles, USA)

P5-S7.15 STI knowledge and testing practices among FSW working outside of the main entertainment district in Tijuana, Mexico

Melanie Rusch (1), Manuel Gallardo (2), Remedios Lozada (2), Valerie J Mercer (1), Mari L Zuniga (1), Thomas L Patterson (1), Steffanie A Strathdee (1); (1) UCSD (La Jolla, USA); (2) PrevenCasa A.C. (Mexico)

P5-S7.16 Easy Access "Community-based HIV Testing Services for Gay Men: A Systematic Review"

Alisa Pedrana (1), Mark Stooove (1), Anna Bowring (1), Margaret Hellard (1), Rebecca Guy (2); (1) Burnet Institute (Melbourne, Australia); (2) National Centre in HIV Epidemiology and Clinical Research (Sydney, Australia)

P5-S7.17 Accepting the good with the bad": Barriers and facilitators of community-based HIV testing services for gay men: A systematic review"

Alisa Pedrana (1), Mark Stooove (1), Anna Bowring (1), Margaret Hellard (1), Rebecca Guy (2); (1) Burnet Institute (Melbourne, Australia); (2) National Centre in HIV Epidemiology and Clinical Research (Sydney, Australia)

Late breaker poster session

LBP - 1.01 The Interdiction Project: An Innovative Program for HIV + Persons to Reduce HIV and STD Co-infection and Improve HIV Treatment Outcomes Phase II.

Samuel Frimpong (1), Maximillion Wilson (1), LeVonne M. Mitchell-Samon (1), Taj Azarian (1); Duval County Health Department

LBP - 1.02 Acceptability and appeal of internet-based STI and HIV testing among a sample of gay men and clients attending STI clinics in British Columbia

Travis S Hottes (1), Mark Gilbert (1), Mark Bondyra (1), Devon Haag (1), Jean Shoveller (2); (1) BC Centre for Disease Control (Vancouver, Canada); (2) University of British Columbia (Canada)

LBP - 1.03 "No one was there to care for us" Ashraya's response to its members' needs in terms of care and support

Claudyne Chevrier (1); (1) Université de Montréal (Montréal, Canada)

LBP - 1.04 International Validation of AmpliSens NAAT Systems Manufactured in Russia for Diagnosis of *N gonorrhoeae*, *C trachomatis*, *M genitalium* and *T vaginalis*

Marius Domeika (1), Alevtina Savicheva (2), Elena Shipitsyna (3), Cheng Y Chen (4), Jorgen Skov-Jenssen (5), Olle Hjelmvoll (6), Ronald Ballard (4), Magnus Unemo (7); (1) Uppsala University (Uppsala, Sweden); (2) Institute of obstetrics and Gynecology DI Ott (St Petersburg, Russian Federation); (3) Inst of Obstetrics and Gynecology DI Ott (St Petersburg, Russian Federation); (4) Centers for Disease Control and Prevention (Atlanta, USA); (5) State Serum Institute (Coopenhagen, Denmark); (6) University Hospital of North Norway (Tromsø, Norway); (7) Örebro University Hospital (Örebro, Sweden)

LBP - 1.05 Challenges and barriers for conducting STI/HIV prevention projects targeting female sex workers within national programs in Benin and Niger

Georges Batona (1), Alary Michel (2), Kéké René (3), Gervais Marie (4), Akinoché Évelyne (3), Ahoussinou Clément (3), Issaka Mahamadou Kamaye (5), Daouda Hassane (5); (1) Université Laval, Unité de recherche en santé des populations (URESP) (Québec, Canada); (2) URESP-CHA, Université Laval (Québec, Canada); (3) Programme National de lutte contre les IST/Sida du Bénin (Cotonou, Benin); (4) Université Laval (Québec, Canada); (5) Programme national de lutte contre les IST/Sida du Niger (Niamey, Niger)

LBP - 1.06 Infectious Syphilis in New Brunswick: Using Data for Action in a Small Canadian Province

Gillian Frosst (1), Francois-William Tremblay (2), Dr. Denis Allard (2); (1) Public Health Agency of Canada (Fredericton, Canada); (2) New Brunswick Department of Health (Canada)

LBP - 1.07 Ecology of Human papillomavirus (HPV) infections in the male, studied using Expressed Prostate Secretions (EPS)

Vitaly Smelov (1), Carina Eklund (2), Joakim Dillner (2); (1) Medical Academy of Postgraduate Studies (St. Petersburg, Russian Federation); (2) Karolinska Institutet (Stockholm, Sweden)

LBP - 1.08 Preliminary Report on Experience with Point of Care Syphilis and HIV Testing in Hard-to-Reach Populations in Outreach Settings in Edmonton, Canada

Joshua Bergman (1), Sabrina Plitt (2), Jennifer Gratrix (1), Patsy Conroy (1), Josettie Li (1), Kelly Rocco (1), Jayne Fenton (3), Chris Archibald (2), Tom Wong (2), Ameeta Singh (1); (1) Alberta Health Services (Edmonton, Canada); (2) Public Health Agency of Canada (Ottawa, Canada); (3) Provincial Laboratory for Public Health (Edmonton, Canada)

LBP - 1.09 Services Utilization and Health Related variables of Person Living with HIV/AIDS in Community in Taiwan

Piao-Yi Chiou (1), Li-Chan Lin (2); (1) Mackay Medicine, Nursing and Management College (Taipei City, Taiwan, China); (2) Yang-Ming University (Taipei city, Taiwan, China)

LBP - 1.10 Misclassification of Syphilis Cases using a Reactive Enzyme Immunoassay and Reactive RPR Algorithm alone for Diagnosis

Ameeta Singh (1), Kevin Fonseca (2), Shamir Mukhi (3), Jennifer Gratrix (1), Sabrina Plitt (3), Ron Read (1), Karen Sutherland (1), George Zahariadis (2), Greg Tyrrell (2), Bonita Lee (4); (1) Alberta Health Services (Edmonton, Canada); (2) Alberta Provincial Laboratory for Public Health (Canada); (3) Public Health Agency of Canada (Canada); (4) University of Alberta (Canada)

LBP - 1.11 Acceptability of short -course AZT prevention regimen by HIV infected pregnant women; should VCT in the antenatal setting be modified

Ssali Abdulah Aziz (1); (1) Positive Union Uganda (Kampala, Uganda)

LBP - 1.12 HIV and Hepatitis C prevalence in individuals leaving prison and entering drug and alcohol services in the area of highest HIV prevalence in the UK

Helen Williams (1), David Axten (1), Fiona Makia (2), Alastair Teague (1), Julie Fox (1); (1) Guy's and St Thomas' NHS Foundation Trust (London, United Kingdom); (2) Guy's and S Thomas' NHS Foundation Trust (United Kingdom)

PRESENTATION
WITHDRAWN

LBP - 1.13 LEEP Conisation and the Risk for Preterm Birth: New Health registry Based Data from Finland

Jorma Paavonen (1), Annu Heinonen (1), Mika Gissler (2), Anna-Maija Tapper (1), Maija Jakobson (1); (1) Helsinki University Hospital (Helsinki, Finland); (2) National Institute of Health and Welfare (Finland)

LBP - 1.14 GENITAL WARTS: CANADIANS' PERCEPTION AND HEALTH RELATED BEHAVIORS

Marc Steben (1), Deborah Labelle (2); (1) Institut national de santé publique du Québec (Montréal, Canada); (2) Graceway pharmaceuticals (Canada)

LBP - 1.15 AN EVALUATION OF THE LONG-TERM EFFECTIVENESS, IMMUNOGENICITY, AND SAFETY OF GARDASIL™ IN PREVIOUSLY VACCINATED WOMEN

Alfred Saah (1); (1) Merck Sharp & Dohme (Whitehouse Station, USA)



Joint Meeting
of the 20th ISSTD
and 14th IUSTI

STI *Threatening past-
promising future.*
WorldCongress
2013 July 14 – 17
Vienna

Hosted by:



Under the aegis of:



In conjunction with:



MAJOR CONTRIBUTORS



CONTRIBUTORS



SPONSORS

Platinum



Gold



Silver



Bronze



SIEMENS

The abstract book is available as a Web supplement of the journal
Sexually Transmitted Infections

http://sti.bmj.com/content/87/Suppl_1.toc